<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Beta‐blockers for suspected or diagnosed acute myocardial infarction - Safi, S - 2019 | Cochrane Library</title> <meta content="Beta‐blockers for suspected or diagnosed acute myocardial infarction - Safi, S - 2019 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012484.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Beta‐blockers for suspected or diagnosed acute myocardial infarction - Safi, S - 2019 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012484.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD012484.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Beta‐blockers for suspected or diagnosed acute myocardial infarction" name="citation_title"/> <meta content="Sanam Safi" name="citation_author"/> <meta content="Department 7812, Rigshospitalet, Copenhagen University Hospital" name="citation_author_institution"/> <meta content="sanam.safi@ctu.dk" name="citation_author_email"/> <meta content="Naqash J Sethi" name="citation_author"/> <meta content="Department 7812, Rigshospitalet, Copenhagen University Hospital" name="citation_author_institution"/> <meta content="Emil Eik Nielsen" name="citation_author"/> <meta content="Joshua Feinberg" name="citation_author"/> <meta content="Department 7812, Rigshospitalet, Copenhagen University Hospital" name="citation_author_institution"/> <meta content="Christian Gluud" name="citation_author"/> <meta content="Janus C Jakobsen" name="citation_author"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="12" name="citation_issue"/> <meta content="10.1002/14651858.CD012484.pub2" name="citation_doi"/> <meta content="2019" name="citation_date"/> <meta content="2019/12/17" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012484.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012484.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012484.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Adrenergic beta‐Antagonists [*therapeutic use]; Myocardial Infarction [diagnosis, *drug therapy, mortality]; Quality of Life; Randomized Controlled Trials as Topic; Treatment Outcome" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012484.pub2&amp;doi=10.1002/14651858.CD012484.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012484.pub2&amp;doi=10.1002/14651858.CD012484.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012484.pub2&amp;doi=10.1002/14651858.CD012484.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012484.pub2&amp;doi=10.1002/14651858.CD012484.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012484.pub2&amp;doi=10.1002/14651858.CD012484.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012484.pub2&amp;doi=10.1002/14651858.CD012484.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012484.pub2&amp;doi=10.1002/14651858.CD012484.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012484.pub2&amp;doi=10.1002/14651858.CD012484.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012484.pub2&amp;doi=10.1002/14651858.CD012484.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012484.pub2&amp;doi=10.1002/14651858.CD012484.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012484.pub2&amp;doi=10.1002/14651858.CD012484.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012484.pub2&amp;doi=10.1002/14651858.CD012484.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012484.pub2&amp;doi=10.1002/14651858.CD012484.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012484.pub2&amp;doi=10.1002/14651858.CD012484.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012484.pub2&amp;doi=10.1002/14651858.CD012484.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012484.pub2&amp;doi=10.1002/14651858.CD012484.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012484.pub2&amp;doi=10.1002/14651858.CD012484.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012484.pub2&amp;doi=10.1002/14651858.CD012484.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012484.pub2&amp;doi=10.1002/14651858.CD012484.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012484.pub2&amp;doi=10.1002/14651858.CD012484.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012484.pub2&amp;doi=10.1002/14651858.CD012484.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012484.pub2&amp;doi=10.1002/14651858.CD012484.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012484.pub2&amp;doi=10.1002/14651858.CD012484.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="uQyIsxpV";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD012484\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD012484\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012484\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012484\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","ru","fr","pl","zh_HANT","hr","fa","ms"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD012484.pub2",title:"Beta\\u2010blockers for suspected or diagnosed acute myocardial infarction",firstPublishedDate:"Dec 17, 2019 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Heart Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=uQyIsxpV&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012484.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012484.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD012484.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD012484.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012484.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD012484.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Abstract&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Antecedentes&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Métodos&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Discusión&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD012484.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD012484.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD012484.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD012484.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>11966 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD012484.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012484.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012484.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012484.pub2/full#CD012484-abs-0005"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012484.pub2/full#CD012484-sec-0126"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012484.pub2/full#CD012484-sec-0029"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012484.pub2/full#CD012484-sec-0030"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012484.pub2/full#CD012484-sec-0041"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012484.pub2/full#CD012484-sec-0042"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012484.pub2/full#CD012484-sec-0072"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012484.pub2/full#CD012484-sec-0111"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012484.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012484.pub2/appendices#CD012484-sec-0131"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012484.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012484.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/table_n/CD012484StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/table_n/CD012484StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012484.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012484.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012484.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012484.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012484.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD012484.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2019 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Beta‐blockers for suspected or diagnosed acute myocardial infarction</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012484.pub2/information#CD012484-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Sanam Safi</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012484.pub2/information#CD012484-cr-0003">Naqash J Sethi</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012484.pub2/information#CD012484-cr-0004">Emil Eik Nielsen</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012484.pub2/information#CD012484-cr-0005">Joshua Feinberg</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012484.pub2/information#CD012484-cr-0006">Christian Gluud</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012484.pub2/information#CD012484-cr-0007">Janus C Jakobsen</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/information/en#CD012484-sec-0143">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 17 December 2019 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD012484.pub2">https://doi.org/10.1002/14651858.CD012484.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD012484-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012484-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012484-abs-0004">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012484-abs-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD012484-abs-0003">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012484-abs-0002">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD012484-abs-0001" lang="en"> <section id="CD012484-sec-0001"> <h3 class="title" id="CD012484-sec-0001">Background</h3> <p>Cardiovascular disease is the number one cause of death globally. According to the World Health Organization, 7.4 million people died from ischaemic heart diseases in 2012, constituting 15% of all deaths. Acute myocardial infarction is caused by blockage of the blood supplied to the heart muscle. Beta‐blockers are often used in patients with acute myocardial infarction. Previous meta‐analyses on the topic have shown conflicting results ranging from harms, neutral effects, to benefits. No previous systematic review using Cochrane methodology has assessed the effects of beta‐blockers for acute myocardial infarction. </p> </section> <section id="CD012484-sec-0002"> <h3 class="title" id="CD012484-sec-0002">Objectives</h3> <p>To assess the benefits and harms of beta‐blockers compared with placebo or no intervention in people with suspected or diagnosed acute myocardial infarction. </p> </section> <section id="CD012484-sec-0003"> <h3 class="title" id="CD012484-sec-0003">Search methods</h3> <p>We searched CENTRAL, MEDLINE, Embase, LILACS, Science Citation Index Expanded and BIOSIS Citation Index in June 2019. We also searched the WHO International Clinical Trials Registry Platform, ClinicalTrials.gov, Turning Research into Practice, Google Scholar, SciSearch, and the reference lists of included trials and previous reviews in August 2019. </p> </section> <section id="CD012484-sec-0004"> <h3 class="title" id="CD012484-sec-0004">Selection criteria</h3> <p>We included all randomised clinical trials assessing the effects of beta‐blockers versus placebo or no intervention in people with suspected or diagnosed acute myocardial infarction. Trials were included irrespective of trial design, setting, blinding, publication status, publication year, language, and reporting of our outcomes. </p> </section> <section id="CD012484-sec-0005"> <h3 class="title" id="CD012484-sec-0005">Data collection and analysis</h3> <p>We followed the Cochrane methodological recommendations. Four review authors independently extracted data. Our primary outcomes were all‐cause mortality, serious adverse events according to the International Conference on Harmonization ‐ Good Clinical Practice (ICH‐GCP), and major adverse cardiovascular events (composite of cardiovascular mortality and non‐fatal myocardial infarction during follow‐up). Our secondary outcomes were quality of life, angina, cardiovascular mortality, and myocardial infarction during follow‐up. Our primary time point of interest was less than three months after randomisation. We also assessed the outcomes at maximum follow‐up beyond three months. Due to risk of multiplicity, we calculated a 97.5% confidence interval (CI) for the primary outcomes and a 98% CI for the secondary outcomes. We assessed the risks of systematic errors through seven bias domains in accordance to the instructions given in the <i>Cochrane Handbook</i>. The quality of the body of evidence was assessed by GRADE. </p> </section> <section id="CD012484-sec-0006"> <h3 class="title" id="CD012484-sec-0006">Main results</h3> <p>We included 63 trials randomising a total of 85,550 participants (mean age 57.4 years). Only one trial was at low risk of bias. The remaining trials were at high risk of bias. The quality of the evidence according to GRADE ranged from very low to high. Fifty‐six trials commenced beta‐blockers during the acute phase of acute myocardial infarction and seven trials during the subacute phase. </p> <p>At our primary time point 'less than three months follow‐up', meta‐analysis showed that beta‐blockers versus placebo or no intervention probably reduce the risk of a reinfarction during follow‐up (risk ratio (RR) 0.82, 98% confidence interval (CI) 0.73 to 0.91; 67,562 participants; 18 trials; moderate‐quality evidence) with an absolute risk reduction of 0.5% and a number needed to treat for an additional beneficial outcome (NNTB) of 196 participants. However, we found little or no effect of beta‐blockers when assessing all‐cause mortality (RR 0.94, 97.5% CI 0.90 to 1.00; 80,452 participants; 46 trials/47 comparisons; high‐quality evidence) with an absolute risk reduction of 0.4% and cardiovascular mortality (RR 0.99, 95% CI 0.91 to 1.08; 45,852 participants; 1 trial; moderate‐quality evidence) with an absolute risk reduction of 0.4%. Regarding angina, it is uncertain whether beta‐blockers have a beneficial or harmful effect (RR 0.70, 98% CI 0.25 to 1.84; 98 participants; 3 trials; very low‐quality evidence) with an absolute risk reduction of 7.1%. None of the trials specifically assessed nor reported serious adverse events according to ICH‐GCP. Only two trials specifically assessed major adverse cardiovascular events, however, no major adverse cardiovascular events occurred in either trial. </p> <p>At maximum follow‐up beyond three months, meta‐analyses showed that beta‐blockers versus placebo or no intervention probably reduce the risk of all‐cause mortality (RR 0.93, 97.5% CI 0.86 to 0.99; 25,210 participants; 21 trials/22 comparisons; moderate‐quality evidence) with an absolute risk reduction of 1.1% and a NNTB of 91 participants, and cardiovascular mortality (RR 0.90, 98% CI 0.83 to 0.98; 22,457 participants; 14 trials/15 comparisons; moderate‐quality evidence) with an absolute risk reduction of 1.2% and a NNTB of 83 participants. However, it is uncertain whether beta‐blockers have a beneficial or harmful effect when assessing major adverse cardiovascular events (RR 0.81, 97.5% CI 0.40 to 1.66; 475 participants; 4 trials; very low‐quality evidence) with an absolute risk reduction of 1.7%; reinfarction (RR 0.89, 98% CI 0.75 to 1.08; 6825 participants; 14 trials; low‐quality evidence) with an absolute risk reduction of 0.9%; and angina (RR 0.64, 98% CI 0.18 to 2.0; 844 participants; 2 trials; very low‐quality evidence). None of the trials specifically assessed nor reported serious adverse events according to ICH‐GCP. </p> <p>None of the trials assessed quality of life.</p> <p>We identified two ongoing randomised clinical trials investigating the effect of early administration of beta‐blockers after percutaneous coronary intervention or thrombolysis to patients with an acute myocardial infarction and one ongoing trial investigating the effect of long‐term beta‐blocker therapy. </p> </section> <section id="CD012484-sec-0007"> <h3 class="title" id="CD012484-sec-0007">Authors' conclusions</h3> <p>Our present review indicates that beta‐blockers for suspected or diagnosed acute myocardial infarction probably reduce the short‐term risk of a reinfarction and the long‐term risk of all‐cause mortality and cardiovascular mortality. Nevertheless, it is most likely that beta‐blockers have little or no effect on the short‐term risk of all‐cause mortality and cardiovascular mortality. Regarding all remaining outcomes (serious adverse events according to ICH‐GCP, major adverse cardiovascular events (composite of cardiovascular mortality and non‐fatal myocardial infarction during follow‐up), the long‐term risk of a reinfarction during follow‐up, quality of life, and angina), further information is needed to confirm or reject the clinical effects of beta‐blockers on these outcomes for people with or suspected of acute myocardial infarction. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD012484-abs-0005" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012484-abs-0005">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012484-abs-0010">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012484-abs-0014">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD012484-abs-0008">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD012484-abs-0012">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ms#CD012484-abs-0015">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD012484-abs-0009">Polski</a> </li> <li class="section-language"> <a class="" href="full/ru#CD012484-abs-0007">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012484-abs-0006">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD012484-abs-0011">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD012484-abs-0005" lang="en"> <h3>Beta‐blockers versus placebo or no intervention for patients with suspected or diagnosed myocardial infarction </h3> <p><b>Background</b> </p> <p>According to the World Health Organization, 7.4 million people died from ischaemic heart disease in 2012, representing 15% of all global deaths. The role of acute or subacute treatment with beta‐blockers in people suspected of or diagnosed with a heart attack, rests on their inhibition of so‐called beta‐receptors. This may result in a reduction in the oxygen demand of the heart. Hence, the inhibition of the beta‐receptor may or may not decrease the complications associated with heart attack. </p> <p><b>Review question</b> </p> <p>The aim of this Cochrane Systematic Review was to assess the benefits and harms of beta‐blockers in people with suspected or diagnosed acute myocardial infarction (heart attack). </p> <p><b>Search date</b> </p> <p>We searched scientific databases from their inception to June 2019.</p> <p><b>Study characteristics</b> </p> <p>We found 63 randomised clinical trials where people with or suspected of a heart attack were randomly allocated to receiving beta‐blockers compared with placebo or no intervention. The 63 trials included 85,550 adults with a mean age of 57.4 years. Only one trial was at low risk of bias. The remaining trials were at high risk of bias. The quality of the evidence according to GRADE ranged from very low to high. Fifty‐six trials commenced beta‐blockers versus control during the acute phase of acute myocardial infarction and seven trials during the subacute phase. </p> <p><b>Study funding sources</b> </p> <p>We found 33 trials that were fully or partly funded by the industry, 20 trials that did not report their funding source, and 10 trials that were funded by other sources than the industry. </p> <p><b>Key results and conclusion</b> </p> <p>Our present review shows that people receiving beta‐blockers compared with people receiving placebo or no intervention seem at lower risk of a new heart attack in the acute phase after a heart attack. People receiving beta‐blockers also seem at lower risk of dying from any cause and from any cardiac cause at long‐term follow‐up after a heart attack. Nevertheless, people receiving beta‐blockers do not seem to have a lower or a higher risk of dying from any cause or from any cardiac cause in the acute phase after a heart attack. The effects of beta‐blockers on all remaining outcomes (serious adverse events according to International Conference on Harmonization ‐ Good Clinical Practice, major adverse cardiovascular events (composite of dying from a cardiac cause and a new non‐fatal heart attack), new heart attack at long‐term follow‐up, quality of life, and angina) are uncertain due to none or sparse data. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD012484-sec-0126" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD012484-sec-0126"></div> <h3 class="title" id="CD012484-sec-0127">Implications for practice</h3> <section id="CD012484-sec-0127"> <p>Our present review indicates with a moderate‐quality of evidence that beta‐blockers for suspected or diagnosed acute myocardial infarction probably reduce the short‐term risk of myocardial infarction during follow up and the long‐term risk of all‐cause mortality and cardiovascular mortality. Nevertheless, it is most likely that beta‐blockers have little or no effect on the short‐term risk of all‐cause mortality and cardiovascular mortality. Regarding all remaining outcomes (serious adverse events according to International Conference on Harmonization ‐ Good Clinical Practice Guidelines (ICH‐GCP), major adverse cardiovascular events (composite of cardiovascular mortality and non‐fatal myocardial infarction during follow‐up), the long‐term risk of myocardial infarction during follow‐up, quality of life, and angina) further information is needed to confirm or reject the clinical effects of beta‐blockers on these outcomes for people with, or suspected of, acute myocardial infarction. </p> </section> <h3 class="title" id="CD012484-sec-0128">Implications for research</h3> <section id="CD012484-sec-0128"> <p>Future trials assessing the effects of beta‐blockers in people with suspected or diagnosed acute myocardial infarction on the risk of all‐cause mortality, cardiovascular mortality, and short‐term risk of myocardial infarction during follow‐up do not seem necessary. However, future trials should assess the effects of beta‐blockers on serious adverse events according to ICH‐GCP, major adverse cardiovascular mortality, long‐term risk of myocardial infarction, quality of life, and angina. Such trials should be conducted with low risk of systematic error and low risk of random errors, and designed and reported according to SPIRIT and CONSORT statements (<a href="./references#CD012484-bbs2-0099" title="ChanA‐W , TetzlaffJM , AltmanDG , LaupacisA , GøtzschePC , Krleža‐JerićK , et al. SPIRIT 2013 Statement: defining standard protocol items for clinical trials. Annals of Internal Medicine2013;158(3):200‐7. ">Chan 2013</a>; <a href="./references#CD012484-bbs2-0168" title="SchulzKF , AltmanDG , MoherD , CONSORT Group. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. Annals of Internal Medicine2010;152(11):726‐32. ">Schulz 2010</a>). </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD012484-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD012484-sec-0029"></div> <div class="table" id="CD012484-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Beta‐blockers versus placebo or no intervention for suspected or diagnosed acute myocardial infarction at the time point less than three months follow‐up</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Beta‐blockers versus placebo or no intervention for patients with suspected or diagnosed myocardial infarction at the time point less than three months follow‐up</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with suspected or diagnosed myocardial infarction </p> <p><b>Settings:</b> any setting </p> <p><b>Intervention:</b> any beta‐blocker </p> <p><b>Comparison:</b> placebo or no intervention </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks*</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect</b> </p> <p><b>(adjusted CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk with placebo or no intervention</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk with beta‐blockers</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause mortality at 'less than 3 months' follow‐up.</b> </p> <p><b>Follow‐up: mean 21.8 days (range 1 hour to 90 days).</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>70 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>67 per 1000</b><br/> (63 to 70) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.94</b>, 97.5% CI (0.90 to 1.0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80,452 (46 RCTs with 47 comparisons)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<sup>1</sup><br/> <b>High</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Since the sensitivity analysis excluding trials at high risk of bias and the overall meta‐analysis showed similar results, we based our summary of findings and conclusion on the overall meta‐analysis. </p> <p>No events occurred in either group in three trials (<a href="./references#CD012484-bbs2-0024" title="HanadaK , HigumaT , NishizakiF , SukekawaT , YokotaT , YamadaM , et al. Randomized study on the efficacy and safety of landiolol, an ultra‐short‐acting beta1‐adrenergic blocker, in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. Circulation Journal2012;76(2):439‐45. ">Hanada 2012</a>; <a href="./references#CD012484-bbs2-0041" title="NorrisRM , ClarkeED , SammelNL , SmithWM , WilliamsB . Protective effect of propranolol in threatened myocardial infarction. Lancet1978;2(8096):907‐9. ">Norris 1978</a>; <a href="./references#CD012484-bbs2-0053" title="ShirotaniM , YokotaR , KouchiI , HiraiT , UemoriN , HabaK , et al. Influence of atenolol on coronary artery spasm after acute myocardial infarction in a Japanese population. International Journal of Cardiology2010;139(2):181‐6. ">Shirotani 2010</a>). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events at 'less than 3 months' follow‐up.</b> </p> <p><b>No data was reported in the included trials.</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the trials specifically assessed nor reported serious adverse events according to ICH‐GCP. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MACE (major adverse cardiovascular event) at 'less than 3 months' follow‐up.</b> </p> <p><b>No data were reported in the included trials.</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Only two trials specifically assessed major adverse cardiovascular events (defined as a composite of cardiovascular mortality and myocardial infarction during follow‐up). However, no major adverse cardiovascular events occurred in either trial. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Quality of life at 'less than 3 months' follow‐up.</b> </p> <p><b>No data were reported in the included trials.</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Angina at 'less than 3 months' follow‐up.</b> </p> <p><b>Follow‐up: mean 21 days (range 12 to 30 days).</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>222 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>155 per 1000</b> (69 to 351) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.70</b>, 98% CI (0.25 to 1.84) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>98 (3 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<sup>2,3</sup> </p> <p><b>VERY LOW</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cardiovascular mortality at 'less than 3 months' follow‐up.</b> </p> <p><b>Follow‐up: mean 28 days.</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>43 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>42 per 1000</b><br/> (39 to 46) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.99</b>, 95% CI </p> <p>(0.91 to 1.08)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45,852 (1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<sup>4</sup> <br/> <b>Moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Since the sensitivity analysis excluding trials at high risk of bias differed from the overall meta‐analysis, we based our summary of findings and conclusion on the sensitivity analysis. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Myocardial infarction at 'less than 3 months' follow‐up.</b> </p> <p><b>Follow‐up: mean 23.3 days (range 3 to 90 days).</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>28 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>23 per 1000</b><br/> (21 to 25) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.82</b>, 98% CI </p> <p>(0.74 to 0.90)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67,562 (18 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<sup>5</sup><br/> <b>MODERATE</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Since the sensitivity analysis excluding trials at high risk of bias and the overall meta‐analysis showed similar results, we based our summary of findings and conclusion on the overall meta‐analysis. </p> <p>No events occurred in either group in two trials (<a href="./references#CD012484-bbs2-0024" title="HanadaK , HigumaT , NishizakiF , SukekawaT , YokotaT , YamadaM , et al. Randomized study on the efficacy and safety of landiolol, an ultra‐short‐acting beta1‐adrenergic blocker, in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. Circulation Journal2012;76(2):439‐45. ">Hanada 2012</a>; <a href="./references#CD012484-bbs2-0053" title="ShirotaniM , YokotaR , KouchiI , HiraiT , UemoriN , HabaK , et al. Influence of atenolol on coronary artery spasm after acute myocardial infarction in a Japanese population. International Journal of Cardiology2010;139(2):181‐6. ">Shirotani 2010</a>). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its adjusted confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its adjusted CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk Ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> When assessing the risk of bias, the trial contributing most weight (<a href="./references#CD012484-bbs2-0016" title="COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo‐controlled trial. Lancet2005;366(9497):1622‐32. Second Chinese Cardiac Study (CCS‐2) Collaborative Group. Rationale, design and organization of the Second Chinese Cardiac Study (CCS‐2): a randomized trial of clopidogrel plus aspirin, and of metoprolol, among patients with suspected acute myocardial infarction. Journal of Cardiovascular Risk2000;7(6):435‐41. ">COMMIT 2005</a>, 63.4%) was assessed as at low risk of bias in all domains. The trial contributing the second highest weight (<a href="./references#CD012484-bbs2-0027" title="ISIS‐1 (first International Study of Infarct Survival) collaborative group. Mechanisms for the early mortality reduction produced by beta‐blockade started early in acute myocardial infarction: ISIS‐1. Lancet1988;1(8591):921‐3. ISIS‐1 (first International Study of Infarct Survival) collaborative group. Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS‐1. Lancet1986;2(8498):57‐66. ">ISIS‐1 1986</a>, 17.4%) was assessed as low risk of bias in random sequence generation, allocation concealment, and incomplete outcome data;'unclear for blinding of outcome assessors and selective reporting and at high risk for blinding of participants and personnel. Since a lack of blinding is less important for the assessment of all‐cause mortality, the overall limitations were not serious and the evidence is not downgraded for risk of bias. </p> <p><sup>2</sup> Downgraded by one level due to serious risk of bias. All the included trials were at high risk of bias due to either unclear or high risk in several bias domains. </p> <p><sup>3</sup> Downgraded by two levels due to very serious risk of imprecision based on the optimal information size not being reached, the very small sample size, and the absolute and relative 98% CI being very wide showing both appreciable benefit and harm. </p> <p><sup>4</sup> Downgraded by one level due to serious risk of imprecision based on the wide absolute and relative 98% where the upper CI does not exclude the possibility of no difference between the groups. When assessing the risk of bias, the evidence was not downgraded since the result was based on the sensitivity analysis consisting of trials at low risk of bias (<a href="./references#CD012484-bbs2-0016" title="COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo‐controlled trial. Lancet2005;366(9497):1622‐32. Second Chinese Cardiac Study (CCS‐2) Collaborative Group. Rationale, design and organization of the Second Chinese Cardiac Study (CCS‐2): a randomized trial of clopidogrel plus aspirin, and of metoprolol, among patients with suspected acute myocardial infarction. Journal of Cardiovascular Risk2000;7(6):435‐41. ">COMMIT 2005</a>). </p> <p><sup>5</sup> Downgraded by one level due to serious risk of bias. The overall limitations and specially in regard to blinding of outcome assessors were serious (around 50% of the trials were assessed at unclear risk of bias in blinding of outcome assessors). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012484-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Beta‐blockers versus placebo or no intervention for suspected or diagnosed acute myocardial infarction at maximum follow‐up beyond three months</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Beta‐blockers compared with placebo or no intervention for patients with suspected or diagnosed myocardial infarction</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with suspected or diagnosed myocardial infarction </p> <p><b>Settings:</b> any setting </p> <p><b>Intervention:</b> beta‐blockers </p> <p><b>Comparison:</b> placebo or no intervention </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks*</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (adjusted CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk with placebo or no intervention</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk with beta‐blockers</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause mortality at maximum follow‐up beyond 3 months.</b> </p> <p><b>Follow‐up: mean 16.4 months (range 6 to 60 months).</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>148 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>138 per 1000</b><br/> (127 to 147) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.93</b>, 97.5% CI (0.86 to 0.99) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25,210 (21 RCTs with 22 comparisons)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<sup>3</sup><br/> <b>Moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No events occurred in either group in one trial (<a href="./references#CD012484-bbs2-0024" title="HanadaK , HigumaT , NishizakiF , SukekawaT , YokotaT , YamadaM , et al. Randomized study on the efficacy and safety of landiolol, an ultra‐short‐acting beta1‐adrenergic blocker, in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. Circulation Journal2012;76(2):439‐45. ">Hanada 2012</a>). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events at maximum follow‐up beyond 3 months.</b> </p> <p><b>No data were reported in the included trials.</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the trials specifically assessed nor reported serious adverse events according to ICH‐GCP. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MACE (major adverse cardiovascular event) at maximum follow‐up beyond 3 months.</b> </p> <p><b>Follow‐up: mean7.5 months (range 6 to 12 months).</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>84 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>68 per 1000</b><br/> (36 to 128) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.81,</b> 97.5% CI (0.43 to 1.52) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>475 (4 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<sup>1, 2</sup><br/> <b>VERY LOW</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life at maximum follow‐up beyond 3 months.</b> </p> <p><b>No data were reported in the included trials.</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Angina at maximum follow‐up beyond 3 months (mean = 6 months).</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>24 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>15 per 1000</b> </p> <p>(5 to 48)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.64</b>, 98% CI 0.18 to 2.0 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>844 ( 2 RTCs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<sup>1,5</sup><br/> <b>VERY LOW</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cardiovascular mortality at maximum follow‐up beyond 3 months.</b> </p> <p><b>Follow‐up: mean 12.9 months (range 6 to 24 months).</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>124 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>112 per 1000</b><br/> (103 to 122) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.90,</b> 98% CI </p> <p>(0.83 to 0.98)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22,457 (14 RCTs with 15 comparisons)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<sup>1</sup><br/> <b>MODERATE</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No events occurred in either group in one trial (<a href="./references#CD012484-bbs2-0024" title="HanadaK , HigumaT , NishizakiF , SukekawaT , YokotaT , YamadaM , et al. Randomized study on the efficacy and safety of landiolol, an ultra‐short‐acting beta1‐adrenergic blocker, in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. Circulation Journal2012;76(2):439‐45. ">Hanada 2012</a>). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Myocardial infarction at maximum follow‐up beyond 3 months.</b> </p> <p><b>Follow‐up: mean 15.5 months (range 6 to 60 months).</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>92 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>83 per 1000</b><br/> (69 to 99) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.89</b>, 98% CI </p> <p>(0.75 to 1.08)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6825 (14 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<sup>1, 6</sup> </p> <p><b>Low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk Ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded by one level due to serious risk of bias. All the included trials were at high risk of bias due to either unclear or high risk in several bias domains. </p> <p><sup>2</sup> Downgraded by two levels due to very serious risk of imprecision based on the optimal information size not being reached, the wide absolute and relative 97.5% CI showing both appreciable benefit and harm, and a small sample size. </p> <p><sup>3</sup> Downgraded by one level due to serious risk of bias. All but one of the included trials were at high risk of bias due to either unclear or high risk in several bias domains and the sensitivity analysis excluding trials at high risk of bias showed different results than the overall analysis including trials at high risk of bias. However, the sensitivity analysis was based on only one small trial, so we have used the main analysis for the 'Summary of findings' table. </p> <p><sup>5</sup> Downgraded by two levels due to very serious risk of imprecision based on the very small sample size included. </p> <p><sup>6</sup> Downgraded by one level due to serious risk of imprecision based on the wide absolute and relative 98% where the upper CI does not exclude the possibility of no difference between the groups. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD012484-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012484-sec-0030">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012484-sec-0152">Español</a> </li> </nav> </div> </div> <section class="background" lang="en"> <div class="section-header" id="CD012484-sec-0030"></div> <section id="CD012484-sec-0031"> <h3 class="title" id="CD012484-sec-0031">Description of the condition</h3> <p>Cardiovascular disease is the number one cause of death globally (<a href="./references#CD012484-bbs2-0104" title="CooperR , CutlerJ , Desvigne‐NickensP , FortmannSP , FriedmanL , HavlikR , et al. Trends and disparities in coronary heart disease, stroke, and other cardiovascular diseases in the United States: findings of the national conference on cardiovascular disease prevention. Circulation2000; Vol. 102, issue 25:3137‐47. [PUBMED: 11120707] ">Cooper 2000</a>; <a href="./references#CD012484-bbs2-0143" title="Lloyd‐JonesD , AdamsRJ , BrownTM , CarnethonM , DaiS , DeSimoneG , et al. Executive summary: heart disease and stroke statistics ‐ 2010 update: a report from the American Heart Association. Circulation2010;121(7):948‐54. [PUBMED: 20177011] ">Lloyd‐Jones 2010</a>; <a href="./references#CD012484-bbs2-0152" title="NicholsM , TownsendN , ScarboroughP , RaynerM . Cardiovascular disease in Europe 2014: epidemiological update. European Heart Journal2014;35(42):2950‐9. [PUBMED: 25139896] ">Nichols 2014</a>; <a href="./references#CD012484-bbs2-0160" title="RosamondW , FlegalK , FurieK , GoA , GreenlundK , HaaseN , et al. Heart disease and stroke statistics ‐ 2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation2008;117(4):e25‐146. [PUBMED: 18086926] ">Rosamond 2008</a>; <a href="./references#CD012484-bbs2-0166" title="SchmidtM , JacobsenJB , LashTL , BotkerHE , SorensenHT . 25 year trends in first time hospitalisation for acute myocardial infarction, subsequent short and long term mortality, and the prognostic impact of sex and comorbidity: a Danish nationwide cohort study. BMJ2012;344:e356. [PUBMED: 22279115] ">Schmidt 2012</a>). Ischaemic heart disease accounts for almost 50% of the disease burden of the cardiovascular diseases (<a href="./references#CD012484-bbs2-0152" title="NicholsM , TownsendN , ScarboroughP , RaynerM . Cardiovascular disease in Europe 2014: epidemiological update. European Heart Journal2014;35(42):2950‐9. [PUBMED: 25139896] ">Nichols 2014</a>). According to the World Health Organization (WHO), 7.4 million people died from ischaemic heart disease in 2012 (<a href="./references#CD012484-bbs2-0183" title="World Health Organization (WHO). Cardiovascular Disease. www.who.int/cardiovascular_diseases/en/ (accessed before 5 December 2016). ">WHO 2015</a>). </p> <p>Ischaemic heart disease is caused by different underlying mechanisms: (1) atherosclerotic plaque‐related obstruction of the coronary arteries; (2) focal or diffuse spasms of normal or plaque‐diseased arteries; (3) microvascular dysfunction; and (4) left ventricular dysfunction caused by acute myocardial necrosis or ischaemic cardiomyopathy (<a href="./references#CD012484-bbs2-0151" title="MontalescotG , SechtemU , AchenbachS , AndreottiF , ArdenC , BudajA . 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. European Heart Journal2013;34(38):2949‐3003. ">Montalescot 2013</a>). Ischaemic heart disease increases the risk of stable angina pectoris and acute coronary syndrome (see below). </p> <p>Acute coronary syndrome is a collective term for: (1) unstable angina pectoris (chest pain during rest related to ischaemia or hypoxia of the heart muscle (<a href="./references#CD012484-bbs2-0159" title="RoffiM , PatronoC , ColletJP , MuellerC , ValgimigliM , AndreottiF , et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST‐segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST‐Segment Elevation of the European Society of Cardiology (ESC). European Heart Journal2016;37(3):267‐315. ">Roffi 2016</a>)); (2) acute non‐ST‐elevation myocardial infarction (NSTEMI); or (3) acute ST‐elevation myocardial infarction (STEMI) (<a href="./references#CD012484-bbs2-0153" title="O'GaraPT , KushnerFG , AscheimDD , CaseyDEJr , ChungMK , deLemosJA , et al. i2013 ACCF/AHA guideline for the management of ST‐elevation myocardial Infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology2013;61(4):e78‐140. ">O'Gara 2013</a>; <a href="./references#CD012484-bbs2-0173" title="StegPG , JamesSK , AtarD , BadanoLP , Blomstrom‐LundqvistC , BorgerMA , et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST‐segment elevation. European Heart Journal2012;33(20):2569‐619. [PUBMED: 22922416] ">Steg 2012</a>). Myocardial infarction is caused by death of cardiac myocytes (myocardial necrosis) due to ischaemia (<a href="./references#CD012484-bbs2-0159" title="RoffiM , PatronoC , ColletJP , MuellerC , ValgimigliM , AndreottiF , et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST‐segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST‐Segment Elevation of the European Society of Cardiology (ESC). European Heart Journal2016;37(3):267‐315. ">Roffi 2016</a>; <a href="./references#CD012484-bbs2-0173" title="StegPG , JamesSK , AtarD , BadanoLP , Blomstrom‐LundqvistC , BorgerMA , et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST‐segment elevation. European Heart Journal2012;33(20):2569‐619. [PUBMED: 22922416] ">Steg 2012</a>). The clinical definition of myocardial infarction is elevated serum levels of cardiac biomarkers (cardiac specific troponins and CK‐MB among others) and changes of the ST‐segment on an electrocardiogram (ECG) (STEMI and NSTEMI) or symptoms of cardiac ischaemia (<a href="./references#CD012484-bbs2-0159" title="RoffiM , PatronoC , ColletJP , MuellerC , ValgimigliM , AndreottiF , et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST‐segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST‐Segment Elevation of the European Society of Cardiology (ESC). European Heart Journal2016;37(3):267‐315. ">Roffi 2016</a>; <a href="./references#CD012484-bbs2-0173" title="StegPG , JamesSK , AtarD , BadanoLP , Blomstrom‐LundqvistC , BorgerMA , et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST‐segment elevation. European Heart Journal2012;33(20):2569‐619. [PUBMED: 22922416] ">Steg 2012</a>). </p> <p>The diagnosis of myocardial infarction is dependent on an elevation of the serum levels of cardiac‐specific troponin I, troponin T, or the myocardial band (MB) isoenzyme of creatine kinase (CK‐MB), among others (<a href="./references#CD012484-bbs2-0159" title="RoffiM , PatronoC , ColletJP , MuellerC , ValgimigliM , AndreottiF , et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST‐segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST‐Segment Elevation of the European Society of Cardiology (ESC). European Heart Journal2016;37(3):267‐315. ">Roffi 2016</a>; <a href="./references#CD012484-bbs2-0173" title="StegPG , JamesSK , AtarD , BadanoLP , Blomstrom‐LundqvistC , BorgerMA , et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST‐segment elevation. European Heart Journal2012;33(20):2569‐619. [PUBMED: 22922416] ">Steg 2012</a>). However, it will often take eight to 24 hours after the first symptoms of the myocardial infarction occur before these enzymes are detectable in serum. Beta‐blockers may accordingly be commenced as an intervention in patients suspected of myocardial infarction or may be commenced as an intervention in patients diagnosed with myocardial infarction. </p> <p>The cause of myocardial infarction is generally divided in to five main classes (<a href="./references#CD012484-bbs2-0178" title="ThygesenK , AlpertJS , JaffeAS , SimoonsML , ChaitmanBR , WhiteHD . Third universal definition of myocardial infarction. Global Heart2012;7(4):275‐95. [PUBMED: 25689940] ">Thygesen 2012</a>). </p> <p> <ul id="CD012484-list-0001"> <li> <p>Type 1: spontaneous myocardial infarction related to atherosclerotic plaque rupture, ulceration, fissuring, erosion, or dissection with resulting intraluminal thrombus in one or more of the coronary arteries often caused by coronary artery disease. </p> </li> <li> <p>Type 2: myocardial infarction secondary to an ischaemic imbalance such as coronary artery spasm, coronary embolism, anaemia, arrhythmias, hypertension, or hypotension. </p> </li> <li> <p>Type 3: myocardial infarction with symptoms suggestive of myocardial ischaemia and resulting in sudden unexpected cardiac death when biomarker values are unavailable or could not be obtained before death. </p> </li> <li> <p>Type 4a: myocardial infarction associated with percutaneous coronary intervention (PCI). </p> </li> <li> <p>Type 4b: myocardial infarction associated with stent thrombosis as documented by angiography or at autopsy. </p> </li> <li> <p>Type 5: myocardial infarction associated with coronary artery bypass graft (CABG).</p> </li> </ul> </p> <section id="CD012484-sec-0032"> <h4 class="title">Major complications associated with myocardial infarction</h4> <p> <ul id="CD012484-list-0002"> <li> <p>Life‐threatening ventricular arrhythmias caused by changes in the electrophysiologic characteristics of the myocyte, electrolyte imbalance, continuous ischaemia, and variations in heart rate all due to obstruction and hence, reduced flow to the myocardium and myocardial necrosis (<a href="./references#CD012484-bbs2-0097" title="BriegerD , FoxKA , FitzgeraldG , EagleKA , BudajA , AvezumA , et al. Predicting freedom from clinical events in non‐ST‐elevation acute coronary syndromes: the Global Registry of Acute Coronary Events. Heart (British Cardiac Society)2009;95(11):888‐94. ">Brieger 2009</a>; <a href="./references#CD012484-bbs2-0175" title="StevensonWG , LinssenGC , HavenithMG , BrugadaP , WellensHJ . The spectrum of death after myocardial infarction: a necropsy study. American Heart Journal1989;118(6):1182‐8. ">Stevenson 1989</a>). </p> </li> <li> <p>Mechanical complications caused by necrosis of the myocardium such as ventricular wall rupture, septum rupture, and papillary muscle rupture (<a href="./references#CD012484-bbs2-0097" title="BriegerD , FoxKA , FitzgeraldG , EagleKA , BudajA , AvezumA , et al. Predicting freedom from clinical events in non‐ST‐elevation acute coronary syndromes: the Global Registry of Acute Coronary Events. Heart (British Cardiac Society)2009;95(11):888‐94. ">Brieger 2009</a>; <a href="./references#CD012484-bbs2-0156" title="Pohjola‐SintonenS , MullerJE , StonePH , WillichSN , AntmanEM , DavisVG , et al. Ventricular septal and free wall rupture complicating acute myocardial infarction: experience in the Multicenter Investigation of Limitation of Infarct Size. American Heart Journal1989;117(4):809‐18. ">Pohjola‐Sintonen 1989</a>; <a href="./references#CD012484-bbs2-0175" title="StevensonWG , LinssenGC , HavenithMG , BrugadaP , WellensHJ . The spectrum of death after myocardial infarction: a necropsy study. American Heart Journal1989;118(6):1182‐8. ">Stevenson 1989</a>). </p> </li> <li> <p>Cardiogenic shock caused by failure of the ventricle to pump adequate amount of blood leading to a systemic hypotension (<a href="./references#CD012484-bbs2-0097" title="BriegerD , FoxKA , FitzgeraldG , EagleKA , BudajA , AvezumA , et al. Predicting freedom from clinical events in non‐ST‐elevation acute coronary syndromes: the Global Registry of Acute Coronary Events. Heart (British Cardiac Society)2009;95(11):888‐94. ">Brieger 2009</a>; <a href="./references#CD012484-bbs2-0175" title="StevensonWG , LinssenGC , HavenithMG , BrugadaP , WellensHJ . The spectrum of death after myocardial infarction: a necropsy study. American Heart Journal1989;118(6):1182‐8. ">Stevenson 1989</a>). </p> </li> <li> <p>Acute decompensated heart failure caused by impairment in systolic and diastolic function due to myocardial ischaemia (<a href="./references#CD012484-bbs2-0097" title="BriegerD , FoxKA , FitzgeraldG , EagleKA , BudajA , AvezumA , et al. Predicting freedom from clinical events in non‐ST‐elevation acute coronary syndromes: the Global Registry of Acute Coronary Events. Heart (British Cardiac Society)2009;95(11):888‐94. ">Brieger 2009</a>). </p> </li> <li> <p>Depression (<a href="./references#CD012484-bbs2-0177" title="ThombsBD , BassEB , FordDE , StewartKJ , TsilidisKK , PatelU , et al. Prevalence of depression in survivors of acute myocardial infarction. Journal of General Internal Medicine2006;21(1):30‐8. ">Thombs 2006</a>). </p> </li> </ul> </p> </section> </section> <section id="CD012484-sec-0033"> <h3 class="title" id="CD012484-sec-0033">Description of the intervention</h3> <p>The discovery of the difference between adrenergic receptors by Raymond Ahlquist in 1948 led Sir James Black to develop the first clinically useful beta‐receptor blocker (propranolol) in 1964 (<a href="./references#CD012484-bbs2-0089" title="AhlquistRP . A study of the adrenotropic receptors. American Journal of Physiology1948;153(3):586‐600. [PUBMED: 18882199] ">Ahlquist 1948</a>; <a href="./references#CD012484-bbs2-0095" title="BlackJW , CrowtherAF , ShanksRG , SmithLH , DornhorstAC . A new adrenergic beta receptor antagonist. Lancet1964;1(7342):1080‐1. [PUBMED: 14132613] ">Black 1964</a>). This discovery was awarded the Nobel Prize in 1988 (<a href="./references#CD012484-bbs2-0157" title="QuirkeV . Putting theory into practice: James Black, receptor theory and the development of the beta‐blockers at ICI, 1958‐1978. Medical History2006;50(1):69‐92. ">Quirke 2006</a>). Beta‐blockers are classified as non‐selective beta‐blockers or selective beta‐blockers according to their selectivity for one of the three subtypes of beta‐receptors. </p> <p> <ul id="CD012484-list-0003"> <li> <p>The beta<sub>1</sub>‐receptor is mainly located in: (1) the heart, where it induces positive chronotropic effects (increases heart rate) and positive inotropic effects (increases contractility of the myocardium); and (2) in the kidneys where activation of the beta<sub>1</sub>‐receptor results in an increased release of renin which in turn increases blood pressure, among other effects (<a href="./references#CD012484-bbs2-0117" title="GolanDE , TashjianAH . Principles of Pharmacology ‐ The Pathophysiologic Basis of Drug Therapy. 3rd Edition. Philadelphia: Lippincott Williams and Wilkins, 2011. ">Golan 2011</a>; <a href="./references#CD012484-bbs2-0147" title="MarlinGE , KumanaCR , KayeCM , SmithDM , TurnerP . An investigation into the cardiac and pulmonary beta‐adrenoceptor blocking activity of ICI 66,082 in man. British Journal of Clinical Pharmacology1975;2(2):151‐7. [PUBMED: 1234497] ">Marlin 1975</a>; <a href="./references#CD012484-bbs2-0172" title="SinghBN , NisbetHE , HarrisEA , WhitlockRM . A comparison of the actions of ICI66082 and propranolol on cardiac and peripheral beta‐adrenoceptors. European Journal of Pharmacology1975;34(1):75‐86. [PUBMED: 11998] ">Singh 1975</a>). </p> </li> </ul> <ul id="CD012484-list-0004"> <li> <p>The beta<sub>2</sub>‐receptor is mainly located in smooth muscle cells where it promotes relaxation, in skeletal muscle cells where it promotes tremor and increased glycogenolysis, and in the liver, where it increases glycogenolysis (<a href="./references#CD012484-bbs2-0117" title="GolanDE , TashjianAH . Principles of Pharmacology ‐ The Pathophysiologic Basis of Drug Therapy. 3rd Edition. Philadelphia: Lippincott Williams and Wilkins, 2011. ">Golan 2011</a>). </p> </li> </ul> <ul id="CD012484-list-0005"> <li> <p>The beta<sub>3</sub>‐receptor is mainly located in adipose tissue where it primarily induces lipolysis (<a href="./references#CD012484-bbs2-0117" title="GolanDE , TashjianAH . Principles of Pharmacology ‐ The Pathophysiologic Basis of Drug Therapy. 3rd Edition. Philadelphia: Lippincott Williams and Wilkins, 2011. ">Golan 2011</a>). </p> </li> </ul> </p> <p>Beta‐blockers may be administered both intravenously and orally. Three different classes of beta‐blockers exist: (1) the first generation non‐selective beta‐blockers (e.g. propranolol, oxprenolol, sotalol, timolol) affecting all beta‐receptors; (2) the second generation selective beta<sub>1</sub>‐blockers (e.g. metoprolol, bisoprolol, acebutolol, atenolol, esmolol) mainly affecting the heart; and (3) the third generation beta‐blockers which have combined non‐selective beta‐blocking effects and alpha‐blocking effects (e.g. carvedilol) affecting all beta‐receptors plus alpha‐receptors in the vessels lowering the blood pressure. </p> <p>Several beta‐blockers have been used in the management of patients with myocardial infarction. The first beta‐blockers used were the non‐selective beta‐blockers (e.g. propranolol) (<a href="./references#CD012484-bbs2-0103" title="ClausenJ , FelsbyM , JorgensenFS , NielsenBL , RoinJ , StrangeB . Absence of prophylactic effect of propranolol in myocardial infarction. Lancet1966;2(7470):920‐4. [PUBMED: 4162366] ">Clausen 1966b</a>; <a href="./references#CD012484-bbs2-0115" title="FriedmanLM , ByingtonRP , CaponeRJ , FurbergCD , GoldsteinS , LichsteinE . Effect of propranolol in patients with myocardial infarction and ventricular arrhythmia. Journal of the American College of Cardiology1986;7(1):1‐8. [PUBMED: 3510232] ">Friedman 1986</a>). Today, the most frequently used beta‐blockers for managing myocardial infarction are the cardiac‐specific beta<sub>1</sub>‐blockers (<a href="./references#CD012484-bbs2-0102" title="ChenZM , PanHC , ChenYP , PetoR , CollinsR , JiangLX , et al. Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo‐controlled trial. Lancet2005;366(9497):1622‐32. [PUBMED: 16271643] ">Chen 2005</a>; <a href="./references#CD012484-bbs2-0159" title="RoffiM , PatronoC , ColletJP , MuellerC , ValgimigliM , AndreottiF , et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST‐segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST‐Segment Elevation of the European Society of Cardiology (ESC). European Heart Journal2016;37(3):267‐315. ">Roffi 2016</a>; <a href="./references#CD012484-bbs2-0173" title="StegPG , JamesSK , AtarD , BadanoLP , Blomstrom‐LundqvistC , BorgerMA , et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST‐segment elevation. European Heart Journal2012;33(20):2569‐619. [PUBMED: 22922416] ">Steg 2012</a>). </p> </section> <section id="CD012484-sec-0034"> <h3 class="title" id="CD012484-sec-0034">How the intervention might work</h3> <p>The beta‐receptor is an adrenergic heterodimeric G‐protein‐coupled receptor (G protein‐coupled receptors are transmembrane proteins that act as key gatekeepers between external signals and cellular responses), located throughout the body. Beta‐receptors are stimulated by the sympathetic nervous system with catecholamines epinephrine (adrenaline) and norepinephrine (noradrenaline) as their primary endogenous agonists. The role of acute treatment or subacute treatment with beta‐blockers in patients suspected of or diagnosed with myocardial infarction, rests on their inhibition of the chronotropic and inotropic effects of the beta‐receptor. This may result in a reduction in heart rate, heart contractility, and blood pressure, thereby decreasing the oxygen demand of the heart (<a href="./references#CD012484-bbs2-0144" title="Lopez‐SendonJ , SwedbergK , McMurrayJ , TamargoJ , MaggioniAP , DargieH , et al. Expert consensus document on beta‐adrenergic receptor blockers. European Heart Journal2004;25(15):1341‐62. [PUBMED: 15288162] ">Lopez‐Sendon 2004</a>). Hence, the inhibition of the beta‐receptor is thought to decrease ischaemia and might decrease the risk of life‐threatening ventricular arrhythmias and other complications associated with myocardial infarction (<a href="./references#CD012484-bbs2-0159" title="RoffiM , PatronoC , ColletJP , MuellerC , ValgimigliM , AndreottiF , et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST‐segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST‐Segment Elevation of the European Society of Cardiology (ESC). European Heart Journal2016;37(3):267‐315. ">Roffi 2016</a>; <a href="./references#CD012484-bbs2-0173" title="StegPG , JamesSK , AtarD , BadanoLP , Blomstrom‐LundqvistC , BorgerMA , et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST‐segment elevation. European Heart Journal2012;33(20):2569‐619. [PUBMED: 22922416] ">Steg 2012</a>). </p> </section> <section id="CD012484-sec-0035"> <h3 class="title" id="CD012484-sec-0035">Why it is important to do this review</h3> <p>The prevalence of ischaemic heart disease is considerable. According to the WHO, 7.4 million people died from ischaemic heart disease in 2012 (<a href="./references#CD012484-bbs2-0143" title="Lloyd‐JonesD , AdamsRJ , BrownTM , CarnethonM , DaiS , DeSimoneG , et al. Executive summary: heart disease and stroke statistics ‐ 2010 update: a report from the American Heart Association. Circulation2010;121(7):948‐54. [PUBMED: 20177011] ">Lloyd‐Jones 2010</a>; <a href="./references#CD012484-bbs2-0152" title="NicholsM , TownsendN , ScarboroughP , RaynerM . Cardiovascular disease in Europe 2014: epidemiological update. European Heart Journal2014;35(42):2950‐9. [PUBMED: 25139896] ">Nichols 2014</a>; <a href="./references#CD012484-bbs2-0160" title="RosamondW , FlegalK , FurieK , GoA , GreenlundK , HaaseN , et al. Heart disease and stroke statistics ‐ 2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation2008;117(4):e25‐146. [PUBMED: 18086926] ">Rosamond 2008</a>; <a href="./references#CD012484-bbs2-0183" title="World Health Organization (WHO). Cardiovascular Disease. www.who.int/cardiovascular_diseases/en/ (accessed before 5 December 2016). ">WHO 2015</a>). A considerable reduction in disease burden and healthcare cost may therefore be alleviated by effective treatment. However, as demonstrated below, previous meta‐analyses and guidelines show contrasting findings and recommendations. </p> <section id="CD012484-sec-0036"> <h4 class="title">Evidence on the effects of beta‐blockers for suspected or diagnosed acute myocardial infarction </h4> <section id="CD012484-sec-0037"> <h5 class="title">Outcomes assessed at hospital discharge</h5> <p>Five studies have compared the effects of beta‐blockers versus placebo, standard medical therapy, or late administration of beta‐blockers in participants with suspected or diagnosed myocardial infarction on outcomes reported at hospital discharge (<a href="./references#CD012484-bbs2-0090" title="Al‐ReesiA , Al‐ZadjaliN , PerryJ , FergussonD , Al‐ShamsiM , Al‐ThagafiM , et al. Do beta‐blockers reduce short‐term mortality following acute myocardial infarction? A systematic review and meta‐analysis. Canadian Journal of Emergency Medicine2008;10(3):215‐23. [PUBMED: 19019272] ">Al‐Reesi 2008</a>; <a href="./references#CD012484-bbs2-0096" title="BrandlerE , PaladinoL , SinertR . Does the early administration of beta‐blockers improve the in‐hospital mortality rate of patients admitted with acute coronary syndrome?. Academic Emergency Medicine2010;17(1):1‐10. [PUBMED: 20078433] ">Brandler 2010</a>; <a href="./references#CD012484-bbs2-0100" title="ChatterjeeS , ChaudhuriD , VedanthanR , FusterV , IbanezB , BangaloreS , et al. Early intravenous beta‐blockers in patients with acute coronary syndrome ‐ a meta‐analysis of randomized trials. International Journal of Cardiology2013;168(2):915‐21. [PUBMED: 23168009] ">Chatterjee 2013</a>; <a href="./references#CD012484-bbs2-0114" title="FreemantleN , ClelandJ , YoungP , MasonJ , HarrisonJ . Beta blockade after myocardial infarction: systematic review and meta regression analysis. BMJ1999;318(7200):1730‐7. [PUBMED: 10381708] ">Freemantle 1999</a>; <a href="./references#CD012484-bbs2-0187" title="YusufS , PetoR , LewisJ , CollinsR , SleightP . Beta blockade during and after myocardial infarction: an overview of the randomized trials. Progress in Cardiovascular Diseases1985;27(5):335‐71. [PUBMED: 2858114] ">Yusuf 1985</a>). While <a href="./references#CD012484-bbs2-0100" title="ChatterjeeS , ChaudhuriD , VedanthanR , FusterV , IbanezB , BangaloreS , et al. Early intravenous beta‐blockers in patients with acute coronary syndrome ‐ a meta‐analysis of randomized trials. International Journal of Cardiology2013;168(2):915‐21. [PUBMED: 23168009] ">Chatterjee 2013</a> only assessed intravenously assessed beta‐blockers and showed a beneficial effect of early beta‐blockers on mortality, <a href="./references#CD012484-bbs2-0090" title="Al‐ReesiA , Al‐ZadjaliN , PerryJ , FergussonD , Al‐ShamsiM , Al‐ThagafiM , et al. Do beta‐blockers reduce short‐term mortality following acute myocardial infarction? A systematic review and meta‐analysis. Canadian Journal of Emergency Medicine2008;10(3):215‐23. [PUBMED: 19019272] ">Al‐Reesi 2008</a>, <a href="./references#CD012484-bbs2-0096" title="BrandlerE , PaladinoL , SinertR . Does the early administration of beta‐blockers improve the in‐hospital mortality rate of patients admitted with acute coronary syndrome?. Academic Emergency Medicine2010;17(1):1‐10. [PUBMED: 20078433] ">Brandler 2010</a>, and <a href="./references#CD012484-bbs2-0114" title="FreemantleN , ClelandJ , YoungP , MasonJ , HarrisonJ . Beta blockade after myocardial infarction: systematic review and meta regression analysis. BMJ1999;318(7200):1730‐7. [PUBMED: 10381708] ">Freemantle 1999</a> assessed any type of beta‐blockers and could not demonstrate a beneficial effect of beta‐blockers on mortality. <a href="./references#CD012484-bbs2-0187" title="YusufS , PetoR , LewisJ , CollinsR , SleightP . Beta blockade during and after myocardial infarction: an overview of the randomized trials. Progress in Cardiovascular Diseases1985;27(5):335‐71. [PUBMED: 2858114] ">Yusuf 1985</a> assessed the effects of beta‐blockers on the size of myocardial infarction and showed a beneficial effect when compared with no beta‐blockers. One of the meta‐analyses showed a beneficial effect of beta‐blockers on the risk of myocardial reinfarction and ventricular arrhythmia, while no beneficial or harmful effects were found on cardiogenic shock (<a href="./references#CD012484-bbs2-0100" title="ChatterjeeS , ChaudhuriD , VedanthanR , FusterV , IbanezB , BangaloreS , et al. Early intravenous beta‐blockers in patients with acute coronary syndrome ‐ a meta‐analysis of randomized trials. International Journal of Cardiology2013;168(2):915‐21. [PUBMED: 23168009] ">Chatterjee 2013</a>). <a href="./references#CD012484-bbs2-0090" title="Al‐ReesiA , Al‐ZadjaliN , PerryJ , FergussonD , Al‐ShamsiM , Al‐ThagafiM , et al. Do beta‐blockers reduce short‐term mortality following acute myocardial infarction? A systematic review and meta‐analysis. Canadian Journal of Emergency Medicine2008;10(3):215‐23. [PUBMED: 19019272] ">Al‐Reesi 2008</a>, <a href="./references#CD012484-bbs2-0096" title="BrandlerE , PaladinoL , SinertR . Does the early administration of beta‐blockers improve the in‐hospital mortality rate of patients admitted with acute coronary syndrome?. Academic Emergency Medicine2010;17(1):1‐10. [PUBMED: 20078433] ">Brandler 2010</a>, and <a href="./references#CD012484-bbs2-0114" title="FreemantleN , ClelandJ , YoungP , MasonJ , HarrisonJ . Beta blockade after myocardial infarction: systematic review and meta regression analysis. BMJ1999;318(7200):1730‐7. [PUBMED: 10381708] ">Freemantle 1999</a> did not assess the effects of beta‐blockers on the risk of myocardial reinfarction, ventricular arrhythmias, or cardiogenic shock. </p> </section> <section id="CD012484-sec-0038"> <h5 class="title">Long‐term outcomes</h5> <p>Three studies compared the effects of beta‐blockers versus no beta‐blockers in participants with suspected or diagnosed myocardial infarction on long‐term outcomes (<a href="./references#CD012484-bbs2-0094" title="BangaloreS , MakaniH , RadfordM , ThakurK , TokluB , KatzSD , et al. Clinical outcomes with beta‐blockers for myocardial infarction: a meta‐analysis of randomized trials. American Journal of Medicine2014;127(10):939‐53. [PUBMED: 24927909] ">Bangalore 2014</a>; <a href="./references#CD012484-bbs2-0114" title="FreemantleN , ClelandJ , YoungP , MasonJ , HarrisonJ . Beta blockade after myocardial infarction: systematic review and meta regression analysis. BMJ1999;318(7200):1730‐7. [PUBMED: 10381708] ">Freemantle 1999</a>; <a href="./references#CD012484-bbs2-0187" title="YusufS , PetoR , LewisJ , CollinsR , SleightP . Beta blockade during and after myocardial infarction: an overview of the randomized trials. Progress in Cardiovascular Diseases1985;27(5):335‐71. [PUBMED: 2858114] ">Yusuf 1985</a>). While <a href="./references#CD012484-bbs2-0114" title="FreemantleN , ClelandJ , YoungP , MasonJ , HarrisonJ . Beta blockade after myocardial infarction: systematic review and meta regression analysis. BMJ1999;318(7200):1730‐7. [PUBMED: 10381708] ">Freemantle 1999</a> and <a href="./references#CD012484-bbs2-0187" title="YusufS , PetoR , LewisJ , CollinsR , SleightP . Beta blockade during and after myocardial infarction: an overview of the randomized trials. Progress in Cardiovascular Diseases1985;27(5):335‐71. [PUBMED: 2858114] ">Yusuf 1985</a> showed a beneficial effect of beta‐blockers on mortality, <a href="./references#CD012484-bbs2-0094" title="BangaloreS , MakaniH , RadfordM , ThakurK , TokluB , KatzSD , et al. Clinical outcomes with beta‐blockers for myocardial infarction: a meta‐analysis of randomized trials. American Journal of Medicine2014;127(10):939‐53. [PUBMED: 24927909] ">Bangalore 2014</a> only found a beneficial effect on mortality in trials where the participants did not receive reperfusion in the form of revascularisation (percutaneous coronary intervention or coronary artery bypass graft) or thrombolytics (e.g. streptokinase). <a href="./references#CD012484-bbs2-0094" title="BangaloreS , MakaniH , RadfordM , ThakurK , TokluB , KatzSD , et al. Clinical outcomes with beta‐blockers for myocardial infarction: a meta‐analysis of randomized trials. American Journal of Medicine2014;127(10):939‐53. [PUBMED: 24927909] ">Bangalore 2014</a> found a beneficial effect of beta‐blockers on symptoms of angina and risk of recurrent myocardial infarction regardless of whether the participants received intervention for reperfusion (revascularisation or thrombolytics) or not. However, <a href="./references#CD012484-bbs2-0094" title="BangaloreS , MakaniH , RadfordM , ThakurK , TokluB , KatzSD , et al. Clinical outcomes with beta‐blockers for myocardial infarction: a meta‐analysis of randomized trials. American Journal of Medicine2014;127(10):939‐53. [PUBMED: 24927909] ">Bangalore 2014</a> also showed that beta‐blockers seem to increase the severity of heart failure in participants receiving intervention for reperfusion (revascularisation or thrombolytics). It must be noted that <a href="./references#CD012484-bbs2-0094" title="BangaloreS , MakaniH , RadfordM , ThakurK , TokluB , KatzSD , et al. Clinical outcomes with beta‐blockers for myocardial infarction: a meta‐analysis of randomized trials. American Journal of Medicine2014;127(10):939‐53. [PUBMED: 24927909] ">Bangalore 2014</a> included a larger number of trials than <a href="./references#CD012484-bbs2-0114" title="FreemantleN , ClelandJ , YoungP , MasonJ , HarrisonJ . Beta blockade after myocardial infarction: systematic review and meta regression analysis. BMJ1999;318(7200):1730‐7. [PUBMED: 10381708] ">Freemantle 1999</a> and <a href="./references#CD012484-bbs2-0187" title="YusufS , PetoR , LewisJ , CollinsR , SleightP . Beta blockade during and after myocardial infarction: an overview of the randomized trials. Progress in Cardiovascular Diseases1985;27(5):335‐71. [PUBMED: 2858114] ">Yusuf 1985</a>, and only <a href="./references#CD012484-bbs2-0094" title="BangaloreS , MakaniH , RadfordM , ThakurK , TokluB , KatzSD , et al. Clinical outcomes with beta‐blockers for myocardial infarction: a meta‐analysis of randomized trials. American Journal of Medicine2014;127(10):939‐53. [PUBMED: 24927909] ">Bangalore 2014</a> included trials after the introduction of reperfusion strategies around 1990s. </p> <p>No newer studies assessing beta‐blocker treatment for patients with suspected or diagnosed myocardial infarction consisting of randomised clinical trials including different types of beta‐blocker interventions and types of myocardial infarctions have been conducted since 2014. <a href="./references#CD012484-bbs2-0128" title="HoedemakerNP , RoolvinkV , deWinterRJ , vanRoyenN , FusterV , Garcia‐RuizJM , et al. Early intravenous beta‐blockers in patients undergoing primary percutaneous coronary intervention for ST‐segment elevation myocardial infarction: A patient‐pooled meta‐analysis of randomized clinical trials. European Heart Journal. Acute Cardiovascular Care2019;Epub ahead of print:2048872619830609. [PUBMED: 30759994] ">Hoedemaker 2019</a> and <a href="./references#CD012484-bbs2-0113" title="ElgendyIY , ElgendyAY , MahmoudAN , MansoorH , MojadidiMK , BavryAA . Intravenous beta‐blockers for patients undergoing primary percutaneous coronary intervention: A meta‐analysis of randomized trials. International Journal of Cardiology2016;223:891‐7. [PUBMED: 27584567] ">Elgendy 2016</a> each included four randomised clinical trials assessing only intravenously‐assessed beta‐blocker treatment in STEMI patients. Two other studies, <a href="./references#CD012484-bbs2-0106" title="Dahl AarvikM , SandvenI , DondoTB , GaleCP , RuddoxV , MunkhaugenJ , et al. Effect of oral β‐blocker treatment on mortality in contemporary post‐myocardial infarction patients: a systematic review and meta‐analysis. European Heart Journal. Cardiovascular Pharmacotherapy2019;5(1):12‐20. [PUBMED: 30192930] ">Dahl 2019</a> and <a href="./references#CD012484-bbs2-0148" title="MisumidaN , HarjaiK , KernisS , KaneiY . Does oral beta‐blocker therapy improve long‐term survival in ST‐segment elevation myocardial infarction with preserved systolic function? A meta‐analysis. Journal of Cardiovascular Pharmacology and Therapeutics2016;21(3):280‐5. [PUBMED: 26424094] ">Misumida 2016</a><b>,</b> only included cohort studies and observational studies, respectively. </p> <p>Despite these studies, the question of whether or not beta‐blockers should be administered in the acute phase of an acute myocardial infarction has not yet been sufficiently answered. The above‐mentioned studies show conflicting results and suggest that more randomised clinical trials are needed to determine the effects of beta‐blockers. Hence, this review is of uttermost importance and is the first to take fully account of all existing randomised clinical trials assessing the effects and harms of beta‐blockers for acute myocardial infarction. </p> </section> <section id="CD012484-sec-0039"> <h5 class="title">Beta‐blockers for other conditions</h5> <p>The role of beta‐blockers for other conditions than myocardial infarction is still debated. Beta‐blockers used to be contraindicated in patients with congestive heart failure. Beta‐blockers and non‐selective combined alpha‐ and beta‐blockers are now a part of standard treatment of congestive heart failure (<a href="./references#CD012484-bbs2-0101" title="ChatterjeeS , Biondi‐ZoccaiG , AbbateA , D'AscenzoF , CastagnoD , VanTassellB , et al. Benefits of beta blockers in patients with heart failure and reduced ejection fraction: network meta‐analysis. BMJ2013;346:f55. [PUBMED: 23325883] ">Chatterjee 2013a</a>; <a href="./references#CD012484-bbs2-0186" title="YancyCW , JessupM , BozkurtB , ButlerJ , CaseyDE , DraznerMH , et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation2013;128:e240‐e327. ">Yancy 2013</a>). </p> <p>Beta‐blockers are also considered an option in the treatment of hypertension, but are rarely used as first‐line treatment (<a href="./references#CD012484-bbs2-0146" title="ManciaG , FagardR , NarkiewiczK , RedonJ , ZanchettiA , BöhmM , et al. 2013 ESH/ESC Guidelines for the Management of Arterial Hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). European Heart Journal2013;34(28):2159‐219. ">Mancia 2013</a>). A recent Cochrane Review found that beta‐blockers were inferior when compared with other antihypertensive drugs (<a href="./references#CD012484-bbs2-0184" title="WiysongeCS , BradleyHA , VolminkJ , MayosiBM , MbewuA , OpieLH . Beta‐blockers for hypertension. Cochrane Database of Systematic Reviews2012, Issue 11. [DOI: 10.1002/14651858.CD002003.pub4] ">Wiysonge 2012</a>). Non‐selective beta‐blockers are used in the treatment of anxiety due to their effect on decreasing tremor and tachycardia (<a href="./references#CD012484-bbs2-0179" title="TurnerSM , BeidelDC , JacobRG . Social phobia: a comparison of behavior therapy and atenolol. Journal of Consulting and Clinical Psychology1994;62(2):350‐8. [PUBMED: 8201073] ">Turner 1994</a>). </p> <p>The adverse effects of beta‐blockers include both cardiac adverse effects and non‐cardiac adverse effects. Among the most serious cardiac adverse effects is exacerbation of heart failure in patients with acute decompensated heart failure, due to the need of sympathetic activity to maintain the cardiac output (<a href="./references#CD012484-bbs2-0176" title="TaylorSH , SilkeB , LeePS . Intravenous beta‐blockade in coronary heart disease: is cardioselectivity or intrinsic sympathomimetic activity hemodynamically useful?. New England Journal of Medicine1982;306(11):631‐5. [PUBMED: 6120457] ">Taylor 1982</a>). In addition, beta‐blocker withdrawal has also been shown to cause exacerbation of ischaemic symptoms and precipitate acute myocardial infarction in patients with ischaemic heart disease (<a href="./references#CD012484-bbs2-0129" title="HoustonMC . Abrupt cessation of treatment in hypertension: consideration of clinical features, mechanisms, prevention and management of the discontinuation syndrome. American Heart Journal1981;102(3 Pt 1):415‐30. [PUBMED: 6115570] ">Houston 1981</a>). </p> <p>Perioperative beta‐blockade for major non‐cardiac surgery in patients with risk factors for ischaemic heart disease has been tested in several trials (<a href="./references#CD012484-bbs2-0093" title="BangaloreS , WetterslevJ , PraneshS , SawhneyS , GluudC , MesserliFH . Perioperative beta blockers in patients having non‐cardiac surgery: a meta‐analysis. Lancet2008;372(9654):1962‐76. [PUBMED: 19012955] ">Bangalore 2008</a>; <a href="./references#CD012484-bbs2-0110" title="DevereauxPJ , YangH , YusufS , GuyattG , LeslieK , VillarJC , et al. Effects of extended‐release metoprolol succinate in patients undergoing non‐cardiac surgery (POISE trial): a randomised controlled trial. Lancet2008;371(9627):1839‐47. ">Devereaux 2008</a>; <a href="./references#CD012484-bbs2-0138" title="JuulAB , WetterslevJ , GluudC , Kofoed‐EnevoldsenA , JensenG , CallesenT , et al. Effect of perioperative beta blockade in patients with diabetes undergoing major non‐cardiac surgery: randomised placebo controlled, blinded multicentre trial. BMJ2006;332(7556):1482. [PUBMED: 16793810] ">Juul 2006</a>), and seems to increase 30‐day all‐cause mortality, increase the risk of stroke, although the risk of non‐fatal myocardial infarction seems to be reduced (<a href="./references#CD012484-bbs2-0093" title="BangaloreS , WetterslevJ , PraneshS , SawhneyS , GluudC , MesserliFH . Perioperative beta blockers in patients having non‐cardiac surgery: a meta‐analysis. Lancet2008;372(9654):1962‐76. [PUBMED: 19012955] ">Bangalore 2008</a>). </p> <p>Studies of individual patients have suggested that depression, fatigue, and sexual dysfunction are among the beta‐blocker induced non‐cardiac adverse effects (<a href="./references#CD012484-bbs2-0118" title="GreenblattDJ , Koch‐WeserJ . Adverse reactions to beta‐adrenergic receptor blocking drugs: a report from the Boston Collaborative Drug Surveillance Program. Drugs1974;7(1):118‐29. [PUBMED: 4151696] ">Greenblatt 1974</a>; <a href="./references#CD012484-bbs2-0180" title="WaalHJ . Propranolol‐induced depression. BMJ1967;2(5543):50. [PUBMED: 6021004] ">Waal 1967</a>; <a href="./references#CD012484-bbs2-0182" title="WarrenSC , WarrenSG . Propranolol and sexual impotence. Annals of Internal Medicine1977; Vol. 86, issue 1:112. [PUBMED: 835912] ">Warren 1977</a>). However, a meta‐analysis comparing beta‐blockers versus placebo showed no difference on depressive symptoms and only a minor increase in sexual dysfunction and fatigue in patients randomised to beta‐blockers compared with placebo (<a href="./references#CD012484-bbs2-0140" title="KoDT , HebertPR , CoffeyCS , SedrakyanA , CurtisJP , KrumholzHM . Beta‐blocker therapy and symptoms of depression, fatigue, and sexual dysfunction. JAMA2002;288(3):351‐7. [PUBMED: 12117400] ">Ko 2002</a>). </p> </section> </section> <section id="CD012484-sec-0040"> <h4 class="title">Current guidelines for using beta‐blockers in patients with suspected or diagnosed myocardial infarction </h4> <p>The American College of Cardiology Foundation/American Heart Association (ACCF/AHA) guideline recommends acute intravenous beta‐blockers in patients suspected of STEMI who are hypertensive or have ongoing ischaemia, unless there are contraindications to beta‐blockers (allergy towards beta‐blockers, signs of acute decompensated heart failure, increased risk of cardiogenic shock, atrio‐ventricular block, asthma, or chronic obstructive lung disease) (<a href="./references#CD012484-bbs2-0153" title="O'GaraPT , KushnerFG , AscheimDD , CaseyDEJr , ChungMK , deLemosJA , et al. i2013 ACCF/AHA guideline for the management of ST‐elevation myocardial Infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology2013;61(4):e78‐140. ">O'Gara 2013</a>). The guideline recommends oral beta‐blockers within the first 24 hours in patients with a STEMI and no contraindications (see above) (<a href="./references#CD012484-bbs2-0153" title="O'GaraPT , KushnerFG , AscheimDD , CaseyDEJr , ChungMK , deLemosJA , et al. i2013 ACCF/AHA guideline for the management of ST‐elevation myocardial Infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology2013;61(4):e78‐140. ">O'Gara 2013</a>). </p> <p>The ACCF/AHA guideline does not recommend acute intravenous beta‐blockers in patients suspected of acute NSTEMI and advise against intravenous beta‐blockers in acute patients with risk factors for cardiogenic shock (<a href="./references#CD012484-bbs2-0092" title="AmsterdamEA , WengerNK , BrindisRG , CaseyDEJr , GaniatsTG , HolmesDRJr , et al. 2014 AHA/ACC Guideline for the Management of Patients With Non–ST‐Elevation Acute Coronary Syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology2014;64(24):e139‐228. ">Amsterdam 2014</a>). However, the guideline recommends oral beta‐blockers commenced within the first 24 hours in patients with a NSTEMI or unstable angina pectoris and no contraindications (see above) (<a href="./references#CD012484-bbs2-0092" title="AmsterdamEA , WengerNK , BrindisRG , CaseyDEJr , GaniatsTG , HolmesDRJr , et al. 2014 AHA/ACC Guideline for the Management of Patients With Non–ST‐Elevation Acute Coronary Syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology2014;64(24):e139‐228. ">Amsterdam 2014</a>). </p> <p>Former meta‐analyses have shown conflicting results and no former reviews have used Cochrane methodology to assess the effects of beta‐blockers as an acute intervention in patients suspected or diagnosed with myocardial infarction. The present systematic review has been the first to use the GRADE approach to assess the quality of a body of evidence associated with each of the outcomes, to assess the risk of systematic errors ('bias'), design errors, and risks of random errors ('play of chance'), and to include trials irrespective of outcome, follow‐up duration, number of participants, language, and publication status (<a href="./references#CD012484-bbs2-0119" title="GuyattGH , OxmanAD , VistGE , KunzR , Falck‐YtterY , Alonso‐CoelloP , et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ2008;336(7650):924‐6. [PUBMED: 18436948] ">Guyatt 2008</a>; <a href="./references#CD012484-bbs2-0125" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>; <a href="./references#CD012484-bbs2-0170" title="SchünemannH , BrożekJ , GuyattG , OxmanA , editor(s) . Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach (updated October 2013). GRADE Working Group, 2013. Available from gdt.guidelinedevelopment.org/app/handbook/handbook.html. ">Schünemann 2013</a>). </p> </section> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD012484-sec-0041" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD012484-sec-0041"></div> <p>We assessed the benefits and harms of beta‐blockers compared with placebo or no intervention in people with suspected or diagnosed acute myocardial infarction. </p> <p>The present review is based on our peer‐reviewed, published protocol (<a href="./references#CD012484-bbs2-0189" title="NielsenEE , FeinbergJ , SafiS , SethiNJ , GluudC , JakobsenJC . Beta‐blockers for suspected or diagnosed acute myocardial infarction. Cochrane Database of Systematic Reviews2016, Issue 12. [DOI: 10.1002/14651858.CD012484] ">Nielsen 2016</a>) with amendments during the review process (see <a href="#CD012484-sec-0147">Differences between protocol and review</a>). </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD012484-sec-0042" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012484-sec-0042">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012484-sec-0156">Español</a> </li> </nav> </div> </div> <section class="methods" lang="en"> <div class="section-header" id="CD012484-sec-0042"></div> <section id="CD012484-sec-0043"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD012484-sec-0044"> <h4 class="title">Types of studies</h4> <p>We included all randomised clinical trials (RCTs) irrespective of trial design, setting, blinding, publication status, publication year, language, and reported outcomes. </p> </section> <section id="CD012484-sec-0045"> <h4 class="title">Types of participants</h4> <p>We included any participant (irrespective of age and sex) with suspected or diagnosed acute myocardial infarction (as defined by trialists). </p> </section> <section id="CD012484-sec-0046"> <h4 class="title">Types of interventions</h4> <p>We included three types of comparisons:</p> <p> <ul id="CD012484-list-0006"> <li> <p>beta‐blockers compared with placebo;</p> </li> <li> <p>beta‐blockers compared with no intervention (including no placebo tablet); and</p> </li> <li> <p>beta‐blockers added to a co‐intervention compared with a similar co‐intervention.</p> </li> </ul> </p> <p>We accepted any type of beta‐blocker (intravenous therapy or oral administration) commenced in the acute or subacute phase of acute myocardial infarction (non‐selective beta‐blockers (propranolol, oxprenolol, sotalol, timolol); selective beta<sub>1</sub>‐blockers (metoprolol, bisoprolol, acebutolol, atenolol, esmolol); and beta‐blockers which are combined alpha‐ and non‐selective beta‐blockers (carvedilol)) as the experimental intervention, irrespective of dose, route of administration, and duration. </p> <p>We accepted any type of co‐intervention (medical therapy as well as revascularisation strategies) provided they were intended to be delivered similarly to the experimental and the control groups. </p> </section> <section id="CD012484-sec-0047"> <h4 class="title">Types of outcome measures</h4> <p>We assessed all outcomes at two time points:</p> <p> <ul id="CD012484-list-0007"> <li> <p>less than three months after randomisation (this was the time point of primary interest). If multiple time points were reported at less than three months, we chose the one closest to one‐month follow‐up. </p> </li> <li> <p>maximum follow‐up beyond three months.</p> </li> </ul> </p> <p>We chose 'less than three months follow‐up' as our primary follow‐up time point because the possible effects of beta‐blockers need some time to show, and the follow‐up period is not too long so other factors unrelated to the given trial affecting the outcomes might decrease the statistical power, i.e. the results are 'diluted' by events (e.g. traffic accidents) unrelated to the trial. </p> <section id="CD012484-sec-0048"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD012484-list-0008"> <li> <p>All‐cause mortality.</p> </li> <li> <p>Serious adverse events. We defined a serious adverse event as any untoward medical occurrence that: resulted in death; was life‐threatening; required hospitalisation or prolongation of existing hospitalisation; resulted in persistent or significant disability; or jeopardised the participant according to the International Conference on Harmonization ‐ Good Clinical Practice (ICH‐GCP Guidelines) (<a href="./references#CD012484-bbs2-0134" title="International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) adopts Consolidated Guideline on Good Clinical Practice in the Conduct of Clinical Trials on Medicinal Products for Human Use. International Digest of Health Legislation1997; Vol. 48, issue 2:231‐4. [PUBMED: 11656783] ">ICH‐GCP 1997</a>). None of the trials specifically assessed serious adverse events according to the definition by ICH‐GCP. Instead, the trials either reported composites of several specific serious adverse events or one specific serious adverse event. </p> </li> <li> <p>Major adverse cardiovascular events (MACE), defined as a composite outcome consisting of cardiovascular mortality (defined by trialists) and non‐fatal myocardial infarction during follow‐up (defined by trialists). Additionally, we assessed cardiovascular mortality and myocardial infarction during follow‐up separately as secondary outcomes (see below). </p> </li> </ul> </p> </section> <section id="CD012484-sec-0049"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD012484-list-0009"> <li> <p>Quality of life measured on any valid continuous scale, such as the Short‐Form (36) Health Survey (SF‐36) (<a href="./references#CD012484-bbs2-0181" title="WareJEJ , SherbourneCD . The MOS 36‐item short‐form health survey (SF‐36). I. Conceptual framework and item selection. Medical Care1992;30(6):473‐83. ">Ware 1992</a>). None of the trials adequately assessed quality of life. </p> </li> <li> <p>Angina measured on any valid scale, such as the Canadian Cardiovascular Angina Score (CCS) (<a href="./references#CD012484-bbs2-0098" title="CampeauL . Letter: Grading of angina pectoris. Circulation1976;54(3):522‐3. [PUBMED: 947585] ">Campeau 1976</a>). </p> </li> <li> <p>Cardiovascular mortality.</p> </li> <li> <p>Myocardial infarction during follow‐up (i.e. reinfarction in the participants who were diagnosed with myocardial infarction at, or shortly after, randomisation, and first myocardial infarction in the participants who were suspected of myocardial infarction at randomisation, but where the suspicion was later rejected). </p> </li> </ul> </p> </section> </section> </section> <section id="CD012484-sec-0050"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD012484-sec-0051"> <h4 class="title">Electronic searches</h4> <p>We searched the following databases on 18 June 2019 to identify reports of relevant randomised clinical trials (<a href="./references#CD012484-bbs2-0161" title="RoyleP , MilneR . Literature searching for randomized controlled trials used in Cochrane reviews: rapid versus exhaustive searches. International Journal of Technology Assessment in Health Care2003;19(4):591‐603. ">Royle 2003</a>). </p> <p> <ul id="CD012484-list-0010"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL; 2019, Issue 6) in the Cochrane Library </p> </li> <li> <p>Epub Ahead of Print, In‐Process &amp; Other Non‐Indexed Citations, MEDLINE Daily and MEDLINE (Ovid, 1946 to 14 June 2019) </p> </li> <li> <p>Embase (Ovid, 1974 to 17 June 2019)</p> </li> <li> <p>LILACS (Latin American and Caribbean Health Science Information Database) (Bireme, 1982 to 18 June 2019) </p> </li> <li> <p>Science Citation Index Expanded on the Web of Science (Clarivate Analytics, 1900 to 18 June 2019) </p> </li> <li> <p>BIOSIS Citation Index on the Web of Science (Clarivate Analytics, 1926 to 18 June 2019) </p> </li> </ul> </p> <p>We adapted the preliminary search strategy for MEDLINE (Ovid) for use in these databases. We applied the Cochrane sensitivity‐maximising filter for randomised clinical trials (<a href="./references#CD012484-bbs2-0141" title="LefebvreC , ManheimerE , GlanvilleJ . Chapter 6: Searching for studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Lefebvre 2011</a>) to MEDLINE Ovid and adaptations of it to the other databases, except CENTRAL. The search strategy can be found in <a href="./appendices#CD012484-sec-0132">Appendix 1</a>. </p> <p>We searched all databases from their inception to the present and we imposed no restriction on language of publication or publication status. We assessed non‐English language papers by asking individuals that speak the language fluently for help. This is acknowledged in the <a href="#CD012484-sec-0129">Acknowledgements</a> section. </p> </section> <section id="CD012484-sec-0052"> <h4 class="title">Searching other resources</h4> <p>We searched the reference lists of included randomised clinical trials, previous systematic reviews, and other kinds of reviews for any unidentified randomised clinical trials. </p> <p>Furthermore, we searched for ongoing and unidentified randomised clinical trials on 14 August 2019: </p> <p> <ul id="CD012484-list-0011"> <li> <p>the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) search portal (<a href="http://apps.who.int/trialsearch" target="_blank">apps.who.int/trialsearch</a>); </p> </li> <li> <p>ClinicalTrials.gov (<a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>); </p> </li> <li> <p>Turning Research Into Practice (TRIP) (<a href="http://www.tripdatabase.com/" target="_blank">http://www.tripdatabase.com/</a>); </p> </li> <li> <p>Google Scholar (<a href="http://scholar.google.dk/" target="_blank">http://scholar.google.dk/</a>); and </p> </li> <li> <p>Scisearch (<a href="http://ipscience.thomsonreuters.com/" target="_blank">http://ipscience.thomsonreuters.com/</a>). </p> </li> </ul> </p> <p>We also examined relevant retraction statements and errata for included trials.</p> </section> </section> <section id="CD012484-sec-0053"> <h3 class="title" id="CD012484-sec-0053">Data collection and analysis</h3> <p>We performed this systematic review following the recommendations of Cochrane (<a href="./references#CD012484-bbs2-0125" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). The analyses were performed using Review Manager 5.3 (<a href="./references#CD012484-bbs2-0158" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). </p> <section id="CD012484-sec-0054"> <h4 class="title">Selection of studies</h4> <p>Two review authors (Sanam Safi (SS) and Naqash J Sethi (NJS)) independently screened titles and abstracts for inclusion of all the potentially eligible trials. We coded all these studies as 'retrieve' (eligible or potentially eligible/unclear) or 'do not retrieve'. If there was any disagreements, a third author were asked to arbitrate (Janus C Jakobsen (JCJ)). We retrieved the full‐text study reports/publications and four review authors (SS, NJS, Emil Eik Nielsen (EEN), and Joshua Feinberg (JF)) independently screened the full‐text reports and identified trials for inclusion. Reasons for exclusion of the ineligible studies were reported (<a href="#CD012484-sec-0076">Excluded studies</a>). We resolved any disagreement through discussion or, if required, we consulted a third author (JCJ). We identified and excluded duplicated and collated multiple reports of the same trial so that each trial rather than each report is the unit of interest in the review. We recorded the selection process in sufficient detail to complete a PRISMA flow diagram (<a href="./references#CD012484-bbs2-0150" title="MoherD , LiberatiA , TetzlaffJ , AltmanDG , PRISMAG . Preferred reporting items for systematic reviews and meta‐analyses: the PRISMA statement. Journal of Clinical Epidemiology2009;62(10):1006‐12. ">Moher 2009</a>) <a href="#CD012484-fig-0001">Figure 1</a> and '<a href="./references#CD012484-sec-0150" title="">Characteristics of excluded studies</a>' table. </p> <div class="figure" id="CD012484-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD012484-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD012484-sec-0055"> <h4 class="title">Data extraction and management</h4> <p>Four review authors (SS, NJS, EEN, JF) extracted and validated data independently from included trials. Any disagreement concerning the extracted data were discussed between the two authors. If no agreement could be reached, a third author (JCJ) resolved the issue. In case of relevant data not being available, we contacted the trial authors. </p> <p>We used a data collection form for trial data and outcome data which was piloted on at least one trial in the review. </p> <p>We extracted the following data mentioned below.</p> <p> <ul id="CD012484-list-0012"> <li> <p>Trial characteristics: trial design (parallel, factorial, or cross‐over); number of intervention arms; duration of the trial; details of any 'run‐in' period; date of publication; inclusion and exclusion criteria; and 'Risk of bias' components (as defined below). </p> </li> <li> <p>Participants characteristics: number of participants randomised; number of participants analysed; number of participants lost to follow‐up; mean age, and sex ratio. </p> </li> <li> <p>Intervention characteristics: type of beta‐blocker; dose of beta‐blocker; duration of beta‐blocker therapy; and mode of administration. </p> </li> <li> <p>Control characteristics: placebo or no intervention.</p> </li> <li> <p>Co‐intervention characteristics: type of co‐intervention; dose of co‐intervention; duration of co‐intervention; and mode of administration. </p> </li> <li> <p>Outcomes: primary, secondary, and exploratory outcomes specified and collected, and time points reported. </p> </li> <li> <p>Notes: funding for trial, and notable conflicts of interest of trial authors.</p> </li> </ul> </p> </section> <section id="CD012484-sec-0056"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>We used the instructions given in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> in our evaluation of the methodology and the risk of bias of the included trials (<a href="./references#CD012484-bbs2-0127" title="HigginsJP , AltmanDG , Sterne JAC(editors) . Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS (editors). Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017. Available from www.training.cochrane.org/handbook. ">Higgins 2017</a>). Four review authors (SS, NJS, EEN, and JF) assessed the included trials independently. We evaluated the risk of bias in the following 'Risk of bias' domains: </p> <p> <ul id="CD012484-list-0013"> <li> <p>random sequence generation;</p> </li> <li> <p>allocation concealment;</p> </li> <li> <p>blinding of participants and personnel;</p> </li> <li> <p>blinding of outcome assessment;</p> </li> <li> <p>incomplete outcome data;</p> </li> <li> <p>selective outcome reporting; and</p> </li> <li> <p>other risks of bias.</p> </li> </ul> </p> <p>This was done because these domains enable classification of randomised clinical trials at low risk of bias and at high risk of bias. The latter trials overestimate positive intervention effects (benefits) and underestimate negative effects (harms) (<a href="./references#CD012484-bbs2-0116" title="GluudLL . Bias in clinical intervention research. American Journal of Epidemiology2006;163(6):493‐501. ">Gluud 2006</a>; <a href="./references#CD012484-bbs2-0139" title="KjaergardLL , VillumsenJ , GluudC . Reported methodologic quality and discrepancies between large and small randomized trials in meta‐analyses. Annals of Internal Medicine2001;135(11):982‐9. ">Kjaergard 2001</a>; <a href="./references#CD012484-bbs2-0145" title="LundhA , LexchinJ , MintzesB , SchrollJB , BeroL . Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews2017, Issue 2. [DOI: 10.1002/14651858.MR000033.pub3] ">Lundh 2017</a>; <a href="./references#CD012484-bbs2-0149" title="MoherD , PhamB , JonesA , CookDJ , JadadAR , MoherM , et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta‐analyses?. Lancet1998;352(9128):609‐13. ">Moher 1998</a>; <a href="./references#CD012484-bbs2-0163" title="SavovicJ , JonesHE , AltmanDG , HarrisRJ , JuniP , PildalJ , et al. Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Annals of Internal Medicine2012;157(6):429‐38. ">Savovic 2012</a>; <a href="./references#CD012484-bbs2-0164" title="SavovicJ , JonesH , AltmanD , HarrisR , JuniP , PildalJ , et al. Influence of reported study design characteristics on intervention effect estimates from randomised controlled trials: combined analysis of meta‐epidemiological studies. Health Technology Assesment2012;16(35):1‐82. ">Savovic 2012a</a>; <a href="./references#CD012484-bbs2-0167" title="SchulzKF , ChalmersI , HayesRJ , AltmanDG . Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA1995;273(5):408‐12. ">Schulz 1995</a>; <a href="./references#CD012484-bbs2-0185" title="WoodL , EggerM , GluudLL , SchulzKF , JuniP , AltmanDG , et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta‐epidemiological study. BMJ2008;336(7644):601‐5. ">Wood 2008</a>). For additional details on how the risk of bias was assessed, please see <a href="./appendices#CD012484-sec-0133">Appendix 2</a>. </p> <p>We graded each potential source of bias as high, low, or unclear and provided evidence from the study report together with a justification for our judgement in the 'Risk of bias' table. We have summarised the 'Risk of bias' judgments across different trials for each of the domains listed (see below). </p> <section id="CD012484-sec-0057"> <h5 class="title">Overall risk of bias</h5> <p> <ul id="CD012484-list-0014"> <li> <p>Low risk of bias: the outcome result was classified as at overall low risk of bias only if all of the bias domains described in the above paragraphs were classified as at low risk of bias. </p> </li> <li> <p>High risk of bias: the outcome result was classified as at overall high risk of bias if any of the bias risk domains described above were classified as at unclear or high risk of bias. </p> </li> </ul> </p> </section> </section> <section id="CD012484-sec-0058"> <h4 class="title">Measures of treatment effect</h4> <p>We calculated risk ratios (RR) with 95% confidence intervals (CI) for dichotomous outcomes. We planned to calculate mean differences (MD) with 95% CI for continuous outcomes. However, none of the included trials adequately reported quality of life (our only continuous outcome). </p> </section> <section id="CD012484-sec-0059"> <h4 class="title">Unit of analysis issues</h4> <p>We only included randomised clinical trials. For trials using cross‐over design, we planned to only include data from the first period (<a href="./references#CD012484-bbs2-0112" title="ElbourneDR , AltmanDG , HigginsJP , CurtinF , WorthingtonHV , VailA . Meta‐analyses involving cross‐over trials: methodological issues. International Journal of Epidemiology2002;31(1):140‐9. ">Elbourne 2002</a>; <a href="./references#CD012484-bbs2-0107" title="DeeksJJ , HigginsJP , AltmanDG . Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JP, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017). Available from www.training.cochrane.org/handbook. ">Deeks 2017</a>). For trials where multiple trial intervention groups were reported, we included only the relevant groups. If two comparisons were combined in the same meta‐analysis, we halved the control group to avoid double‐counting (<a href="./references#CD012484-bbs2-0107" title="DeeksJJ , HigginsJP , AltmanDG . Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JP, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017). Available from www.training.cochrane.org/handbook. ">Deeks 2017</a>). </p> </section> <section id="CD012484-sec-0060"> <h4 class="title">Dealing with missing data</h4> <p>We contacted trial authors to obtain missing data (i.e. for data extraction and for assessment of risk of bias, as specified above). However, not all trial authors responded (see <a href="./references#CD012484-sec-0149" title="">Characteristics of included studies</a>). </p> <section id="CD012484-sec-0061"> <h5 class="title">Dichotomous outcomes</h5> <p>If included trials used rigorous methodology (i.e. reporting on outcomes for all participants or multiple imputation to deal with missing data), we used these data in our primary analysis (<a href="./references#CD012484-bbs2-0174" title="SterneJA , WhiteIR , CarlinJB , SprattM , RoystonP , KenwardMG , et al. Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls. BMJ2009;338:b2393. [PUBMED: 19564179] ">Sterne 2009</a>). We did not impute missing values for any outcomes in our primary analysis. In two of our sensitivity analyses ('best‐worst' and 'worst‐best'), we imputed data; see below. </p> </section> <section id="CD012484-sec-0062"> <h5 class="title">Continuous outcomes</h5> <p>If included trials used rigorous methodology (i.e. reporting on outcomes for all participants or multiple imputation to deal with missing data), we planned to use these data in our primary analysis (<a href="./references#CD012484-bbs2-0174" title="SterneJA , WhiteIR , CarlinJB , SprattM , RoystonP , KenwardMG , et al. Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls. BMJ2009;338:b2393. [PUBMED: 19564179] ">Sterne 2009</a>). We did not impute missing values for any outcomes in our primary analysis. If standard deviations (SDs) were not reported, we planned to calculate the SDs using data from the trial if possible. In two of our sensitivity analyses outcomes ('best‐worst' and 'worst‐best'), we planned to impute data, see below. However, none of the included trials adequately reported quality of life (our only continuous outcome). </p> </section> <section id="CD012484-sec-0063"> <h5 class="title">Best‐worst and worst‐best case scenarios</h5> <p>To assess the potential impact of the missing data for dichotomous outcomes, we performed the following two sensitivity analyses when assessing each dichotomous outcome (all‐cause mortality, cardiovascular mortality, and myocardial infarction during follow‐up). We were not able to perform the following sensitivity analyses on 'MACE' as limited data were available and on serious adverse events as no data were available. </p> <p> <ul id="CD012484-list-0015"> <li> <p>'Best‐worst' case scenario: we assumed that all participants lost to follow‐up in the experimental group survived and had no cardiovascular event; and all those participants with missing outcomes in the control group did not survive and had a cardiovascular event. </p> </li> <li> <p>'Worst‐best' case scenario: we assumed that all participants lost to follow‐up in the experimental group did not survive and had a cardiovascular event; and all those participants with missing outcomes in the control group survived and had no cardiovascular event. </p> </li> </ul> </p> <p>Results from both scenarios are presented in our review.</p> <p>We planned that when analysing quality of life (our only continuous outcome), a ‘beneficial outcome’ would have been the group mean plus two SDs (we would then have used one SD in another sensitivity analysis) of the group mean, and a ‘harmful outcome’ would have been the group mean minus two SDs (we would then have used one SD in another sensitivity analysis) of the group mean (<a href="./references#CD012484-bbs2-0136" title="JakobsenJC , WetterslevJ , WinkelP , LangeT , GluudC . Thresholds for statistical and clinical significance in systematic reviews with meta‐analytic methods. BMC Medical Research Methodology2014;14:120. [PUBMED: 25416419] ">Jakobsen 2014</a>). </p> <p>To assess the potential impact of missing SDs for continuous outcomes, we performed the following sensitivity analysis. </p> <p> <ul id="CD012484-list-0016"> <li> <p>Where SDs were missing and not possible to calculate, we planned to impute SDs from trials with similar populations and low risk of bias. If no such trials could be found, we planned to impute SDs from trials with a similar population. As the final option, we planned to impute SDs from all trials. </p> </li> </ul> </p> <p>We planned to present results of this scenario in our review. However, none of the included trials adequately reported quality of life (our only continuous outcome). </p> </section> </section> <section id="CD012484-sec-0064"> <h4 class="title">Assessment of heterogeneity</h4> <p>Initially, we investigated forest plots to visually assess any sign of heterogeneity. We secondly assessed the presence of statistical heterogeneity by Chi<sup>2</sup> test (threshold P &lt; 0.10) and measured the quantities of heterogeneity by the I<sup>2</sup> statistic (<a href="./references#CD012484-bbs2-0123" title="HigginsJP , ThompsonSG . Quantifying heterogeneity in a meta‐analysis. Statistics in Medicine2002;21(11):1539‐58. ">Higgins 2002</a>; <a href="./references#CD012484-bbs2-0124" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327(7414):557‐60. ">Higgins 2003</a>). </p> <p>We followed the recommendations for threshold by the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012484-bbs2-0107" title="DeeksJJ , HigginsJP , AltmanDG . Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JP, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017). Available from www.training.cochrane.org/handbook. ">Deeks 2017</a>): </p> <p> <ul id="CD012484-list-0017"> <li> <p>0% to 40%: might not be important;</p> </li> <li> <p>30% to 60%: may represent moderate heterogeneity;</p> </li> <li> <p>50% to 90%: may represent substantial heterogeneity;</p> </li> <li> <p>75% to 100%: may represent considerable heterogeneity.</p> </li> </ul> </p> <p>We investigated possible heterogeneity through subgroup analyses. We had to decide whether or not a meta‐analysis might have to be avoided (<a href="./references#CD012484-bbs2-0125" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). Ultimately however, none of the planned meta‐analyses were avoided. </p> </section> <section id="CD012484-sec-0065"> <h4 class="title">Assessment of reporting biases</h4> <p>We used a funnel plot to assess reporting bias in the meta‐analyses including 10 or more trials. We visually inspected the funnel plots to assess the risk of bias. For dichotomous outcomes, we tested asymmetry with the Harbord test (<a href="./references#CD012484-bbs2-0121" title="HarbordRM , EggerM , SterneJA . A modified test for small‐study effects in meta‐analyses of controlled trials with binary endpoints. Statistics in Medicine2006;25(20):3443‐57. [PUBMED: 16345038] ">Harbord 2006</a>) if tau<sup>2</sup> &lt; 0.1 and with the Rücker test (<a href="./references#CD012484-bbs2-0162" title="RückerG , SchwarzerG , CarpenterJ . Arcsine test for publication bias in meta‐analyses with binary outcomes. Statistics in Medicine2008;27(5):746‐63. [PUBMED: 17592831] ">Rücker 2008</a>) if tau<sup>2</sup> &gt; 0.1. For continuous outcomes, we planned to use the regression asymmetry test (<a href="./references#CD012484-bbs2-0111" title="EggerM , Davey SmithG , SchneiderM , MinderC . Bias in meta‐analysis detected by a simple, graphical test. BMJ1997;315(7109):629‐34. ">Egger 1997</a>). However, none of the included trials adequately reported quality of life (our only continuous outcome). </p> </section> <section id="CD012484-sec-0066"> <h4 class="title">Data synthesis</h4> <section id="CD012484-sec-0067"> <h5 class="title">Meta‐analysis</h5> <p>We undertook this systematic review according to the recommendations stated in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012484-bbs2-0107" title="DeeksJJ , HigginsJP , AltmanDG . Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JP, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017). Available from www.training.cochrane.org/handbook. ">Deeks 2017</a>; <a href="./references#CD012484-bbs2-0125" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>) for better validation of meta‐analytic results in systematic reviews. We used the statistical software Review Manager 5.3 (<a href="./references#CD012484-bbs2-0158" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>) provided by Cochrane to meta‐analyse data. </p> </section> <section id="CD012484-sec-0068"> <h5 class="title">Assessment of significance</h5> <p>We assessed our intervention effects with both random‐effects model meta‐analyses (<a href="./references#CD012484-bbs2-0109" title="DerSimonianR , LairdN . Meta‐analysis in clinical trials. Controlled Clinical Trials1986;7(3):177‐88. [PUBMED: 3802833] ">DerSimonian 1986</a>) and fixed‐effect model meta‐analyses (<a href="./references#CD012484-bbs2-0108" title="DeMetsDL . Methods for combining randomized clinical trials: strengths and limitations. Statistics in Medicine1987;6(3):341‐50. [PUBMED: 3616287] ">DeMets 1987</a>). We used the more conservative result of the two as out primary result (<a href="./references#CD012484-bbs2-0136" title="JakobsenJC , WetterslevJ , WinkelP , LangeT , GluudC . Thresholds for statistical and clinical significance in systematic reviews with meta‐analytic methods. BMC Medical Research Methodology2014;14:120. [PUBMED: 25416419] ">Jakobsen 2014</a>). The more conservative result was the result with the highest P value and the widest confidence interval (CI). If there was a substantial discrepancy between the results of the two models, we reported both and discussed the results (<a href="./references#CD012484-bbs2-0091" title="AmrheinValentin , Greenland . Sander , McShane . Blake . Retire statistical significance.. Springer NatureMarch 2019;567(7748):305‐307. ">Amrhein 2019</a>; <a href="./references#CD012484-bbs2-0136" title="JakobsenJC , WetterslevJ , WinkelP , LangeT , GluudC . Thresholds for statistical and clinical significance in systematic reviews with meta‐analytic methods. BMC Medical Research Methodology2014;14:120. [PUBMED: 25416419] ">Jakobsen 2014</a>). We used three primary outcomes and due to the risk of multiplicity we calculated a P value less than P ≤ 0.025 and a 97.5% CI for the primary outcomes (<a href="./references#CD012484-bbs2-0136" title="JakobsenJC , WetterslevJ , WinkelP , LangeT , GluudC . Thresholds for statistical and clinical significance in systematic reviews with meta‐analytic methods. BMC Medical Research Methodology2014;14:120. [PUBMED: 25416419] ">Jakobsen 2014</a>). We used four secondary outcomes and we, therefore, calculated a P value less than P ≤ 0.020 and a 98% CI for the secondary outcomes (<a href="./references#CD012484-bbs2-0136" title="JakobsenJC , WetterslevJ , WinkelP , LangeT , GluudC . Thresholds for statistical and clinical significance in systematic reviews with meta‐analytic methods. BMC Medical Research Methodology2014;14:120. [PUBMED: 25416419] ">Jakobsen 2014</a>). We used an online calculator for the 97.5% and 98% CI (<a href="https://www.omnicalculator.com/statistics/relative-risk" target="_blank">/www.omnicalculator.com/statistics/relative‐risk</a>). </p> </section> </section> <section id="CD012484-sec-0069"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We performed the following subgroup analyses when assessing each outcome (all‐cause mortality, cardiovascular mortality, and myocardial infarction during follow‐up) at both our time points. We were not able to perform subgroup analyses on 'MACE' and angina as limited data were available and on serious adverse events according to ICH‐GCP and quality of life as no data were available. </p> <p>A: Comparison of the effects between trials where the participants commenced beta‐blockers at different time points. </p> <p> <ul id="CD012484-list-0018"> <li> <p>Acute phase ‐ suspected of myocardial infarction.</p> </li> </ul> <ul id="CD012484-list-0019"> <li> <p>Subacute phase ‐ diagnosed with myocardial infarction.</p> </li> </ul> </p> <p>B: Comparison of the effects between trials where the participants received intervention for reperfusion (coronary artery bypass graft, percutaneous coronary intervention or thrombolytics) to that in trials where the participants did not receive intervention for reperfusion. </p> <p>C: Comparison of the effects between trials where the experimental group received different types of beta‐blockers. </p> <p>D: Comparison of the effects between trials with different age of participants.</p> <p> <ul id="CD012484-list-0020"> <li> <p>Age 0 to 18 years.</p> </li> <li> <p>Age 19 to 75 years.</p> </li> <li> <p>Age 76 years or above.</p> </li> </ul> </p> <p>E: Comparision of the effects between trials with different clinical trial registration status. </p> <p> <ul id="CD012484-list-0021"> <li> <p>Pre‐registration.</p> </li> <li> <p>Post‐registration.</p> </li> <li> <p>No registration.</p> </li> </ul> </p> <p>F: Comparison of the effects between trials including different types of acute myocardial infarction. </p> <p> <ul id="CD012484-list-0022"> <li> <p>NSTEMI.</p> </li> <li> <p>STEMI.</p> </li> <li> <p>Unstable angina pectoris.</p> </li> <li> <p>Mixed.</p> </li> </ul> </p> <p><b>Post hoc subgroup analysis</b> </p> <p>After the publication of the protocol, we added two subgroups.</p> <p>G: Comparison of the effects between trials with different lengths of intervention period. This subgroup analysis was only performed at maximum follow‐up. </p> <p> <ul id="CD012484-list-0023"> <li> <p>0 to 7 days length of intervention,</p> </li> <li> <p>7 to 30 days length of intervention,</p> </li> <li> <p>1 month or more length of intervention.</p> </li> </ul> </p> <p>H: Comparison of the effects between trials with different funding.</p> <p> <ul id="CD012484-list-0024"> <li> <p>Industry funded trials or unknown funding,</p> </li> <li> <p>Non‐industry funded trials.</p> </li> </ul> </p> <p>We used the formal test for subgroup differences in RevMan 5.3 (<a href="./references#CD012484-bbs2-0158" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). </p> </section> <section id="CD012484-sec-0070"> <h4 class="title">Sensitivity analysis</h4> <p>To assess the potential impact of bias, we performed a sensitivity analysis in which we excluded trials at overall high risk of bias. </p> <p>To assess the potential impact of the missing data for dichotomous outcomes, we performed best‐worst and worst‐best case scenarios (see <a href="#CD012484-sec-0060">Dealing with missing data</a>). </p> <section id="CD012484-sec-0071"> <h5 class="title">'Summary of findings' tables</h5> <p>We used the GRADE system (<a href="./references#CD012484-bbs2-0119" title="GuyattGH , OxmanAD , VistGE , KunzR , Falck‐YtterY , Alonso‐CoelloP , et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ2008;336(7650):924‐6. [PUBMED: 18436948] ">Guyatt 2008</a>; <a href="https://gdt.gradepro.org/app/handbook/handbook.html" target="_blank">https://gdt.gradepro.org/app/handbook/handbook.html</a>) to assess the quality of the body of evidence associated with each of the primary outcomes (all‐cause mortality, serious adverse events according to ICH‐GCP, and major adverse cardiovascular events); and secondary outcomes (quality of life, angina, cardiovascular mortality, and myocardial infarction during follow‐up) at both our time points constructing 'Summary of Findings' tables using the GRADEpro GDT software (<a href="http://ims.cochrane.org/revman/other-resources/gradepro" target="_blank">ims.cochrane.org/revman/other‐resources/gradepro</a>). The GRADE approach appraises the quality of a body of evidence based on the extent to which one can be confident that an estimate of effect or association reflects the item being assessed (<a href="./references#CD012484-bbs2-0169" title="SchünemannHJ , BestD , VistG , OxmanAD . Letters, numbers, symbols and words: how to communicate grades of evidence and recommendations. CMAJ: Canadian Medical Association journal2003;169(7):677‐80. ">Schünemann 2003</a>; <a href="./references#CD012484-bbs2-0119" title="GuyattGH , OxmanAD , VistGE , KunzR , Falck‐YtterY , Alonso‐CoelloP , et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ2008;336(7650):924‐6. [PUBMED: 18436948] ">Guyatt 2008</a>; <a href="./references#CD012484-bbs2-0120" title="GuyattGH , OxmanAD , SchunemannHJ , TugwellP , KnottnerusA . GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. Journal of Clinical Epidemiology2011;64(4):380‐2. ">Guyatt 2011</a>). We assessed the GRADE levels of evidence as high, moderate, low, and very low and downgraded the evidence by one or two levels depending on the following quality measures: within‐study risk of bias, the directness of the evidence, heterogeneity of the data, precision of effect estimates, and risk of publication bias (<a href="./references#CD012484-bbs2-0169" title="SchünemannHJ , BestD , VistG , OxmanAD . Letters, numbers, symbols and words: how to communicate grades of evidence and recommendations. CMAJ: Canadian Medical Association journal2003;169(7):677‐80. ">Schünemann 2003</a>; <a href="./references#CD012484-bbs2-0119" title="GuyattGH , OxmanAD , VistGE , KunzR , Falck‐YtterY , Alonso‐CoelloP , et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ2008;336(7650):924‐6. [PUBMED: 18436948] ">Guyatt 2008</a>; <a href="./references#CD012484-bbs2-0120" title="GuyattGH , OxmanAD , SchunemannHJ , TugwellP , KnottnerusA . GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. Journal of Clinical Epidemiology2011;64(4):380‐2. ">Guyatt 2011</a>). We used the methods and recommendations described in Chapter 8 (section 8.5) (<a href="./references#CD012484-bbs2-0127" title="HigginsJP , AltmanDG , Sterne JAC(editors) . Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS (editors). Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017. Available from www.training.cochrane.org/handbook. ">Higgins 2017</a>) and chapter 12 (<a href="./references#CD012484-bbs2-0171" title="SchünemannHJ , OxmanAD , VistGE , HigginsJP , DeeksJJ , GlasziouP , et al. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JP, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017). Cochrane, 2017. Available from www.training.cochrane.org/handbook. ">Schünemann 2017</a>) of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012484-bbs2-0125" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>) and the GRADE handbook (<a href="https://gdt.gradepro.org/app/handbook/handbook.html" target="_blank">https://gdt.gradepro.org/app/handbook/handbook.html</a>). We justified all decisions to downgrade the quality of trials using footnotes and we made comments to aid the reader's understanding of the review where necessary. </p> <p>We included all trials in our analyses, and conducted a sensitivity analysis excluding trials at high risk of bias. If the results were similar, we based our 'Summary of findings' tables and conclusions on the overall analysis. If they differed, we based our 'Summary of findings' tables and conclusions on trials at low risk of bias. </p> <p>We found one low risk of bias trial and reported its findings. For cardiovascular mortality, the results on all trials and on trials at low risk of bias differed significantly. For all other outcomes, the results did not differ significantly. Consequently, we based our 'Summary of findings' tables and conclusions on the results of trials at low risk of bias when assessing cardiovascular mortality and on the results of all trials when assessing all other outcomes (<a href="./full#CD012484-tbl-0001">summary of findings Table for the main comparison</a> (less than three months follow‐up) and <a href="./full#CD012484-tbl-0002">summary of findings Table 2</a> (maximum follow‐up beyond three months)). </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD012484-sec-0072" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD012484-sec-0072"></div> <section id="CD012484-sec-0073"> <h3 class="title">Description of studies</h3> <p>We assessed all trials according to the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012484-bbs2-0126" title="HigginsJP , WhiteheadA , SimmondsM . Sequential methods for random‐effects meta‐analysis. Statistics in Medicine2011;30(9):903‐21. [PUBMED: 21472757] ">Higgins 2011a</a>), and the protocol for this review (<a href="./references#CD012484-bbs2-0189" title="NielsenEE , FeinbergJ , SafiS , SethiNJ , GluudC , JakobsenJC . Beta‐blockers for suspected or diagnosed acute myocardial infarction. Cochrane Database of Systematic Reviews2016, Issue 12. [DOI: 10.1002/14651858.CD012484] ">Nielsen 2016</a>). Characteristics of each trial can be found in '<a href="./references#CD012484-sec-0149" title="">Characteristics of included studies</a>' and '<a href="./references#CD012484-sec-0150" title="">Characteristics of excluded studies</a>'. We identified three eligible ongoing studies (<a href="./references#CD012484-sec-0151" title="">Characteristics of ongoing studies</a>). </p> <section id="CD012484-sec-0074"> <h4 class="title">Results of the search</h4> <p>We identified a total of 18,450 potentially relevant references through searching CENTRAL (the Cochrane Library) (n = 2749), MEDLINE (n = 2412), Embase (n = 5798), Science Citation Index Expanded (n = 4862), BIOSIS (n = 2537), LILACS (n = 92), and four additional records were identified through other sources. The search strategies are presented in <a href="./appendices#CD012484-sec-0132">Appendix 1</a>. After removing duplicates, 12,315 records were screened, and 11,842 references were excluded based on titles and abstracts. Four hundred and seventy‐three full‐text articles were assessed for eligibility and we excluded 50 reports reporting on 22 trials according to our inclusion criteria and exclusion criteria (only the main references are listed for these trials). Reasons for exclusion are listed in the table '<a href="./references#CD012484-sec-0150" title="">Characteristics of excluded studies</a>'. We therefore included 423 publications reporting results from 66 trials. Accordingly, 63 trials could be included in our analyses while three trials were still on‐going. The study flow chart can be seen in <a href="#CD012484-fig-0001">Figure 1</a>. </p> </section> <section id="CD012484-sec-0075"> <h4 class="title">Included studies</h4> <p>We included 417 publications reporting on 63 trials comparing beta‐blockers versus placebo or no intervention in patients with suspected or diagnosed acute myocardial infarction (<a href="#CD012484-fig-0001">Figure 1</a>). The trials were conducted between 1966 and 2018. The trials (often conducted in more than one country) were conducted at sites in 31 different countries: 15 from the UK; eight each from Australia and New Zealand; seven each from Ireland, Norway, and Sweden; five each from Belgium, Denmark, and Germany; four each from Italy and the USA; three each from Canada, Japan, Scotland, France, Russia, and Spain; two each from Finland, India, and the Netherlands; one each from Argentina, Austria, China, Hungary, Israel, Lithuania, Luxemborg, Malaysia,the Phillippines, Singapore, South Africa, and Switzerland. </p> <p>We included 56 trials where the beta‐blockers were commenced in the acute phase of a myocardial infarction (48 trials enrolled patients within 24 hours of the onset of symptoms, three trials within 48 hours of the onset of symptoms, and five trials did not report the specific time point of enrolment). The remaining seven trials were included where the beta‐blockers were commenced in the subacute phase of a myocardial infarction (timing from the initial symptoms to randomisation varied from three to 21 days after a myocardial infarction). </p> <p>Twenty‐four trials received the intervention for zero to seven days; 23 trials received the intervention for seven to 30 days; and the remaining 16 trials received the intervention for at least one month or more. </p> <p>Seven trials specifically randomised participants suspected of or diagnosed with ST‐elevation myocardial infarction, 20 trials randomised a mixed group of participants (ST‐myocardial infarction, non‐ST myocardial infarction, unstable angina), and the remaining 36 trials did not report data on the different kinds of acute coronary syndrome included. </p> <p>Two trials were multi‐arm trials with more than one comparison (<a href="./references#CD012484-bbs2-0060" title="WaagsteinF , HjalmarsonÅC . Double‐blind study of the effect of cardioselective beta‐blockade on chest pain in acute myocardial infarction. Acta Medica Scandinavica. Supplementum.1976;587:201‐8. ">Waagstein 1975</a>; <a href="./references#CD012484-bbs2-0061" title="WilcoxRG , RolandJM , BanksDC , HamptonJR , MitchellJRA . Randomised trial comparing propranolol with atenolol in immediate treatment of suspected myocardial infarction. BMJ2980;280(6218):885‐8. ">Wilcox 1980</a>). </p> <p>Four trials did not report data on any of our outcomes (<a href="./references#CD012484-bbs2-0005" title="AzancotI , LorenteP , GeorgiopoulosG , BeaufilsP , MasquetC , BaudouyY , et al. Effects of acebutolol on myocardial infarct extension: a randomised electrocardiographic, enzymatic and angiographic study. Circulation1982;66(5):986‐94. ">Azancot 1982</a>; <a href="./references#CD012484-bbs2-0018" title="DagaMK , ChaudharyM , SharmaB , BhattacharjeeJ , GhambhirDS , AroraN , et al. Effect of esmolol on oxidant status and antioxidant activity in acute myocardial infarction. Journal of the Association of Physicians of India2003;51:677‐80. SharmaB , DagaMK , GambhirDS , KaushikM . Effect of esmolol, an ultra‐short acting beta blocker on oxidant status and antioxidant activity in acute myocardial infarction: Results of a randomized double‐blind, controlled, prospective clinical study. Chest2003;124(4):152S‐152S. ">Daga 2003</a>; <a href="./references#CD012484-bbs2-0030" title="KorochkinIM , ChukaevaII , AleshkinAV , SmolinaNV , LitvinovaSN , AleksandrovAA . Effects of beta blockers on the parameters of acute phase response and level of circulating immune complexes in myocardial infarct. Sovetskaia Meditsina1991;6:45‐7. ">Korochkin 1991</a>; <a href="./references#CD012484-bbs2-0060" title="WaagsteinF , HjalmarsonÅC . Double‐blind study of the effect of cardioselective beta‐blockade on chest pain in acute myocardial infarction. Acta Medica Scandinavica. Supplementum.1976;587:201‐8. ">Waagstein 1975</a>). Forty‐nine out of the 63 included trials reported data on all‐cause mortality at less than three months follow‐up and 22 trials reported data at maximum follow‐up beyond three months. None of the trials specifically assessed serious adverse events according to ICH‐GCP. Only two trials at the time point 'less than three months' follow‐up (with no events reported) and four trials at maximum follow‐up specifically assessed major adverse cardiovascular events according to our definition (composite of cardiovascular mortality and non‐fatal myocardial infarction during follow‐up). </p> <p>Thirty‐three trials were fully or partly funded by the industry, 20 trials did not report how they were funded, and 10 trials were funded by other sources than the industry. </p> <p>For further details on included studies and baseline characteristics of included participants, see '<a href="./references#CD012484-sec-0149" title="">Characteristics of included studies</a>'. </p> <p><b>Participants</b> </p> <p>A total of 85,550 participants with suspected or diagnosed acute myocardial infarction were randomised in the 63 included trials. The number of participants in each trial ranged from 18 participants to 45,852 participants. The mean age was 57.4 years (mean range 45.9 to 70.0 years) (13 out of the 63 trials did not report the mean age among the participants). Fifteen trials included participants older than 75 years. The mean proportion of women was 25.5% (10 out of the 63 trials did not report the sex distribution). The mean proportion of participants with a myocardial infarction at the time of randomisation was 80.2%. The mean proportion of participants with a former myocardial infarction was 11.8%. The majority of the trials based their inclusion criteria only on signs and symptoms suggestive of myocardial infarction. Hence, the majority of the trials included participants with suspected myocardial infarction, while a few trials only included participants with diagnosed myocardial infarction. </p> <p><b>Experimental intervention</b> </p> <p>The included trials used 16 different types of beta‐blockers as their experimental intervention: 12 trials used propranolol, eight trials used metoprolol, five trials used timolol, four trials used atenolol, four trials used carvedilol, three trials used practolol, two trials used alprenolol, two trials used pindolol, two trials used sotalol, one trial used acebutolol, one trial used betaxolol, one trial used H 87/07, one trial used labetalol, one trial used oxprenolol, one trial used xamoterol, one trial used esmolol, one trial used landiolol, and one trial used mixed beta‐blockers (esmolol + metoprolol). </p> <p><b>Control intervention</b> </p> <p>We included 41 trials where the control group received placebo. In the remaining 22 trials, the control group either received only the co‐intervention (in 18 trials) or no intervention (in four trials). </p> <p><b>Co‐interventions</b> </p> <p>We included 40 trials where the participants received a co‐intervention. In 27 trials, the co‐interventions consisted of digitalis, diuretics, nitrates, antiarrhythmics, anticoagulants, and aspirin; in six trials, the co‐intervention consisted of either percutaneous coronary intervention or thrombolysis; in two trials, the co‐intervention consisted of only heparin; in two trials, the co‐intervention consisted of only morphine; in two trials, the co‐intervention consisted of only lidocaine; and in one trial, the co‐intervention consisted of only captopril. In the remaining 23 trials,any use of co‐interventions was not mentioned. For further details, see '<a href="./references#CD012484-sec-0149" title="">Characteristics of included studies'</a>. </p> </section> <section id="CD012484-sec-0076"> <h4 class="title">Excluded studies</h4> <p>We excluded 22 studies after full‐text assessment based on our inclusion and exclusion criteria: eight studies were not randomised, six studies did not use a control or placebo group, three studies did not assess acute or subacute patients with myocardial infarction, two studies where either the control group or the experimental group did not meet our criteria, one study assessed participants with Ischaemic heart disease, one study was a cohort study, and one study was quasi‐randomised. For further details, see '<a href="./references#CD012484-sec-0150" title="">Characteristics of excluded studies'</a>. </p> </section> </section> <section id="CD012484-sec-0077"> <h3 class="title">Risk of bias in included studies</h3> <p>Based on information that we collected from published reports and from study authors, we considered one trial to be at low risk of bias (<a href="./references#CD012484-bbs2-0016" title="COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo‐controlled trial. Lancet2005;366(9497):1622‐32. Second Chinese Cardiac Study (CCS‐2) Collaborative Group. Rationale, design and organization of the Second Chinese Cardiac Study (CCS‐2): a randomized trial of clopidogrel plus aspirin, and of metoprolol, among patients with suspected acute myocardial infarction. Journal of Cardiovascular Risk2000;7(6):435‐41. ">COMMIT 2005</a>) and the remaining 62 trials to be at high risk of bias. We judged many trials to be at unclear risk of bias in several domains and could not obtain additional information from study authors when we contacted them. We have provided additional information in the 'Risk of bias' summary (<a href="#CD012484-fig-0002">Figure 2</a>), the 'Risk of bias' graph (<a href="#CD012484-fig-0003">Figure 3</a>), and the <a href="./references#CD012484-sec-0149" title="">Characteristics of included studies</a> table. </p> <div class="figure" id="CD012484-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD012484-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <div class="figure" id="CD012484-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD012484-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <section id="CD012484-sec-0078"> <h4 class="title">Allocation</h4> <p>The generation of the random sequence was at low risk of bias in eight trials. The remaining 55 trials were described as being randomised, but the method used for sequence generation was either not described or insufficiently described and were therefore judged to be of unclear risk of bias. </p> <p>The method used to conceal allocation was at low risk of bias in 11 trials. The remaining 52 trials were described as being randomised, but the method used for allocation concealment was either not described or insufficiently described and were judged to be of unclear risk of bias. </p> </section> <section id="CD012484-sec-0079"> <h4 class="title">Blinding</h4> <p>The blinding of participants and personnel was performed and adequately described in five trials and were judged to be at low risk of bias. Sixteen trials were either open‐label or single‐blinded and were judged to be at high risk of bias. In the remaining 42 trials, the method for blinding of participants and personnel was either not described or insufficiently described and were judged to be of unclear risk of bias. </p> <p>The blinding of outcome assessors was performed and adequately described in 17 trials and were judged to be at low risk of bias. In one trial, the outcome assessors were not blinded and were judged to be at high risk of bias (<a href="./references#CD012484-bbs2-0050" title="ColettaC , RicciR , CeciV , SeccarecciaF , RulliF , MazzucaV , et al. Effects of early treatment with captopril and metoprolol singly or together on six‐month mortality and morbidity after acute myocardial infarction. Results of the RIMA (Rimodellamento Infarto Miocardico Acuto) study. Giornale Italiano di Cardiologia1999;29(2):115‐24. ">RIMA 1999</a>). In the remaining 45 trials, the method for blinding of outcome assessors were either not described or insufficiently described and were judged to be at unclear risk of bias. </p> </section> <section id="CD012484-sec-0080"> <h4 class="title">Incomplete outcome data</h4> <p>Incomplete outcome data were addressed adequately in 25 trials and were judged to be at low risk of bias. Seven trials did not properly deal with incomplete outcome data and were judged to be at high risk of bias. In the remaining 31 trials, incomplete outcome data was either not described or insufficiently described and were judged to be at unclear risk of bias. </p> </section> <section id="CD012484-sec-0081"> <h4 class="title">Selective reporting</h4> <p>Six trials reported the results of the outcomes stated in their respective protocols, or reported our primary outcomes, resulting in low risk of bias according to our predefined bias risk assessment. In the remaining 57 trials, no protocol could be obtained and the trial did not adequately report on our primary outcomes and were judged to be of unclear risk of bias. </p> </section> <section id="CD012484-sec-0082"> <h4 class="title">Other potential sources of bias</h4> <p>Fifty‐seven trials had no other biases resulting in low risk of bias. The remaining six trials reported insufficient information to assess whether an important risk of bias exists or terminated the trial prematurely and were judged to be at 'unclear risk of bias'. </p> </section> </section> <section id="CD012484-sec-0083"> <h3 class="title" id="CD012484-sec-0083">Effects of interventions</h3> <p>See: <a href="./full#CD012484-tbl-0001"><b>Summary of findings for the main comparison</b> Beta‐blockers versus placebo or no intervention for suspected or diagnosed acute myocardial infarction at the time point less than three months follow‐up</a>; <a href="./full#CD012484-tbl-0002"><b>Summary of findings 2</b> Beta‐blockers versus placebo or no intervention for suspected or diagnosed acute myocardial infarction at maximum follow‐up beyond three months</a> </p> <section id="CD012484-sec-0084"> <h4 class="title">Primary outcomes</h4> <section id="CD012484-sec-0085"> <h5 class="title">All‐cause mortality</h5> <section id="CD012484-sec-0086"> <h6 class="title">Time point at less than three months follow‐up</h6> <p>In total 46/63 trials involving 80,452 participants and a median follow‐up of 21.8 days (range one hour to 90 days) reported all‐cause mortality at the time point 'less than three months follow‐up'. The specific assessment time points in each trial are presented in <a href="#CD012484-tbl-0003">Table 1</a>. No events occurred in either group in three trials (<a href="./references#CD012484-bbs2-0024" title="HanadaK , HigumaT , NishizakiF , SukekawaT , YokotaT , YamadaM , et al. Randomized study on the efficacy and safety of landiolol, an ultra‐short‐acting beta1‐adrenergic blocker, in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. Circulation Journal2012;76(2):439‐45. ">Hanada 2012</a>; <a href="./references#CD012484-bbs2-0041" title="NorrisRM , ClarkeED , SammelNL , SmithWM , WilliamsB . Protective effect of propranolol in threatened myocardial infarction. Lancet1978;2(8096):907‐9. ">Norris 1978</a>; <a href="./references#CD012484-bbs2-0053" title="ShirotaniM , YokotaR , KouchiI , HiraiT , UemoriN , HabaK , et al. Influence of atenolol on coronary artery spasm after acute myocardial infarction in a Japanese population. International Journal of Cardiology2010;139(2):181‐6. ">Shirotani 2010</a>). A total of 2686/40,347 (6.66%) participants receiving beta‐blockers died versus 2825/40,105 (7.04%) control participants. Fixed‐effect meta‐analysis showed no sufficient evidence of a difference (risk ratio (RR) 0.94, 97.5% confidence interval (CI) 0.90 to 1.00; I<sup>2</sup> = 0%; 80,452 participants; 46 trials/47 comparisons; high‐quality evidence; <a href="./references#CD012484-fig-0010" title="">Analysis 1.1</a>). Hence, the absolute risk for mortality at less than three months follow‐up corresponds to 67 out of 1000 participants receiving beta‐blockers dying of any reason compared with 71 out of 1000 participants receiving placebo or no intervention. The optimal information size according to the GRADE Handbook using a proportion of 7.04% in the control group, a relative risk reduction (RRR) of 10%, an alpha of 2.5%, and a beta of 10% was estimated to be 63,246 participants and we included 80,452 participants (see <a href="./full#CD012484-tbl-0001">summary of findings Table for the main comparison</a>). </p> <div class="table" id="CD012484-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Time points used at less than three months</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Trial</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Year</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>All‐cause mortality</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Major adverse cardiovascular events</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cardiovascular mortality</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Myocardial infarction during follow‐up</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Andersen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1979</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Åström</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1986</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Australian</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1984</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Australia &amp; Swedish</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1983</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Balcon</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1967</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Barbar</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1967</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Barber</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1976</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>90 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>BEAT‐AMI trial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2016</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>During hospitalisation (no mean time)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>During hospitalisation (no mean time)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>During hospitalisation (no mean time)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Briant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1970</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Campbell</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1984</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CAPRICORN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clausen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1966</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>COMMIT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28 days</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CPRG</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1980</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>56 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>56 days</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EARLY‐BAMI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2016</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30 days</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EMIT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42 days</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Evemy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1977</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gardtman</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Göteborg Metoprolol Trial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1981</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>90 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>90 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>90 days</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hanada</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>During hospitalisation (no mean time) (no events)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>During hospitalisation (no mean time) (no events)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>During hospitalisation (no mean time) (no events)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>During hospitalisation (no mean time) (no events)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Heber</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1986</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ICSG</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1984</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>During hospitalisation (no mean time)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>During hospitalisation (no mean time)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>During hospitalisation (no mean time)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ISIS‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1986</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7 days</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Johannessen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1987</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ledwich</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1968</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>McMurray</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1991</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10 days</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>METOCARD‐CNIC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7 days</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MIAMI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1985</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15 days</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MILIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1984</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mueller</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1980</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Multicenter trial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1966</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nielsen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1967</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28 days</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Norris</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1968</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Norris</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1978</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.5 days (no events)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.5 days (no events)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Norris</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1980</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>During hospitalisation (no mean time)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>During hospitalisation (no mean time)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Norris</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1984</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Owensby</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1985</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 days</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Peter</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1978</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 days</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Raeder</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1967</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ranganathan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1988</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rolli</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1980</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Salathia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1985</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>During hospitalisation (no mean time)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>90 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Shirotani</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30 days (no events)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30 days (no events)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30 days (no events)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30 days (no events)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tereschenko</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Thompson</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1979</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TIARA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1987</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30 days</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tonkin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1981</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7 days</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Van De Werf</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1993</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14 days</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Von Essen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1982</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wilcox</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1980</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yang</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1984</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yusuf</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1980</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>During hospitalisation (no mean time)</p> </td> </tr> </tbody> </table> </div> <p><i>Heterogeneity</i> </p> <p>The visual inspection of the forest plot and the tests for statistical heterogeneity (I<sup>2</sup> = 0%; P = 0.94) indicated no signs of heterogeneity. </p> <section id="CD012484-sec-0087"> <p><b>Risk of bias and sensitivity analyses</b></p> <p>One trial was assessed at low risk of bias in all domains (<a href="./references#CD012484-bbs2-0016" title="COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo‐controlled trial. Lancet2005;366(9497):1622‐32. Second Chinese Cardiac Study (CCS‐2) Collaborative Group. Rationale, design and organization of the Second Chinese Cardiac Study (CCS‐2): a randomized trial of clopidogrel plus aspirin, and of metoprolol, among patients with suspected acute myocardial infarction. Journal of Cardiovascular Risk2000;7(6):435‐41. ">COMMIT 2005</a>). One trial was assessed at low risk of bias in all but one domain and since the blinding of participants and personnel was not considered of key importance for an objective outcome like all‐cause mortality, the study was assessed at overall low risk of bias (<a href="./references#CD012484-bbs2-0034" title="IbanezB , FusterV , MacayaC , Sánchez‐BruneteV , PizarroG , López‐RomeroP , et al. Study design for the “effect of METOprolol in CARDioproteCtioN during an acute myocardial InfarCtion” (METOCARD‐CNIC): A randomized, controlled parallel‐group, observer‐blinded clinical trial of early pre‐reperfusion metoprolol administration in ST‐segment elevation myocardial infarction. American Heart Journal2012;164(4):473‐480. IbanezB , MacayaC , Sánchez‐BruneteV , PizarroG , Fernández‐FrieraL , MateosA , et al. Effect of early metoprolol on infarct size in ST‐segment‐elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: the effect of metoprolol in cardioprotection during an acute myocardial infarction (METOCARD‐CNIC) trial. Circulation2013;128(14):1495‐1503. MateosA , García‐LunarI , García‐RuizJM , PizarroG , Fernández‐JiménezR , HuertasP , et al. Efficacy and safety of out‐of‐hospital intravenous metoprolol administration in anterior ST‐segment elevation acute myocardial infarction: insights from the METOCARD‐CNIC trial. Annals of Emergency MedicineMar 2015;65(3):318‐24. PizarroG , Fernández‐FrieraL , FusterV , Fernández‐JiménezR , García‐RuizJM , García‐ÁlvarezA , et al. Long‐term benefit of early pre‐reperfusion metoprolol administration in patients with acute myocardial infarction: results from the METOCARD‐CNIC trial (Effect of Metoprolol in Cardioprotection During an Acute Myocardial Infarction). Journal of the American College of Cardiology2014;63(22):2356‐62. Sala‐VilaA , Fernández‐JiménezR , PizarroG , CalvoC , García‐RuizJM , Fernández‐FrieraL , et al. Nutritional preconditioning by marine omega‐3 fatty acids in patients with ST‐segment elevation myocardial infarction: A METOCARD‐CNIC trial substudy.. International Journal of CardiologyFeb 2017;228:828‐833. Valle‐CaballeroMJ , Fernández‐JiménezR , Díaz‐MunozR , MateosA , Rodríguez‐ÁlvarezM , Iglesias‐VázquezJA , et al. QRS distortion in pre‐reperfusion electrocardiogram is a bedside predictor of large myocardium at risk and infarct size (a METOCARD‐CNIC trial substudy).. International Journal of CardiologyJan 2016;202:666‐73. ">METOCARD‐CNIC 2013</a>). Hence, the most weighted trials of the meta‐analysis were either at overall low risk of bias or had few domains of key importance that were not at low risk of bias and the risk of bias of the outcome result was assessed as low risk of bias. </p> <p>The sensitivity analysis excluding trials at high risk of bias showed no evidence of a difference (RR 0.99, 95% CI 0.93 to 1.05; 46,122 participants; 2 trials; high‐quality evidence; <a href="./references#CD012484-fig-0019" title="">Analysis 1.10</a>). Since the sensitivity analysis and the overall meta‐analysis showed similar results, we based our summary of findings and conclusion on the overall meta‐analysis. </p> <p>The sensitivity analysis on incomplete outcome data showed that incomplete outcome data bias alone had the potential to influence the results in the best‐worst sensitivity analysis, but not in the worst‐best sensitivity analysis: best‐worst fixed‐effect meta‐analysis (RR 0.93, 95% CI 0.89 to 0.98; I<sup>2</sup> = 1%; 80,522 participants; 45 trials/46 comparisons; <a href="./references#CD012484-fig-0020" title="">Analysis 1.11</a>); worst‐best random‐effects meta‐analysis (RR 0.93, 95% CI 0.86 to 1.02; I<sup>2</sup> = 9%; 80,522 participants; 45 trials/46 comparisons; <a href="./references#CD012484-fig-0021" title="">Analysis 1.12</a>). Data were imputed for 5 trials. </p> <p>Visual inspection of the funnel plot showed no signs of asymmetry (<a href="#CD012484-fig-0004">Figure 4</a>). Based on the visual inspection of the funnel plot, we assessed the risk of publication bias as low. </p> <div class="figure" id="CD012484-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 Beta‐blockers versus placebo or no intervention at 'less than 3 months' follow‐up, outcome: 1.1 All‐cause mortality." data-id="CD012484-fig-0004" src="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Beta‐blockers versus placebo or no intervention at 'less than 3 months' follow‐up, outcome: 1.1 All‐cause mortality. </p> </div> </div> </div> <p><i>Subgroup analyses</i> </p> <p>Tests for subgroup differences showed evidence of a difference when comparing trials according to the clinical trial registration status (I<sup>2</sup> = 67.8%; P = 0.04; <a href="./references#CD012484-fig-0017" title="">Analysis 1.8</a>). The unregistered trials showed evidence of a beneficial effect of beta‐blockers versus placebo or no intervention on all‐cause mortality (RR 0.87, 95% CI 0.80 to 0.95; I<sup>2</sup> = 0%; 32,541 participants; 40 trials; <a href="./references#CD012484-fig-0017" title="">Analysis 1.8</a>), while the pre‐registered trials (RR 0.99, 95% CI 0.93 to 1.05; I<sup>2</sup> = 0%; 47,642 participants, 5 trials; <a href="./references#CD012484-fig-0017" title="">Analysis 1.8</a>) and the post‐registered trial (RR 0.50, 95% CI 0.16 to 1.63; 269 participants, 1 trial; <a href="./references#CD012484-fig-0017" title="">Analysis 1.8</a>) showed no evidence of a difference on all‐cause mortality. </p> <p>All remaining tests for subgroup differences showed no evidence of a difference in subgroup analyses according to the acute and subacute phase of commencing beta‐blockers (<a href="./references#CD012484-fig-0011" title="">Analysis 1.2</a>); reperfusion compared to no reperfusion (<a href="./references#CD012484-fig-0012" title="">Analysis 1.3</a>); types of beta‐blockers (<a href="./references#CD012484-fig-0013" title="">Analysis 1.4</a>); intravenously compared to orally commenced beta‐blockers (<a href="./references#CD012484-fig-0014" title="">Analysis 1.5</a>); age either below compared to a mixture of above/below 75 years (40/45 trials reported the age of the participants) (<a href="./references#CD012484-fig-0015" title="">Analysis 1.6</a>); different types of acute myocardial infarction (NSTEMI, STEMI, UAP, or mixed) (24/45 trials reported data on the different types of acute myocardial infarction) (<a href="./references#CD012484-fig-0016" title="">Analysis 1.7</a>), and funding (<a href="./references#CD012484-fig-0018" title="">Analysis 1.9</a>). </p> </section> </section> <section id="CD012484-sec-0088"> <h6 class="title">Maximum follow‐up beyond three months</h6> <p>A total of 21/63 trials involving 25,210 participants and a median follow‐up of 17.7 months (range 6 to 60 months) reported all‐cause mortality at maximum follow‐up beyond three months. The specific assessment time points in each trial are presented in <a href="#CD012484-tbl-0004">Table 2</a>. No events occurred in either group in one trial (<a href="./references#CD012484-bbs2-0024" title="HanadaK , HigumaT , NishizakiF , SukekawaT , YokotaT , YamadaM , et al. Randomized study on the efficacy and safety of landiolol, an ultra‐short‐acting beta1‐adrenergic blocker, in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. Circulation Journal2012;76(2):439‐45. ">Hanada 2012</a>). A total of 1742/12,708 (13.7%) participants receiving beta‐blockers died versus 1850/12,502 (14.8%) control participants. Fixed‐effect meta‐analysis showed evidence of a beneficial effect of beta‐blockers versus placebo or no intervention (RR 0.93, 97.5% CI 0.86 to 0.99; I<sup>2</sup> = 0%; 25,210 participants; 21 trials/22 comparisons; moderate‐quality evidence, <a href="./references#CD012484-fig-0022" title="">Analysis 2.1</a>). Hence, the absolute risk for mortality at maximum follow‐up corresponds to 140 out of 1000 participants receiving beta‐blockers dying of any reason compared with 151 out of 1000 participants receiving placebo or no intervention and a number needed to treat for an additional beneficial outcome (NNTB) of 91 participants. The optimal information size according to the GRADE Handbook using a proportion of 14.8% in the control group, a RRR of 10%, an alpha of 2.5%, and a beta of 10% was estimated to be 27,387 participants and we included 25,210 participants. </p> <div class="table" id="CD012484-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Time points used at maximum follow‐up beyond three months</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Trial</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Year</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>All‐cause mortality</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Major adverse cardiovascular events</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cardiovascular mortality</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Myocardial infarction</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Andersen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1979</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Australia &amp; Swedish</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1983</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Barber</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1976</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Basu</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1997</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>BEAT‐AMI trial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2016</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Briant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1970</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CAPRICORN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15.6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15.6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15.6 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EARLY‐BAMI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2016</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 month (not included)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Evemy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1977</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Göteborg Metoprolol Trial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1981</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hanada</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 months (no events)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 months (no events)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Heber</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1986</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ISIS‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1986</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.23 months (not included)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kaul</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1988</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>METOCARD‐CNIC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MILIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1984</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NPT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1982</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RIMA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Salathia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1985</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TIARA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1987</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 month (not included)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 month (not included)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tonkin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1981</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.23 months (not included)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wilcox</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1980</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yusuf</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1980</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>During hospitalisation (no mean time) (not included)</p> </td> </tr> </tbody> </table> </div> <section id="CD012484-sec-0089"> <p><b>Heterogeneity</b></p> <p>The visual inspection of the forest plot and the tests for statistical heterogeneity (I<sup>2</sup> = 0%; P = 0.95) indicated no sign of heterogeneity. </p> </section> <section id="CD012484-sec-0090"> <p><b>Risk of bias and sensitivity analyses</b></p> <p>One trial was assessed at low risk of bias in all but one domain (blinding) and since the blinding of participants and personnel was not considered of key importance for an objective outcome like all‐cause mortality, the study was assessed at low risk of bias (<a href="./references#CD012484-bbs2-0034" title="IbanezB , FusterV , MacayaC , Sánchez‐BruneteV , PizarroG , López‐RomeroP , et al. Study design for the “effect of METOprolol in CARDioproteCtioN during an acute myocardial InfarCtion” (METOCARD‐CNIC): A randomized, controlled parallel‐group, observer‐blinded clinical trial of early pre‐reperfusion metoprolol administration in ST‐segment elevation myocardial infarction. American Heart Journal2012;164(4):473‐480. IbanezB , MacayaC , Sánchez‐BruneteV , PizarroG , Fernández‐FrieraL , MateosA , et al. Effect of early metoprolol on infarct size in ST‐segment‐elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: the effect of metoprolol in cardioprotection during an acute myocardial infarction (METOCARD‐CNIC) trial. Circulation2013;128(14):1495‐1503. MateosA , García‐LunarI , García‐RuizJM , PizarroG , Fernández‐JiménezR , HuertasP , et al. Efficacy and safety of out‐of‐hospital intravenous metoprolol administration in anterior ST‐segment elevation acute myocardial infarction: insights from the METOCARD‐CNIC trial. Annals of Emergency MedicineMar 2015;65(3):318‐24. PizarroG , Fernández‐FrieraL , FusterV , Fernández‐JiménezR , García‐RuizJM , García‐ÁlvarezA , et al. Long‐term benefit of early pre‐reperfusion metoprolol administration in patients with acute myocardial infarction: results from the METOCARD‐CNIC trial (Effect of Metoprolol in Cardioprotection During an Acute Myocardial Infarction). Journal of the American College of Cardiology2014;63(22):2356‐62. Sala‐VilaA , Fernández‐JiménezR , PizarroG , CalvoC , García‐RuizJM , Fernández‐FrieraL , et al. Nutritional preconditioning by marine omega‐3 fatty acids in patients with ST‐segment elevation myocardial infarction: A METOCARD‐CNIC trial substudy.. International Journal of CardiologyFeb 2017;228:828‐833. Valle‐CaballeroMJ , Fernández‐JiménezR , Díaz‐MunozR , MateosA , Rodríguez‐ÁlvarezM , Iglesias‐VázquezJA , et al. QRS distortion in pre‐reperfusion electrocardiogram is a bedside predictor of large myocardium at risk and infarct size (a METOCARD‐CNIC trial substudy).. International Journal of CardiologyJan 2016;202:666‐73. ">METOCARD‐CNIC 2013</a>). All other trials were at high risk of bias mainly due to domains being at unclear risk of bias. Overall, the risk of bias of the outcome result was assessed as high risk of bias. </p> <p>The sensitivity analysis excluding trials at high risk of bias showed, however, no evidence of a difference (RR 0.94, 95% CI 0.31 to 2.85; 270 participants; 1 trial; low‐quality evidence; <a href="./references#CD012484-fig-0032" title="">Analysis 2.11</a>). Nevertheless, only one small trial (<a href="./references#CD012484-bbs2-0034" title="IbanezB , FusterV , MacayaC , Sánchez‐BruneteV , PizarroG , López‐RomeroP , et al. Study design for the “effect of METOprolol in CARDioproteCtioN during an acute myocardial InfarCtion” (METOCARD‐CNIC): A randomized, controlled parallel‐group, observer‐blinded clinical trial of early pre‐reperfusion metoprolol administration in ST‐segment elevation myocardial infarction. American Heart Journal2012;164(4):473‐480. IbanezB , MacayaC , Sánchez‐BruneteV , PizarroG , Fernández‐FrieraL , MateosA , et al. Effect of early metoprolol on infarct size in ST‐segment‐elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: the effect of metoprolol in cardioprotection during an acute myocardial infarction (METOCARD‐CNIC) trial. Circulation2013;128(14):1495‐1503. MateosA , García‐LunarI , García‐RuizJM , PizarroG , Fernández‐JiménezR , HuertasP , et al. Efficacy and safety of out‐of‐hospital intravenous metoprolol administration in anterior ST‐segment elevation acute myocardial infarction: insights from the METOCARD‐CNIC trial. Annals of Emergency MedicineMar 2015;65(3):318‐24. PizarroG , Fernández‐FrieraL , FusterV , Fernández‐JiménezR , García‐RuizJM , García‐ÁlvarezA , et al. Long‐term benefit of early pre‐reperfusion metoprolol administration in patients with acute myocardial infarction: results from the METOCARD‐CNIC trial (Effect of Metoprolol in Cardioprotection During an Acute Myocardial Infarction). Journal of the American College of Cardiology2014;63(22):2356‐62. Sala‐VilaA , Fernández‐JiménezR , PizarroG , CalvoC , García‐RuizJM , Fernández‐FrieraL , et al. Nutritional preconditioning by marine omega‐3 fatty acids in patients with ST‐segment elevation myocardial infarction: A METOCARD‐CNIC trial substudy.. International Journal of CardiologyFeb 2017;228:828‐833. Valle‐CaballeroMJ , Fernández‐JiménezR , Díaz‐MunozR , MateosA , Rodríguez‐ÁlvarezM , Iglesias‐VázquezJA , et al. QRS distortion in pre‐reperfusion electrocardiogram is a bedside predictor of large myocardium at risk and infarct size (a METOCARD‐CNIC trial substudy).. International Journal of CardiologyJan 2016;202:666‐73. ">METOCARD‐CNIC 2013</a>) with a low event rate in the control group (4.56%) was included in this sensitivity analysis. Hence, the result from this sensitivity analysis might be assessed at low risk of bias, but has other very serious problems such as imprecision and indirectness. As a consequence of these serious limitations, we have not based our summary of findings and conclusions on this sensitivity analysis. Instead, we have based our summary of findings and conclusion on the overall meta‐analysis. </p> <p>The sensitivity analysis on incomplete outcome data showed that incomplete outcome data bias alone had the potential to influence the results in the best‐worst sensitivity analysis, but not in the worst‐best sensitivity analysis: best‐worst random‐effects meta‐analysis (RR 0.89, 95% CI 0.81 to 0.97; I<sup>2</sup> = 15%; 25,283 participants; 21 trials/22 comparisons; <a href="./references#CD012484-fig-0033" title="">Analysis 2.12</a>); worst‐best random‐effects meta‐analysis (RR 0.95, 95% CI 0.85 to 1.06; I<sup>2</sup> = 33%; 25,283 participants; 21 trials/22 comparisons; <a href="./references#CD012484-fig-0034" title="">Analysis 2.13</a>). Data were imputed for five trials. </p> <p>Visual inspection of the funnel plot showed no signs of asymmetry (<a href="#CD012484-fig-0005">Figure 5</a>). Based on the visual inspection of the funnel plot, we assessed the risk of publication bias as low. </p> <div class="figure" id="CD012484-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 2 Beta‐blockers versus placebo or no intervention at maximum follow‐up beyond 3 months, outcome: 2.1 All‐cause mortality." data-id="CD012484-fig-0005" src="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 2 Beta‐blockers versus placebo or no intervention at maximum follow‐up beyond 3 months, outcome: 2.1 All‐cause mortality. </p> </div> </div> </div> <p><i>Subgroup analyses</i> </p> <p>Tests for subgroup differences showed no evidence of a difference in subgroup analyses according to the acute and subacute phase of commencing beta‐blockers (<a href="./references#CD012484-fig-0023" title="">Analysis 2.2</a>); reperfusion compared to no reperfusion (<a href="./references#CD012484-fig-0024" title="">Analysis 2.3</a>); types of beta‐blockers (<a href="./references#CD012484-fig-0025" title="">Analysis 2.4</a>); age either below compared to a mixture of above/below 75 years (<a href="./references#CD012484-fig-0026" title="">Analysis 2.5</a>); intravenously compared to orally commenced (<a href="./references#CD012484-fig-0027" title="">Analysis 2.6</a>); different types of acute myocardial infarction (NSTEMI, STEMI, UAP, or mixed) (7/20 trials reported data on the different types of acute myocardial infarction) (<a href="./references#CD012484-fig-0029" title="">Analysis 2.8</a>); clinical trial registration status (<a href="./references#CD012484-fig-0028" title="">Analysis 2.7</a>); length of the intervention period (<a href="./references#CD012484-fig-0030" title="">Analysis 2.9</a>); and funding (<a href="./references#CD012484-fig-0031" title="">Analysis 2.10</a>). </p> </section> </section> </section> <section id="CD012484-sec-0091"> <h5 class="title">Serious adverse events</h5> <section id="CD012484-sec-0092"> <h6 class="title">Time point less than three months follow‐up</h6> <p>None of the trials specifically assessed nor reported serious adverse events according to ICH‐GCP. Instead, the trials either reported composites of several specific serious adverse events or one specific serious adverse event. </p> <p>We reported narratively the individual types of serious adverse events in each trial at the time point less than three months follow‐up in <a href="#CD012484-tbl-0005">Table 3</a>. </p> <div class="table" id="CD012484-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Serious adverse events ‐ less than three months</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Trial</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Year</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Type and number of serious adverse events (beta‐blocker group)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Type and number of serious adverse events (control group)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Andersen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1979</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0025"> <li> <p>41 deaths from all causes</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0026"> <li> <p>37 deaths from all causes</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Åstrøm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1986</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0027"> <li> <p>1 atrial fibrillation</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Australian trial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1984</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0028"> <li> <p>1 death from all causes</p> </li> </ul> <ul id="CD012484-list-0029"> <li> <p>6 heart failure</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0030"> <li> <p>2 death from all causes</p> </li> <li> <p>3 heart failure</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Australia &amp; Swedish</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1983</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0031"> <li> <p>13 deaths from all causes</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0032"> <li> <p>13 deaths from all causes</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Balcon</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1967</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0033"> <li> <p>13 deaths from all causes</p> </li> <li> <p>11 heart failure</p> </li> <li> <p>7 shock</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0034"> <li> <p>14 deaths from all causes</p> </li> <li> <p>5 heart failure</p> </li> <li> <p>7 shock</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Barbar</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1967</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0035"> <li> <p>10 deaths from all causes</p> </li> <li> <p>20 heart failure</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0036"> <li> <p>12 deaths from all causes</p> </li> <li> <p>18 heart failure</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Barber</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1976</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0037"> <li> <p>23 deaths from all causes</p> </li> <li> <p>49 heart failure</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0038"> <li> <p>25 deaths from all causes</p> </li> <li> <p>29 heart failure</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>BEAT‐AMI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2016</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0039"> <li> <p>4 ventricular tachycardia</p> </li> <li> <p>1 atrial fibrillation</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0040"> <li> <p>1 deaths from all causes</p> </li> <li> <p>11 ventricular tachycardia</p> </li> <li> <p>3 cardiogenic shock</p> </li> <li> <p>2 myocardial infarction during follow‐up</p> </li> <li> <p>3 atrial fibrillation</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Briant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1970</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0041"> <li> <p>5 deaths from all causes</p> </li> <li> <p>8 ventricular tachycardia</p> </li> <li> <p>3 ventricular fibrillation</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0042"> <li> <p>4 deaths from all causes</p> </li> <li> <p>2 ventricular tachycardia</p> </li> <li> <p>2 ventricular fibrillation</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Campbell</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1984</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0043"> <li> <p>1 death from all causes</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0044"> <li> <p>2 deaths from all causes</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CAPRICORN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0045"> <li> <p>10 deaths from all causes</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0046"> <li> <p>20 deaths from all causes</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clausen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1966</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0047"> <li> <p>18 deaths from all causes</p> </li> <li> <p>9 thromboembolic complications</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0048"> <li> <p>19 deaths from all causes</p> </li> <li> <p>6 thromboembolic complications</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>COMMIT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0049"> <li> <p>1774 deaths from all causes</p> </li> <li> <p>464 myocardial infarction during follow‐up</p> </li> <li> <p>3224 heart failure</p> </li> <li> <p>247 stroke</p> </li> <li> <p>200 presumed cardiac rupture</p> </li> <li> <p>30 pulmonary embolus</p> </li> <li> <p>370 atrioventricular block</p> </li> <li> <p>1141 cardiogenic shock</p> </li> <li> <p>581 ventricular fibrillation</p> </li> <li> <p>685 other cardiac arrest (including asystole, but excluding ventricular fibrillation and arrhythmia) </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0050"> <li> <p>1797 deaths from all causes</p> </li> <li> <p>568 myocardial infarction during follow‐up</p> </li> <li> <p>2902 heart failure</p> </li> <li> <p>220 stroke</p> </li> <li> <p>233 presumed cardiac rupture</p> </li> <li> <p>35 pulmonary embolus</p> </li> <li> <p>357 atrioventricular block</p> </li> <li> <p>885 cardiogenic shock</p> </li> <li> <p>698 ventricular fibrillation</p> </li> <li> <p>632 other cardiac arrest (including asystole, but excluding ventricular fibrillation and arrhythmia) </p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CPRG</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1980</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0051"> <li> <p>9 deaths from all causes</p> </li> <li> <p>3 myocardial infarction during follow‐up</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0052"> <li> <p>5 deaths from all causes</p> </li> <li> <p>7 myocardial infarction during follow‐up</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EARLY‐BAMI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2016</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0053"> <li> <p>7 deaths from cardiac causes</p> </li> <li> <p>3 myocardial infarction during follow‐up</p> </li> <li> <p>2 cardiogenic shock</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0054"> <li> <p>7 deaths from cardiac causes</p> </li> <li> <p>2 myocardial infarction during follow‐up</p> </li> <li> <p>1 cardiogenic shock</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EMIT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0055"> <li> <p>2 deaths from all causes</p> </li> <li> <p>4 myocardial infarction during follow‐up</p> </li> <li> <p>7 heart failure</p> </li> <li> <p>2 AV‐block</p> </li> <li> <p>1 VT/VF</p> </li> <li> <p>8 silent myocardial ischaemic episode</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0056"> <li> <p>1 death from all causes</p> </li> <li> <p>2 myocardial infarction during follow‐up</p> </li> <li> <p>8 heart failure</p> </li> <li> <p>2 AV‐block</p> </li> <li> <p>2 VT/VF</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Evemy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1977</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0057"> <li> <p>7 deaths from all causes</p> </li> <li> <p>12 heart failure</p> </li> <li> <p>3 cardiogenic shock</p> </li> <li> <p>3 ventricular fibrillation</p> </li> <li> <p>2 ventricular tachycardia</p> </li> <li> <p>4 second degree AV‐block</p> </li> <li> <p>3 complete AV‐block</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0058"> <li> <p>4 deaths from all causes</p> </li> <li> <p>14 heart failure</p> </li> <li> <p>3 ventricular fibrillation</p> </li> <li> <p>4 ventricular tachycardia</p> </li> <li> <p>9 atrial fibrillation</p> </li> <li> <p>1 complete AV‐block</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gardtman</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0059"> <li> <p>5 deaths from all causes</p> </li> <li> <p>1 ventricular tachycardia</p> </li> <li> <p>17 heart failure</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0060"> <li> <p>4 deaths from all causes</p> </li> <li> <p>4 ventricular tachycardia</p> </li> <li> <p>1 AV block III</p> </li> <li> <p>19 heart failure</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Göteborg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1981</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0061"> <li> <p>40 deaths from all causes</p> </li> <li> <p>35 myocardial infarction during follow‐up</p> </li> <li> <p>70 hospitalisation for any cause</p> </li> <li> <p>12 heart failure</p> </li> <li> <p>16 AV‐block II‐III</p> </li> <li> <p>6 ventricular fibrillation</p> </li> <li> <p>15 sudden circulatory collapse</p> </li> <li> <p>10 rupture of ventricular wall</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0062"> <li> <p>62 deaths from all causes</p> </li> <li> <p>54 myocardial infarction during follow‐up</p> </li> <li> <p>91 hospitalisation for any cause</p> </li> <li> <p>25 heart failure</p> </li> <li> <p>11 AV‐block II‐III</p> </li> <li> <p>17 ventricular fibrillation</p> </li> <li> <p>25 sudden circulatory collapse</p> </li> <li> <p>15 rupture of ventricular wall</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Heber</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1986</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0063"> <li> <p>5 deaths from all causes</p> </li> <li> <p>11 heart failure</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0064"> <li> <p>1 death from all causes</p> </li> <li> <p>6 heart failure</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ICSG</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1984</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0065"> <li> <p>3 deaths from all causes</p> </li> <li> <p>2 myocardial infarction during follow‐up</p> </li> <li> <p>11 heart failure</p> </li> <li> <p>2 ventricular fibrillation</p> </li> <li> <p>3 cerebrovascular accident</p> </li> <li> <p>3 II/III AV‐block</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0066"> <li> <p>4 deaths from all causes</p> </li> <li> <p>2 myocardial infarction during follow‐up</p> </li> <li> <p>12 heart failure</p> </li> <li> <p>4 ventricular fibrillation</p> </li> <li> <p>1 cerebrovascular accident</p> </li> <li> <p>3 II/III AV‐block</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ISIS‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1986</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0067"> <li> <p>423 deaths from all causes</p> </li> <li> <p>148 myocardial infarctions during follow‐up</p> </li> <li> <p>189 cardiac arrest</p> </li> <li> <p>180 complete heart block</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0068"> <li> <p>493 deaths from all causes</p> </li> <li> <p>161 myocardial infarction during follow‐up</p> </li> <li> <p>198 cardiac arrest</p> </li> <li> <p>152 complete heart block</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Johannessen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1987</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0069"> <li> <p>2 deaths from all causes</p> </li> <li> <p>1 peripheral abdominal embolus</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0070"> <li> <p>3 atrial fibrillation</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ledwich</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1968</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0071"> <li> <p>2 deaths from all causes</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0072"> <li> <p>3 deaths from all causes</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lloyd</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1988</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0073"> <li> <p>3 ventricular tachycardia</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0074"> <li> <p>14 ventricular tachycardia</p> </li> <li> <p>2 ventricular fibrillation</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mcmurray</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1991</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0075"> <li> <p>1 ventricular fibrillation</p> </li> <li> <p>2 2nd degree AV‐block</p> </li> <li> <p>1 atrial fibrillation</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0076"> <li> <p>1 ventricular tachycardia</p> </li> <li> <p>1 heart failure</p> </li> <li> <p>1 AV‐block II</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>METOCARD‐CNIC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0077"> <li> <p>3 deaths from all causes</p> </li> <li> <p>1 myocardial infarction during follow‐up</p> </li> <li> <p>5 malignant ventricular arrhythmia</p> </li> <li> <p>1 advanced AV‐block</p> </li> <li> <p>6 cardiogenic shock</p> </li> <li> <p>11 heart failure</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0078"> <li> <p>3 deaths from all causes</p> </li> <li> <p>10 malignant ventricular arrhythmia</p> </li> <li> <p>2 advanced AV‐block</p> </li> <li> <p>7 cardiogenic shock</p> </li> <li> <p>9 heart failure</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Miami</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1985</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0079"> <li> <p>123 deaths from all causes</p> </li> <li> <p>85 myocardial infarction during follow‐up</p> </li> <li> <p>37 ventricular tachycardia</p> </li> <li> <p>74 asystole</p> </li> <li> <p>160 AV block II‐III</p> </li> <li> <p>699 heart failure</p> </li> <li> <p>86 cardiogenic shock</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0080"> <li> <p>142 deaths from all causes</p> </li> <li> <p>111 myocardial infarction during follow‐up</p> </li> <li> <p>40 ventricular tachycardia</p> </li> <li> <p>64 asystole</p> </li> <li> <p>153 AV block II‐III</p> </li> <li> <p>660 heart failure</p> </li> <li> <p>93 cardiogenic shock</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MILIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1984</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0081"> <li> <p>4 deaths from all causes</p> </li> <li> <p>25 heart failure</p> </li> <li> <p>17 ventricular tachycardia</p> </li> <li> <p>8 heart block</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0082"> <li> <p>8 deaths from all causes</p> </li> <li> <p>31 heart failure</p> </li> <li> <p>28 ventricular tachycardia</p> </li> <li> <p>9 heart block</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mueller</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1980</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0083"> <li> <p>2 deaths from all causes</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0084"> <li> <p>1 death from all causes</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Multicenter trial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1966</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0085"> <li> <p>15 deaths from all causes</p> </li> <li> <p>17 heart failure</p> </li> <li> <p>9 cardiac arrest</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0086"> <li> <p>12 deaths from all causes</p> </li> <li> <p>7 heart failure</p> </li> <li> <p>7 cardiac arrest</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nielsen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1967</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0087"> <li> <p>18 deaths from all causes</p> </li> <li> <p>2 myocardial infarction during follow‐up</p> </li> <li> <p>7 thrombo‐embolic complications</p> </li> <li> <p>2 heart failure</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0088"> <li> <p>19 deaths from all causes</p> </li> <li> <p>6 thrombo‐embolic complications</p> </li> <li> <p>6 heart failure</p> </li> <li> <p>2 cardiogenic shock</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Norris</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1968</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0089"> <li> <p>20 deaths from all causes</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0090"> <li> <p>17 deaths</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Norris</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1978</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0091"> <li> <p>1 heart failure</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0092"> <li> <p>1 heart failure</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Norris</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1980</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0093"> <li> <p>1 death from all causes</p> </li> <li> <p>1 ventricular fibrillation</p> </li> <li> <p>1 cardiogenic shock</p> </li> <li> <p>3 heart failure</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0094"> <li> <p>1 ventricular fibrillation</p> </li> <li> <p>1 cardiogenic shock</p> </li> <li> <p>2 AV‐block II‐III</p> </li> <li> <p>8 heart failure</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Norris</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1984</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0095"> <li> <p>15 deaths from all causes,</p> </li> <li> <p>7 ventricular fibrillation</p> </li> <li> <p>22 atrial fibrillation</p> </li> <li> <p>13 AV block II‐III</p> </li> <li> <p>14 bundle‐branch block</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0096"> <li> <p>14 deaths from all causes,</p> </li> <li> <p>18 ventricular fibrillation</p> </li> <li> <p>23 atrial fibrillation</p> </li> <li> <p>8 AV block II‐III</p> </li> <li> <p>14 bundle‐branch block</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Owensby</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1985</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0097"> <li> <p>1 death from all causes</p> </li> <li> <p>2 myocardial infarction during follow‐up</p> </li> <li> <p>23 heart failure</p> </li> <li> <p>6 AV‐block II‐III</p> </li> <li> <p>13 ventricular tachycardia</p> </li> <li> <p>4 ventricular fibrillation</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0098"> <li> <p>1 death from all causes</p> </li> <li> <p>2 myocardial infarction during follow‐up</p> </li> <li> <p>23 heart failure</p> </li> <li> <p>5 AV‐block II‐III</p> </li> <li> <p>12 ventricular tachycardia</p> </li> <li> <p>3 ventricular fibrillation</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Peter</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1978</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0099"> <li> <p>1 death from all causes</p> </li> <li> <p>1 myocardial infarction during follow‐up</p> </li> <li> <p>5 heart failure</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0100"> <li> <p>2 deaths from all causes</p> </li> <li> <p>3 myocardial infarction during follow‐up</p> </li> <li> <p>5 heart failure</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Raeder</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1967</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0101"> <li> <p>2 deaths from all causes</p> </li> <li> <p>1 AV‐block II‐III</p> </li> <li> <p>2 atrial fibrillation</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0102"> <li> <p>2 deaths from all causes</p> </li> <li> <p>1 AV‐block II‐III</p> </li> <li> <p>1 atrial fibrillation</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ramsdale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1982</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0103"> <li> <p>1 heart failure</p> </li> <li> <p>1 complete heart block</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ranganathan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1988</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0104"> <li> <p>1 death from all causes</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0105"> <li> <p>3 deaths from all causes</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rolli</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1980</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0106"> <li> <p>1 bundle block or hemiblock</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0107"> <li> <p>2 ventricular fibrillation</p> </li> <li> <p>3 heart failure</p> </li> <li> <p>2 bundle branch block or hemiblock</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Salathia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1985</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0108"> <li> <p>25 deaths from all causes</p> </li> <li> <p>11 ventricular fibrillation</p> </li> <li> <p>9 with AV‐block II‐III</p> </li> <li> <p>47 heart failure</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0109"> <li> <p>20 deaths from all causes</p> </li> <li> <p>14 ventricular fibrillation</p> </li> <li> <p>18 with AV‐block II‐III</p> </li> <li> <p>35 heart failure</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tereschenko</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0110"> <li> <p>3 deaths from all causes</p> </li> <li> <p>4 heart failure</p> </li> <li> <p>6 post‐infarction angina pectoris</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0111"> <li> <p>2 deaths from all causes</p> </li> <li> <p>7 heart failure</p> </li> <li> <p>5 post‐infarction angina pectoris</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Thompson</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1979</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0112"> <li> <p>3 deaths from all causes</p> </li> <li> <p>6 heart failure</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0113"> <li> <p>3 deaths from all causes</p> </li> <li> <p>6 heart failure</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TIARA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1987</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0114"> <li> <p>3 deaths from all causes</p> </li> <li> <p>3 myocardial infarction during follow‐up</p> </li> <li> <p>7 ventricular tachycardia</p> </li> <li> <p>10 heart failure</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0115"> <li> <p>7 deaths from all causes</p> </li> <li> <p>6 myocardial infarction during follow‐up</p> </li> <li> <p>16 ventricular tachycardia</p> </li> <li> <p>3 ventricular fibrillation</p> </li> <li> <p>18 heart failure</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tonkin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1981</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0116"> <li> <p>1 death from all causes</p> </li> <li> <p>1 reinfarction</p> </li> <li> <p>14 heart failure</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0117"> <li> <p>1 death from all causes</p> </li> <li> <p>16 heart failure</p> </li> <li> <p>1 AV‐block</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Van De Werf</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1993</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0118"> <li> <p>1 death from all causes</p> </li> <li> <p>9 myocardial infarction during follow‐up</p> </li> <li> <p>6 pulmonary edema</p> </li> <li> <p>4 pericarditis</p> </li> <li> <p>3 cardiogenic shock</p> </li> <li> <p>9 AV block II‐III</p> </li> <li> <p>21 ventricular tachycardia</p> </li> <li> <p>2 ventricular fibrillation</p> </li> <li> <p>1 stroke</p> </li> <li> <p>2 bleeding requiring transfusion</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0119"> <li> <p>4 death from all causes</p> </li> <li> <p>10 myocardial infarction during follow‐up</p> </li> <li> <p>3 pericarditis</p> </li> <li> <p>1 cardiac rupture</p> </li> <li> <p>7 AV block II‐III</p> </li> <li> <p>18 ventricular tachycardia</p> </li> <li> <p>3 ventricular fibrillation</p> </li> <li> <p>2 stroke</p> </li> <li> <p>1 bleeding requiring transfusion</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Von Essen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1982</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0120"> <li> <p>1 death from all causes</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0121"> <li> <p>1 death from all causes</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wilcox (atenolol)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1980</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0122"> <li> <p>11 deaths from all causes</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0123"> <li> <p>8 deaths from all causes</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wilcox (propranolol)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1980</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0124"> <li> <p>10 death from all causes</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0125"> <li> <p>7 deaths from all causes</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yang</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1984</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0126"> <li> <p>2 AV‐block II</p> </li> <li> <p>1 ventricular fibrillation</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0127"> <li> <p>1 AV‐block II</p> </li> <li> <p>2 atrial fibrillation</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yusuf</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1980</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0128"> <li> <p>7 death form all causes</p> </li> <li> <p>46 heart failure</p> </li> <li> <p>13 AV block II‐III</p> </li> <li> <p>4 cardiac arrest</p> </li> <li> <p>3 pulmonary embolus</p> </li> <li> <p>1 renal failure</p> </li> <li> <p>1 cardiogenic shock</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0129"> <li> <p>16 death form all causes</p> </li> <li> <p>6 myocardial infarction during follow‐up</p> </li> <li> <p>56 heart failure</p> </li> <li> <p>18 AV block II‐III</p> </li> <li> <p>15 cardiac arrest</p> </li> <li> <p>2 ventricular septal defect</p> </li> <li> <p>4 cardiogenic shock</p> </li> </ul> </p> </td> </tr> </tbody> </table> </div> </section> <section id="CD012484-sec-0093"> <h6 class="title">Maximum follow‐up beyond three months</h6> <p>None of the trials specifically assessed nor reported serious adverse events according to ICH‐GCP. Instead, the trials either reported composites of several specific serious adverse events or one specific serious adverse event. </p> <p>We reported narratively the individual types of serious adverse events in each trial at maximum follow‐up beyond three months in <a href="#CD012484-tbl-0006">Table 4</a>. </p> <div class="table" id="CD012484-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Serious adverse events ‐ maximum follow‐up</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Trial</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Year</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Type and number of serious adverse events (beta‐blocker group)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Type and number of serious adverse events (control group)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Andersen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1979</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0130"> <li> <p>62 deaths from all causes</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0131"> <li> <p>60 deaths from all causes</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Åstrøm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1986</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0132"> <li> <p>1 atrial fibrillation</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Australian trial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1984</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0133"> <li> <p>1 death from all causes</p> </li> </ul> <ul id="CD012484-list-0134"> <li> <p>6 heart failure</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0135"> <li> <p>2 death from all causes</p> </li> <li> <p>3 heart failure</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Australia &amp; Swedish</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1983</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0136"> <li> <p>45 deaths from all causes</p> </li> <li> <p>37 myocardial infarction during follow‐up</p> </li> <li> <p>20 heart failure</p> </li> <li> <p>2 surgery</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0137"> <li> <p>47 deaths from all causes</p> </li> <li> <p>41 myocardial infarction during follow‐up</p> </li> <li> <p>11 heart failure</p> </li> <li> <p>1 ventricular arrhythmia</p> </li> <li> <p>6 surgery</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Balcon</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1967</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0138"> <li> <p>13 deaths from all causes</p> </li> <li> <p>11 heart failure</p> </li> <li> <p>7 shock</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0139"> <li> <p>14 deaths from all causes</p> </li> <li> <p>5 heart failure</p> </li> <li> <p>7 shock</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Barbar</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1967</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0140"> <li> <p>10 deaths from all causes</p> </li> <li> <p>20 heart failure</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0141"> <li> <p>12 deaths from all causes</p> </li> <li> <p>18 heart failure</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Barber</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1976</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0142"> <li> <p>47 deaths from all causes</p> </li> <li> <p>9 heart failure</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0143"> <li> <p>46 deaths from all causes</p> </li> <li> <p>17 heart failure</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Basu</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1997</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0144"> <li> <p>2 deaths from cardiac causes</p> </li> <li> <p>4 myocardial infarction during follow‐up</p> </li> <li> <p>5 heart failure</p> </li> <li> <p>3 unstable angina</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0145"> <li> <p>3 deaths from cardiac causes</p> </li> <li> <p>8 myocardial infarction during follow‐up</p> </li> <li> <p>5 heart failure</p> </li> <li> <p>6 unstable angina</p> </li> <li> <p>2 CABG/PTCA</p> </li> <li> <p>1 cerebrovascular accident</p> </li> <li> <p>1 ventricular arrhythmia</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>BEAT‐AMI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2016</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0146"> <li> <p>4 ventricular tachycardia</p> </li> <li> <p>8 revascularisation</p> </li> <li> <p>1 atrial fibrillation</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0147"> <li> <p>1 deaths from all causes</p> </li> <li> <p>2 myocardial infarction during follow‐up</p> </li> <li> <p>11 ventricular tachycardia</p> </li> <li> <p>3 cardiogenic shock</p> </li> <li> <p>1 stroke</p> </li> <li> <p>13 revascularisations</p> </li> <li> <p>3 atrial fibrillation</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Briant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1970</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0148"> <li> <p>8 deaths from all causes</p> </li> <li> <p>4 myocardial infarction during follow‐up</p> </li> <li> <p>3 heart failure</p> </li> <li> <p>1 pulmonary edema</p> </li> <li> <p>1 post‐infarction angina pectoris</p> </li> <li> <p>1 coronary insufficiency</p> </li> <li> <p>8 ventricular tachycardia</p> </li> <li> <p>3 ventricular fibrillation</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0149"> <li> <p>7 deaths from all causes</p> </li> <li> <p>4 myocardial infarction during follow‐up</p> </li> <li> <p>3 heart failure</p> </li> <li> <p>4 post‐infarction angina pectoris</p> </li> <li> <p>2 coronary insufficiency</p> </li> <li> <p>2 ventricular tachycardia</p> </li> <li> <p>2 ventricular fibrillation</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Campbell</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1984</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0150"> <li> <p>1 death from all causes</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0151"> <li> <p>2 deaths from all causes</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CAPRICORN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0152"> <li> <p>116 deaths from all causes</p> </li> <li> <p>34 myocardial infarction during follow‐up</p> </li> <li> <p>118 hospitalisations for heart failure</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0153"> <li> <p>151 deaths from all causes</p> </li> <li> <p>57 myocardial infarction during follow‐up</p> </li> <li> <p>138 hospitalisations for heart failure</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clausen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1966</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0154"> <li> <p>18 deaths from all causes</p> </li> <li> <p>9 thromboembolic complications</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0155"> <li> <p>19 deaths from all causes</p> </li> <li> <p>6 thromboembolic complications</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>COMMIT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0156"> <li> <p>1774 deaths from all causes</p> </li> <li> <p>464 myocardial infarction during follow‐up</p> </li> <li> <p>3224 heart failure</p> </li> <li> <p>247 stroke</p> </li> <li> <p>200 presumed cardiac rupture</p> </li> <li> <p>30 pulmonary embolus</p> </li> <li> <p>370 atrioventricular block</p> </li> <li> <p>1141 cardiogenic shock</p> </li> <li> <p>581 ventricular fibrillation</p> </li> <li> <p>685 other cardiac arrest (including asystole, but excluding ventricular fibrillation and arrhythmia) </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0157"> <li> <p>1797 deaths from all causes</p> </li> <li> <p>568 myocardial infarction during follow‐up</p> </li> <li> <p>2902 heart failure</p> </li> <li> <p>220 stroke</p> </li> <li> <p>233 presumed cardiac rupture</p> </li> <li> <p>35 pulmonary embolus</p> </li> <li> <p>357 atrioventricular block</p> </li> <li> <p>885 cardiogenic shock</p> </li> <li> <p>698 ventricular fibrillation</p> </li> <li> <p>632 other cardiac arrest (including asystole, but excluding ventricular fibrillation and arrhythmia) </p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CPRG</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1980</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0158"> <li> <p>9 deaths from all causes</p> </li> <li> <p>3 myocardial infarction during follow‐up</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0159"> <li> <p>5 deaths from all causes</p> </li> <li> <p>7 myocardial infarction during follow‐up</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EARLY‐BAMI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2016</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0160"> <li> <p>11 deaths from all causes</p> </li> <li> <p>3 myocardial infarction during follow‐up</p> </li> <li> <p>8 ICD implantation</p> </li> <li> <p>4 hospitalisation for heart failure</p> </li> <li> <p>2 cardiogenic shock</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0161"> <li> <p>11 deaths from all causes</p> </li> <li> <p>2 myocardial infarction during follow‐up</p> </li> <li> <p>4 ICD implantation</p> </li> <li> <p>3 hospitalisation for heart failure</p> </li> <li> <p>1 cardiogenic shock</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EMIT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0162"> <li> <p>2 deaths from all causes</p> </li> <li> <p>4 myocardial infarction during follow‐up</p> </li> <li> <p>7 heart failure</p> </li> <li> <p>2 AV‐block</p> </li> <li> <p>1 VT/VF</p> </li> <li> <p>8 silent myocardial ischaemic episode</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0163"> <li> <p>1 death from all causes</p> </li> <li> <p>2 myocardial infarction during follow‐up</p> </li> <li> <p>8 heart failure</p> </li> <li> <p>2 AV‐block</p> </li> <li> <p>2 VT/VF</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Evemy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1977</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0164"> <li> <p>9 deaths from all causes</p> </li> <li> <p>5 heart failure</p> </li> <li> <p>3 cardiogenic shock</p> </li> <li> <p>3 ventricular fibrillation</p> </li> <li> <p>2 ventricular tachycardia</p> </li> <li> <p>4 second degree AV‐block</p> </li> <li> <p>3 complete AV‐block</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0165"> <li> <p>6 deaths from all causes</p> </li> <li> <p>8 heart failure</p> </li> <li> <p>3 ventricular fibrillation</p> </li> <li> <p>4 ventricular tachycardia</p> </li> <li> <p>9 atrial fibrillation</p> </li> <li> <p>1 complete AV‐block</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gardtman</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0166"> <li> <p>5 deaths from all causes</p> </li> <li> <p>1 ventricular tachycardia</p> </li> <li> <p>17 heart failure</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0167"> <li> <p>4 deaths from all causes</p> </li> <li> <p>4 ventricular tachycardia</p> </li> <li> <p>1 AV block III</p> </li> <li> <p>19 heart failure</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Göteborg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1981</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0168"> <li> <p>169 deaths from all causes</p> </li> <li> <p>157 myocardial infarction during follow‐up</p> </li> <li> <p>34 stroke</p> </li> <li> <p>16 CABG</p> </li> <li> <p>70 hospitalisation for any cause</p> </li> <li> <p>42 heart failure</p> </li> <li> <p>16 AV‐block II‐III</p> </li> <li> <p>6 ventricular fibrillation</p> </li> <li> <p>15 sudden circulatory collapse</p> </li> <li> <p>10 rupture of ventricular wall</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0169"> <li> <p>179 deaths from all causes</p> </li> <li> <p>156 myocardial infarction during follow‐up</p> </li> <li> <p>37 stroke</p> </li> <li> <p>22 CABG</p> </li> <li> <p>91 hospitalisation for any cause</p> </li> <li> <p>42 heart failure</p> </li> <li> <p>11 AV‐block II‐III</p> </li> <li> <p>17 ventricular fibrillation</p> </li> <li> <p>25 sudden circulatory collapse</p> </li> <li> <p>15 rupture of ventricular wall</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hanada</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0170"> <li> <p>1 myocardial infarction during follow‐up</p> </li> <li> <p>1 heart failure</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Heber</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1986</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0171"> <li> <p>12 deaths from all causes</p> </li> <li> <p>14 heart failure</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0172"> <li> <p>7 death from all causes</p> </li> <li> <p>9 heart failure</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ICSG</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1984</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0173"> <li> <p>3 deaths from all causes</p> </li> <li> <p>2 myocardial infarction during follow‐up</p> </li> <li> <p>11 heart failure</p> </li> <li> <p>2 ventricular fibrillation</p> </li> <li> <p>3 cerebrovascular accident</p> </li> <li> <p>3 II/III AV‐block</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0174"> <li> <p>4 deaths from all causes</p> </li> <li> <p>2 myocardial infarction during follow‐up</p> </li> <li> <p>12 heart failure</p> </li> <li> <p>4 ventricular fibrillation</p> </li> <li> <p>1 cerebrovascular accident</p> </li> <li> <p>3 II/III AV‐block</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ISIS‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1986</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0175"> <li> <p>1071 deaths from all causes</p> </li> <li> <p>148 myocardial infarctions during follow‐up</p> </li> <li> <p>189 cardiac arrest</p> </li> <li> <p>180 complete heart block</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0176"> <li> <p>1120 deaths from all causes</p> </li> <li> <p>161 myocardial infarction during follow‐up</p> </li> <li> <p>198 cardiac arrest</p> </li> <li> <p>152 complete heart block</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Johannessen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1987</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0177"> <li> <p>2 deaths from all causes</p> </li> <li> <p>1 peripheral abdominal embolus</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0178"> <li> <p>3 atrial fibrillation</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kaul</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1988</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0179"> <li> <p>4 deaths from all causes</p> </li> <li> <p>4 post‐infarction angina pectoris</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0180"> <li> <p>3 deaths from all causes</p> </li> <li> <p>4 myocardial infarction during follow‐up</p> </li> <li> <p>9 post‐infarction angina pectoris</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ledwich</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1968</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0181"> <li> <p>2 deaths from all causes</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0182"> <li> <p>3 deaths from all causes</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lloyd</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1988</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0183"> <li> <p>3 ventricular tachycardia</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0184"> <li> <p>14 ventricular tachycardia</p> </li> <li> <p>2 ventricular fibrillation</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mcmurray</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1991</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0185"> <li> <p>1 ventricular fibrillation</p> </li> <li> <p>2 2nd degree AV‐block</p> </li> <li> <p>1 atrial fibrillation</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0186"> <li> <p>1 ventricular tachycardia</p> </li> <li> <p>1 heart failure</p> </li> <li> <p>1 AV‐block II</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>METOCARD‐CNIC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0187"> <li> <p>6 deaths from all causes</p> </li> <li> <p>1 myocardial infarction during follow‐up</p> </li> <li> <p>5 malignant ventricular arrhythmia</p> </li> <li> <p>1 advanced AV‐block</p> </li> <li> <p>6 cardiogenic shock</p> </li> <li> <p>11 heart failure</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0188"> <li> <p>6 deaths from all causes</p> </li> <li> <p>3 myocardial infarction during follow‐up</p> </li> <li> <p>10 malignant ventricular arrhythmia</p> </li> <li> <p>2 advanced AV‐block</p> </li> <li> <p>7 cardiogenic shock</p> </li> <li> <p>9 heart failure</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Miami</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1985</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0189"> <li> <p>123 deaths from all causes</p> </li> <li> <p>85 myocardial infarction during follow‐up</p> </li> <li> <p>37 ventricular tachycardia</p> </li> <li> <p>74 asystole</p> </li> <li> <p>160 AV block II‐III</p> </li> <li> <p>699 heart failure</p> </li> <li> <p>86 cardiogenic shock</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0190"> <li> <p>142 deaths from all causes</p> </li> <li> <p>111 myocardial infarction during follow‐up</p> </li> <li> <p>40 ventricular tachycardia</p> </li> <li> <p>64 asystole</p> </li> <li> <p>153 AV block II‐III</p> </li> <li> <p>660 heart failure</p> </li> <li> <p>93 cardiogenic shock</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MILIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1984</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0191"> <li> <p>24 deaths from all causes</p> </li> <li> <p>25 heart failure</p> </li> <li> <p>17 ventricular tachycardia</p> </li> <li> <p>8 heart block</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0192"> <li> <p>20 deaths from all causes</p> </li> <li> <p>31 heart failure</p> </li> <li> <p>28 ventricular tachycardia</p> </li> <li> <p>9 heart block</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mueller</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1980</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0193"> <li> <p>2 deaths from all causes</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0194"> <li> <p>1 death from all causes</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Multicenter trial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1966</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0195"> <li> <p>15 deaths from all causes</p> </li> <li> <p>17 heart failure</p> </li> <li> <p>9 cardiac arrest</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0196"> <li> <p>12 deaths from all causes</p> </li> <li> <p>7 heart failure</p> </li> <li> <p>7 cardiac arrest</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nielsen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1967</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0197"> <li> <p>18 deaths from all causes</p> </li> <li> <p>2 myocardial infarction during follow‐up</p> </li> <li> <p>7 thrombo‐embolic complications</p> </li> <li> <p>2 heart failure</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0198"> <li> <p>19 deaths from all causes</p> </li> <li> <p>6 thrombo‐embolic complications</p> </li> <li> <p>6 heart failure</p> </li> <li> <p>2 cardiogenic shock</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Norris</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1968</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0199"> <li> <p>31 deaths from all causes</p> </li> <li> <p>7 AV‐block</p> </li> <li> <p>38 heart failure</p> </li> <li> <p>7 VT/VF</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0200"> <li> <p>24 deaths from all causes</p> </li> <li> <p>7 AV‐block</p> </li> <li> <p>43 heart failure</p> </li> <li> <p>9 VT/VF</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Norris</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1978</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0201"> <li> <p>1 heart failure</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0202"> <li> <p>1 heart failure</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Norris</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1980</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0203"> <li> <p>1 death from all causes</p> </li> <li> <p>1 ventricular fibrillation</p> </li> <li> <p>1 cardiogenic shock</p> </li> <li> <p>3 heart failure</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0204"> <li> <p>1 ventricular fibrillation</p> </li> <li> <p>1 cardiogenic shock</p> </li> <li> <p>2 AV‐block II‐III</p> </li> <li> <p>8 heart failure</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Norris</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1984</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0205"> <li> <p>15 deaths from all causes,</p> </li> <li> <p>7 ventricular fibrillation</p> </li> <li> <p>22 atrial fibrillation</p> </li> <li> <p>13 AV block II‐III</p> </li> <li> <p>14 bundle‐branch block</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0206"> <li> <p>14 deaths from all causes,</p> </li> <li> <p>18 ventricular fibrillation</p> </li> <li> <p>23 atrial fibrillation</p> </li> <li> <p>8 AV block II‐III</p> </li> <li> <p>14 bundle‐branch block</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NPT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1982</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0207"> <li> <p>25 deaths from all causes</p> </li> <li> <p>27 myocardial infarction during follow‐up</p> </li> <li> <p>22 heart failure</p> </li> <li> <p>1 ventricular fibrillation</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0208"> <li> <p>37 deaths from all causes</p> </li> <li> <p>31 myocardial infarction during follow‐up</p> </li> <li> <p>16 heart failure</p> </li> <li> <p>4 ventricular fibrillation</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Owensby</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1985</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0209"> <li> <p>1 death from all causes</p> </li> <li> <p>2 myocardial infarction during follow‐up</p> </li> <li> <p>23 heart failure</p> </li> <li> <p>6 AV‐block II‐III</p> </li> <li> <p>13 ventricular tachycardia</p> </li> <li> <p>4 ventricular fibrillation</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0210"> <li> <p>1 death from all causes</p> </li> <li> <p>2 myocardial infarction during follow‐up</p> </li> <li> <p>23 heart failure</p> </li> <li> <p>5 AV‐block II‐III</p> </li> <li> <p>12 ventricular tachycardia</p> </li> <li> <p>3 ventricular fibrillation</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Peter</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1978</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0211"> <li> <p>1 death from all causes</p> </li> <li> <p>1 myocardial infarction during follow‐up</p> </li> <li> <p>5 heart failure</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0212"> <li> <p>2 deaths from all causes</p> </li> <li> <p>3 myocardial infarction during follow‐up</p> </li> <li> <p>5 heart failure</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Raeder</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1967</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0213"> <li> <p>2 deaths from all causes</p> </li> <li> <p>1 AV‐block II‐III</p> </li> <li> <p>2 atrial fibrillation</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0214"> <li> <p>2 deaths from all causes</p> </li> <li> <p>1 AV‐block II‐III</p> </li> <li> <p>1 atrial fibrillation</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ramsdale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1982</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0215"> <li> <p>1 heart failure</p> </li> <li> <p>1 complete heart block</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ranganathan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1988</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0216"> <li> <p>1 death from all causes</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0217"> <li> <p>3 deaths from all causes</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RIMA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0218"> <li> <p>1 death from cardiac causes</p> </li> <li> <p>3 myocardial infarction during follow‐up</p> </li> <li> <p>3 unstable angina</p> </li> <li> <p>3 heart failure</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0219"> <li> <p>1 death from cardiac causes</p> </li> <li> <p>2 myocardial infarction during follow‐up</p> </li> <li> <p>6 unstable angina</p> </li> <li> <p>2 heart failure</p> </li> <li> <p>6 revascularisations</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rolli</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1980</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0220"> <li> <p>1 bundle block or hemiblock</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0221"> <li> <p>2 ventricular fibrillation</p> </li> <li> <p>3 heart failure</p> </li> <li> <p>2 bundle branch block or hemiblock</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Salathia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1985</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0222"> <li> <p>49 deaths from all causes</p> </li> <li> <p>11 ventricular fibrillation</p> </li> <li> <p>9 with AV‐block II‐III</p> </li> <li> <p>47 heart failure</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0223"> <li> <p>52 deaths from all causes</p> </li> <li> <p>14 ventricular fibrillation</p> </li> <li> <p>18 with AV‐block II‐III</p> </li> <li> <p>35 heart failure</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tereschenko</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0224"> <li> <p>3 deaths from all causes</p> </li> <li> <p>4 heart failure</p> </li> <li> <p>6 post‐infarction angina pectoris</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0225"> <li> <p>2 deaths from all causes</p> </li> <li> <p>7 heart failure</p> </li> <li> <p>5 post‐infarction angina pectoris</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Thompson</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1979</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0226"> <li> <p>3 deaths from all causes</p> </li> <li> <p>6 heart failure</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0227"> <li> <p>3 deaths from all causes</p> </li> <li> <p>6 heart failure</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TIARA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1987</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0228"> <li> <p>7 deaths from all causes</p> </li> <li> <p>3 myocardial infarction during follow‐up</p> </li> <li> <p>7 ventricular tachycardia</p> </li> <li> <p>10 heart failure</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0229"> <li> <p>12 deaths from all causes</p> </li> <li> <p>6 myocardial infarction during follow‐up</p> </li> <li> <p>16 ventricular tachycardia</p> </li> <li> <p>3 ventricular fibrillation</p> </li> <li> <p>18 heart failure</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tonkin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1981</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0230"> <li> <p>1 death from all causes</p> </li> <li> <p>6 myocardial infarction during follow‐up</p> </li> <li> <p>14 heart failure</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0231"> <li> <p>1 death from all causes</p> </li> <li> <p>1 myocardial infarction during follow‐up</p> </li> <li> <p>16 heart failure</p> </li> <li> <p>1 AV‐block</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Van De Werf</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1993</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0232"> <li> <p>1 death from all causes</p> </li> <li> <p>9 myocardial infarction during follow‐up</p> </li> <li> <p>6 pulmonary edema</p> </li> <li> <p>4 pericarditis</p> </li> <li> <p>3 cardiogenic shock</p> </li> <li> <p>9 AV block II‐III</p> </li> <li> <p>21 ventricular tachycardia</p> </li> <li> <p>2 ventricular fibrillation</p> </li> <li> <p>1 stroke</p> </li> <li> <p>2 bleeding requiring transfusion</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0233"> <li> <p>4 death from all causes</p> </li> <li> <p>10 myocardial infarction during follow‐up</p> </li> <li> <p>3 pericarditis</p> </li> <li> <p>1 cardiac rupture</p> </li> <li> <p>7 AV block II‐III</p> </li> <li> <p>18 ventricular tachycardia</p> </li> <li> <p>3 ventricular fibrillation</p> </li> <li> <p>2 stroke</p> </li> <li> <p>1 bleeding requiring transfusion</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Von Essen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1982</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0234"> <li> <p>1 death from all causes</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0235"> <li> <p>1 death from all causes</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wilcox (atenolol)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1980</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0236"> <li> <p>19 deaths from all causes</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0237"> <li> <p>10 deaths from all causes</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wilcox (propranolol)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1980</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0238"> <li> <p>17 death from all causes</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0239"> <li> <p>9 deaths from all causes</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yang</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1984</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0240"> <li> <p>2 AV‐block II</p> </li> <li> <p>1 ventricular fibrillation</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0241"> <li> <p>1 AV‐block II</p> </li> <li> <p>2 atrial fibrillation</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yusuf</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1980</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0242"> <li> <p>36 death form all causes</p> </li> <li> <p>46 heart failure</p> </li> <li> <p>13 AV block II‐III</p> </li> <li> <p>4 cardiac arrest</p> </li> <li> <p>3 pulmonary embolus</p> </li> <li> <p>1 renal failure</p> </li> <li> <p>1 cardiogenic shock</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0243"> <li> <p>44 death form all causes</p> </li> <li> <p>6 myocardial infarction during follow‐up</p> </li> <li> <p>56 heart failure</p> </li> <li> <p>18 AV block II‐III</p> </li> <li> <p>15 cardiac arrest</p> </li> <li> <p>2 ventricular septal defect</p> </li> <li> <p>4 cardiogenic shock</p> </li> </ul> </p> </td> </tr> </tbody> </table> </div> </section> </section> <section id="CD012484-sec-0094"> <h5 class="title">Major adverse cardiovascular events</h5> <section id="CD012484-sec-0095"> <h6 class="title">Time point less than three months follow‐up</h6> <p>Only two trials specifically assessed major adverse cardiovascular events (defined as a composite of cardiovascular mortality and non‐fatal myocardial infarction during follow‐up) at the time point less than three months follow‐up. Nevertheless, no major adverse cardiovascular events occurred in either trial (<a href="./references#CD012484-fig-0035" title="">Analysis 3.1</a>). The specific assessment time points in each trial are presented in <a href="#CD012484-tbl-0003">Table 1</a>. </p> <p>The rest of the trials reported either cardiovascular mortality <i>or</i> myocardial infarction during follow‐up. </p> <p><b>Maximum follow‐up beyond three months</b> </p> <p>In total 4/62 trials involving 475 participants with a median follow‐up of 7.5 months (range 6 to 12 months) reported major adverse cardiovascular events (defined as a composite of cardiovascular mortality and non‐fatal myocardial infarction during follow‐up) at maximum follow‐up beyond three months. The specific assessment time points in each trial are presented in <a href="#CD012484-tbl-0004">Table 2</a>. A total of 16/237 (6.74%) participants receiving beta‐blockers had a major adverse cardiovascular event versus 20/238 (8.40%) control participants. Random‐effects meta‐analysis showed no evidence of a difference of beta‐blockers versus placebo or no intervention on major adverse cardiovascular events (RR 0.81, 97.5% CI 0.40 to 1.66; I<sup>2</sup> = 0%; 475 participants; 4 trials; very low‐quality evidence; <a href="./references#CD012484-fig-0036" title="">Analysis 4.1</a>). Hence, the absolute risk for a major adverse cardiovascular event at maximum follow‐up corresponds to 68 out of 1000 participants receiving beta‐blockers having a major adverse cardiovascular event compared with 84 out of 1000 participants receiving placebo or no intervention. The optimal information size according to the GRADE Handbook using a proportion of 8.40% in the control group, a RRR of 10%, an alpha of 2.5%, and a beta of 10% was estimated to be 51,666 participants and we only included 475 participants. </p> <p>No further analyses were conducted due to sparse data.</p> </section> </section> </section> <section id="CD012484-sec-0096"> <h4 class="title">Secondary outcomes</h4> <section id="CD012484-sec-0097"> <h5 class="title">Cardiovascular mortality</h5> <p><b>Time point less than three months follow‐up</b> </p> <p>In total 18/62 trials involving 72,622 participants and a median follow‐up of 27.0 days (range 7 to 90 days) reported cardiovascular mortality at the time point less than three months follow‐up. The specific assessment time points in each trial are presented in <a href="#CD012484-tbl-0003">Table 1</a>. No events occurred in either group in three trials (<a href="./references#CD012484-bbs2-0024" title="HanadaK , HigumaT , NishizakiF , SukekawaT , YokotaT , YamadaM , et al. Randomized study on the efficacy and safety of landiolol, an ultra‐short‐acting beta1‐adrenergic blocker, in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. Circulation Journal2012;76(2):439‐45. ">Hanada 2012</a>; <a href="./references#CD012484-bbs2-0041" title="NorrisRM , ClarkeED , SammelNL , SmithWM , WilliamsB . Protective effect of propranolol in threatened myocardial infarction. Lancet1978;2(8096):907‐9. ">Norris 1978</a>; <a href="./references#CD012484-bbs2-0053" title="ShirotaniM , YokotaR , KouchiI , HiraiT , UemoriN , HabaK , et al. Influence of atenolol on coronary artery spasm after acute myocardial infarction in a Japanese population. International Journal of Cardiology2010;139(2):181‐6. ">Shirotani 2010</a>). A total of 1640/36,364 (4.51%) participants receiving beta‐blockers died because of a cardiovascular event versus 1765/36,258 (4.87%) control participants. Fixed‐effect meta‐analysis showed no sufficient evidence of a difference when assessing beta‐blockers versus placebo or no intervention on cardiovascular mortality (RR 0.93, 98% CI 0.86 to 1.00; I<sup>2</sup> = 0%; 72,622 participants; 18 trials; low‐quality evidence; <a href="./references#CD012484-fig-0037" title="">Analysis 5.1</a>). Hence, the absolute risk for a cardiovascular death at less than three months follow‐up corresponds to 45 out of 1000 participants receiving beta‐blockers dying of a cardiovascular event compared with 49 out of 1000 participants receiving placebo or no intervention and a NNTB of 278 participants.The optimal information size according to the GRADE Handbook using a proportion of 4.85% in the control group, a RRR of 10%, an alpha of 2.0%, and a beta of 10% was estimated to be 95,569 participants and we included 72,622 participants. </p> <section id="CD012484-sec-0098"> <h6 class="title">Heterogeneity</h6> <p>The visual inspection of the forest plot and the tests for statistical heterogeneity (I<sup>2</sup> = 0 %; P = 0.72) indicated no signs of heterogeneity. </p> </section> <section id="CD012484-sec-0099"> <h6 class="title">Risk of bias and sensitivity analyses</h6> <p>One trial was assessed at low risk of bias (<a href="./references#CD012484-bbs2-0016" title="COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo‐controlled trial. Lancet2005;366(9497):1622‐32. Second Chinese Cardiac Study (CCS‐2) Collaborative Group. Rationale, design and organization of the Second Chinese Cardiac Study (CCS‐2): a randomized trial of clopidogrel plus aspirin, and of metoprolol, among patients with suspected acute myocardial infarction. Journal of Cardiovascular Risk2000;7(6):435‐41. ">COMMIT 2005</a>) contributing to 55.4% of the weight to the analysis. All other trials were at high risk of bias mainly due to domains being at unclear risk of bias. Overall, the risk of bias of the outcome result was assessed as high risk of bias. </p> <p>The sensitivity analysis excluding trials at high risk of bias showed, however, no evidence of a difference (RR 0.99, 95% CI 0.91 to 1.08; 45,852 participants; 1 trial; moderate‐quality evidence; <a href="./references#CD012484-fig-0046" title="">Analysis 5.10</a>). Hence, the absolute risk for a cardiovascular death at less than three months follow‐up corresponds to 42 out of 1000 participants receiving beta‐blockers dying of a cardiovascular event compared with 43 out of 1000 participants receiving placebo or no intervention. The optimal information size according to the GRADE Handbook using a proportion of 4.28% in the control group, a RRR of 10%, an alpha of 2.0%, and a beta of 10% was estimated to be 109,817 participants and we included 45,852 participants (see <a href="./full#CD012484-tbl-0001">summary of findings Table for the main comparison</a>). Since the sensitivity analysis and the overall meta‐analysis showed different results, we based our summary of findings and conclusions on the sensitivity meta‐analysis only including trials at low risk of bias. </p> <p>The sensitivity analyses on incomplete outcome data showed that incomplete outcome data bias alone had the potential to influence the results in the best‐worst sensitivity analysis, but not in the worst‐best sensitivity analysis: best‐worst random‐effects meta‐analysis (RR 0.84, 95% CI 0.72 to 0.97; I<sup>2</sup> = 38%; 72,681 participants; 18 trials; <a href="./references#CD012484-fig-0047" title="">Analysis 5.11</a>); worst‐best random‐effects meta‐analysis (RR 0.93, 95% CI 0.79 to 1.10; I<sup>2</sup> = 46%; 72,681 participants; 18 trials; <a href="./references#CD012484-fig-0048" title="">Analysis 5.12</a>). Data were imputed for three trials. </p> <p>Visual inspection of the funnel plots showed no signs of asymmetry (<a href="#CD012484-fig-0006">Figure 6</a>). Based on the visual inspection of the funnel plot, we assessed the risk of publication bias as low. </p> <div class="figure" id="CD012484-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 5 Beta‐blockers versus placebo or no intervention at 'less than 3 months' follow‐up beyond 3 months, outcome: 5.1 Cardiovascular mortality." data-id="CD012484-fig-0006" src="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-AFig-FIG06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 5 Beta‐blockers versus placebo or no intervention at 'less than 3 months' follow‐up beyond 3 months, outcome: 5.1 Cardiovascular mortality. </p> </div> </div> </div> <p><i>Subgroup analyses</i> </p> <p>Tests for subgroup differences showed evidence of a difference when comparing trials according to the clinical trial registration status (I<sup>2</sup> = 81.8%; P = 0.02; <a href="./references#CD012484-fig-0044" title="">Analysis 5.8</a>). The unregistered trials showed evidence of a beneficial effect of beta‐blockers versus placebo or no intervention on cardiovascular mortality (RR 0.84, 95% CI 0.76 to 0.93; I<sup>2</sup> = 0%; 26,044 participants; 15 trials; <a href="./references#CD012484-fig-0044" title="">Analysis 5.8</a>), while the pre‐registered trials showed no evidence of a difference on cardiovascular mortality (RR 0.99, 95% CI 0.91 to 1.08; I<sup>2</sup> = 0%; 46,578 participants; 3 trials; <a href="./references#CD012484-fig-0044" title="">Analysis 5.8</a>). </p> <p>All remaining tests for subgroup differences showed no evidence of a difference in subgroup analyses according to the acute and subacute phase of commencing beta‐blockers (<a href="./references#CD012484-fig-0038" title="">Analysis 5.2</a>); reperfusion compared to no reperfusion (<a href="./references#CD012484-fig-0039" title="">Analysis 5.3</a>); types of beta‐blockers (<a href="./references#CD012484-fig-0040" title="">Analysis 5.4</a>); age either below compared to a mixture of above/below 75 years (<a href="./references#CD012484-fig-0041" title="">Analysis 5.5</a>); intravenous compared to oral administration of beta‐blockers (<a href="./references#CD012484-fig-0042" title="">Analysis 5.6</a>); different types of acute myocardial infarction (NSTEMI, STEMI, UAP or mixed) (9/18 trials reported data on the different types of acute myocardial infarction) (<a href="./references#CD012484-fig-0043" title="">Analysis 5.7</a>); and funding (<a href="./references#CD012484-fig-0045" title="">Analysis 5.9</a>). </p> <p><b>Maximum follow‐up beyond three months</b> </p> <p>In total, 14/63 trials involving 22,457 participants and a median follow‐up of 12.9 months (range 6 to 24 months) reported cardiovascular mortality at maximum follow‐up beyond three months. The specific assessment time points in each trial are presented in <a href="#CD012484-tbl-0004">Table 2</a>. No events occurred in either group in one trial (<a href="./references#CD012484-bbs2-0024" title="HanadaK , HigumaT , NishizakiF , SukekawaT , YokotaT , YamadaM , et al. Randomized study on the efficacy and safety of landiolol, an ultra‐short‐acting beta1‐adrenergic blocker, in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. Circulation Journal2012;76(2):439‐45. ">Hanada 2012</a>). A total of 1269/11.323 (11.2%) participants receiving beta‐blockers died because of a cardiovascular event versus 1379/11,134 (12.4%) control participants. Fixed‐effect meta‐analysis showed evidence of a beneficial effect of beta‐blockers versus placebo or no intervention on cardiovascular mortality (RR 0.90, 98% CI 0.83 to 0.98; I<sup>2</sup> = 0%; 22,457 participants; 14 trials/15 comparisons; moderate‐quality evidence; <a href="./references#CD012484-fig-0049" title="">Analysis 6.1</a>). Hence, the absolute risk for a cardiovascular death at maximum follow‐up corresponds to 116 out of 1000 participants receiving beta‐blockers dying of a cardiovascular event compared with 128 out of 1000 participants receiving placebo or no intervention and a NNTB of 83 participants (see <a href="./full#CD012484-tbl-0002">summary of findings Table 2</a>). The optimal information size according to the GRADE Handbook using a proportion of 12.4% in the control group, a RRR of 10%, an alpha of 2.0%, and a beta of 10% was estimated to be 35,192 participants and we included 22,457 participants. </p> </section> <section id="CD012484-sec-0100"> <h6 class="title">Heterogeneity</h6> <p>The visual inspection of the forest plot and the tests for statistical heterogeneity (I<sup>2</sup> = 0 %; P = 0.96) indicated no signs of heterogeneity. </p> </section> <section id="CD012484-sec-0101"> <h6 class="title">Risk of bias and sensitivity analyses</h6> <p>All trials were at high risk of bias mainly due to domains being at unclear risk of bias. Overall, the risk of bias of the outcome result was assessed as high risk of bias. </p> <p>The sensitivity analyses on incomplete outcome data showed that incomplete outcome data bias alone had the potential to influence the results in the best‐worst sensitivity analysis, but not in the worst‐best sensitivity analysis: best‐worst random‐effects meta‐analysis (RR 0.67, 95% CI 0.53 to 0.86; I<sup>2</sup> = 65%; 22,587 participants; 14 trials/15 comparisons; <a href="./references#CD012484-fig-0059" title="">Analysis 6.11</a>); worst‐best random‐effects meta‐analysis (RR 1.06, 95% CI 0.83 to 1.36; I<sup>2</sup> = 67%; 22,587 participants; 14 trials/15 comparisons; <a href="./references#CD012484-fig-0060" title="">Analysis 6.12</a>). Data were imputed for five trials. </p> <p>Visual inspection of the funnel plots showed no signs of asymmetry (<a href="#CD012484-fig-0007">Figure 7</a>). Based on the visual inspection of the funnel plot, we assessed the risk of publication bias as low. </p> <div class="figure" id="CD012484-fig-0007"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 7</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 6 Beta‐blockers versus placebo or no intervention at maximum follow‐up beyond 3 months, outcome: 6.1 Cardiovascular mortality." data-id="CD012484-fig-0007" src="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-AFig-FIG07.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 6 Beta‐blockers versus placebo or no intervention at maximum follow‐up beyond 3 months, outcome: 6.1 Cardiovascular mortality. </p> </div> </div> </div> <p><i>Subgroup analyses</i> </p> <p>All remaining tests for subgroup differences showed no evidence of a difference in subgroup analyses according to the acute and subacute phase of commencing beta‐blockers (<a href="./references#CD012484-fig-0050" title="">Analysis 6.2</a>); reperfusion compared to no reperfusion (<a href="./references#CD012484-fig-0051" title="">Analysis 6.3</a>); types of beta‐blockers (<a href="./references#CD012484-fig-0052" title="">Analysis 6.4</a>); age either below compared to a mixture of above/below 75 years (<a href="./references#CD012484-fig-0053" title="">Analysis 6.5</a>); intravenous compared to oral administration of beta‐blockers (<a href="./references#CD012484-fig-0054" title="">Analysis 6.6</a>); different types of acute myocardial infarction (NSTEMI, STEMI, UAP or mixed) (6/14 trials reported data on the different types of acute myocardial infarction) (<a href="./references#CD012484-fig-0055" title="">Analysis 6.7</a>); clinical trial registration status (<a href="./references#CD012484-fig-0056" title="">Analysis 6.8</a>); different lengths of the intervention period (<a href="./references#CD012484-fig-0057" title="">Analysis 6.9</a>); and funding (<a href="./references#CD012484-fig-0058" title="">Analysis 6.10</a>). </p> </section> </section> <section id="CD012484-sec-0102"> <h5 class="title">Myocardial infarction during follow‐up</h5> <p><b>Time point less than three months follow up</b> </p> <p>In total, 18/62 trials involving 67,562 participants and a median follow‐up of 20.6 days (range 3 to 90 days) reported myocardial infarction during follow‐up at the time point less than three months follow‐up. The specific assessment time points in each trial are presented in <a href="#CD012484-tbl-0003">Table 1</a>. No events occurred in either group in two trials (<a href="./references#CD012484-bbs2-0024" title="HanadaK , HigumaT , NishizakiF , SukekawaT , YokotaT , YamadaM , et al. Randomized study on the efficacy and safety of landiolol, an ultra‐short‐acting beta1‐adrenergic blocker, in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. Circulation Journal2012;76(2):439‐45. ">Hanada 2012</a>; <a href="./references#CD012484-bbs2-0053" title="ShirotaniM , YokotaR , KouchiI , HiraiT , UemoriN , HabaK , et al. Influence of atenolol on coronary artery spasm after acute myocardial infarction in a Japanese population. International Journal of Cardiology2010;139(2):181‐6. ">Shirotani 2010</a>). A total of 764/33,788 (2.26%) participants receiving beta‐blockers had a reinfarction versus 936/33,744 (2.77%) control participants. Fixed‐effect meta‐analysis showed evidence of a beneficial effect of beta‐blockers versus placebo or no intervention on myocardial infarction during follow‐up (RR 0.82, 98% CI 0.73 to 0.91; I<sup>2</sup> = 0%; 67,562 participants; 18 trials; moderate‐quality evidence; <a href="./references#CD012484-fig-0061" title="">Analysis 7.1</a>). Hence, the absolute risk for a reinfarction at less than three months follow‐up corresponds to 23 out of 1000 participants receiving beta‐blockers having a reinfarction compared with 28 out of 1000 participants receiving placebo or no intervention and a NNTB of 196 participants (see <a href="./full#CD012484-tbl-0001">summary of findings Table for the main comparison</a>). The optimal information size according to the GRADE Handbook using a proportion of 2.77% in the control group, a RRR of 10%, an alpha of 2.0%, and a beta of 10% was estimated to be 170,073 participants and we only included 67,562 participants. </p> <section id="CD012484-sec-0103"> <h6 class="title">Heterogeneity</h6> <p>The visual inspection of the forest plot and the tests for statistical heterogeneity (I<sup>2</sup> = 0 %; P = 0.66) indicated no signs of heterogeneity. </p> </section> <section id="CD012484-sec-0104"> <h6 class="title">Risk of bias and sensitivity analyses</h6> <p>One trial was assessed at overall low risk of bias (<a href="./references#CD012484-bbs2-0016" title="COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo‐controlled trial. Lancet2005;366(9497):1622‐32. Second Chinese Cardiac Study (CCS‐2) Collaborative Group. Rationale, design and organization of the Second Chinese Cardiac Study (CCS‐2): a randomized trial of clopidogrel plus aspirin, and of metoprolol, among patients with suspected acute myocardial infarction. Journal of Cardiovascular Risk2000;7(6):435‐41. ">COMMIT 2005</a>). All other trials were at high risk of bias mainly due to domains being at unclear risk of bias. Overall, the risk of bias of the outcome result was assessed as high risk of bias. </p> <p>The sensitivity analysis excluding trials at high risk of bias showed evidence of a beneficial effect of beta‐blockers versus placebo or no intervention on myocardial infarction during follow‐up at the time point less than three months follow‐up (RR 0.82, 95% CI 0.72 to 0.92; 45,852 participants; 1 trial; high‐quality evidence; <a href="./references#CD012484-fig-0070" title="">Analysis 7.10</a>). Since the sensitivity analysis and the overall meta‐analysis showed similar results, we based our'Ssummary of findings' tables and conclusion on the overall meta‐analysis. </p> <p>The sensitivity analyses on incomplete outcome data showed that incomplete outcome data bias alone had the potential to influence the results in the best‐worst sensitivity analysis, but not in the worst‐best sensitivity analysis: (best‐worst random‐effects meta‐analysis: RR 0.75, 95% CI 0.61 to 0.92; I<sup>2</sup> = 34%; 67,620 participants; 18 trials; <a href="./references#CD012484-fig-0071" title="">Analysis 7.11</a>); worst‐best random‐effects meta‐analysis: RR 0.85, 95% CI 0.67 to 1.07; I<sup>2</sup> = 45%; 67,620 participants; 18 trials; <a href="./references#CD012484-fig-0072" title="">Analysis 7.12</a>). Data were imputed for two trials. </p> <p>Visual inspection of the funnel plots showed no signs of asymmetry (<a href="#CD012484-fig-0008">Figure 8</a>). Based on the visual inspection of the funnel plot, we assessed the risk of publication bias as low. </p> <div class="figure" id="CD012484-fig-0008"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 8</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 7 Beta‐blockers versus placebo or no intervention at 'less than 3 months' follow‐up, outcome: 7.1 Myocardial infarction." data-id="CD012484-fig-0008" src="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-AFig-FIG08.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 7 Beta‐blockers versus placebo or no intervention at 'less than 3 months' follow‐up, outcome: 7.1 Myocardial infarction. </p> </div> </div> </div> <p><i>Subgroup analyses</i> </p> <p>Tests for subgroup differences showed no evidence of a difference in subgroup analyses according to the acute and subacute phase of commencing beta‐blockers (<a href="./references#CD012484-fig-0062" title="">Analysis 7.2</a>); reperfusion compared to no reperfusion (<a href="./references#CD012484-fig-0063" title="">Analysis 7.3</a>); types of beta‐blockers (<a href="./references#CD012484-fig-0064" title="">Analysis 7.4</a>); age either below compared to a mixture of above/below 75 years (<a href="./references#CD012484-fig-0065" title="">Analysis 7.5</a>); intravenous compared to oral administration of beta‐blockers (<a href="./references#CD012484-fig-0066" title="">Analysis 7.6</a>); different types of acute myocardial infarction (NSTEMI, STEMI, UAP, or mixed) (11/18 trials reported data on the different types of acute myocardial infarction) (<a href="./references#CD012484-fig-0067" title="">Analysis 7.7</a>); clinical trial registration status (<a href="./references#CD012484-fig-0068" title="">Analysis 7.8</a>); and funding (<a href="./references#CD012484-fig-0069" title="">Analysis 7.9</a>). </p> <p><b>Maximum follow‐up beyond three months</b> </p> <p>In total, 14/63 trials involving 6825 participants and a median follow‐up of 15.5 months (range 6 to 60 months) reported myocardial infarction during follow‐up at maximum follow‐up beyond three months. The specific assessment time points in each trial are presented in <a href="#CD012484-tbl-0004">Table 2</a>. A total of 282/3401 (8.3%) participants receiving beta‐blockers had a reinfarction versus 314/3424 (9.2%) control participants. Random‐effects meta‐analysis showed no evidence of a difference on myocardial infarction during follow‐up at maximum follow‐up beyond three months (RR 0.89, 98% CI 0.75 to 1.08; I<sup>2</sup> = 10%; 6825 participants; 14 trials; low‐quality evidence; <a href="./references#CD012484-fig-0073" title="">Analysis 8.1</a>). (see <a href="./full#CD012484-tbl-0001">summary of findings Table for the main comparison</a>). Hence, the absolute risk for a reinfarction at maximum follow‐up corresponds to 89 out of 1000 participants receiving beta‐blockers having a reinfarction compared with 102 out of 1000 participants receiving placebo or no intervention. The optimal information size according to the GRADE Handbook using a proportion of 9.2% in the control group, a RRR of 10%, an alpha of 2.0%, and a beta of 10% was estimated to be 49,069 participants and we only included 6825 participants. </p> </section> <section id="CD012484-sec-0105"> <h6 class="title">Heterogeneity</h6> <p>The visual inspection of the forest plot and the tests for statistical heterogeneity (I<sup>2</sup> = 10%; P = 0.35) indicated no signs of heterogeneity. </p> </section> <section id="CD012484-sec-0106"> <h6 class="title">Risk of bias and sensitivity analyses</h6> <p>All trials were at high risk of bias mainly due to domains being at unclear risk of bias. Overall, the risk of bias of the outcome result was assessed as high risk of bias. </p> <p>The sensitivity analyses on incomplete outcome data showed that incomplete outcome data bias alone had the potential to influence the results in the best‐worst sensitivity analysis, but not in the worst‐best sensitivity analysis: best‐worst random‐effects meta‐analysis (RR 0.56, 95% CI 0.37 to 0.85; I<sup>2</sup> = 71%; 6951 participants; 14 trials; <a href="./references#CD012484-fig-0083" title="">Analysis 8.11</a>); worst‐best random‐effects meta‐analysis: RR 1.10, 95% CI 0.95 to 1.26; I<sup>2</sup> = 74%; 6951 participants; 14 trials; <a href="./references#CD012484-fig-0084" title="">Analysis 8.12</a>). Data were imputed for four trials. </p> <p>Visual inspection of the funnel plots showed no signs of asymmetry (<a href="#CD012484-fig-0009">Figure 9</a>). Based on the visual inspection of the funnel plot, we assessed the risk of publication bias as low. </p> <div class="figure" id="CD012484-fig-0009"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 9</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 8 Beta‐blockers versus placebo or no intervention at maximum follow‐up beyond 3 months, outcome: 8.1 Myocardial infarction." data-id="CD012484-fig-0009" src="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-AFig-FIG09.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 8 Beta‐blockers versus placebo or no intervention at maximum follow‐up beyond 3 months, outcome: 8.1 Myocardial infarction. </p> </div> </div> </div> <p><i>Subgroup analyses</i> </p> <p>Tests for subgroup differences showed no evidence of a difference in subgroup analyses according to the acute and subacute phase of commencing beta‐blockers (<a href="./references#CD012484-fig-0074" title="">Analysis 8.2</a>); reperfusion compared to no reperfusion (<a href="./references#CD012484-fig-0075" title="">Analysis 8.3</a>); types of beta‐blockers (<a href="./references#CD012484-fig-0076" title="">Analysis 8.4</a>); age either below compared to a mixture of above/below 75 years (12/13 trials reported the age of the participants) (<a href="./references#CD012484-fig-0077" title="">Analysis 8.5</a>); intravenous compared to oral administration of beta‐blockers (<a href="./references#CD012484-fig-0078" title="">Analysis 8.6</a>); different types of acute myocardial infarction (NSTEMI, STEMI, UAP, or mixed) (6/13 trials reported data on the different types of acute myocardial infarction) (<a href="./references#CD012484-fig-0079" title="">Analysis 8.7</a>); clinical trial registration status (<a href="./references#CD012484-fig-0080" title="">Analysis 8.8</a>); different lengths of the intervention periods (<a href="./references#CD012484-fig-0081" title="">Analysis 8.9</a>); and funding (<a href="./references#CD012484-fig-0082" title="">Analysis 8.10</a>). </p> </section> </section> <section id="CD012484-sec-0107"> <h5 class="title">Quality of life</h5> <p>None of the included trials reported any data on quality of life on a continuous or any other scale at any time point. </p> </section> <section id="CD012484-sec-0108"> <h5 class="title">Angina</h5> <p><b>Time point less than three months follow‐up</b> </p> <p>Four trials reported angina with a median follow‐up of 29 days (range 12 days to 42 days) at the time point less than three months follow‐up (<a href="./references#CD012484-bbs2-0020" title="MitchellRG , StoddardMF , Ben‐YehudaO , AggarwalKB , AllenbyKS , TrilloRA , et al. Esmolol in acute ischaemic syndromes. American Heart Journal2002;144(5):E9. ">EMIT 2002</a>; <a href="./references#CD012484-bbs2-0042" title="NorrisRM , SammelNL , ClarkeED , BrandtPW . Treatment of acute myocardial infarction with propranolol. Further studies on enzyme appearance and subsequent left ventricular function in treated and control patients with developing infarcts. British Heart Journal1980;43(6):617‐22. ">Norris 1980</a>; <a href="./references#CD012484-bbs2-0054" title="TereshchenkoSN , KositsynaIV , DzhaianiNA , GolubevAV , KochetovAG . The use of esmolol in patients with myocardial infarction complicated with acute left ventricular failure. Kardiologiia2005;45(6):19‐22. ">Tereshchenko 2005</a>; and <a href="./references#CD012484-bbs2-0062" title="YangXS , CoupezR , EctorH , KestelootH , DeGeestH . Effects of betaxolol on heart rate in patients with a recent transmural myocardial infarction. Acta Cardiologica1987;42(4):273‐86. ">Yang 1986</a>). Different definitions and ways of measuring angina were used: <a href="./references#CD012484-bbs2-0042" title="NorrisRM , SammelNL , ClarkeED , BrandtPW . Treatment of acute myocardial infarction with propranolol. Further studies on enzyme appearance and subsequent left ventricular function in treated and control patients with developing infarcts. British Heart Journal1980;43(6):617‐22. ">Norris 1980</a> and <a href="./references#CD012484-bbs2-0062" title="YangXS , CoupezR , EctorH , KestelootH , DeGeestH . Effects of betaxolol on heart rate in patients with a recent transmural myocardial infarction. Acta Cardiologica1987;42(4):273‐86. ">Yang 1986</a> reported angina on exercise testing, <a href="./references#CD012484-bbs2-0054" title="TereshchenkoSN , KositsynaIV , DzhaianiNA , GolubevAV , KochetovAG . The use of esmolol in patients with myocardial infarction complicated with acute left ventricular failure. Kardiologiia2005;45(6):19‐22. ">Tereshchenko 2005</a> reported post‐infarction angina without defining it, and <a href="./references#CD012484-bbs2-0020" title="MitchellRG , StoddardMF , Ben‐YehudaO , AggarwalKB , AllenbyKS , TrilloRA , et al. Esmolol in acute ischaemic syndromes. American Heart Journal2002;144(5):E9. ">EMIT 2002</a> reported angina on an ordinal scale using anginal status defined by the NYHA functional capacity classification. </p> <p>In total, 3/62 trials involving 98 participants reported on the proportion of participants with angina (<a href="./references#CD012484-bbs2-0042" title="NorrisRM , SammelNL , ClarkeED , BrandtPW . Treatment of acute myocardial infarction with propranolol. Further studies on enzyme appearance and subsequent left ventricular function in treated and control patients with developing infarcts. British Heart Journal1980;43(6):617‐22. ">Norris 1980</a>; <a href="./references#CD012484-bbs2-0054" title="TereshchenkoSN , KositsynaIV , DzhaianiNA , GolubevAV , KochetovAG . The use of esmolol in patients with myocardial infarction complicated with acute left ventricular failure. Kardiologiia2005;45(6):19‐22. ">Tereshchenko 2005</a>; <a href="./references#CD012484-bbs2-0062" title="YangXS , CoupezR , EctorH , KestelootH , DeGeestH . Effects of betaxolol on heart rate in patients with a recent transmural myocardial infarction. Acta Cardiologica1987;42(4):273‐86. ">Yang 1986</a>). A total of 8/53 (15.1%) participants receiving beta‐blockers had angina compared with 10/45 (22.2%) control participants. Random‐effects meta‐analysis showed no evidence of a difference of beta‐blockers versus placebo or no intervention on angina (RR 0.70, 98% CI 0.25 to 1.84; I<sup>2</sup> = 0%; 98 participants; 3 trials; very low‐quality evidence; <a href="./references#CD012484-fig-0085" title="">Analysis 9.1</a>). The optimal information size according to the GRADE Handbook using a proportion of 22.2% in the control group, a RRR of 10%, an alpha of 2.0%, and a beta of 10% was estimated to be 17,583 participants and we only included 98 participants. </p> <p>No further analyses were conducted due to sparse data.</p> <section id="CD012484-sec-0109"> <h6 class="title">Narrative description of the remaining trials reporting angina</h6> <p><a href="./references#CD012484-bbs2-0020" title="MitchellRG , StoddardMF , Ben‐YehudaO , AggarwalKB , AllenbyKS , TrilloRA , et al. Esmolol in acute ischaemic syndromes. American Heart Journal2002;144(5):E9. ">EMIT 2002</a> reported angina on an ordinal scale using anginal status defined by the NYHA functional capacity classification. This classification reported four categories of angina: class I, II, III, and IV. In the experimental group, 34 patients were classified with class I, four with class II, two with class III, and two with class IV. In the control group, 34 patients were classified with class I, two with class II, two with class III, and one with class IV. </p> <p><b>Maximum follow‐up beyond three months</b> </p> <p><b>Two trials reported angina</b> with a total of 844 participants reported on the proportion of participants with angina at maximum follow‐up beyond three months (average months) (<a href="./references#CD012484-bbs2-0029" title="KaulUA , VermaR , GargKC . Early intervention with propranolol after acute myocardial infarction: serial left ventricular function determined by M‐mode and cross‐sectional echocardiography. International Journal of Cardiology1988;21(3):301‐10. ">Kaul 1988</a>; <a href="./references#CD012484-bbs2-0013" title="WatanabeH , OzasaN , MorimotoT , ShiomiH , BingyuanB , SuwaS , et al. Long‐term use of carvedilol in patients with ST‐segment elevation myocardial infarction treated with primary percutaneous coronary intervention. PLoS One2018;13(8):e0199347. [DOI: doi.org/10.1371/journal.pone.0199347] ">CAPITAL ‐ RCT 2018</a>). <a href="./references#CD012484-bbs2-0029" title="KaulUA , VermaR , GargKC . Early intervention with propranolol after acute myocardial infarction: serial left ventricular function determined by M‐mode and cross‐sectional echocardiography. International Journal of Cardiology1988;21(3):301‐10. ">Kaul 1988</a> reported post‐infarction angina without further definition, and <a href="./references#CD012484-bbs2-0013" title="WatanabeH , OzasaN , MorimotoT , ShiomiH , BingyuanB , SuwaS , et al. Long‐term use of carvedilol in patients with ST‐segment elevation myocardial infarction treated with primary percutaneous coronary intervention. PLoS One2018;13(8):e0199347. [DOI: doi.org/10.1371/journal.pone.0199347] ">CAPITAL ‐ RCT 2018</a> reported vasospastic angina. A total of 6/419 (1.43%) participants receiving beta‐blockers had angina compared with 10/425 (2.35%%) control participants. Random‐effects meta‐analysis showed no evidence of a difference of beta‐blockers versus placebo or no intervention on angina (RR 0.64, 98% CI 0.18 to 2.00; I<sup>2</sup> = 24%; 844 participants; 2 trials; very low‐quality evidence; <a href="./references#CD012484-fig-0086" title="">Analysis 10.1</a>). The optimal information size according to the GRADE Handbook using a proportion of 2.35% in the control group, a RRR of 10%, an alpha of 2.0%, and a beta of 10% was estimated to be 215,068 participants and we only included 844 participants. </p> <p>No further analyses were conducted due to sparse data.</p> </section> </section> </section> <section id="CD012484-sec-0110"> <h4 class="title">'Summary of findings' tables</h4> <p>Our main results (i.e. primary and secondary outcomes) are summarised in the <a href="./full#CD012484-tbl-0001">summary of findings Table for the main comparison</a> (time point less than three months follow‐up) and <a href="./full#CD012484-tbl-0002">summary of findings Table 2</a> (maximum follow‐up beyond three months). </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD012484-sec-0111" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012484-sec-0111">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012484-sec-0183">Español</a> </li> </nav> </div> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD012484-sec-0111"></div> <section id="CD012484-sec-0112"> <h3 class="title" id="CD012484-sec-0112">Summary of main results</h3> <p>We were able to include 63 trials randomising a total of 85,550 participants (mean age 57.4 years; mean range 45.9 to 70.0 years). One trial (<a href="./references#CD012484-bbs2-0016" title="COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo‐controlled trial. Lancet2005;366(9497):1622‐32. Second Chinese Cardiac Study (CCS‐2) Collaborative Group. Rationale, design and organization of the Second Chinese Cardiac Study (CCS‐2): a randomized trial of clopidogrel plus aspirin, and of metoprolol, among patients with suspected acute myocardial infarction. Journal of Cardiovascular Risk2000;7(6):435‐41. ">COMMIT 2005</a>) was considered to be at low risk of bias for all outcomes at the time point 'less than three months' follow‐up. One trial was assessed at low risk of bias in all but one domain (blinding) but since the blinding of participants and personnel was not considered of key importance for an objective outcome like all‐cause mortality, the study was assessed at low risk of bias for all‐cause mortality (<a href="./references#CD012484-bbs2-0034" title="IbanezB , FusterV , MacayaC , Sánchez‐BruneteV , PizarroG , López‐RomeroP , et al. Study design for the “effect of METOprolol in CARDioproteCtioN during an acute myocardial InfarCtion” (METOCARD‐CNIC): A randomized, controlled parallel‐group, observer‐blinded clinical trial of early pre‐reperfusion metoprolol administration in ST‐segment elevation myocardial infarction. American Heart Journal2012;164(4):473‐480. IbanezB , MacayaC , Sánchez‐BruneteV , PizarroG , Fernández‐FrieraL , MateosA , et al. Effect of early metoprolol on infarct size in ST‐segment‐elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: the effect of metoprolol in cardioprotection during an acute myocardial infarction (METOCARD‐CNIC) trial. Circulation2013;128(14):1495‐1503. MateosA , García‐LunarI , García‐RuizJM , PizarroG , Fernández‐JiménezR , HuertasP , et al. Efficacy and safety of out‐of‐hospital intravenous metoprolol administration in anterior ST‐segment elevation acute myocardial infarction: insights from the METOCARD‐CNIC trial. Annals of Emergency MedicineMar 2015;65(3):318‐24. PizarroG , Fernández‐FrieraL , FusterV , Fernández‐JiménezR , García‐RuizJM , García‐ÁlvarezA , et al. Long‐term benefit of early pre‐reperfusion metoprolol administration in patients with acute myocardial infarction: results from the METOCARD‐CNIC trial (Effect of Metoprolol in Cardioprotection During an Acute Myocardial Infarction). Journal of the American College of Cardiology2014;63(22):2356‐62. Sala‐VilaA , Fernández‐JiménezR , PizarroG , CalvoC , García‐RuizJM , Fernández‐FrieraL , et al. Nutritional preconditioning by marine omega‐3 fatty acids in patients with ST‐segment elevation myocardial infarction: A METOCARD‐CNIC trial substudy.. International Journal of CardiologyFeb 2017;228:828‐833. Valle‐CaballeroMJ , Fernández‐JiménezR , Díaz‐MunozR , MateosA , Rodríguez‐ÁlvarezM , Iglesias‐VázquezJA , et al. QRS distortion in pre‐reperfusion electrocardiogram is a bedside predictor of large myocardium at risk and infarct size (a METOCARD‐CNIC trial substudy).. International Journal of CardiologyJan 2016;202:666‐73. ">METOCARD‐CNIC 2013</a>). The remaining trials and all our meta‐analysed outcome results were considered to be at high risk of bias, mainly due to domains being at unclear risk of bias. The quality of the evidence according to GRADE ranged from very low to high at the time point 'less than three months' follow‐up and very low to moderate at maximum follow‐up beyond three months. The mean proportion of participants with a diagnosis of acute myocardial infarction at the time of randomisation was 80.3%. eight out of 63 trials specifically randomised participants suspected of or diagnosed with ST‐elevation myocardial infarction; 20 out of 63 trials randomised a mixed group of participants (ST‐elevation myocardial infarction, non‐ST‐elevation myocardial infarction, or unstable angina); and the remaining 35 trials did not report data on the different kinds of acute myocardial infarction included. 24 trials received the trial interventions for zero to seven days, 23 trials received the trial interventions for seven to 30 days, and the remaining 16 trials received the trial interventions for at least one month or more. </p> <p>At the time point 'less than three months' follow‐up, meta‐analysis with a moderate‐quality of evidence showed that beta‐blockers versus placebo or no intervention probably reduce the risk of a new myocardial infarction during follow‐up. The effects of beta‐blockers versus placebo or no intervention on the risks of all‐cause mortality and cardiovascular mortality were with a high‐ to moderate‐quality evidence less convincing and showed little to no evidence of a difference. Regarding angina, very low‐quality evidence suggests that it is uncertain whether beta‐blockers have a beneficial, neutral, or harmful effect versus placebo or no intervention. The optimal information size was reached for all‐cause mortality but not for cardiovascular mortality, myocardial infarction, and angina. Accordingly, all‐cause mortality was not downgraded for imprecision. However, due to the large sample sizes and narrow 98% confidence intervals (CIs) not showing any appreciable benefit nor harm, cardiovascular mortality and myocardial infarction during follow‐up were not downgraded for the risk of imprecision. Nervertheless, when assessing angina, we downgraded two levels for imprecision due to the optimal information size not being reached, the very small sample size included, and the wide 98% CIs showing both appreciable benefit and harm. </p> <p>At maximum follow‐up beyond three months, meta‐analysis with moderate‐quality evidence showed that beta‐blockers versus placebo or no intervention probably reduce the risk of all‐cause mortality and cardiovascular mortality. The effects of beta‐blockers versus placebo or no intervention on the risk of myocardial infarction during follow‐up were with low quality of evidence uncertain, as the risk ratio (RR) and lower CI suggested a trend towards a beneficial effect but the upper CI did not exclude the possibility of no difference between the two groups. When assessing major adverse cardiovascular events and angina, very low‐quality evidence suggests that it is uncertain whether beta‐blockers have a beneficial, neutral, or harmful effect. The optimal information size was not reached for any of the outcomes at maximum follow‐up beyond three months. However, due to the large sample sizes and narrow 97.5% and 98% CIs only showing benefit, all‐cause mortality and cardiovascular mortality were not downgraded for risk of imprecision. Nevertheless, when assessing myocardial infarction during follow‐up, we downgraded one level for imprecision due to the wide 98% CI where the upper CI did not exclude the possibility of no difference between the two groups. When assessing major adverse cardiovascular events and angina, we downgraded two levels for imprecision due to the optimal information size not being reached, the very small sample size included and the wide 97.5% CI showing both appreciable benefit and harm. </p> <p>None of the trials specifically assessed serious adverse events according to International Conference on Harmonization ‐ Good Clinical Practice Guidelines (ICH‐GCP; <a href="./references#CD012484-bbs2-0134" title="International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) adopts Consolidated Guideline on Good Clinical Practice in the Conduct of Clinical Trials on Medicinal Products for Human Use. International Digest of Health Legislation1997; Vol. 48, issue 2:231‐4. [PUBMED: 11656783] ">ICH‐GCP 1997</a>). Instead, the trials either reported composites of several specific serious adverse events or one specific serious adverse event. </p> <p>Two trials at the time point 'less than three months' follow‐up (no events reported) and four trials at maximum follow‐up beyond three months specifically assessed major adverse cardiovascular events according to our definition (composite of cardiovascular mortality and non‐fatal myocardial infarction during follow‐up). Instead, the trials reported either cardiovascular mortality or myocardial infarction. Due to sparse data, no further analyses were conducted. </p> <p>No data were provided on quality of life.</p> </section> <section id="CD012484-sec-0113"> <h3 class="title" id="CD012484-sec-0113">Overall completeness and applicability of evidence</h3> <p>This review provides the most comprehensive and contemporary appraisal of the evidence on beta‐blockers for suspected or diagnosed myocardial infarction to date. We searched for published and unpublished trials irrespective of trial design, setting, blinding, publication status, publication year, language, and reporting of our outcomes. None of our funnel plots indicated any significant signs of publication bias. Otherwise, all trials but one (<a href="./references#CD012484-bbs2-0016" title="COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo‐controlled trial. Lancet2005;366(9497):1622‐32. Second Chinese Cardiac Study (CCS‐2) Collaborative Group. Rationale, design and organization of the Second Chinese Cardiac Study (CCS‐2): a randomized trial of clopidogrel plus aspirin, and of metoprolol, among patients with suspected acute myocardial infarction. Journal of Cardiovascular Risk2000;7(6):435‐41. ">COMMIT 2005</a>) were at high risk of bias which suggests that our results might overestimate benefits and underestimate harms (<a href="./references#CD012484-bbs2-0116" title="GluudLL . Bias in clinical intervention research. American Journal of Epidemiology2006;163(6):493‐501. ">Gluud 2006</a>; <a href="./references#CD012484-bbs2-0139" title="KjaergardLL , VillumsenJ , GluudC . Reported methodologic quality and discrepancies between large and small randomized trials in meta‐analyses. Annals of Internal Medicine2001;135(11):982‐9. ">Kjaergard 2001</a>; <a href="./references#CD012484-bbs2-0145" title="LundhA , LexchinJ , MintzesB , SchrollJB , BeroL . Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews2017, Issue 2. [DOI: 10.1002/14651858.MR000033.pub3] ">Lundh 2017</a>; <a href="./references#CD012484-bbs2-0149" title="MoherD , PhamB , JonesA , CookDJ , JadadAR , MoherM , et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta‐analyses?. Lancet1998;352(9128):609‐13. ">Moher 1998</a>; <a href="./references#CD012484-bbs2-0163" title="SavovicJ , JonesHE , AltmanDG , HarrisRJ , JuniP , PildalJ , et al. Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Annals of Internal Medicine2012;157(6):429‐38. ">Savovic 2012</a>; <a href="./references#CD012484-bbs2-0164" title="SavovicJ , JonesH , AltmanD , HarrisR , JuniP , PildalJ , et al. Influence of reported study design characteristics on intervention effect estimates from randomised controlled trials: combined analysis of meta‐epidemiological studies. Health Technology Assesment2012;16(35):1‐82. ">Savovic 2012a</a>; <a href="./references#CD012484-bbs2-0167" title="SchulzKF , ChalmersI , HayesRJ , AltmanDG . Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA1995;273(5):408‐12. ">Schulz 1995</a>; <a href="./references#CD012484-bbs2-0185" title="WoodL , EggerM , GluudLL , SchulzKF , JuniP , AltmanDG , et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta‐epidemiological study. BMJ2008;336(7644):601‐5. ">Wood 2008</a>). However, our positive meta‐analytic findings were supported by the findings of <a href="./references#CD012484-bbs2-0016" title="COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo‐controlled trial. Lancet2005;366(9497):1622‐32. Second Chinese Cardiac Study (CCS‐2) Collaborative Group. Rationale, design and organization of the Second Chinese Cardiac Study (CCS‐2): a randomized trial of clopidogrel plus aspirin, and of metoprolol, among patients with suspected acute myocardial infarction. Journal of Cardiovascular Risk2000;7(6):435‐41. ">COMMIT 2005</a> for all outcomes beside cardiovascular mortality at the time point 'less than three months' follow‐up. </p> <p>We included all participants with either suspected or diagnosed acute myocardial infarction irrespective of age, sex, severity of disease, type of beta‐blocker used, and type of control group intervention (placebo or no intervention). Nevertheless, we found limited signs of statistical heterogeneity which indicates that the pooling of these diverse participants and interventions was appropriate. </p> <p>There were no data on the effects of beta‐blockers versus placebo or no intervention on serious adverse events according to the definition of ICH‐GCP and quality of life, and only very limited data on major adverse cardiovascular events according to our definition (composite of cardiovascular mortality or non‐fatal myocardial infarction during follow‐up) and angina. We were, therefore, not able to adequately assess the harmful effects and the overall safety of beta‐blockers. A balanced assessment of interventions requires analysis of both benefits and harms (<a href="./references#CD012484-bbs2-0188" title="ZorzelaL , GolderS , LiuY , PilkingtonK , HartlingL , JoffeA , et al. Quality of reporting in systematic reviews of adverse events: systematic review. BMJ (Clinical research ed.)2014;348:f7668. [PUBMED: 24401468] ">Zorzela 2014</a>). Hence, without adequate reporting of both harms and benefits, it is more difficult to estimate if an intervention is safe (<a href="./references#CD012484-bbs2-0135" title="IoannidisJP . Adverse events in randomized trials: neglected, restricted, distorted, and silenced. Archives of Internal Medicine2009;169(19):1737‐9. ">Ioannidis 2009</a>; <a href="./references#CD012484-bbs2-0188" title="ZorzelaL , GolderS , LiuY , PilkingtonK , HartlingL , JoffeA , et al. Quality of reporting in systematic reviews of adverse events: systematic review. BMJ (Clinical research ed.)2014;348:f7668. [PUBMED: 24401468] ">Zorzela 2014</a>). Poorly reported data on adverse events in randomised trials (especially in small randomised trials lacking the power to study major but uncommon harms) has in many years led to systematic reviews and meta‐analyses providing inadequate information concerning safety data of the drug (<a href="./references#CD012484-bbs2-0105" title="CorneliusVR , PerrioMJ , ShakirSA , SmithLA . Systematic reviews of adverse effects of drug interventions: a survey of their conduct and reporting quality. Pharmacoepidemiology and Drug Safety2009;18(12):1223‐31. [PUBMED: 19757414] ">Cornelius 2009</a>; <a href="./references#CD012484-bbs2-0154" title="PapanikolaouPN , IoannidisJP . Availability of large‐scale evidence on specific harms from systematic reviews of randomized trials. American Journal of Medicine2004;117(8):582‐9. [PUBMED: 15465507] ">Papanikolaou 2004</a>; <a href="./references#CD012484-bbs2-0188" title="ZorzelaL , GolderS , LiuY , PilkingtonK , HartlingL , JoffeA , et al. Quality of reporting in systematic reviews of adverse events: systematic review. BMJ (Clinical research ed.)2014;348:f7668. [PUBMED: 24401468] ">Zorzela 2014</a>). However, besides reporting on all‐cause mortality, cardiovascular mortality, and myocardial reinfarction, the trials also reported other adverse events that were described as serious according to the trialists. These serious adverse events reported were mainly cardiovascular for all trials. We reported narratively the individual types of serious adverse events in each trial in <a href="#CD012484-tbl-0005">Table 3</a> (less than three months follow‐up) and <a href="#CD012484-tbl-0006">Table 4</a> (maximum follow‐up beyond three months). </p> </section> <section id="CD012484-sec-0114"> <h3 class="title" id="CD012484-sec-0114">Quality of the evidence</h3> <section id="CD012484-sec-0115"> <h4 class="title">Risk of systematic error (bias)</h4> <p>Our 'Risk of bias' assessment showed that only one trial was at low risk of bias in all domains (<a href="./references#CD012484-bbs2-0016" title="COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo‐controlled trial. Lancet2005;366(9497):1622‐32. Second Chinese Cardiac Study (CCS‐2) Collaborative Group. Rationale, design and organization of the Second Chinese Cardiac Study (CCS‐2): a randomized trial of clopidogrel plus aspirin, and of metoprolol, among patients with suspected acute myocardial infarction. Journal of Cardiovascular Risk2000;7(6):435‐41. ">COMMIT 2005</a>). One trial was assessed at 'ow risk of bias in all but one domain and since the blinding of participants and personnel was not considered of key importance for an objective outcome like all‐cause mortality, the study was assessed at low risk of bias (<a href="./references#CD012484-bbs2-0034" title="IbanezB , FusterV , MacayaC , Sánchez‐BruneteV , PizarroG , López‐RomeroP , et al. Study design for the “effect of METOprolol in CARDioproteCtioN during an acute myocardial InfarCtion” (METOCARD‐CNIC): A randomized, controlled parallel‐group, observer‐blinded clinical trial of early pre‐reperfusion metoprolol administration in ST‐segment elevation myocardial infarction. American Heart Journal2012;164(4):473‐480. IbanezB , MacayaC , Sánchez‐BruneteV , PizarroG , Fernández‐FrieraL , MateosA , et al. Effect of early metoprolol on infarct size in ST‐segment‐elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: the effect of metoprolol in cardioprotection during an acute myocardial infarction (METOCARD‐CNIC) trial. Circulation2013;128(14):1495‐1503. MateosA , García‐LunarI , García‐RuizJM , PizarroG , Fernández‐JiménezR , HuertasP , et al. Efficacy and safety of out‐of‐hospital intravenous metoprolol administration in anterior ST‐segment elevation acute myocardial infarction: insights from the METOCARD‐CNIC trial. Annals of Emergency MedicineMar 2015;65(3):318‐24. PizarroG , Fernández‐FrieraL , FusterV , Fernández‐JiménezR , García‐RuizJM , García‐ÁlvarezA , et al. Long‐term benefit of early pre‐reperfusion metoprolol administration in patients with acute myocardial infarction: results from the METOCARD‐CNIC trial (Effect of Metoprolol in Cardioprotection During an Acute Myocardial Infarction). Journal of the American College of Cardiology2014;63(22):2356‐62. Sala‐VilaA , Fernández‐JiménezR , PizarroG , CalvoC , García‐RuizJM , Fernández‐FrieraL , et al. Nutritional preconditioning by marine omega‐3 fatty acids in patients with ST‐segment elevation myocardial infarction: A METOCARD‐CNIC trial substudy.. International Journal of CardiologyFeb 2017;228:828‐833. Valle‐CaballeroMJ , Fernández‐JiménezR , Díaz‐MunozR , MateosA , Rodríguez‐ÁlvarezM , Iglesias‐VázquezJA , et al. QRS distortion in pre‐reperfusion electrocardiogram is a bedside predictor of large myocardium at risk and infarct size (a METOCARD‐CNIC trial substudy).. International Journal of CardiologyJan 2016;202:666‐73. ">METOCARD‐CNIC 2013</a>). However, recent data show that even all‐cause mortality may be biased due to lack of blinding (<a href="./references#CD012484-bbs2-0165" title="SavovicJ , TurnerRM , MawdsleyD , JonesHE , BeynonR , HigginsJP , et al. Association between Risk‐of‐Bias assessments and results of randomized trials in Cochrane Reviews: the ROBES meta‐epidemiologic study. American jJournal of Epidemiology2018;187(5):1113‐22. [PUBMED: 29126260] ">Savovic 2018</a>). All other trials were at high risk of bias (mainly due to domains being assessed at unclear risk of bias) (see <a href="#CD012484-sec-0077">Risk of bias in included studies</a>). There is, therefore, a risk of our results overestimating the beneficial effects and underestimating the harmful effects of beta‐blockers (<a href="./references#CD012484-bbs2-0116" title="GluudLL . Bias in clinical intervention research. American Journal of Epidemiology2006;163(6):493‐501. ">Gluud 2006</a>; <a href="./references#CD012484-bbs2-0139" title="KjaergardLL , VillumsenJ , GluudC . Reported methodologic quality and discrepancies between large and small randomized trials in meta‐analyses. Annals of Internal Medicine2001;135(11):982‐9. ">Kjaergard 2001</a>; <a href="./references#CD012484-bbs2-0145" title="LundhA , LexchinJ , MintzesB , SchrollJB , BeroL . Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews2017, Issue 2. [DOI: 10.1002/14651858.MR000033.pub3] ">Lundh 2017</a>; <a href="./references#CD012484-bbs2-0149" title="MoherD , PhamB , JonesA , CookDJ , JadadAR , MoherM , et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta‐analyses?. Lancet1998;352(9128):609‐13. ">Moher 1998</a>; <a href="./references#CD012484-bbs2-0163" title="SavovicJ , JonesHE , AltmanDG , HarrisRJ , JuniP , PildalJ , et al. Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Annals of Internal Medicine2012;157(6):429‐38. ">Savovic 2012</a>; <a href="./references#CD012484-bbs2-0164" title="SavovicJ , JonesH , AltmanD , HarrisR , JuniP , PildalJ , et al. Influence of reported study design characteristics on intervention effect estimates from randomised controlled trials: combined analysis of meta‐epidemiological studies. Health Technology Assesment2012;16(35):1‐82. ">Savovic 2012a</a>; <a href="./references#CD012484-bbs2-0167" title="SchulzKF , ChalmersI , HayesRJ , AltmanDG . Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA1995;273(5):408‐12. ">Schulz 1995</a>; <a href="./references#CD012484-bbs2-0185" title="WoodL , EggerM , GluudLL , SchulzKF , JuniP , AltmanDG , et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta‐epidemiological study. BMJ2008;336(7644):601‐5. ">Wood 2008</a>). </p> <p>When assessing all‐cause mortality at the time point 'less than three months' follow‐up, the trial contributing most weight (<a href="./references#CD012484-bbs2-0016" title="COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo‐controlled trial. Lancet2005;366(9497):1622‐32. Second Chinese Cardiac Study (CCS‐2) Collaborative Group. Rationale, design and organization of the Second Chinese Cardiac Study (CCS‐2): a randomized trial of clopidogrel plus aspirin, and of metoprolol, among patients with suspected acute myocardial infarction. Journal of Cardiovascular Risk2000;7(6):435‐41. ">COMMIT 2005</a>, 63.4%) was assessed at low risk of bias in all domains. The trials contributing the second highest weight (<a href="./references#CD012484-bbs2-0027" title="ISIS‐1 (first International Study of Infarct Survival) collaborative group. Mechanisms for the early mortality reduction produced by beta‐blockade started early in acute myocardial infarction: ISIS‐1. Lancet1988;1(8591):921‐3. ISIS‐1 (first International Study of Infarct Survival) collaborative group. Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS‐1. Lancet1986;2(8498):57‐66. ">ISIS‐1 1986</a>, 17.4%) and third highest weight (<a href="./references#CD012484-bbs2-0035" title="HerlitzJ , HjalmarsonA , KarlsonBW . Prognosis during one year for patients with myocardial infarction in relation to the development of Q waves: experiences from the Miami trial. Clinical Cardiology1990;13(4):261‐4. HerlitzJ , KarlsonBW , HjalmarsonA . Mortality and morbidity during one year of follow‐up in suspected acute myocardial infarction in relation to early diagnosis: experiences from the MIAMI trial. Journal of Internal Medicine1990;228(2):125‐31. MurrayDP , WatsonRD , ZezulkaAV , MurrayRG , LittlerWA . Plasma catecholamine levels in acute myocardial infarction: influence of beta‐adrenergic blockade and relation to central hemodynamics. American Heart Journal1988;115(1 Pt 1):38‐44. MurrayDP1 , MurrayRG , RafiqiE , LittlerWA . Does acute‐phase beta‐blockade reduce mortality in acute myocardial infarction by limiting infarct size?. International Journal of Cardiology1988;20(3):327‐39. RehnqvistN , OlssonG , ErhardtL , EkmanAM . Metoprolol in acute myocardial infarction reduces ventricular arrhythmias both in the early stage and after the acute event. International Journal of Cardiology1987;15(3):301‐8. The MIAMI Trial Research Group. Arrhythmias. American Journal of Cardiology1985;56(14):G35‐G38. The MIAMI Trial Research Group. Narcotic analgesics and other antianginal drugs. American Journal of Cardiology1985;56(14):G30‐G34. The MIAMI Trial Research Group. Other clinical findings and tolerability. American Journal of Cardiology1985;56(14):G39‐G46. The MIAMI Trial Research Group. Patients and methods. The American Journal of Cardiology1985;56(14):G3‐G9. The MIAMI trial research group. Metoprolol in acute myocardial infarction (MIAMI). A randomised placebo‐controlled international trial. European Heart Journal1985;6:199‐226. ">MIAMI 1985</a>, 5.0%) were assessed as low risk of bias in most key domains. Hence, since the overall limitations of <a href="./references#CD012484-bbs2-0027" title="ISIS‐1 (first International Study of Infarct Survival) collaborative group. Mechanisms for the early mortality reduction produced by beta‐blockade started early in acute myocardial infarction: ISIS‐1. Lancet1988;1(8591):921‐3. ISIS‐1 (first International Study of Infarct Survival) collaborative group. Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS‐1. Lancet1986;2(8498):57‐66. ">ISIS‐1 1986</a> and <a href="./references#CD012484-bbs2-0035" title="HerlitzJ , HjalmarsonA , KarlsonBW . Prognosis during one year for patients with myocardial infarction in relation to the development of Q waves: experiences from the Miami trial. Clinical Cardiology1990;13(4):261‐4. HerlitzJ , KarlsonBW , HjalmarsonA . Mortality and morbidity during one year of follow‐up in suspected acute myocardial infarction in relation to early diagnosis: experiences from the MIAMI trial. Journal of Internal Medicine1990;228(2):125‐31. MurrayDP , WatsonRD , ZezulkaAV , MurrayRG , LittlerWA . Plasma catecholamine levels in acute myocardial infarction: influence of beta‐adrenergic blockade and relation to central hemodynamics. American Heart Journal1988;115(1 Pt 1):38‐44. MurrayDP1 , MurrayRG , RafiqiE , LittlerWA . Does acute‐phase beta‐blockade reduce mortality in acute myocardial infarction by limiting infarct size?. International Journal of Cardiology1988;20(3):327‐39. RehnqvistN , OlssonG , ErhardtL , EkmanAM . Metoprolol in acute myocardial infarction reduces ventricular arrhythmias both in the early stage and after the acute event. International Journal of Cardiology1987;15(3):301‐8. The MIAMI Trial Research Group. Arrhythmias. American Journal of Cardiology1985;56(14):G35‐G38. The MIAMI Trial Research Group. Narcotic analgesics and other antianginal drugs. American Journal of Cardiology1985;56(14):G30‐G34. The MIAMI Trial Research Group. Other clinical findings and tolerability. American Journal of Cardiology1985;56(14):G39‐G46. The MIAMI Trial Research Group. Patients and methods. The American Journal of Cardiology1985;56(14):G3‐G9. The MIAMI trial research group. Metoprolol in acute myocardial infarction (MIAMI). A randomised placebo‐controlled international trial. European Heart Journal1985;6:199‐226. ">MIAMI 1985</a> were not of key importance for an objective outcome like all‐cause mortality, the evidence was not downgraded for risk of bias. However, when assessing all‐cause mortality at maximum follow‐up beyond three months, the overall analysis including trials at high risk of bias due to either unclear or high risk in several bias domains showed different results compared to the sensitivity analysis excluding trials at high risk of bias. Hence, the evidence was downgraded by one level for risk of bias. </p> <p>When assessing cardiovascular mortality at the time point 'less than three months' follow‐up, the result was based on the sensitivity analysis excluding trials at high risk of bias and the evidence was not downgraded for risk of bias. However, when assessing cardiovascular mortality at maximum follow‐up beyond three months, the evidence was downgraded by one level since all the included trials were at high risk of bias due to either unclear or high risk in several bias domains. </p> <p>When assessing myocardial infarction at the time point 'less than three months' follow‐up, the trial contributing most weight (<a href="./references#CD012484-bbs2-0016" title="COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo‐controlled trial. Lancet2005;366(9497):1622‐32. Second Chinese Cardiac Study (CCS‐2) Collaborative Group. Rationale, design and organization of the Second Chinese Cardiac Study (CCS‐2): a randomized trial of clopidogrel plus aspirin, and of metoprolol, among patients with suspected acute myocardial infarction. Journal of Cardiovascular Risk2000;7(6):435‐41. ">COMMIT 2005</a>, 60,4%) was assessed at low risk of bias in all domains. The trial contributing the second highest weight (<a href="./references#CD012484-bbs2-0027" title="ISIS‐1 (first International Study of Infarct Survival) collaborative group. Mechanisms for the early mortality reduction produced by beta‐blockade started early in acute myocardial infarction: ISIS‐1. Lancet1988;1(8591):921‐3. ISIS‐1 (first International Study of Infarct Survival) collaborative group. Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS‐1. Lancet1986;2(8498):57‐66. ">ISIS‐1 1986</a>, 17,1%) was assessed at low risk of bias in random sequence generation, allocation concealment, and incomplete outcome data; unclear for blinding of outcome assessors and selective reporting and at high risk for blinding of participants and personnel. The third highest contributing trial (<a href="./references#CD012484-bbs2-0035" title="HerlitzJ , HjalmarsonA , KarlsonBW . Prognosis during one year for patients with myocardial infarction in relation to the development of Q waves: experiences from the Miami trial. Clinical Cardiology1990;13(4):261‐4. HerlitzJ , KarlsonBW , HjalmarsonA . Mortality and morbidity during one year of follow‐up in suspected acute myocardial infarction in relation to early diagnosis: experiences from the MIAMI trial. Journal of Internal Medicine1990;228(2):125‐31. MurrayDP , WatsonRD , ZezulkaAV , MurrayRG , LittlerWA . Plasma catecholamine levels in acute myocardial infarction: influence of beta‐adrenergic blockade and relation to central hemodynamics. American Heart Journal1988;115(1 Pt 1):38‐44. MurrayDP1 , MurrayRG , RafiqiE , LittlerWA . Does acute‐phase beta‐blockade reduce mortality in acute myocardial infarction by limiting infarct size?. International Journal of Cardiology1988;20(3):327‐39. RehnqvistN , OlssonG , ErhardtL , EkmanAM . Metoprolol in acute myocardial infarction reduces ventricular arrhythmias both in the early stage and after the acute event. International Journal of Cardiology1987;15(3):301‐8. The MIAMI Trial Research Group. Arrhythmias. American Journal of Cardiology1985;56(14):G35‐G38. The MIAMI Trial Research Group. Narcotic analgesics and other antianginal drugs. American Journal of Cardiology1985;56(14):G30‐G34. The MIAMI Trial Research Group. Other clinical findings and tolerability. American Journal of Cardiology1985;56(14):G39‐G46. The MIAMI Trial Research Group. Patients and methods. The American Journal of Cardiology1985;56(14):G3‐G9. The MIAMI trial research group. Metoprolol in acute myocardial infarction (MIAMI). A randomised placebo‐controlled international trial. European Heart Journal1985;6:199‐226. ">MIAMI 1985</a>, 11,5%) was assessed at unclear risk of bias in selective reporting and at low risk of bias in all the other domains. Since the overall limitations and especially in regard to blinding of outcome assessors were serious (approximately 50% of the trials contributing with more than 30% of the total weight were assessed as unclear risk of bias in blinding of outcome assessors), the evidence was downgraded by one level for risk of bias. The evidence was also downgraded by one level at maximum follow‐up beyond three months since all the included trials were at high risk of bias due to either unclear or high risk in several bias domains. </p> <p>When assessing major adverse cardiovascular events and angina, the evidence was downgraded by one level since all the included trials were at high risk of bias due to either unclear or high risk in several bias domains at both time points. </p> <p>None of the funnel plots showed any clear signs of asymmetry. Hence, there is not a strong suspicion of small‐study bias or publication bias. </p> </section> <section id="CD012484-sec-0116"> <h4 class="title">Risk of random errors ‐ imprecision ('play of chance')</h4> <p>When assessing the GRADE optimal information sizes, the optimal information size was only reached for all‐cause mortality at less than three months follow‐up. Accordingly, all‐cause mortality was not downgraded for imprecision. Regarding all‐cause mortality at maximum follow‐up beyond three months, the overall‐analysis was not downgraded due to the large sample size and the narrow absolute 97.5% CI showing only appreciable benefit and no harm, while the sensitivity analysis excluding trials at high risk of bias was downgraded by two levels due to the very small sample size included. </p> <p>When assessing cardiovascular mortality at maximum follow‐up beyond three months and myocardial infarction during follow‐up at 'less than three months' follow‐up, the evidence was not downgraded for imprecision due to a large sample size and a narrow 98% CI not showing any appreciable benefit or harm. Nevertheless, when assessing cardiovascular mortality at 'less than three months' follow‐up and myocardial infarction during follow‐up at maximum follow‐up beyond three months, we downgraded by one level for imprecision, due to the wide absolute 98% CI where the upper CI did not exclude the possibility of no difference between the groups. </p> <p>When assessing major adverse cardiovascular events at maximum follow‐up beyond three months and angina at both time points, the evidence was downgraded by two levels due to the very small sample sizes included, the optimal information sizes not being reached, and the wide 97.5% and 98% CIs, respectively, showing both appreciable benefit and harm. </p> </section> <section id="CD012484-sec-0117"> <h4 class="title">Heterogeneity ‐ inconsistency</h4> <p>We assessed the statistical heterogeneity in the planned analyses of our primary and secondary outcomes as low. The limited signs of statistical heterogeneity increases the validity of our results. We have therefore not downgraded any outcomes for risk of inconsistency. </p> </section> <section id="CD012484-sec-0118"> <h4 class="title">Indirectness of evidence</h4> <p>We assessed the risk of indirectness in the planned analyses and found that the sensitivity analysis excluding trials at high risk of bias when assessing all‐cause mortality beyond three months had serious risk of indirectness. This was due to the only trial included in the sensitivity analysis having several specific inclusion and exclusion criteria, which were not comparable to our pragmatic objective and inclusion and exclusion criteria. Regarding all the other analyses of our primary and secondary outcomes, we found no, or a low risk of indirectness due to the included trials directly comparing the intervention which we were interested in, delivered to the population in which we were interested, and most of the times measured the outcomes important to patients. </p> </section> <section id="CD012484-sec-0119"> <h4 class="title">Publication bias</h4> <p>We assessed the risk of publication bias in the planned analyses of our primary and secondary outcomes as low due to none of the funnel plots showing asymmetry. </p> </section> <section id="CD012484-sec-0120"> <h4 class="title">Funding</h4> <p>We found no effect of funding from industry in our subgroup analyses.</p> </section> <section id="CD012484-sec-0121"> <h4 class="title">GRADE</h4> <p>We have assessed the quality of evidence of each outcome results using GRADE both at the time point 'less than three months' follow‐up (<a href="./full#CD012484-tbl-0001">summary of findings Table for the main comparison</a>) and maximum follow‐up beyond three months (<a href="./full#CD012484-tbl-0002">summary of findings Table 2</a>). The GRADE assessment showed that the quality of the evidence was very low to high at the time point 'less than three months' follow‐up and very low to moderate at maximum follow‐up beyond three months. Reasons for the GRADE assessment are given in the footnotes of the table (<a href="./full#CD012484-tbl-0001">summary of findings Table for the main comparison</a> (time point 'less than three months' follow‐up) and <a href="./full#CD012484-tbl-0002">summary of findings Table 2</a> (maximum follow‐up beyond three months)). </p> </section> </section> <section id="CD012484-sec-0122"> <h3 class="title" id="CD012484-sec-0122">Potential biases in the review process</h3> <section id="CD012484-sec-0123"> <h4 class="title">Strengths</h4> <p>Our review has several strengths. We are the first to conduct a systematic review using Cochrane methodology comparing beta‐blockers versus placebo or no intervention in patients with suspected or diagnosed myocardial infarction. We followed our peer‐reviewed protocol, which was published before the literature search began regarding Cochrane methodology (<a href="./references#CD012484-bbs2-0189" title="NielsenEE , FeinbergJ , SafiS , SethiNJ , GluudC , JakobsenJC . Beta‐blockers for suspected or diagnosed acute myocardial infarction. Cochrane Database of Systematic Reviews2016, Issue 12. [DOI: 10.1002/14651858.CD012484] ">Nielsen 2016</a>), and we conducted the review using the methods recommended by Cochrane (<a href="./references#CD012484-bbs2-0125" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). We included trials regardless of language of publication and whether they reported data on the outcomes we had planned to assess. We contacted all relevant authors if additional information was needed. We included more trials and more participants than any previous systematic review or meta‐analysis which gives us increased power and precision to detect any evidence of a difference between the intervention and control group. Data were double‐extracted by independent review authors minimising the risk of inaccurate data‐extraction, and we assessed the risk of bias in all trials according to the <i>Cochrane Handbook for Systematic Reviews of Interventions (</i><a href="./references#CD012484-bbs2-0125" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>)<i>.</i> We used GRADE to assess the quality of the body of evidence (<a href="./references#CD012484-bbs2-0119" title="GuyattGH , OxmanAD , VistGE , KunzR , Falck‐YtterY , Alonso‐CoelloP , et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ2008;336(7650):924‐6. [PUBMED: 18436948] ">Guyatt 2008</a>; <a href="./references#CD012484-bbs2-0120" title="GuyattGH , OxmanAD , SchunemannHJ , TugwellP , KnottnerusA . GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. Journal of Clinical Epidemiology2011;64(4):380‐2. ">Guyatt 2011</a>; <a href="./references#CD012484-bbs2-0169" title="SchünemannHJ , BestD , VistG , OxmanAD . Letters, numbers, symbols and words: how to communicate grades of evidence and recommendations. CMAJ: Canadian Medical Association journal2003;169(7):677‐80. ">Schünemann 2003</a>; <a href="./references#CD012484-bbs2-0171" title="SchünemannHJ , OxmanAD , VistGE , HigginsJP , DeeksJJ , GlasziouP , et al. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JP, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017). Cochrane, 2017. Available from www.training.cochrane.org/handbook. ">Schünemann 2017</a>), and sensitivity analyses (best‐worst and worst‐best) to test the potential impact of incomplete outcome data bias. Hence, this systematic review considered both risks of random errors and risks of systematic errors which adds further robustness to our results and conclusions. </p> <p>Our meta‐analyses had little statistical heterogeneity strengthening the validity of our results. </p> </section> <section id="CD012484-sec-0124"> <h4 class="title">Limitations</h4> <p>Our systematic review has several limitations. Our findings, interpretations, and conclusions are affected by the quality, quantity, and outcome reporting of the included trials. Some limitations have already been discussed in the above section <a href="#CD012484-sec-0113">Overall completeness and applicability of evidence</a>). </p> <p><b>'Risk of bias' assessment</b> </p> <p>Our 'Risk of bias' assessment showed that only one trial was at low risk of bias in all domains (<a href="./references#CD012484-bbs2-0016" title="COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo‐controlled trial. Lancet2005;366(9497):1622‐32. Second Chinese Cardiac Study (CCS‐2) Collaborative Group. Rationale, design and organization of the Second Chinese Cardiac Study (CCS‐2): a randomized trial of clopidogrel plus aspirin, and of metoprolol, among patients with suspected acute myocardial infarction. Journal of Cardiovascular Risk2000;7(6):435‐41. ">COMMIT 2005</a>). We conducted sensitivity analyses excluding trials at high risk of bias to assess if the results differed compared to the overall analyses. We based our primary analyses and primary conclusions on trials at low risk of bias if their results differed compared to the overall analyses, since meta‐epidemiological studies have shown that trials at high risk of bias overestimate benefits and underestimate harms (<a href="./references#CD012484-bbs2-0130" title="HrobjartssonA , ThomsenAS , EmanuelssonF , TendalB , HildenJ , BoutronI , et al. Observer bias in randomised clinical trials with binary outcomes: systematic review of trials with both blinded and non‐blinded outcome assessors. BMJ (Clinical Research Ed.)2012;344:e1119. ">Hrobjartsson 2012</a>; <a href="./references#CD012484-bbs2-0131" title="HrobjartssonA , ThomsenAS , EmanuelssonF , TendalB , HildenJ , BoutronI , et al. Observer bias in randomized clinical trials with measurement scale outcomes: a systematic review of trials with both blinded and nonblinded assessors. Canadian Medical Association Journal2013;185(4):E201‐11. ">Hrobjartsson 2013</a>; <a href="./references#CD012484-bbs2-0132" title="HrobjartssonA , ThomsenAS , EmanuelssonF , TendalB , RasmussenJV , HildenJ , et al. Observer bias in randomized clinical trials with time‐to‐event outcomes: systematic review of trials with both blinded and non‐blinded outcome assessors. International Journal of Epidemiology2014;43(3):937‐48. ">Hrobjartsson 2014</a>; <a href="./references#CD012484-bbs2-0133" title="HrobjartssonA , EmanuelssonF , Skou ThomsenAS , HildenJ , BrorsonS . Bias due to lack of patient blinding in clinical trials. A systematic review of trials randomizing patients to blind and non‐blind sub‐studies. International Journal of Epidemiology2014;43(4):1272‐83. [PUBMED: 24881045] ">Hrobjartsson 2014a</a>; <a href="./references#CD012484-bbs2-0136" title="JakobsenJC , WetterslevJ , WinkelP , LangeT , GluudC . Thresholds for statistical and clinical significance in systematic reviews with meta‐analytic methods. BMC Medical Research Methodology2014;14:120. [PUBMED: 25416419] ">Jakobsen 2014</a>; <a href="./references#CD012484-bbs2-0145" title="LundhA , LexchinJ , MintzesB , SchrollJB , BeroL . Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews2017, Issue 2. [DOI: 10.1002/14651858.MR000033.pub3] ">Lundh 2017</a>; <a href="./references#CD012484-bbs2-0163" title="SavovicJ , JonesHE , AltmanDG , HarrisRJ , JuniP , PildalJ , et al. Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Annals of Internal Medicine2012;157(6):429‐38. ">Savovic 2012</a>; <a href="./references#CD012484-bbs2-0185" title="WoodL , EggerM , GluudLL , SchulzKF , JuniP , AltmanDG , et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta‐epidemiological study. BMJ2008;336(7644):601‐5. ">Wood 2008</a>). For cardiovascular mortality at the time point 'less than three months' follow‐up, we based our primary analyses and primary conclusions on trials at low risk of bias. For all the other outcomes, we based our primary analyses and primary conclusions on the overall analyses. </p> <p><b>Incomplete outcome data</b> </p> <p>We assessed 38/62 trials as either at unclear or high risk of bias on the incomplete outcome data bias domain. Our 'best‐worst' and 'worst‐best' case analyses confirmed that there is a high risk of incomplete outcome data bias influencing our primary analyses for all our outcomes. In 31/62 trials, it was not reported in sufficient detail if any participant was lost to follow‐up. It was often only reported that a certain number of participants died or experienced a type of serious adverse event without reporting if any of the participants were lost to follow‐up, etc. If insufficient data were reported by the trialists, we tried to contact the authors, but often the authors did not reply. Hence, the extent of the incomplete outcome data was often unclear. Our 'best‐worst' and 'worst‐best' case analyses might underestimate the potential impact of missing data because only the data on the reported population were used if no other information was available. Incomplete outcome data might potentially have an even greater bias impact than our 'best‐worst' and 'worst‐best' case analyses show, i.e. the 'true' differences between the actually observed cases and the intention‐to‐treat population might be larger than our data suggest. </p> <p><b>Assessed time points</b> </p> <p>We predefined the time point 'less than three months' as our primary assessment time point. However, only a few studies reported data at this time point (<a href="#CD012484-tbl-0003">Table 1</a>). We chose 'less than three months' as the possible effects of beta‐blockers would have some time to show and the follow‐up period would be short enough to assess any short term effect of beta‐blockers without other factors (e.g. non‐cardiac‐related deaths) diluting the intervention effect. Nevertheless, we also assessed all outcomes at maximum follow‐up beyond three months. The meta‐analyses at maximum follow‐up showed different results in regard to all‐cause mortality, cardiovascular mortality, and myocardial infarction during follow‐up when compared to the results at the time point 'less than 3' months follow‐up. </p> <p><b>Continous outcomes</b> </p> <p>We included quality of life and angina as continuous outcomes. However, no trials reported quality of life and angina on a continuous scale. </p> <p><b>Clinical heterogeneity</b> </p> <p>The beta‐blockers used in the experimental group, the control group and the co‐interventions used in the different trials differed. Furthermore, the length of intervention period, the dosage of the beta‐blockers, and the follow‐up period differed between the trials. Even though our results showed limited sign of statistical heterogeneity, this is a limitation of our review because the subsequent transferability into a specific clinical context may be impaired. </p> <p><b>Serious adverse events</b> </p> <p>The trials included in this review reported harms inadequately. None of the trials specifically assessed nor reported serious adverse events as planned according to ICH‐GCP (<a href="./references#CD012484-bbs2-0134" title="International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) adopts Consolidated Guideline on Good Clinical Practice in the Conduct of Clinical Trials on Medicinal Products for Human Use. International Digest of Health Legislation1997; Vol. 48, issue 2:231‐4. [PUBMED: 11656783] ">ICH‐GCP 1997</a>). Instead, the trials either reported composites of several specific serious adverse events or one specific serious adverse event. We could therefore not conduct a meta‐analysis as planned on all serious adverse events. Hence, it was not possible to assess the overall safety of beta‐blockers in patients with suspected or diagnosed myocardial infarction. This is problematic, as the reporting of harm is as important as the reporting of efficacy. Without adequate reporting of both harms and benefits, it is not possible to estimate if an intervention is useful or not (<a href="./references#CD012484-bbs2-0135" title="IoannidisJP . Adverse events in randomized trials: neglected, restricted, distorted, and silenced. Archives of Internal Medicine2009;169(19):1737‐9. ">Ioannidis 2009</a>). Because of the utmost importance of assessing harmful effects and to not lose important data reported by the trialists, one could conduct an exploratory outcome assessing either the composite of several specific adverse events described as 'serious adverse event' by the trialists (without referring to ICH‐GCP), or one single reported serious adverse event that had the largest number of events when it was unclear if participants had experienced more than one serious adverse event to avoid double‐counting. In addition, an exploratory meta‐analysis could be conducted according to different types of serious adverse events assessed. These exploratory outcomes were not presented in this present review in accordance with the Cochrane Heart Group's methods. </p> <p><b>Major adverse cardiovascular events</b> </p> <p>Only two trials at the time point 'less than three months' follow‐up (with no events reported) and four trials at maximum follow‐up beyond three months specifically assesseD major adverse cardiovascular events according to our definition (composite of cardiovascular mortality and non‐fatal myocardial infarction during follow‐up). The effects of beta‐blockers on major adverse cardiovascular events are therefore uncertain due to lack of data. Instead, the trials reported either cardiovascular mortality <i>or</i> myocardial infarction during follow‐up. Because of the utmost importance of assessing harmful effects and not to lose important data reported by the trialists, one could conduct exploratory meta‐analyses assessing the composite of <i>either</i> cardiovascular mortality <i>or</i> myocardial infarction with the largest number of events to avoid double‐counting. In addition. an exploratory meta‐analysis could be conducted according to different types of major adverse cardiovascular events assessed. These exploratory outcomes were not presented in this present review in accordance with the Cochrane Heart Group's methods. </p> <p><b>Multiplicity</b> </p> <p>We used broad inclusion criteria to fully assess the effects of beta‐blockers in patients with suspected or diagnosed myocardial infarction. Therefore, we included a large number of outcomes, time points, subgroup analyses, and sensitivity analyses. We are aware that this increases the risk of type 1 error due to multiplicity. To minimise the potential risk, we decided on a more conservative alpha of 2.5% with a 97.5% CI for our primary outcomes and an alpha of 2.0% with a 98% CI for our secondary outcomes (<a href="./references#CD012484-bbs2-0136" title="JakobsenJC , WetterslevJ , WinkelP , LangeT , GluudC . Thresholds for statistical and clinical significance in systematic reviews with meta‐analytic methods. BMC Medical Research Methodology2014;14:120. [PUBMED: 25416419] ">Jakobsen 2014</a>; <a href="./references#CD012484-bbs2-0137" title="JakobsenJ C , WetterslevJ , LangeT , GluudC . Viewpoint: taking into account risks of random errors when analysing multiple outcomes in systematic reviews. Cochrane Database of Systematic Reviews2016;3:Ed000111. [DOI: 10.1002/14651858.ED000111] ">Jakobsen 2016</a>). </p> <p><b>Disease‐related outcomes</b> </p> <p>The validity of the results of this meta‐analysis in regard to our disease‐related outcomes (major adverse cardiovascular events, cardiovascular mortality, and myocardial infarction) might be questionable as there are numerous methodological limitations of the use of disease‐related mortality and other outcomes (<a href="./references#CD012484-bbs2-0122" title="HeneghanC , GoldacreB , MahtaniKR . Why clinical trial outcomes fail to translate into benefits for patients. Trials2017; Vol. 18, issue 1:122. [PUBMED: 28288676] ">Heneghan 2017</a>; <a href="./references#CD012484-bbs2-0125" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). </p> <p> <ul id="CD012484-list-0244"> <li> <p>When assessing disease‐related outcomes, the ’true’ causality of an outcome (e.g. disease‐specific death) will often be unclear and the validity of results on disease‐related mortality might therefore also be unclear. As a consequence, the results on disease‐related events might not reflect the ‘true’ effect due to the risk of erroneous classifications of certain causes of events. </p> </li> <li> <p>Clinical events that are apparently unrelated to a disease might actually be caused by the disease or the intervention for the disease. For example, if a trial participant suddenly dies in a traffic accident, the underlying cause might be nausea or dizziness caused by the disease or it might be an adverse reaction of an intervention for the disease. Hence, the impact of possible unknown adverse reactions might be overlooked in the results. </p> </li> <li> <p>As the trials included in this review used different definitions of cardiovascular mortality and reinfarction, the validity of such meta‐analyses result might be questionable. Even if the definitions of the disease‐related mortality such as cardiovascular mortality are described similarly in each trial, the subjective assessment of whether or not an event is disease‐related might still differ substantially between trials. This is, for obvious reasons, particularly a problem if the outcome assessors in the trials are not adequately blinded to treatment allocation of the patients. The vast majority of the included trials did not adequately blind the personnel and outcome assessors, one should, therefore, interpret outcomes such as major adverse cardiovascular events, cardiovascular mortality, and myocardial infarction with even greater caution. </p> </li> </ul> </p> <p>The most valid outcome is considered to be all‐cause mortality assessed at low risk of bias. When the intervention effect estimates differ between disease‐related mortality and all‐cause mortality, the results should especially be interpreted with caution. Our apparent beneficial effect of beta‐blockers on myocardial infarction during follow‐up at the time point 'less than three months' follow‐up does not comply with our findings in regard to all‐cause mortality at the time point 'less than three months' follow‐up showing little to no benefit. One should, therefore, interpret this apparent beneficial effect on myocardial infarction with some caution. Nevertheless, at maximum follow‐up beyond three months, cardiovascular mortality and the overall analysis when assessing all‐cause mortality showed a beneficial effect of beta‐blockers on these outcomes. </p> </section> </section> <section id="CD012484-sec-0125"> <h3 class="title" id="CD012484-sec-0125">Agreements and disagreements with other studies or reviews</h3> <p>We have identified multiple reviews assessing the effects of beta‐blockers versus placebo or no intervention. However, only one of the reviews systematically assessed the risks of random errors and employed adequate assessments of risks of bias using some of the Cochrane domains (<a href="./references#CD012484-bbs2-0094" title="BangaloreS , MakaniH , RadfordM , ThakurK , TokluB , KatzSD , et al. Clinical outcomes with beta‐blockers for myocardial infarction: a meta‐analysis of randomized trials. American Journal of Medicine2014;127(10):939‐53. [PUBMED: 24927909] ">Bangalore 2014</a>), while the rest of them had either a very limited bias risk assessment (<a href="./references#CD012484-bbs2-0090" title="Al‐ReesiA , Al‐ZadjaliN , PerryJ , FergussonD , Al‐ShamsiM , Al‐ThagafiM , et al. Do beta‐blockers reduce short‐term mortality following acute myocardial infarction? A systematic review and meta‐analysis. Canadian Journal of Emergency Medicine2008;10(3):215‐23. [PUBMED: 19019272] ">Al‐Reesi 2008</a>; <a href="./references#CD012484-bbs2-0114" title="FreemantleN , ClelandJ , YoungP , MasonJ , HarrisonJ . Beta blockade after myocardial infarction: systematic review and meta regression analysis. BMJ1999;318(7200):1730‐7. [PUBMED: 10381708] ">Freemantle 1999</a>; <a href="./references#CD012484-bbs2-0096" title="BrandlerE , PaladinoL , SinertR . Does the early administration of beta‐blockers improve the in‐hospital mortality rate of patients admitted with acute coronary syndrome?. Academic Emergency Medicine2010;17(1):1‐10. [PUBMED: 20078433] ">Brandler 2010</a>; <a href="./references#CD012484-bbs2-0100" title="ChatterjeeS , ChaudhuriD , VedanthanR , FusterV , IbanezB , BangaloreS , et al. Early intravenous beta‐blockers in patients with acute coronary syndrome ‐ a meta‐analysis of randomized trials. International Journal of Cardiology2013;168(2):915‐21. [PUBMED: 23168009] ">Chatterjee 2013</a>) or no bias risk assessment at all (<a href="./references#CD012484-bbs2-0142" title="LewisJA . Beta‐blockade after myocardial infarction ‐ a statistical view. British Journal of Clinical Pharmacology1982;14 Suppl 1:15S‐21S. [PUBMED: 6126204] ">Lewis 1982</a>; <a href="./references#CD012484-bbs2-0187" title="YusufS , PetoR , LewisJ , CollinsR , SleightP . Beta blockade during and after myocardial infarction: an overview of the randomized trials. Progress in Cardiovascular Diseases1985;27(5):335‐71. [PUBMED: 2858114] ">Yusuf 1985</a>). None of the reviews used the GRADE system to assess the quality of the body of evidence associated with the outcome results reported. </p> <p><a href="./references#CD012484-bbs2-0090" title="Al‐ReesiA , Al‐ZadjaliN , PerryJ , FergussonD , Al‐ShamsiM , Al‐ThagafiM , et al. Do beta‐blockers reduce short‐term mortality following acute myocardial infarction? A systematic review and meta‐analysis. Canadian Journal of Emergency Medicine2008;10(3):215‐23. [PUBMED: 19019272] ">Al‐Reesi 2008</a> assessed patients randomised within the first 72 hours following an acute myocardial infarction receiving any type of beta‐blockers commenced either intravenously or orally. The review found no evidence of a beneficial effect on all‐cause mortality at six weeks follow‐up (odds ratio (OR) 0.95, 95% CI 0.90 to 1.01). The same was true when assessing the subgroup of only high‐quality studies (studies were considered high‐quality if they scored 2 on the Jadad score and had adequate allocation concealment (A), or if they scored 3 or more on the Jadad score with an allocation concealment score of at least B) (OR 0.96, 95% CI 0.91 to 1.02). The study limited their search to only English studies. </p> <p><a href="./references#CD012484-bbs2-0114" title="FreemantleN , ClelandJ , YoungP , MasonJ , HarrisonJ . Beta blockade after myocardial infarction: systematic review and meta regression analysis. BMJ1999;318(7200):1730‐7. [PUBMED: 10381708] ">Freemantle 1999</a> assessed patients who had had a myocardial infarction and where treatment with any type of beta‐blockers commenced either intravenously or orally started at any stage before or after the myocardial infarction. The review found no evidence of a beneficial effect on mortality at short‐term follow‐up (OR 0.96, 95% CI 0.85 to 1.08). However, when assessing long‐term treatment effect, evidence of a beneficial effect was found (OR 0.77, 95% CI 0.69 to 0.85). </p> <p><a href="./references#CD012484-bbs2-0096" title="BrandlerE , PaladinoL , SinertR . Does the early administration of beta‐blockers improve the in‐hospital mortality rate of patients admitted with acute coronary syndrome?. Academic Emergency Medicine2010;17(1):1‐10. [PUBMED: 20078433] ">Brandler 2010</a> assessed patients with an acute or suspected myocardial infarction within 24 hours of onset of chest pain treated within eight hours with any type of beta‐blockers commenced either intravenously or orally. The review found no evidence of a beneficial effect on in‐hospital mortality (RR 0.95, 95% CI 0.90 to 1.01). </p> <p><a href="./references#CD012484-bbs2-0155" title="PerezMI , MusiniVM , WrightJM . Effect of early treatment with anti‐hypertensive drugs on short and long‐term mortality in patients with an acute cardiovascular event. Cochrane Database of Systematic Reviews2009, Issue 4. [DOI: 10.1002/14651858.CD006743.pub2; PUBMED: 19821384] ">Perez 2009</a> assessed patients with an acute cardiovascular event (e.g. myocardial infarction) treated with different anti‐hypertensive drugs (e.g. beta‐blockers) within 24 hours of the onset of symptoms. The review found 20 trials where patients were treated with beta‐blockers commenced either intravenously or orally and showed no evidence of a difference on all‐cause mortality at 10 days follow‐up (RR 0.96, 95% CI 0.91 to 1.02, P = 0.21, I<sup>2</sup>=0%), nor at weighted average of 12 months of follow‐up (RR 0.91, 95% CI 0.84 to 0.99, P = 0.03, I<sup>2</sup> = 0%). </p> <p><a href="./references#CD012484-bbs2-0100" title="ChatterjeeS , ChaudhuriD , VedanthanR , FusterV , IbanezB , BangaloreS , et al. Early intravenous beta‐blockers in patients with acute coronary syndrome ‐ a meta‐analysis of randomized trials. International Journal of Cardiology2013;168(2):915‐21. [PUBMED: 23168009] ">Chatterjee 2013</a> assessed patients with an acute or suspected myocardial infarction within 48 hours of onset of chest pain treated with intravenously commenced beta‐blockers within 12 hours. The review only included 16 trials and showed a beneficial effect of early beta‐blockers on mortality (RR 0.92, 95% CI 0.86 to 1; P = 0.04) and myocardial reinfarction rates (RR 0.73, 95% CI 0.59 to 0.91, P = 0.004). </p> <p><a href="./references#CD012484-bbs2-0142" title="LewisJA . Beta‐blockade after myocardial infarction ‐ a statistical view. British Journal of Clinical Pharmacology1982;14 Suppl 1:15S‐21S. [PUBMED: 6126204] ">Lewis 1982</a> assessed patients with myocardial infarction treated with either intravenously or orally commenced beta‐blockers and distinguished between early (within 48 hours) and late intervention. The review showed evidence of a beneficial effect when pooling both late and early intervention (RR 0.79, 95% CI 0.72 to 0.87). However, when assessing only the early‐entry trials, it found evidence of a small beneficial effect (RR 0.92). The review only included 17 trials compared to our 62 trials. </p> <p><a href="./references#CD012484-bbs2-0187" title="YusufS , PetoR , LewisJ , CollinsR , SleightP . Beta blockade during and after myocardial infarction: an overview of the randomized trials. Progress in Cardiovascular Diseases1985;27(5):335‐71. [PUBMED: 2858114] ">Yusuf 1985</a> assessed the effects of beta‐blockers on all‐cause mortality at short‐term and long‐term treatment with beta‐blockers commenced either intravenously or orally and showed evidence of a beneficial effect at long‐term treatment while no effect was seen in the short‐term treatment with beta‐blockers. Furthermore, a reduction in reinfarction was found at long‐term treatment with beta‐blockers. </p> <p><a href="./references#CD012484-bbs2-0094" title="BangaloreS , MakaniH , RadfordM , ThakurK , TokluB , KatzSD , et al. Clinical outcomes with beta‐blockers for myocardial infarction: a meta‐analysis of randomized trials. American Journal of Medicine2014;127(10):939‐53. [PUBMED: 24927909] ">Bangalore 2014</a> assessed participants with myocardial infarction treated with beta‐blockers commenced either intravenously or orally and distinguished between the pre‐reperfusion and reperfusion period (if &gt; 50% of patients received reperfusion either with thrombolytics or with revascularisation or aspirin/statin). In the pre‐reperfusion period, beta‐blockers were associated with a statistically significant reduction in mortality (IRR 0.86, 95% CI 0.79 to 0.94), cardiovascular mortality, and myocardial infarction at both short‐term follow up (30 days) and long‐term follow‐up (12 months). In the reperfusion period, beta‐blockers were associated with no beneficial effect at both time points except for myocardial infarction and angina at 30 days follow‐up. However, a significant increase in heart failure, cardiogenic shock, and drug discontinuation was found in the reperfusion period. Furthermore, a reduction in all‐cause mortality, myocardial infarction, and angina pectoris was seen in the pre‐reperfusion period when observing trials where early intravenous beta‐blockers were administered. In the reperfusion period the beneficial effect was only associated with myocardial infarction and angina and not all‐cause mortality when observing trials where early intravenous beta‐blockers were administered. </p> <p>Our present review result, when analysing the short‐term effect of beta‐blockers on all‐cause mortality, is in agreement with <a href="./references#CD012484-bbs2-0090" title="Al‐ReesiA , Al‐ZadjaliN , PerryJ , FergussonD , Al‐ShamsiM , Al‐ThagafiM , et al. Do beta‐blockers reduce short‐term mortality following acute myocardial infarction? A systematic review and meta‐analysis. Canadian Journal of Emergency Medicine2008;10(3):215‐23. [PUBMED: 19019272] ">Al‐Reesi 2008</a>, <a href="./references#CD012484-bbs2-0114" title="FreemantleN , ClelandJ , YoungP , MasonJ , HarrisonJ . Beta blockade after myocardial infarction: systematic review and meta regression analysis. BMJ1999;318(7200):1730‐7. [PUBMED: 10381708] ">Freemantle 1999</a>, <a href="./references#CD012484-bbs2-0096" title="BrandlerE , PaladinoL , SinertR . Does the early administration of beta‐blockers improve the in‐hospital mortality rate of patients admitted with acute coronary syndrome?. Academic Emergency Medicine2010;17(1):1‐10. [PUBMED: 20078433] ">Brandler 2010</a>, <a href="./references#CD012484-bbs2-0155" title="PerezMI , MusiniVM , WrightJM . Effect of early treatment with anti‐hypertensive drugs on short and long‐term mortality in patients with an acute cardiovascular event. Cochrane Database of Systematic Reviews2009, Issue 4. [DOI: 10.1002/14651858.CD006743.pub2; PUBMED: 19821384] ">Perez 2009</a>, and <a href="./references#CD012484-bbs2-0187" title="YusufS , PetoR , LewisJ , CollinsR , SleightP . Beta blockade during and after myocardial infarction: an overview of the randomized trials. Progress in Cardiovascular Diseases1985;27(5):335‐71. [PUBMED: 2858114] ">Yusuf 1985</a>, where the conclusions are that beta‐blockers do not seem to have any short‐term effect on the risk of all‐cause mortality. The same is seen in <a href="./references#CD012484-bbs2-0094" title="BangaloreS , MakaniH , RadfordM , ThakurK , TokluB , KatzSD , et al. Clinical outcomes with beta‐blockers for myocardial infarction: a meta‐analysis of randomized trials. American Journal of Medicine2014;127(10):939‐53. [PUBMED: 24927909] ">Bangalore 2014</a>, when assessing all‐cause mortality for the reperfusion period, while the pre‐reperfusion period shows evidence of a beneficial effect on all‐cause mortality. However, our present review's results are not in agreement with <a href="./references#CD012484-bbs2-0100" title="ChatterjeeS , ChaudhuriD , VedanthanR , FusterV , IbanezB , BangaloreS , et al. Early intravenous beta‐blockers in patients with acute coronary syndrome ‐ a meta‐analysis of randomized trials. International Journal of Cardiology2013;168(2):915‐21. [PUBMED: 23168009] ">Chatterjee 2013</a> and <a href="./references#CD012484-bbs2-0142" title="LewisJA . Beta‐blockade after myocardial infarction ‐ a statistical view. British Journal of Clinical Pharmacology1982;14 Suppl 1:15S‐21S. [PUBMED: 6126204] ">Lewis 1982</a>, as these reviews showed a beneficial short‐term effect of beta‐blockers on all‐cause mortality. This disagreement may potentially be due to different inclusion criteria as <a href="./references#CD012484-bbs2-0100" title="ChatterjeeS , ChaudhuriD , VedanthanR , FusterV , IbanezB , BangaloreS , et al. Early intravenous beta‐blockers in patients with acute coronary syndrome ‐ a meta‐analysis of randomized trials. International Journal of Cardiology2013;168(2):915‐21. [PUBMED: 23168009] ">Chatterjee 2013</a> included only trials where participants were treated with intravenous beta‐blockers within 12 hours and not oral beta‐blockers, which differs from our review where we have included both oral and intravenous beta‐blocker treatment as the reviews mentioned above. This beneficial effect on mortality observed in <a href="./references#CD012484-bbs2-0100" title="ChatterjeeS , ChaudhuriD , VedanthanR , FusterV , IbanezB , BangaloreS , et al. Early intravenous beta‐blockers in patients with acute coronary syndrome ‐ a meta‐analysis of randomized trials. International Journal of Cardiology2013;168(2):915‐21. [PUBMED: 23168009] ">Chatterjee 2013</a> may reflect the superior effect of intravenous beta‐blocker administration, which is also seen in <a href="./references#CD012484-bbs2-0094" title="BangaloreS , MakaniH , RadfordM , ThakurK , TokluB , KatzSD , et al. Clinical outcomes with beta‐blockers for myocardial infarction: a meta‐analysis of randomized trials. American Journal of Medicine2014;127(10):939‐53. [PUBMED: 24927909] ">Bangalore 2014</a> in the pre‐reperfusion period, however, this has not been observed with our subgroup analysis differentiating between orally and intravenously commenced beta‐blockers. Furthermore, both <a href="./references#CD012484-bbs2-0100" title="ChatterjeeS , ChaudhuriD , VedanthanR , FusterV , IbanezB , BangaloreS , et al. Early intravenous beta‐blockers in patients with acute coronary syndrome ‐ a meta‐analysis of randomized trials. International Journal of Cardiology2013;168(2):915‐21. [PUBMED: 23168009] ">Chatterjee 2013</a> and <a href="./references#CD012484-bbs2-0142" title="LewisJA . Beta‐blockade after myocardial infarction ‐ a statistical view. British Journal of Clinical Pharmacology1982;14 Suppl 1:15S‐21S. [PUBMED: 6126204] ">Lewis 1982</a> only included respectively, 16 and 17 trials each which differs from our review and the majority of the reviews mentioned above. </p> <p>When assessing the long‐term effect of beta‐blockers on all‐cause mortality, our present review result is in agreement with <a href="./references#CD012484-bbs2-0114" title="FreemantleN , ClelandJ , YoungP , MasonJ , HarrisonJ . Beta blockade after myocardial infarction: systematic review and meta regression analysis. BMJ1999;318(7200):1730‐7. [PUBMED: 10381708] ">Freemantle 1999</a> and <a href="./references#CD012484-bbs2-0187" title="YusufS , PetoR , LewisJ , CollinsR , SleightP . Beta blockade during and after myocardial infarction: an overview of the randomized trials. Progress in Cardiovascular Diseases1985;27(5):335‐71. [PUBMED: 2858114] ">Yusuf 1985</a>, but not with <a href="./references#CD012484-bbs2-0155" title="PerezMI , MusiniVM , WrightJM . Effect of early treatment with anti‐hypertensive drugs on short and long‐term mortality in patients with an acute cardiovascular event. Cochrane Database of Systematic Reviews2009, Issue 4. [DOI: 10.1002/14651858.CD006743.pub2; PUBMED: 19821384] ">Perez 2009</a> which differs from our review and the other reviews mentioned above as this review included only five trials in the assessment of the long‐term follow‐up effect of beta‐blockers. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD012484-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/urn:x-wiley:14651858:media:CD012484:CD012484-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_t/tCD012484-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD012484-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/full#CD012484-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012484-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/urn:x-wiley:14651858:media:CD012484:CD012484-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_t/tCD012484-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD012484-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/full#CD012484-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012484-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/urn:x-wiley:14651858:media:CD012484:CD012484-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_t/tCD012484-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD012484-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/full#CD012484-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012484-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/urn:x-wiley:14651858:media:CD012484:CD012484-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_t/tCD012484-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 Beta‐blockers versus placebo or no intervention at 'less than 3 months' follow‐up, outcome: 1.1 All‐cause mortality." data-id="CD012484-fig-0004" src="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Beta‐blockers versus placebo or no intervention at 'less than 3 months' follow‐up, outcome: 1.1 All‐cause mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/full#CD012484-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012484-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/urn:x-wiley:14651858:media:CD012484:CD012484-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_t/tCD012484-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 2 Beta‐blockers versus placebo or no intervention at maximum follow‐up beyond 3 months, outcome: 2.1 All‐cause mortality." data-id="CD012484-fig-0005" src="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Funnel plot of comparison: 2 Beta‐blockers versus placebo or no intervention at maximum follow‐up beyond 3 months, outcome: 2.1 All‐cause mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/full#CD012484-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012484-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/urn:x-wiley:14651858:media:CD012484:CD012484-AFig-FIG06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_t/tCD012484-AFig-FIG06.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 5 Beta‐blockers versus placebo or no intervention at 'less than 3 months' follow‐up beyond 3 months, outcome: 5.1 Cardiovascular mortality." data-id="CD012484-fig-0006" src="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-AFig-FIG06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Funnel plot of comparison: 5 Beta‐blockers versus placebo or no intervention at 'less than 3 months' follow‐up beyond 3 months, outcome: 5.1 Cardiovascular mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/full#CD012484-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-AFig-FIG06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012484-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/urn:x-wiley:14651858:media:CD012484:CD012484-AFig-FIG07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_t/tCD012484-AFig-FIG07.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 6 Beta‐blockers versus placebo or no intervention at maximum follow‐up beyond 3 months, outcome: 6.1 Cardiovascular mortality." data-id="CD012484-fig-0007" src="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-AFig-FIG07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 7</div> <div class="figure-caption"> <p>Funnel plot of comparison: 6 Beta‐blockers versus placebo or no intervention at maximum follow‐up beyond 3 months, outcome: 6.1 Cardiovascular mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/full#CD012484-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-AFig-FIG07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012484-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/urn:x-wiley:14651858:media:CD012484:CD012484-AFig-FIG08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_t/tCD012484-AFig-FIG08.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 7 Beta‐blockers versus placebo or no intervention at 'less than 3 months' follow‐up, outcome: 7.1 Myocardial infarction." data-id="CD012484-fig-0008" src="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-AFig-FIG08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 8</div> <div class="figure-caption"> <p>Funnel plot of comparison: 7 Beta‐blockers versus placebo or no intervention at 'less than 3 months' follow‐up, outcome: 7.1 Myocardial infarction. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/full#CD012484-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-AFig-FIG08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012484-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/urn:x-wiley:14651858:media:CD012484:CD012484-AFig-FIG09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_t/tCD012484-AFig-FIG09.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 8 Beta‐blockers versus placebo or no intervention at maximum follow‐up beyond 3 months, outcome: 8.1 Myocardial infarction." data-id="CD012484-fig-0009" src="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-AFig-FIG09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 9</div> <div class="figure-caption"> <p>Funnel plot of comparison: 8 Beta‐blockers versus placebo or no intervention at maximum follow‐up beyond 3 months, outcome: 8.1 Myocardial infarction. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/full#CD012484-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-AFig-FIG09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012484-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/urn:x-wiley:14651858:media:CD012484:CD012484-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_t/tCD012484-CMP-001-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Beta‐blockers versus placebo or no intervention less than 3 months follow‐up, Outcome 1 All‐cause mortality." data-id="CD012484-fig-0010" src="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Beta‐blockers versus placebo or no intervention less than 3 months follow‐up, Outcome 1 All‐cause mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/references#CD012484-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012484-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/urn:x-wiley:14651858:media:CD012484:CD012484-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_t/tCD012484-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Beta‐blockers versus placebo or no intervention less than 3 months follow‐up, Outcome 2 All‐cause mortality ‐ Acute/subacute phase." data-id="CD012484-fig-0011" src="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Beta‐blockers versus placebo or no intervention less than 3 months follow‐up, Outcome 2 All‐cause mortality ‐ Acute/subacute phase. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/references#CD012484-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012484-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/urn:x-wiley:14651858:media:CD012484:CD012484-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_t/tCD012484-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Beta‐blockers versus placebo or no intervention less than 3 months follow‐up, Outcome 3 All‐cause mortality ‐ Reperfusion/no reperfusion." data-id="CD012484-fig-0012" src="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Beta‐blockers versus placebo or no intervention less than 3 months follow‐up, Outcome 3 All‐cause mortality ‐ Reperfusion/no reperfusion. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/references#CD012484-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012484-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/urn:x-wiley:14651858:media:CD012484:CD012484-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_t/tCD012484-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Beta‐blockers versus placebo or no intervention less than 3 months follow‐up, Outcome 4 All‐cause mortality ‐ Type of beta‐blocker." data-id="CD012484-fig-0013" src="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Beta‐blockers versus placebo or no intervention less than 3 months follow‐up, Outcome 4 All‐cause mortality ‐ Type of beta‐blocker. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/references#CD012484-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012484-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/urn:x-wiley:14651858:media:CD012484:CD012484-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_t/tCD012484-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Beta‐blockers versus placebo or no intervention less than 3 months follow‐up, Outcome 5 All‐cause mortality ‐ Intravenously/orally commenced." data-id="CD012484-fig-0014" src="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Beta‐blockers versus placebo or no intervention less than 3 months follow‐up, Outcome 5 All‐cause mortality ‐ Intravenously/orally commenced. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/references#CD012484-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012484-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/urn:x-wiley:14651858:media:CD012484:CD012484-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_t/tCD012484-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Beta‐blockers versus placebo or no intervention less than 3 months follow‐up, Outcome 6 All‐cause mortality ‐ Above/below 75 years of age." data-id="CD012484-fig-0015" src="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Beta‐blockers versus placebo or no intervention less than 3 months follow‐up, Outcome 6 All‐cause mortality ‐ Above/below 75 years of age. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/references#CD012484-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012484-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/urn:x-wiley:14651858:media:CD012484:CD012484-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_t/tCD012484-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Beta‐blockers versus placebo or no intervention less than 3 months follow‐up, Outcome 7 All‐cause mortality ‐ NSTEMI/STEMI/UAP." data-id="CD012484-fig-0016" src="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Beta‐blockers versus placebo or no intervention less than 3 months follow‐up, Outcome 7 All‐cause mortality ‐ NSTEMI/STEMI/UAP. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/references#CD012484-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012484-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/urn:x-wiley:14651858:media:CD012484:CD012484-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_t/tCD012484-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Beta‐blockers versus placebo or no intervention less than 3 months follow‐up, Outcome 8 All‐cause mortality ‐ Registration status." data-id="CD012484-fig-0017" src="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Beta‐blockers versus placebo or no intervention less than 3 months follow‐up, Outcome 8 All‐cause mortality ‐ Registration status. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/references#CD012484-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012484-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/urn:x-wiley:14651858:media:CD012484:CD012484-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_t/tCD012484-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Beta‐blockers versus placebo or no intervention less than 3 months follow‐up, Outcome 9 All‐cause mortality ‐ Funding." data-id="CD012484-fig-0018" src="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Beta‐blockers versus placebo or no intervention less than 3 months follow‐up, Outcome 9 All‐cause mortality ‐ Funding. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/references#CD012484-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012484-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/urn:x-wiley:14651858:media:CD012484:CD012484-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_t/tCD012484-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Beta‐blockers versus placebo or no intervention less than 3 months follow‐up, Outcome 10 All‐cause mortality ‐ Trials at low risk of bias." data-id="CD012484-fig-0019" src="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 Beta‐blockers versus placebo or no intervention less than 3 months follow‐up, Outcome 10 All‐cause mortality ‐ Trials at low risk of bias. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/references#CD012484-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012484-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/urn:x-wiley:14651858:media:CD012484:CD012484-CMP-001-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_t/tCD012484-CMP-001-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Beta‐blockers versus placebo or no intervention less than 3 months follow‐up, Outcome 11 All‐cause mortality ‐ 'Best‐worst case scenario'." data-id="CD012484-fig-0020" src="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-001-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 Beta‐blockers versus placebo or no intervention less than 3 months follow‐up, Outcome 11 All‐cause mortality ‐ 'Best‐worst case scenario'. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/references#CD012484-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-001-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012484-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/urn:x-wiley:14651858:media:CD012484:CD012484-CMP-001-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_t/tCD012484-CMP-001-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Beta‐blockers versus placebo or no intervention less than 3 months follow‐up, Outcome 12 All‐cause mortality ‐ 'Worst‐best case scenario'." data-id="CD012484-fig-0021" src="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-001-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1 Beta‐blockers versus placebo or no intervention less than 3 months follow‐up, Outcome 12 All‐cause mortality ‐ 'Worst‐best case scenario'. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/references#CD012484-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-001-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012484-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/urn:x-wiley:14651858:media:CD012484:CD012484-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_t/tCD012484-CMP-002-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Beta‐blockers versus placebo or no intervention at maximum follow‐up beyond 3 months, Outcome 1 All‐cause mortality." data-id="CD012484-fig-0022" src="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Beta‐blockers versus placebo or no intervention at maximum follow‐up beyond 3 months, Outcome 1 All‐cause mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/references#CD012484-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012484-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/urn:x-wiley:14651858:media:CD012484:CD012484-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_t/tCD012484-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Beta‐blockers versus placebo or no intervention at maximum follow‐up beyond 3 months, Outcome 2 All‐cause mortality ‐ Acute/subacute phase." data-id="CD012484-fig-0023" src="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Beta‐blockers versus placebo or no intervention at maximum follow‐up beyond 3 months, Outcome 2 All‐cause mortality ‐ Acute/subacute phase. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/references#CD012484-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012484-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/urn:x-wiley:14651858:media:CD012484:CD012484-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_t/tCD012484-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Beta‐blockers versus placebo or no intervention at maximum follow‐up beyond 3 months, Outcome 3 All‐cause mortality ‐ Reperfusion/no reperfusion." data-id="CD012484-fig-0024" src="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Beta‐blockers versus placebo or no intervention at maximum follow‐up beyond 3 months, Outcome 3 All‐cause mortality ‐ Reperfusion/no reperfusion. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/references#CD012484-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012484-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/urn:x-wiley:14651858:media:CD012484:CD012484-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_t/tCD012484-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Beta‐blockers versus placebo or no intervention at maximum follow‐up beyond 3 months, Outcome 4 All‐cause mortality ‐ Type of beta‐blocker." data-id="CD012484-fig-0025" src="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Beta‐blockers versus placebo or no intervention at maximum follow‐up beyond 3 months, Outcome 4 All‐cause mortality ‐ Type of beta‐blocker. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/references#CD012484-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012484-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/urn:x-wiley:14651858:media:CD012484:CD012484-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_t/tCD012484-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Beta‐blockers versus placebo or no intervention at maximum follow‐up beyond 3 months, Outcome 5 All‐cause mortality ‐ Above/below 75 years of age." data-id="CD012484-fig-0026" src="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 Beta‐blockers versus placebo or no intervention at maximum follow‐up beyond 3 months, Outcome 5 All‐cause mortality ‐ Above/below 75 years of age. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/references#CD012484-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012484-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/urn:x-wiley:14651858:media:CD012484:CD012484-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_t/tCD012484-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Beta‐blockers versus placebo or no intervention at maximum follow‐up beyond 3 months, Outcome 6 All‐cause mortality ‐ Intravenously/orally commenced." data-id="CD012484-fig-0027" src="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 Beta‐blockers versus placebo or no intervention at maximum follow‐up beyond 3 months, Outcome 6 All‐cause mortality ‐ Intravenously/orally commenced. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/references#CD012484-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012484-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/urn:x-wiley:14651858:media:CD012484:CD012484-CMP-002-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_t/tCD012484-CMP-002-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Beta‐blockers versus placebo or no intervention at maximum follow‐up beyond 3 months, Outcome 7 All‐cause mortality ‐ Registration status." data-id="CD012484-fig-0028" src="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-002-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2 Beta‐blockers versus placebo or no intervention at maximum follow‐up beyond 3 months, Outcome 7 All‐cause mortality ‐ Registration status. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/references#CD012484-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-002-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012484-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/urn:x-wiley:14651858:media:CD012484:CD012484-CMP-002-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_t/tCD012484-CMP-002-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Beta‐blockers versus placebo or no intervention at maximum follow‐up beyond 3 months, Outcome 8 All‐cause mortality ‐ NSTEMI/STEMI/UAP." data-id="CD012484-fig-0029" src="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-002-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2 Beta‐blockers versus placebo or no intervention at maximum follow‐up beyond 3 months, Outcome 8 All‐cause mortality ‐ NSTEMI/STEMI/UAP. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/references#CD012484-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-002-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012484-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/urn:x-wiley:14651858:media:CD012484:CD012484-CMP-002-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_t/tCD012484-CMP-002-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Beta‐blockers versus placebo or no intervention at maximum follow‐up beyond 3 months, Outcome 9 All‐cause mortality ‐ Length of intervention period." data-id="CD012484-fig-0030" src="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-002-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2 Beta‐blockers versus placebo or no intervention at maximum follow‐up beyond 3 months, Outcome 9 All‐cause mortality ‐ Length of intervention period. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/references#CD012484-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-002-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012484-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/urn:x-wiley:14651858:media:CD012484:CD012484-CMP-002-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_t/tCD012484-CMP-002-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Beta‐blockers versus placebo or no intervention at maximum follow‐up beyond 3 months, Outcome 10 All‐cause mortality ‐ Funding." data-id="CD012484-fig-0031" src="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-002-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.10</div> <div class="figure-caption"> <p>Comparison 2 Beta‐blockers versus placebo or no intervention at maximum follow‐up beyond 3 months, Outcome 10 All‐cause mortality ‐ Funding. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/references#CD012484-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-002-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012484-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/urn:x-wiley:14651858:media:CD012484:CD012484-CMP-002-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_t/tCD012484-CMP-002-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Beta‐blockers versus placebo or no intervention at maximum follow‐up beyond 3 months, Outcome 11 All‐cause mortality ‐ Trials at low risk of bias." data-id="CD012484-fig-0032" src="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-002-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.11</div> <div class="figure-caption"> <p>Comparison 2 Beta‐blockers versus placebo or no intervention at maximum follow‐up beyond 3 months, Outcome 11 All‐cause mortality ‐ Trials at low risk of bias. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/references#CD012484-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-002-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012484-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/urn:x-wiley:14651858:media:CD012484:CD012484-CMP-002-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_t/tCD012484-CMP-002-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Beta‐blockers versus placebo or no intervention at maximum follow‐up beyond 3 months, Outcome 12 All‐cause mortality ‐ 'Best‐worst case scenario'." data-id="CD012484-fig-0033" src="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-002-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.12</div> <div class="figure-caption"> <p>Comparison 2 Beta‐blockers versus placebo or no intervention at maximum follow‐up beyond 3 months, Outcome 12 All‐cause mortality ‐ 'Best‐worst case scenario'. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/references#CD012484-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-002-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012484-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/urn:x-wiley:14651858:media:CD012484:CD012484-CMP-002-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_t/tCD012484-CMP-002-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Beta‐blockers versus placebo or no intervention at maximum follow‐up beyond 3 months, Outcome 13 All‐cause mortality ‐ 'Worst‐best case scenario'." data-id="CD012484-fig-0034" src="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-002-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.13</div> <div class="figure-caption"> <p>Comparison 2 Beta‐blockers versus placebo or no intervention at maximum follow‐up beyond 3 months, Outcome 13 All‐cause mortality ‐ 'Worst‐best case scenario'. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/references#CD012484-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-002-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012484-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/urn:x-wiley:14651858:media:CD012484:CD012484-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_t/tCD012484-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Beta‐blockers versus placebo or no intervention less than 3 months follow‐up, Outcome 1 MACE (Composite of cardiovascular death and non‐fatal myocardial infarction)." data-id="CD012484-fig-0035" src="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Beta‐blockers versus placebo or no intervention less than 3 months follow‐up, Outcome 1 MACE (Composite of cardiovascular death and non‐fatal myocardial infarction). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/references#CD012484-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012484-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/urn:x-wiley:14651858:media:CD012484:CD012484-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_t/tCD012484-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Beta‐blockers versus placebo or no intervention at maximum follow‐up beyond 3 months, Outcome 1 MACE (Composite of cardiovascular death and non‐fatal myocardial infarction)." data-id="CD012484-fig-0036" src="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Beta‐blockers versus placebo or no intervention at maximum follow‐up beyond 3 months, Outcome 1 MACE (Composite of cardiovascular death and non‐fatal myocardial infarction). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/references#CD012484-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012484-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/urn:x-wiley:14651858:media:CD012484:CD012484-CMP-005-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_t/tCD012484-CMP-005-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Beta‐blockers versus placebo or no intervention less than 3 months follow‐up, Outcome 1 Cardiovascular mortality." data-id="CD012484-fig-0037" src="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-005-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 Beta‐blockers versus placebo or no intervention less than 3 months follow‐up, Outcome 1 Cardiovascular mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/references#CD012484-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-005-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012484-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/urn:x-wiley:14651858:media:CD012484:CD012484-CMP-005-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_t/tCD012484-CMP-005-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Beta‐blockers versus placebo or no intervention less than 3 months follow‐up, Outcome 2 Cardiovascular mortality ‐ Acute/subacute phase." data-id="CD012484-fig-0038" src="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-005-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5 Beta‐blockers versus placebo or no intervention less than 3 months follow‐up, Outcome 2 Cardiovascular mortality ‐ Acute/subacute phase. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/references#CD012484-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-005-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012484-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/urn:x-wiley:14651858:media:CD012484:CD012484-CMP-005-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_t/tCD012484-CMP-005-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Beta‐blockers versus placebo or no intervention less than 3 months follow‐up, Outcome 3 Cardiovascular mortality ‐ Reperfusion/no reperfusion." data-id="CD012484-fig-0039" src="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-005-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5 Beta‐blockers versus placebo or no intervention less than 3 months follow‐up, Outcome 3 Cardiovascular mortality ‐ Reperfusion/no reperfusion. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/references#CD012484-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-005-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012484-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/urn:x-wiley:14651858:media:CD012484:CD012484-CMP-005-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_t/tCD012484-CMP-005-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Beta‐blockers versus placebo or no intervention less than 3 months follow‐up, Outcome 4 Cardiovascular mortality ‐ Type of beta‐blocker." data-id="CD012484-fig-0040" src="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-005-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.4</div> <div class="figure-caption"> <p>Comparison 5 Beta‐blockers versus placebo or no intervention less than 3 months follow‐up, Outcome 4 Cardiovascular mortality ‐ Type of beta‐blocker. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/references#CD012484-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-005-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012484-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/urn:x-wiley:14651858:media:CD012484:CD012484-CMP-005-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_t/tCD012484-CMP-005-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Beta‐blockers versus placebo or no intervention less than 3 months follow‐up, Outcome 5 Cardiovascular mortality ‐ Above/below 75 years of age." data-id="CD012484-fig-0041" src="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-005-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.5</div> <div class="figure-caption"> <p>Comparison 5 Beta‐blockers versus placebo or no intervention less than 3 months follow‐up, Outcome 5 Cardiovascular mortality ‐ Above/below 75 years of age. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/references#CD012484-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-005-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012484-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/urn:x-wiley:14651858:media:CD012484:CD012484-CMP-005-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_t/tCD012484-CMP-005-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Beta‐blockers versus placebo or no intervention less than 3 months follow‐up, Outcome 6 Cardiovascular mortality ‐ Intravenously/orally commenced." data-id="CD012484-fig-0042" src="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-005-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.6</div> <div class="figure-caption"> <p>Comparison 5 Beta‐blockers versus placebo or no intervention less than 3 months follow‐up, Outcome 6 Cardiovascular mortality ‐ Intravenously/orally commenced. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/references#CD012484-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-005-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012484-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/urn:x-wiley:14651858:media:CD012484:CD012484-CMP-005-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_t/tCD012484-CMP-005-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Beta‐blockers versus placebo or no intervention less than 3 months follow‐up, Outcome 7 Cardiovascular mortality ‐ NSTEMI/STEMI/UAP." data-id="CD012484-fig-0043" src="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-005-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.7</div> <div class="figure-caption"> <p>Comparison 5 Beta‐blockers versus placebo or no intervention less than 3 months follow‐up, Outcome 7 Cardiovascular mortality ‐ NSTEMI/STEMI/UAP. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/references#CD012484-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-005-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012484-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/urn:x-wiley:14651858:media:CD012484:CD012484-CMP-005-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_t/tCD012484-CMP-005-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Beta‐blockers versus placebo or no intervention less than 3 months follow‐up, Outcome 8 Cardiovascular mortality ‐ Registration status." data-id="CD012484-fig-0044" src="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-005-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.8</div> <div class="figure-caption"> <p>Comparison 5 Beta‐blockers versus placebo or no intervention less than 3 months follow‐up, Outcome 8 Cardiovascular mortality ‐ Registration status. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/references#CD012484-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-005-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012484-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/urn:x-wiley:14651858:media:CD012484:CD012484-CMP-005-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_t/tCD012484-CMP-005-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Beta‐blockers versus placebo or no intervention less than 3 months follow‐up, Outcome 9 Cardiovascular mortality ‐ Funding." data-id="CD012484-fig-0045" src="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-005-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.9</div> <div class="figure-caption"> <p>Comparison 5 Beta‐blockers versus placebo or no intervention less than 3 months follow‐up, Outcome 9 Cardiovascular mortality ‐ Funding. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/references#CD012484-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-005-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012484-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/urn:x-wiley:14651858:media:CD012484:CD012484-CMP-005-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_t/tCD012484-CMP-005-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Beta‐blockers versus placebo or no intervention less than 3 months follow‐up, Outcome 10 Cardiovascular mortality ‐ Trials with low risk of bias." data-id="CD012484-fig-0046" src="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-005-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.10</div> <div class="figure-caption"> <p>Comparison 5 Beta‐blockers versus placebo or no intervention less than 3 months follow‐up, Outcome 10 Cardiovascular mortality ‐ Trials with low risk of bias. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/references#CD012484-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-005-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012484-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/urn:x-wiley:14651858:media:CD012484:CD012484-CMP-005-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_t/tCD012484-CMP-005-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Beta‐blockers versus placebo or no intervention less than 3 months follow‐up, Outcome 11 Cardiovascular mortality ‐ 'Best‐worst case scenario'." data-id="CD012484-fig-0047" src="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-005-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.11</div> <div class="figure-caption"> <p>Comparison 5 Beta‐blockers versus placebo or no intervention less than 3 months follow‐up, Outcome 11 Cardiovascular mortality ‐ 'Best‐worst case scenario'. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/references#CD012484-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-005-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012484-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/urn:x-wiley:14651858:media:CD012484:CD012484-CMP-005-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_t/tCD012484-CMP-005-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Beta‐blockers versus placebo or no intervention less than 3 months follow‐up, Outcome 12 Cardiovascular mortality ‐ 'Worst‐best case scenario'." data-id="CD012484-fig-0048" src="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-005-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.12</div> <div class="figure-caption"> <p>Comparison 5 Beta‐blockers versus placebo or no intervention less than 3 months follow‐up, Outcome 12 Cardiovascular mortality ‐ 'Worst‐best case scenario'. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/references#CD012484-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-005-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012484-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/urn:x-wiley:14651858:media:CD012484:CD012484-CMP-006-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_t/tCD012484-CMP-006-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Beta‐blockers versus placebo or no intervention at maximum follow‐up beyond 3 months, Outcome 1 Cardiovascular mortality." data-id="CD012484-fig-0049" src="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-006-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6 Beta‐blockers versus placebo or no intervention at maximum follow‐up beyond 3 months, Outcome 1 Cardiovascular mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/references#CD012484-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-006-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012484-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/urn:x-wiley:14651858:media:CD012484:CD012484-CMP-006-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_t/tCD012484-CMP-006-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Beta‐blockers versus placebo or no intervention at maximum follow‐up beyond 3 months, Outcome 2 Cardiovascular mortality ‐ Acute/subacute phase." data-id="CD012484-fig-0050" src="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-006-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6 Beta‐blockers versus placebo or no intervention at maximum follow‐up beyond 3 months, Outcome 2 Cardiovascular mortality ‐ Acute/subacute phase. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/references#CD012484-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-006-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012484-fig-0051"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/urn:x-wiley:14651858:media:CD012484:CD012484-CMP-006-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_t/tCD012484-CMP-006-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Beta‐blockers versus placebo or no intervention at maximum follow‐up beyond 3 months, Outcome 3 Cardiovascular mortality ‐ Reperfusion/no reperfusion." data-id="CD012484-fig-0051" src="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-006-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.3</div> <div class="figure-caption"> <p>Comparison 6 Beta‐blockers versus placebo or no intervention at maximum follow‐up beyond 3 months, Outcome 3 Cardiovascular mortality ‐ Reperfusion/no reperfusion. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/references#CD012484-fig-0051">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-006-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012484-fig-0052"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/urn:x-wiley:14651858:media:CD012484:CD012484-CMP-006-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_t/tCD012484-CMP-006-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Beta‐blockers versus placebo or no intervention at maximum follow‐up beyond 3 months, Outcome 4 Cardiovascular mortality ‐ Type of beta‐blocker." data-id="CD012484-fig-0052" src="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-006-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.4</div> <div class="figure-caption"> <p>Comparison 6 Beta‐blockers versus placebo or no intervention at maximum follow‐up beyond 3 months, Outcome 4 Cardiovascular mortality ‐ Type of beta‐blocker. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/references#CD012484-fig-0052">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-006-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012484-fig-0053"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/urn:x-wiley:14651858:media:CD012484:CD012484-CMP-006-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_t/tCD012484-CMP-006-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Beta‐blockers versus placebo or no intervention at maximum follow‐up beyond 3 months, Outcome 5 Cardiovascular mortality ‐ Above/below 75 years of age." data-id="CD012484-fig-0053" src="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-006-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.5</div> <div class="figure-caption"> <p>Comparison 6 Beta‐blockers versus placebo or no intervention at maximum follow‐up beyond 3 months, Outcome 5 Cardiovascular mortality ‐ Above/below 75 years of age. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/references#CD012484-fig-0053">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-006-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012484-fig-0054"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/urn:x-wiley:14651858:media:CD012484:CD012484-CMP-006-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_t/tCD012484-CMP-006-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Beta‐blockers versus placebo or no intervention at maximum follow‐up beyond 3 months, Outcome 6 Cardiovascular mortality ‐ Intravenously/orally commenced." data-id="CD012484-fig-0054" src="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-006-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.6</div> <div class="figure-caption"> <p>Comparison 6 Beta‐blockers versus placebo or no intervention at maximum follow‐up beyond 3 months, Outcome 6 Cardiovascular mortality ‐ Intravenously/orally commenced. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/references#CD012484-fig-0054">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-006-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012484-fig-0055"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/urn:x-wiley:14651858:media:CD012484:CD012484-CMP-006-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_t/tCD012484-CMP-006-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Beta‐blockers versus placebo or no intervention at maximum follow‐up beyond 3 months, Outcome 7 Cardiovascular mortality ‐ NSTEMI/STEMI/UAP." data-id="CD012484-fig-0055" src="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-006-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.7</div> <div class="figure-caption"> <p>Comparison 6 Beta‐blockers versus placebo or no intervention at maximum follow‐up beyond 3 months, Outcome 7 Cardiovascular mortality ‐ NSTEMI/STEMI/UAP. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/references#CD012484-fig-0055">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-006-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012484-fig-0056"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/urn:x-wiley:14651858:media:CD012484:CD012484-CMP-006-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_t/tCD012484-CMP-006-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Beta‐blockers versus placebo or no intervention at maximum follow‐up beyond 3 months, Outcome 8 Cardiovascular mortality ‐ Registration status." data-id="CD012484-fig-0056" src="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-006-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.8</div> <div class="figure-caption"> <p>Comparison 6 Beta‐blockers versus placebo or no intervention at maximum follow‐up beyond 3 months, Outcome 8 Cardiovascular mortality ‐ Registration status. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/references#CD012484-fig-0056">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-006-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012484-fig-0057"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/urn:x-wiley:14651858:media:CD012484:CD012484-CMP-006-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_t/tCD012484-CMP-006-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Beta‐blockers versus placebo or no intervention at maximum follow‐up beyond 3 months, Outcome 9 Cardiovascular mortality ‐ Length of intervention period." data-id="CD012484-fig-0057" src="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-006-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.9</div> <div class="figure-caption"> <p>Comparison 6 Beta‐blockers versus placebo or no intervention at maximum follow‐up beyond 3 months, Outcome 9 Cardiovascular mortality ‐ Length of intervention period. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/references#CD012484-fig-0057">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-006-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012484-fig-0058"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/urn:x-wiley:14651858:media:CD012484:CD012484-CMP-006-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_t/tCD012484-CMP-006-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Beta‐blockers versus placebo or no intervention at maximum follow‐up beyond 3 months, Outcome 10 Cardiovascular mortality ‐ Funding." data-id="CD012484-fig-0058" src="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-006-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.10</div> <div class="figure-caption"> <p>Comparison 6 Beta‐blockers versus placebo or no intervention at maximum follow‐up beyond 3 months, Outcome 10 Cardiovascular mortality ‐ Funding. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/references#CD012484-fig-0058">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-006-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012484-fig-0059"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/urn:x-wiley:14651858:media:CD012484:CD012484-CMP-006-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_t/tCD012484-CMP-006-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Beta‐blockers versus placebo or no intervention at maximum follow‐up beyond 3 months, Outcome 11 Cardiovascular mortality ‐ 'Best‐worst case scenario'." data-id="CD012484-fig-0059" src="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-006-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.11</div> <div class="figure-caption"> <p>Comparison 6 Beta‐blockers versus placebo or no intervention at maximum follow‐up beyond 3 months, Outcome 11 Cardiovascular mortality ‐ 'Best‐worst case scenario'. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/references#CD012484-fig-0059">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-006-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012484-fig-0060"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/urn:x-wiley:14651858:media:CD012484:CD012484-CMP-006-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_t/tCD012484-CMP-006-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Beta‐blockers versus placebo or no intervention at maximum follow‐up beyond 3 months, Outcome 12 Cardiovascular mortality ‐ 'Worst‐best case scenario'." data-id="CD012484-fig-0060" src="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-006-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.12</div> <div class="figure-caption"> <p>Comparison 6 Beta‐blockers versus placebo or no intervention at maximum follow‐up beyond 3 months, Outcome 12 Cardiovascular mortality ‐ 'Worst‐best case scenario'. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/references#CD012484-fig-0060">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-006-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012484-fig-0061"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/urn:x-wiley:14651858:media:CD012484:CD012484-CMP-007-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_t/tCD012484-CMP-007-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Beta‐blockers versus placebo or no intervention less than 3 months follow‐up, Outcome 1 Myocardial infarction." data-id="CD012484-fig-0061" src="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-007-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7 Beta‐blockers versus placebo or no intervention less than 3 months follow‐up, Outcome 1 Myocardial infarction. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/references#CD012484-fig-0061">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-007-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012484-fig-0062"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/urn:x-wiley:14651858:media:CD012484:CD012484-CMP-007-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_t/tCD012484-CMP-007-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Beta‐blockers versus placebo or no intervention less than 3 months follow‐up, Outcome 2 Myocardial infarction ‐ Acute/subacute phase." data-id="CD012484-fig-0062" src="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-007-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.2</div> <div class="figure-caption"> <p>Comparison 7 Beta‐blockers versus placebo or no intervention less than 3 months follow‐up, Outcome 2 Myocardial infarction ‐ Acute/subacute phase. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/references#CD012484-fig-0062">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-007-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012484-fig-0063"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/urn:x-wiley:14651858:media:CD012484:CD012484-CMP-007-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_t/tCD012484-CMP-007-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Beta‐blockers versus placebo or no intervention less than 3 months follow‐up, Outcome 3 Myocardial infarction ‐ Reperfusion/no reperfusion." data-id="CD012484-fig-0063" src="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-007-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.3</div> <div class="figure-caption"> <p>Comparison 7 Beta‐blockers versus placebo or no intervention less than 3 months follow‐up, Outcome 3 Myocardial infarction ‐ Reperfusion/no reperfusion. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/references#CD012484-fig-0063">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-007-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012484-fig-0064"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/urn:x-wiley:14651858:media:CD012484:CD012484-CMP-007-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_t/tCD012484-CMP-007-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Beta‐blockers versus placebo or no intervention less than 3 months follow‐up, Outcome 4 Myocardial infarction ‐ Type of beta‐blocker." data-id="CD012484-fig-0064" src="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-007-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.4</div> <div class="figure-caption"> <p>Comparison 7 Beta‐blockers versus placebo or no intervention less than 3 months follow‐up, Outcome 4 Myocardial infarction ‐ Type of beta‐blocker. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/references#CD012484-fig-0064">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-007-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012484-fig-0065"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/urn:x-wiley:14651858:media:CD012484:CD012484-CMP-007-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_t/tCD012484-CMP-007-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Beta‐blockers versus placebo or no intervention less than 3 months follow‐up, Outcome 5 Myocardial infarction ‐ Above/below 75 years of age." data-id="CD012484-fig-0065" src="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-007-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.5</div> <div class="figure-caption"> <p>Comparison 7 Beta‐blockers versus placebo or no intervention less than 3 months follow‐up, Outcome 5 Myocardial infarction ‐ Above/below 75 years of age. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/references#CD012484-fig-0065">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-007-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012484-fig-0066"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/urn:x-wiley:14651858:media:CD012484:CD012484-CMP-007-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_t/tCD012484-CMP-007-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Beta‐blockers versus placebo or no intervention less than 3 months follow‐up, Outcome 6 Myocardial infarction ‐ Intravenously/orally commenced." data-id="CD012484-fig-0066" src="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-007-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.6</div> <div class="figure-caption"> <p>Comparison 7 Beta‐blockers versus placebo or no intervention less than 3 months follow‐up, Outcome 6 Myocardial infarction ‐ Intravenously/orally commenced. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/references#CD012484-fig-0066">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-007-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012484-fig-0067"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/urn:x-wiley:14651858:media:CD012484:CD012484-CMP-007-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_t/tCD012484-CMP-007-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Beta‐blockers versus placebo or no intervention less than 3 months follow‐up, Outcome 7 Myocardial infarction ‐ NSTEMI/STEMI/UAP." data-id="CD012484-fig-0067" src="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-007-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.7</div> <div class="figure-caption"> <p>Comparison 7 Beta‐blockers versus placebo or no intervention less than 3 months follow‐up, Outcome 7 Myocardial infarction ‐ NSTEMI/STEMI/UAP. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/references#CD012484-fig-0067">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-007-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012484-fig-0068"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/urn:x-wiley:14651858:media:CD012484:CD012484-CMP-007-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_t/tCD012484-CMP-007-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Beta‐blockers versus placebo or no intervention less than 3 months follow‐up, Outcome 8 Myocardial infarction ‐ Registration status." data-id="CD012484-fig-0068" src="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-007-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.8</div> <div class="figure-caption"> <p>Comparison 7 Beta‐blockers versus placebo or no intervention less than 3 months follow‐up, Outcome 8 Myocardial infarction ‐ Registration status. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/references#CD012484-fig-0068">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-007-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012484-fig-0069"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/urn:x-wiley:14651858:media:CD012484:CD012484-CMP-007-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_t/tCD012484-CMP-007-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Beta‐blockers versus placebo or no intervention less than 3 months follow‐up, Outcome 9 Myocardial infarction ‐ Funding." data-id="CD012484-fig-0069" src="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-007-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.9</div> <div class="figure-caption"> <p>Comparison 7 Beta‐blockers versus placebo or no intervention less than 3 months follow‐up, Outcome 9 Myocardial infarction ‐ Funding. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/references#CD012484-fig-0069">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-007-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012484-fig-0070"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/urn:x-wiley:14651858:media:CD012484:CD012484-CMP-007-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_t/tCD012484-CMP-007-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Beta‐blockers versus placebo or no intervention less than 3 months follow‐up, Outcome 10 Myocardial infarction ‐ Trials with low risk of bias." data-id="CD012484-fig-0070" src="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-007-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.10</div> <div class="figure-caption"> <p>Comparison 7 Beta‐blockers versus placebo or no intervention less than 3 months follow‐up, Outcome 10 Myocardial infarction ‐ Trials with low risk of bias. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/references#CD012484-fig-0070">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-007-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012484-fig-0071"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/urn:x-wiley:14651858:media:CD012484:CD012484-CMP-007-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_t/tCD012484-CMP-007-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Beta‐blockers versus placebo or no intervention less than 3 months follow‐up, Outcome 11 Myocardial infarction ‐ 'Best‐worst case scenario'." data-id="CD012484-fig-0071" src="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-007-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.11</div> <div class="figure-caption"> <p>Comparison 7 Beta‐blockers versus placebo or no intervention less than 3 months follow‐up, Outcome 11 Myocardial infarction ‐ 'Best‐worst case scenario'. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/references#CD012484-fig-0071">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-007-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012484-fig-0072"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/urn:x-wiley:14651858:media:CD012484:CD012484-CMP-007-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_t/tCD012484-CMP-007-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Beta‐blockers versus placebo or no intervention less than 3 months follow‐up, Outcome 12 Myocardial infarction ‐ 'Worst‐best case scenario'." data-id="CD012484-fig-0072" src="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-007-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.12</div> <div class="figure-caption"> <p>Comparison 7 Beta‐blockers versus placebo or no intervention less than 3 months follow‐up, Outcome 12 Myocardial infarction ‐ 'Worst‐best case scenario'. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/references#CD012484-fig-0072">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-007-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012484-fig-0073"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/urn:x-wiley:14651858:media:CD012484:CD012484-CMP-008-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_t/tCD012484-CMP-008-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Beta‐blockers versus placebo or no intervention at maximum follow‐up beyond 3 months, Outcome 1 Myocardial infarction." data-id="CD012484-fig-0073" src="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-008-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.1</div> <div class="figure-caption"> <p>Comparison 8 Beta‐blockers versus placebo or no intervention at maximum follow‐up beyond 3 months, Outcome 1 Myocardial infarction. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/references#CD012484-fig-0073">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-008-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012484-fig-0074"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/urn:x-wiley:14651858:media:CD012484:CD012484-CMP-008-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_t/tCD012484-CMP-008-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Beta‐blockers versus placebo or no intervention at maximum follow‐up beyond 3 months, Outcome 2 Myocardial infarction ‐ Acute/subacute phase." data-id="CD012484-fig-0074" src="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-008-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.2</div> <div class="figure-caption"> <p>Comparison 8 Beta‐blockers versus placebo or no intervention at maximum follow‐up beyond 3 months, Outcome 2 Myocardial infarction ‐ Acute/subacute phase. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/references#CD012484-fig-0074">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-008-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012484-fig-0075"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/urn:x-wiley:14651858:media:CD012484:CD012484-CMP-008-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_t/tCD012484-CMP-008-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Beta‐blockers versus placebo or no intervention at maximum follow‐up beyond 3 months, Outcome 3 Myocardial infarction ‐ Reperfusion/no reperfusion." data-id="CD012484-fig-0075" src="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-008-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.3</div> <div class="figure-caption"> <p>Comparison 8 Beta‐blockers versus placebo or no intervention at maximum follow‐up beyond 3 months, Outcome 3 Myocardial infarction ‐ Reperfusion/no reperfusion. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/references#CD012484-fig-0075">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-008-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012484-fig-0076"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/urn:x-wiley:14651858:media:CD012484:CD012484-CMP-008-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_t/tCD012484-CMP-008-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Beta‐blockers versus placebo or no intervention at maximum follow‐up beyond 3 months, Outcome 4 Myocardial infarction ‐ Type of beta‐blocker." data-id="CD012484-fig-0076" src="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-008-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.4</div> <div class="figure-caption"> <p>Comparison 8 Beta‐blockers versus placebo or no intervention at maximum follow‐up beyond 3 months, Outcome 4 Myocardial infarction ‐ Type of beta‐blocker. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/references#CD012484-fig-0076">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-008-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012484-fig-0077"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/urn:x-wiley:14651858:media:CD012484:CD012484-CMP-008-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_t/tCD012484-CMP-008-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Beta‐blockers versus placebo or no intervention at maximum follow‐up beyond 3 months, Outcome 5 Myocardial infarction ‐ Above/below 75 years of age." data-id="CD012484-fig-0077" src="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-008-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.5</div> <div class="figure-caption"> <p>Comparison 8 Beta‐blockers versus placebo or no intervention at maximum follow‐up beyond 3 months, Outcome 5 Myocardial infarction ‐ Above/below 75 years of age. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/references#CD012484-fig-0077">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-008-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012484-fig-0078"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/urn:x-wiley:14651858:media:CD012484:CD012484-CMP-008-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_t/tCD012484-CMP-008-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Beta‐blockers versus placebo or no intervention at maximum follow‐up beyond 3 months, Outcome 6 Myocardial infarction ‐ Intravenously/orally commenced." data-id="CD012484-fig-0078" src="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-008-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.6</div> <div class="figure-caption"> <p>Comparison 8 Beta‐blockers versus placebo or no intervention at maximum follow‐up beyond 3 months, Outcome 6 Myocardial infarction ‐ Intravenously/orally commenced. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/references#CD012484-fig-0078">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-008-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012484-fig-0079"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/urn:x-wiley:14651858:media:CD012484:CD012484-CMP-008-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_t/tCD012484-CMP-008-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Beta‐blockers versus placebo or no intervention at maximum follow‐up beyond 3 months, Outcome 7 Myocardial infarction ‐ NSTEMI/STEMI/UAP." data-id="CD012484-fig-0079" src="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-008-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.7</div> <div class="figure-caption"> <p>Comparison 8 Beta‐blockers versus placebo or no intervention at maximum follow‐up beyond 3 months, Outcome 7 Myocardial infarction ‐ NSTEMI/STEMI/UAP. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/references#CD012484-fig-0079">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-008-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012484-fig-0080"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/urn:x-wiley:14651858:media:CD012484:CD012484-CMP-008-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_t/tCD012484-CMP-008-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Beta‐blockers versus placebo or no intervention at maximum follow‐up beyond 3 months, Outcome 8 Myocardial infarction ‐ Registration status." data-id="CD012484-fig-0080" src="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-008-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.8</div> <div class="figure-caption"> <p>Comparison 8 Beta‐blockers versus placebo or no intervention at maximum follow‐up beyond 3 months, Outcome 8 Myocardial infarction ‐ Registration status. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/references#CD012484-fig-0080">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-008-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012484-fig-0081"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/urn:x-wiley:14651858:media:CD012484:CD012484-CMP-008-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_t/tCD012484-CMP-008-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Beta‐blockers versus placebo or no intervention at maximum follow‐up beyond 3 months, Outcome 9 Myocardial infarction ‐ Length of intervention period." data-id="CD012484-fig-0081" src="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-008-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.9</div> <div class="figure-caption"> <p>Comparison 8 Beta‐blockers versus placebo or no intervention at maximum follow‐up beyond 3 months, Outcome 9 Myocardial infarction ‐ Length of intervention period. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/references#CD012484-fig-0081">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-008-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012484-fig-0082"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/urn:x-wiley:14651858:media:CD012484:CD012484-CMP-008-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_t/tCD012484-CMP-008-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Beta‐blockers versus placebo or no intervention at maximum follow‐up beyond 3 months, Outcome 10 Myocardial infarction ‐ Funding." data-id="CD012484-fig-0082" src="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-008-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.10</div> <div class="figure-caption"> <p>Comparison 8 Beta‐blockers versus placebo or no intervention at maximum follow‐up beyond 3 months, Outcome 10 Myocardial infarction ‐ Funding. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/references#CD012484-fig-0082">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-008-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012484-fig-0083"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/urn:x-wiley:14651858:media:CD012484:CD012484-CMP-008-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_t/tCD012484-CMP-008-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Beta‐blockers versus placebo or no intervention at maximum follow‐up beyond 3 months, Outcome 11 Myocardial infarction ‐ 'Best‐worst case scenario'." data-id="CD012484-fig-0083" src="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-008-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.11</div> <div class="figure-caption"> <p>Comparison 8 Beta‐blockers versus placebo or no intervention at maximum follow‐up beyond 3 months, Outcome 11 Myocardial infarction ‐ 'Best‐worst case scenario'. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/references#CD012484-fig-0083">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-008-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012484-fig-0084"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/urn:x-wiley:14651858:media:CD012484:CD012484-CMP-008-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_t/tCD012484-CMP-008-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Beta‐blockers versus placebo or no intervention at maximum follow‐up beyond 3 months, Outcome 12 Myocardial infarction ‐ 'Worst‐best case scenario'." data-id="CD012484-fig-0084" src="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-008-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.12</div> <div class="figure-caption"> <p>Comparison 8 Beta‐blockers versus placebo or no intervention at maximum follow‐up beyond 3 months, Outcome 12 Myocardial infarction ‐ 'Worst‐best case scenario'. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/references#CD012484-fig-0084">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-008-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012484-fig-0085"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/urn:x-wiley:14651858:media:CD012484:CD012484-CMP-009-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_t/tCD012484-CMP-009-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Beta‐blockers versus placebo or no intervention less than 3 months follow‐up, Outcome 1 Angina on a dichotomous scale." data-id="CD012484-fig-0085" src="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-009-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.1</div> <div class="figure-caption"> <p>Comparison 9 Beta‐blockers versus placebo or no intervention less than 3 months follow‐up, Outcome 1 Angina on a dichotomous scale. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/references#CD012484-fig-0085">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-009-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012484-fig-0086"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/urn:x-wiley:14651858:media:CD012484:CD012484-CMP-010-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_t/tCD012484-CMP-010-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 Beta‐blockers versus placebo or no intervention at maximum follow‐up beyond 3 months, Outcome 1 Angina on a dichotomous scale." data-id="CD012484-fig-0086" src="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-010-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.1</div> <div class="figure-caption"> <p>Comparison 10 Beta‐blockers versus placebo or no intervention at maximum follow‐up beyond 3 months, Outcome 1 Angina on a dichotomous scale. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/references#CD012484-fig-0086">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/media/CDSR/CD012484/image_n/nCD012484-CMP-010-01.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD012484-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Beta‐blockers versus placebo or no intervention for suspected or diagnosed acute myocardial infarction at the time point less than three months follow‐up</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Beta‐blockers versus placebo or no intervention for patients with suspected or diagnosed myocardial infarction at the time point less than three months follow‐up</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with suspected or diagnosed myocardial infarction </p> <p><b>Settings:</b> any setting </p> <p><b>Intervention:</b> any beta‐blocker </p> <p><b>Comparison:</b> placebo or no intervention </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks*</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect</b> </p> <p><b>(adjusted CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk with placebo or no intervention</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk with beta‐blockers</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause mortality at 'less than 3 months' follow‐up.</b> </p> <p><b>Follow‐up: mean 21.8 days (range 1 hour to 90 days).</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>70 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>67 per 1000</b><br/> (63 to 70) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.94</b>, 97.5% CI (0.90 to 1.0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80,452 (46 RCTs with 47 comparisons)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<sup>1</sup><br/> <b>High</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Since the sensitivity analysis excluding trials at high risk of bias and the overall meta‐analysis showed similar results, we based our summary of findings and conclusion on the overall meta‐analysis. </p> <p>No events occurred in either group in three trials (<a href="./references#CD012484-bbs2-0024" title="HanadaK , HigumaT , NishizakiF , SukekawaT , YokotaT , YamadaM , et al. Randomized study on the efficacy and safety of landiolol, an ultra‐short‐acting beta1‐adrenergic blocker, in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. Circulation Journal2012;76(2):439‐45. ">Hanada 2012</a>; <a href="./references#CD012484-bbs2-0041" title="NorrisRM , ClarkeED , SammelNL , SmithWM , WilliamsB . Protective effect of propranolol in threatened myocardial infarction. Lancet1978;2(8096):907‐9. ">Norris 1978</a>; <a href="./references#CD012484-bbs2-0053" title="ShirotaniM , YokotaR , KouchiI , HiraiT , UemoriN , HabaK , et al. Influence of atenolol on coronary artery spasm after acute myocardial infarction in a Japanese population. International Journal of Cardiology2010;139(2):181‐6. ">Shirotani 2010</a>). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events at 'less than 3 months' follow‐up.</b> </p> <p><b>No data was reported in the included trials.</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the trials specifically assessed nor reported serious adverse events according to ICH‐GCP. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MACE (major adverse cardiovascular event) at 'less than 3 months' follow‐up.</b> </p> <p><b>No data were reported in the included trials.</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Only two trials specifically assessed major adverse cardiovascular events (defined as a composite of cardiovascular mortality and myocardial infarction during follow‐up). However, no major adverse cardiovascular events occurred in either trial. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Quality of life at 'less than 3 months' follow‐up.</b> </p> <p><b>No data were reported in the included trials.</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Angina at 'less than 3 months' follow‐up.</b> </p> <p><b>Follow‐up: mean 21 days (range 12 to 30 days).</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>222 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>155 per 1000</b> (69 to 351) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.70</b>, 98% CI (0.25 to 1.84) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>98 (3 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<sup>2,3</sup> </p> <p><b>VERY LOW</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cardiovascular mortality at 'less than 3 months' follow‐up.</b> </p> <p><b>Follow‐up: mean 28 days.</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>43 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>42 per 1000</b><br/> (39 to 46) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.99</b>, 95% CI </p> <p>(0.91 to 1.08)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45,852 (1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<sup>4</sup> <br/> <b>Moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Since the sensitivity analysis excluding trials at high risk of bias differed from the overall meta‐analysis, we based our summary of findings and conclusion on the sensitivity analysis. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Myocardial infarction at 'less than 3 months' follow‐up.</b> </p> <p><b>Follow‐up: mean 23.3 days (range 3 to 90 days).</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>28 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>23 per 1000</b><br/> (21 to 25) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.82</b>, 98% CI </p> <p>(0.74 to 0.90)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67,562 (18 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<sup>5</sup><br/> <b>MODERATE</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Since the sensitivity analysis excluding trials at high risk of bias and the overall meta‐analysis showed similar results, we based our summary of findings and conclusion on the overall meta‐analysis. </p> <p>No events occurred in either group in two trials (<a href="./references#CD012484-bbs2-0024" title="HanadaK , HigumaT , NishizakiF , SukekawaT , YokotaT , YamadaM , et al. Randomized study on the efficacy and safety of landiolol, an ultra‐short‐acting beta1‐adrenergic blocker, in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. Circulation Journal2012;76(2):439‐45. ">Hanada 2012</a>; <a href="./references#CD012484-bbs2-0053" title="ShirotaniM , YokotaR , KouchiI , HiraiT , UemoriN , HabaK , et al. Influence of atenolol on coronary artery spasm after acute myocardial infarction in a Japanese population. International Journal of Cardiology2010;139(2):181‐6. ">Shirotani 2010</a>). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its adjusted confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its adjusted CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk Ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> When assessing the risk of bias, the trial contributing most weight (<a href="./references#CD012484-bbs2-0016" title="COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo‐controlled trial. Lancet2005;366(9497):1622‐32. Second Chinese Cardiac Study (CCS‐2) Collaborative Group. Rationale, design and organization of the Second Chinese Cardiac Study (CCS‐2): a randomized trial of clopidogrel plus aspirin, and of metoprolol, among patients with suspected acute myocardial infarction. Journal of Cardiovascular Risk2000;7(6):435‐41. ">COMMIT 2005</a>, 63.4%) was assessed as at low risk of bias in all domains. The trial contributing the second highest weight (<a href="./references#CD012484-bbs2-0027" title="ISIS‐1 (first International Study of Infarct Survival) collaborative group. Mechanisms for the early mortality reduction produced by beta‐blockade started early in acute myocardial infarction: ISIS‐1. Lancet1988;1(8591):921‐3. ISIS‐1 (first International Study of Infarct Survival) collaborative group. Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS‐1. Lancet1986;2(8498):57‐66. ">ISIS‐1 1986</a>, 17.4%) was assessed as low risk of bias in random sequence generation, allocation concealment, and incomplete outcome data;'unclear for blinding of outcome assessors and selective reporting and at high risk for blinding of participants and personnel. Since a lack of blinding is less important for the assessment of all‐cause mortality, the overall limitations were not serious and the evidence is not downgraded for risk of bias. </p> <p><sup>2</sup> Downgraded by one level due to serious risk of bias. All the included trials were at high risk of bias due to either unclear or high risk in several bias domains. </p> <p><sup>3</sup> Downgraded by two levels due to very serious risk of imprecision based on the optimal information size not being reached, the very small sample size, and the absolute and relative 98% CI being very wide showing both appreciable benefit and harm. </p> <p><sup>4</sup> Downgraded by one level due to serious risk of imprecision based on the wide absolute and relative 98% where the upper CI does not exclude the possibility of no difference between the groups. When assessing the risk of bias, the evidence was not downgraded since the result was based on the sensitivity analysis consisting of trials at low risk of bias (<a href="./references#CD012484-bbs2-0016" title="COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo‐controlled trial. Lancet2005;366(9497):1622‐32. Second Chinese Cardiac Study (CCS‐2) Collaborative Group. Rationale, design and organization of the Second Chinese Cardiac Study (CCS‐2): a randomized trial of clopidogrel plus aspirin, and of metoprolol, among patients with suspected acute myocardial infarction. Journal of Cardiovascular Risk2000;7(6):435‐41. ">COMMIT 2005</a>). </p> <p><sup>5</sup> Downgraded by one level due to serious risk of bias. The overall limitations and specially in regard to blinding of outcome assessors were serious (around 50% of the trials were assessed at unclear risk of bias in blinding of outcome assessors). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Beta‐blockers versus placebo or no intervention for suspected or diagnosed acute myocardial infarction at the time point less than three months follow‐up</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/full#CD012484-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012484-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Beta‐blockers versus placebo or no intervention for suspected or diagnosed acute myocardial infarction at maximum follow‐up beyond three months</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Beta‐blockers compared with placebo or no intervention for patients with suspected or diagnosed myocardial infarction</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with suspected or diagnosed myocardial infarction </p> <p><b>Settings:</b> any setting </p> <p><b>Intervention:</b> beta‐blockers </p> <p><b>Comparison:</b> placebo or no intervention </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks*</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (adjusted CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk with placebo or no intervention</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk with beta‐blockers</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause mortality at maximum follow‐up beyond 3 months.</b> </p> <p><b>Follow‐up: mean 16.4 months (range 6 to 60 months).</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>148 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>138 per 1000</b><br/> (127 to 147) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.93</b>, 97.5% CI (0.86 to 0.99) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25,210 (21 RCTs with 22 comparisons)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<sup>3</sup><br/> <b>Moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No events occurred in either group in one trial (<a href="./references#CD012484-bbs2-0024" title="HanadaK , HigumaT , NishizakiF , SukekawaT , YokotaT , YamadaM , et al. Randomized study on the efficacy and safety of landiolol, an ultra‐short‐acting beta1‐adrenergic blocker, in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. Circulation Journal2012;76(2):439‐45. ">Hanada 2012</a>). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events at maximum follow‐up beyond 3 months.</b> </p> <p><b>No data were reported in the included trials.</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the trials specifically assessed nor reported serious adverse events according to ICH‐GCP. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MACE (major adverse cardiovascular event) at maximum follow‐up beyond 3 months.</b> </p> <p><b>Follow‐up: mean7.5 months (range 6 to 12 months).</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>84 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>68 per 1000</b><br/> (36 to 128) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.81,</b> 97.5% CI (0.43 to 1.52) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>475 (4 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<sup>1, 2</sup><br/> <b>VERY LOW</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life at maximum follow‐up beyond 3 months.</b> </p> <p><b>No data were reported in the included trials.</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Angina at maximum follow‐up beyond 3 months (mean = 6 months).</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>24 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>15 per 1000</b> </p> <p>(5 to 48)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.64</b>, 98% CI 0.18 to 2.0 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>844 ( 2 RTCs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<sup>1,5</sup><br/> <b>VERY LOW</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cardiovascular mortality at maximum follow‐up beyond 3 months.</b> </p> <p><b>Follow‐up: mean 12.9 months (range 6 to 24 months).</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>124 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>112 per 1000</b><br/> (103 to 122) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.90,</b> 98% CI </p> <p>(0.83 to 0.98)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22,457 (14 RCTs with 15 comparisons)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<sup>1</sup><br/> <b>MODERATE</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No events occurred in either group in one trial (<a href="./references#CD012484-bbs2-0024" title="HanadaK , HigumaT , NishizakiF , SukekawaT , YokotaT , YamadaM , et al. Randomized study on the efficacy and safety of landiolol, an ultra‐short‐acting beta1‐adrenergic blocker, in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. Circulation Journal2012;76(2):439‐45. ">Hanada 2012</a>). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Myocardial infarction at maximum follow‐up beyond 3 months.</b> </p> <p><b>Follow‐up: mean 15.5 months (range 6 to 60 months).</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>92 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>83 per 1000</b><br/> (69 to 99) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.89</b>, 98% CI </p> <p>(0.75 to 1.08)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6825 (14 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<sup>1, 6</sup> </p> <p><b>Low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk Ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded by one level due to serious risk of bias. All the included trials were at high risk of bias due to either unclear or high risk in several bias domains. </p> <p><sup>2</sup> Downgraded by two levels due to very serious risk of imprecision based on the optimal information size not being reached, the wide absolute and relative 97.5% CI showing both appreciable benefit and harm, and a small sample size. </p> <p><sup>3</sup> Downgraded by one level due to serious risk of bias. All but one of the included trials were at high risk of bias due to either unclear or high risk in several bias domains and the sensitivity analysis excluding trials at high risk of bias showed different results than the overall analysis including trials at high risk of bias. However, the sensitivity analysis was based on only one small trial, so we have used the main analysis for the 'Summary of findings' table. </p> <p><sup>5</sup> Downgraded by two levels due to very serious risk of imprecision based on the very small sample size included. </p> <p><sup>6</sup> Downgraded by one level due to serious risk of imprecision based on the wide absolute and relative 98% where the upper CI does not exclude the possibility of no difference between the groups. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Beta‐blockers versus placebo or no intervention for suspected or diagnosed acute myocardial infarction at maximum follow‐up beyond three months</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/full#CD012484-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012484-tbl-0003"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Time points used at less than three months</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Trial</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Year</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>All‐cause mortality</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Major adverse cardiovascular events</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cardiovascular mortality</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Myocardial infarction during follow‐up</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Andersen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1979</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Åström</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1986</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Australian</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1984</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Australia &amp; Swedish</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1983</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Balcon</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1967</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Barbar</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1967</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Barber</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1976</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>90 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>BEAT‐AMI trial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2016</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>During hospitalisation (no mean time)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>During hospitalisation (no mean time)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>During hospitalisation (no mean time)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Briant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1970</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Campbell</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1984</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CAPRICORN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clausen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1966</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>COMMIT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28 days</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CPRG</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1980</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>56 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>56 days</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EARLY‐BAMI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2016</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30 days</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EMIT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42 days</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Evemy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1977</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gardtman</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Göteborg Metoprolol Trial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1981</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>90 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>90 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>90 days</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hanada</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>During hospitalisation (no mean time) (no events)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>During hospitalisation (no mean time) (no events)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>During hospitalisation (no mean time) (no events)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>During hospitalisation (no mean time) (no events)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Heber</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1986</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ICSG</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1984</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>During hospitalisation (no mean time)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>During hospitalisation (no mean time)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>During hospitalisation (no mean time)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ISIS‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1986</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7 days</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Johannessen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1987</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ledwich</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1968</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>McMurray</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1991</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10 days</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>METOCARD‐CNIC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7 days</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MIAMI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1985</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15 days</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MILIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1984</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mueller</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1980</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Multicenter trial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1966</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nielsen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1967</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28 days</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Norris</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1968</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Norris</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1978</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.5 days (no events)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.5 days (no events)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Norris</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1980</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>During hospitalisation (no mean time)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>During hospitalisation (no mean time)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Norris</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1984</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Owensby</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1985</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 days</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Peter</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1978</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 days</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Raeder</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1967</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ranganathan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1988</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rolli</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1980</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Salathia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1985</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>During hospitalisation (no mean time)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>90 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Shirotani</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30 days (no events)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30 days (no events)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30 days (no events)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30 days (no events)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tereschenko</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Thompson</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1979</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TIARA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1987</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30 days</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tonkin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1981</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7 days</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Van De Werf</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1993</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14 days</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Von Essen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1982</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wilcox</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1980</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yang</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1984</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yusuf</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1980</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>During hospitalisation (no mean time)</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Time points used at less than three months</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/full#CD012484-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012484-tbl-0004"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Time points used at maximum follow‐up beyond three months</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Trial</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Year</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>All‐cause mortality</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Major adverse cardiovascular events</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cardiovascular mortality</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Myocardial infarction</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Andersen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1979</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Australia &amp; Swedish</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1983</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Barber</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1976</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Basu</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1997</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>BEAT‐AMI trial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2016</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Briant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1970</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CAPRICORN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15.6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15.6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15.6 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EARLY‐BAMI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2016</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 month (not included)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Evemy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1977</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Göteborg Metoprolol Trial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1981</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hanada</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 months (no events)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 months (no events)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Heber</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1986</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ISIS‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1986</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.23 months (not included)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kaul</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1988</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>METOCARD‐CNIC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MILIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1984</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NPT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1982</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RIMA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Salathia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1985</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TIARA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1987</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 month (not included)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 month (not included)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tonkin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1981</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.23 months (not included)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wilcox</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1980</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yusuf</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1980</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>During hospitalisation (no mean time) (not included)</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Time points used at maximum follow‐up beyond three months</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/full#CD012484-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012484-tbl-0005"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Serious adverse events ‐ less than three months</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Trial</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Year</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Type and number of serious adverse events (beta‐blocker group)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Type and number of serious adverse events (control group)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Andersen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1979</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0025"> <li> <p>41 deaths from all causes</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0026"> <li> <p>37 deaths from all causes</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Åstrøm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1986</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0027"> <li> <p>1 atrial fibrillation</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Australian trial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1984</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0028"> <li> <p>1 death from all causes</p> </li> </ul> <ul id="CD012484-list-0029"> <li> <p>6 heart failure</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0030"> <li> <p>2 death from all causes</p> </li> <li> <p>3 heart failure</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Australia &amp; Swedish</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1983</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0031"> <li> <p>13 deaths from all causes</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0032"> <li> <p>13 deaths from all causes</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Balcon</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1967</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0033"> <li> <p>13 deaths from all causes</p> </li> <li> <p>11 heart failure</p> </li> <li> <p>7 shock</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0034"> <li> <p>14 deaths from all causes</p> </li> <li> <p>5 heart failure</p> </li> <li> <p>7 shock</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Barbar</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1967</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0035"> <li> <p>10 deaths from all causes</p> </li> <li> <p>20 heart failure</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0036"> <li> <p>12 deaths from all causes</p> </li> <li> <p>18 heart failure</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Barber</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1976</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0037"> <li> <p>23 deaths from all causes</p> </li> <li> <p>49 heart failure</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0038"> <li> <p>25 deaths from all causes</p> </li> <li> <p>29 heart failure</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>BEAT‐AMI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2016</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0039"> <li> <p>4 ventricular tachycardia</p> </li> <li> <p>1 atrial fibrillation</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0040"> <li> <p>1 deaths from all causes</p> </li> <li> <p>11 ventricular tachycardia</p> </li> <li> <p>3 cardiogenic shock</p> </li> <li> <p>2 myocardial infarction during follow‐up</p> </li> <li> <p>3 atrial fibrillation</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Briant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1970</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0041"> <li> <p>5 deaths from all causes</p> </li> <li> <p>8 ventricular tachycardia</p> </li> <li> <p>3 ventricular fibrillation</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0042"> <li> <p>4 deaths from all causes</p> </li> <li> <p>2 ventricular tachycardia</p> </li> <li> <p>2 ventricular fibrillation</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Campbell</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1984</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0043"> <li> <p>1 death from all causes</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0044"> <li> <p>2 deaths from all causes</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CAPRICORN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0045"> <li> <p>10 deaths from all causes</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0046"> <li> <p>20 deaths from all causes</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clausen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1966</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0047"> <li> <p>18 deaths from all causes</p> </li> <li> <p>9 thromboembolic complications</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0048"> <li> <p>19 deaths from all causes</p> </li> <li> <p>6 thromboembolic complications</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>COMMIT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0049"> <li> <p>1774 deaths from all causes</p> </li> <li> <p>464 myocardial infarction during follow‐up</p> </li> <li> <p>3224 heart failure</p> </li> <li> <p>247 stroke</p> </li> <li> <p>200 presumed cardiac rupture</p> </li> <li> <p>30 pulmonary embolus</p> </li> <li> <p>370 atrioventricular block</p> </li> <li> <p>1141 cardiogenic shock</p> </li> <li> <p>581 ventricular fibrillation</p> </li> <li> <p>685 other cardiac arrest (including asystole, but excluding ventricular fibrillation and arrhythmia) </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0050"> <li> <p>1797 deaths from all causes</p> </li> <li> <p>568 myocardial infarction during follow‐up</p> </li> <li> <p>2902 heart failure</p> </li> <li> <p>220 stroke</p> </li> <li> <p>233 presumed cardiac rupture</p> </li> <li> <p>35 pulmonary embolus</p> </li> <li> <p>357 atrioventricular block</p> </li> <li> <p>885 cardiogenic shock</p> </li> <li> <p>698 ventricular fibrillation</p> </li> <li> <p>632 other cardiac arrest (including asystole, but excluding ventricular fibrillation and arrhythmia) </p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CPRG</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1980</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0051"> <li> <p>9 deaths from all causes</p> </li> <li> <p>3 myocardial infarction during follow‐up</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0052"> <li> <p>5 deaths from all causes</p> </li> <li> <p>7 myocardial infarction during follow‐up</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EARLY‐BAMI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2016</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0053"> <li> <p>7 deaths from cardiac causes</p> </li> <li> <p>3 myocardial infarction during follow‐up</p> </li> <li> <p>2 cardiogenic shock</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0054"> <li> <p>7 deaths from cardiac causes</p> </li> <li> <p>2 myocardial infarction during follow‐up</p> </li> <li> <p>1 cardiogenic shock</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EMIT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0055"> <li> <p>2 deaths from all causes</p> </li> <li> <p>4 myocardial infarction during follow‐up</p> </li> <li> <p>7 heart failure</p> </li> <li> <p>2 AV‐block</p> </li> <li> <p>1 VT/VF</p> </li> <li> <p>8 silent myocardial ischaemic episode</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0056"> <li> <p>1 death from all causes</p> </li> <li> <p>2 myocardial infarction during follow‐up</p> </li> <li> <p>8 heart failure</p> </li> <li> <p>2 AV‐block</p> </li> <li> <p>2 VT/VF</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Evemy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1977</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0057"> <li> <p>7 deaths from all causes</p> </li> <li> <p>12 heart failure</p> </li> <li> <p>3 cardiogenic shock</p> </li> <li> <p>3 ventricular fibrillation</p> </li> <li> <p>2 ventricular tachycardia</p> </li> <li> <p>4 second degree AV‐block</p> </li> <li> <p>3 complete AV‐block</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0058"> <li> <p>4 deaths from all causes</p> </li> <li> <p>14 heart failure</p> </li> <li> <p>3 ventricular fibrillation</p> </li> <li> <p>4 ventricular tachycardia</p> </li> <li> <p>9 atrial fibrillation</p> </li> <li> <p>1 complete AV‐block</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gardtman</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0059"> <li> <p>5 deaths from all causes</p> </li> <li> <p>1 ventricular tachycardia</p> </li> <li> <p>17 heart failure</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0060"> <li> <p>4 deaths from all causes</p> </li> <li> <p>4 ventricular tachycardia</p> </li> <li> <p>1 AV block III</p> </li> <li> <p>19 heart failure</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Göteborg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1981</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0061"> <li> <p>40 deaths from all causes</p> </li> <li> <p>35 myocardial infarction during follow‐up</p> </li> <li> <p>70 hospitalisation for any cause</p> </li> <li> <p>12 heart failure</p> </li> <li> <p>16 AV‐block II‐III</p> </li> <li> <p>6 ventricular fibrillation</p> </li> <li> <p>15 sudden circulatory collapse</p> </li> <li> <p>10 rupture of ventricular wall</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0062"> <li> <p>62 deaths from all causes</p> </li> <li> <p>54 myocardial infarction during follow‐up</p> </li> <li> <p>91 hospitalisation for any cause</p> </li> <li> <p>25 heart failure</p> </li> <li> <p>11 AV‐block II‐III</p> </li> <li> <p>17 ventricular fibrillation</p> </li> <li> <p>25 sudden circulatory collapse</p> </li> <li> <p>15 rupture of ventricular wall</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Heber</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1986</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0063"> <li> <p>5 deaths from all causes</p> </li> <li> <p>11 heart failure</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0064"> <li> <p>1 death from all causes</p> </li> <li> <p>6 heart failure</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ICSG</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1984</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0065"> <li> <p>3 deaths from all causes</p> </li> <li> <p>2 myocardial infarction during follow‐up</p> </li> <li> <p>11 heart failure</p> </li> <li> <p>2 ventricular fibrillation</p> </li> <li> <p>3 cerebrovascular accident</p> </li> <li> <p>3 II/III AV‐block</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0066"> <li> <p>4 deaths from all causes</p> </li> <li> <p>2 myocardial infarction during follow‐up</p> </li> <li> <p>12 heart failure</p> </li> <li> <p>4 ventricular fibrillation</p> </li> <li> <p>1 cerebrovascular accident</p> </li> <li> <p>3 II/III AV‐block</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ISIS‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1986</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0067"> <li> <p>423 deaths from all causes</p> </li> <li> <p>148 myocardial infarctions during follow‐up</p> </li> <li> <p>189 cardiac arrest</p> </li> <li> <p>180 complete heart block</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0068"> <li> <p>493 deaths from all causes</p> </li> <li> <p>161 myocardial infarction during follow‐up</p> </li> <li> <p>198 cardiac arrest</p> </li> <li> <p>152 complete heart block</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Johannessen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1987</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0069"> <li> <p>2 deaths from all causes</p> </li> <li> <p>1 peripheral abdominal embolus</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0070"> <li> <p>3 atrial fibrillation</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ledwich</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1968</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0071"> <li> <p>2 deaths from all causes</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0072"> <li> <p>3 deaths from all causes</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lloyd</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1988</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0073"> <li> <p>3 ventricular tachycardia</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0074"> <li> <p>14 ventricular tachycardia</p> </li> <li> <p>2 ventricular fibrillation</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mcmurray</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1991</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0075"> <li> <p>1 ventricular fibrillation</p> </li> <li> <p>2 2nd degree AV‐block</p> </li> <li> <p>1 atrial fibrillation</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0076"> <li> <p>1 ventricular tachycardia</p> </li> <li> <p>1 heart failure</p> </li> <li> <p>1 AV‐block II</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>METOCARD‐CNIC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0077"> <li> <p>3 deaths from all causes</p> </li> <li> <p>1 myocardial infarction during follow‐up</p> </li> <li> <p>5 malignant ventricular arrhythmia</p> </li> <li> <p>1 advanced AV‐block</p> </li> <li> <p>6 cardiogenic shock</p> </li> <li> <p>11 heart failure</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0078"> <li> <p>3 deaths from all causes</p> </li> <li> <p>10 malignant ventricular arrhythmia</p> </li> <li> <p>2 advanced AV‐block</p> </li> <li> <p>7 cardiogenic shock</p> </li> <li> <p>9 heart failure</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Miami</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1985</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0079"> <li> <p>123 deaths from all causes</p> </li> <li> <p>85 myocardial infarction during follow‐up</p> </li> <li> <p>37 ventricular tachycardia</p> </li> <li> <p>74 asystole</p> </li> <li> <p>160 AV block II‐III</p> </li> <li> <p>699 heart failure</p> </li> <li> <p>86 cardiogenic shock</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0080"> <li> <p>142 deaths from all causes</p> </li> <li> <p>111 myocardial infarction during follow‐up</p> </li> <li> <p>40 ventricular tachycardia</p> </li> <li> <p>64 asystole</p> </li> <li> <p>153 AV block II‐III</p> </li> <li> <p>660 heart failure</p> </li> <li> <p>93 cardiogenic shock</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MILIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1984</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0081"> <li> <p>4 deaths from all causes</p> </li> <li> <p>25 heart failure</p> </li> <li> <p>17 ventricular tachycardia</p> </li> <li> <p>8 heart block</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0082"> <li> <p>8 deaths from all causes</p> </li> <li> <p>31 heart failure</p> </li> <li> <p>28 ventricular tachycardia</p> </li> <li> <p>9 heart block</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mueller</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1980</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0083"> <li> <p>2 deaths from all causes</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0084"> <li> <p>1 death from all causes</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Multicenter trial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1966</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0085"> <li> <p>15 deaths from all causes</p> </li> <li> <p>17 heart failure</p> </li> <li> <p>9 cardiac arrest</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0086"> <li> <p>12 deaths from all causes</p> </li> <li> <p>7 heart failure</p> </li> <li> <p>7 cardiac arrest</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nielsen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1967</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0087"> <li> <p>18 deaths from all causes</p> </li> <li> <p>2 myocardial infarction during follow‐up</p> </li> <li> <p>7 thrombo‐embolic complications</p> </li> <li> <p>2 heart failure</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0088"> <li> <p>19 deaths from all causes</p> </li> <li> <p>6 thrombo‐embolic complications</p> </li> <li> <p>6 heart failure</p> </li> <li> <p>2 cardiogenic shock</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Norris</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1968</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0089"> <li> <p>20 deaths from all causes</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0090"> <li> <p>17 deaths</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Norris</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1978</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0091"> <li> <p>1 heart failure</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0092"> <li> <p>1 heart failure</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Norris</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1980</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0093"> <li> <p>1 death from all causes</p> </li> <li> <p>1 ventricular fibrillation</p> </li> <li> <p>1 cardiogenic shock</p> </li> <li> <p>3 heart failure</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0094"> <li> <p>1 ventricular fibrillation</p> </li> <li> <p>1 cardiogenic shock</p> </li> <li> <p>2 AV‐block II‐III</p> </li> <li> <p>8 heart failure</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Norris</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1984</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0095"> <li> <p>15 deaths from all causes,</p> </li> <li> <p>7 ventricular fibrillation</p> </li> <li> <p>22 atrial fibrillation</p> </li> <li> <p>13 AV block II‐III</p> </li> <li> <p>14 bundle‐branch block</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0096"> <li> <p>14 deaths from all causes,</p> </li> <li> <p>18 ventricular fibrillation</p> </li> <li> <p>23 atrial fibrillation</p> </li> <li> <p>8 AV block II‐III</p> </li> <li> <p>14 bundle‐branch block</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Owensby</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1985</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0097"> <li> <p>1 death from all causes</p> </li> <li> <p>2 myocardial infarction during follow‐up</p> </li> <li> <p>23 heart failure</p> </li> <li> <p>6 AV‐block II‐III</p> </li> <li> <p>13 ventricular tachycardia</p> </li> <li> <p>4 ventricular fibrillation</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0098"> <li> <p>1 death from all causes</p> </li> <li> <p>2 myocardial infarction during follow‐up</p> </li> <li> <p>23 heart failure</p> </li> <li> <p>5 AV‐block II‐III</p> </li> <li> <p>12 ventricular tachycardia</p> </li> <li> <p>3 ventricular fibrillation</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Peter</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1978</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0099"> <li> <p>1 death from all causes</p> </li> <li> <p>1 myocardial infarction during follow‐up</p> </li> <li> <p>5 heart failure</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0100"> <li> <p>2 deaths from all causes</p> </li> <li> <p>3 myocardial infarction during follow‐up</p> </li> <li> <p>5 heart failure</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Raeder</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1967</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0101"> <li> <p>2 deaths from all causes</p> </li> <li> <p>1 AV‐block II‐III</p> </li> <li> <p>2 atrial fibrillation</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0102"> <li> <p>2 deaths from all causes</p> </li> <li> <p>1 AV‐block II‐III</p> </li> <li> <p>1 atrial fibrillation</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ramsdale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1982</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0103"> <li> <p>1 heart failure</p> </li> <li> <p>1 complete heart block</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ranganathan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1988</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0104"> <li> <p>1 death from all causes</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0105"> <li> <p>3 deaths from all causes</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rolli</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1980</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0106"> <li> <p>1 bundle block or hemiblock</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0107"> <li> <p>2 ventricular fibrillation</p> </li> <li> <p>3 heart failure</p> </li> <li> <p>2 bundle branch block or hemiblock</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Salathia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1985</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0108"> <li> <p>25 deaths from all causes</p> </li> <li> <p>11 ventricular fibrillation</p> </li> <li> <p>9 with AV‐block II‐III</p> </li> <li> <p>47 heart failure</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0109"> <li> <p>20 deaths from all causes</p> </li> <li> <p>14 ventricular fibrillation</p> </li> <li> <p>18 with AV‐block II‐III</p> </li> <li> <p>35 heart failure</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tereschenko</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0110"> <li> <p>3 deaths from all causes</p> </li> <li> <p>4 heart failure</p> </li> <li> <p>6 post‐infarction angina pectoris</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0111"> <li> <p>2 deaths from all causes</p> </li> <li> <p>7 heart failure</p> </li> <li> <p>5 post‐infarction angina pectoris</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Thompson</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1979</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0112"> <li> <p>3 deaths from all causes</p> </li> <li> <p>6 heart failure</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0113"> <li> <p>3 deaths from all causes</p> </li> <li> <p>6 heart failure</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TIARA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1987</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0114"> <li> <p>3 deaths from all causes</p> </li> <li> <p>3 myocardial infarction during follow‐up</p> </li> <li> <p>7 ventricular tachycardia</p> </li> <li> <p>10 heart failure</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0115"> <li> <p>7 deaths from all causes</p> </li> <li> <p>6 myocardial infarction during follow‐up</p> </li> <li> <p>16 ventricular tachycardia</p> </li> <li> <p>3 ventricular fibrillation</p> </li> <li> <p>18 heart failure</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tonkin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1981</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0116"> <li> <p>1 death from all causes</p> </li> <li> <p>1 reinfarction</p> </li> <li> <p>14 heart failure</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0117"> <li> <p>1 death from all causes</p> </li> <li> <p>16 heart failure</p> </li> <li> <p>1 AV‐block</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Van De Werf</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1993</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0118"> <li> <p>1 death from all causes</p> </li> <li> <p>9 myocardial infarction during follow‐up</p> </li> <li> <p>6 pulmonary edema</p> </li> <li> <p>4 pericarditis</p> </li> <li> <p>3 cardiogenic shock</p> </li> <li> <p>9 AV block II‐III</p> </li> <li> <p>21 ventricular tachycardia</p> </li> <li> <p>2 ventricular fibrillation</p> </li> <li> <p>1 stroke</p> </li> <li> <p>2 bleeding requiring transfusion</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0119"> <li> <p>4 death from all causes</p> </li> <li> <p>10 myocardial infarction during follow‐up</p> </li> <li> <p>3 pericarditis</p> </li> <li> <p>1 cardiac rupture</p> </li> <li> <p>7 AV block II‐III</p> </li> <li> <p>18 ventricular tachycardia</p> </li> <li> <p>3 ventricular fibrillation</p> </li> <li> <p>2 stroke</p> </li> <li> <p>1 bleeding requiring transfusion</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Von Essen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1982</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0120"> <li> <p>1 death from all causes</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0121"> <li> <p>1 death from all causes</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wilcox (atenolol)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1980</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0122"> <li> <p>11 deaths from all causes</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0123"> <li> <p>8 deaths from all causes</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wilcox (propranolol)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1980</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0124"> <li> <p>10 death from all causes</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0125"> <li> <p>7 deaths from all causes</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yang</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1984</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0126"> <li> <p>2 AV‐block II</p> </li> <li> <p>1 ventricular fibrillation</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0127"> <li> <p>1 AV‐block II</p> </li> <li> <p>2 atrial fibrillation</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yusuf</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1980</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0128"> <li> <p>7 death form all causes</p> </li> <li> <p>46 heart failure</p> </li> <li> <p>13 AV block II‐III</p> </li> <li> <p>4 cardiac arrest</p> </li> <li> <p>3 pulmonary embolus</p> </li> <li> <p>1 renal failure</p> </li> <li> <p>1 cardiogenic shock</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0129"> <li> <p>16 death form all causes</p> </li> <li> <p>6 myocardial infarction during follow‐up</p> </li> <li> <p>56 heart failure</p> </li> <li> <p>18 AV block II‐III</p> </li> <li> <p>15 cardiac arrest</p> </li> <li> <p>2 ventricular septal defect</p> </li> <li> <p>4 cardiogenic shock</p> </li> </ul> </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Serious adverse events ‐ less than three months</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/full#CD012484-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012484-tbl-0006"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Serious adverse events ‐ maximum follow‐up</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Trial</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Year</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Type and number of serious adverse events (beta‐blocker group)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Type and number of serious adverse events (control group)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Andersen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1979</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0130"> <li> <p>62 deaths from all causes</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0131"> <li> <p>60 deaths from all causes</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Åstrøm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1986</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0132"> <li> <p>1 atrial fibrillation</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Australian trial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1984</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0133"> <li> <p>1 death from all causes</p> </li> </ul> <ul id="CD012484-list-0134"> <li> <p>6 heart failure</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0135"> <li> <p>2 death from all causes</p> </li> <li> <p>3 heart failure</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Australia &amp; Swedish</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1983</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0136"> <li> <p>45 deaths from all causes</p> </li> <li> <p>37 myocardial infarction during follow‐up</p> </li> <li> <p>20 heart failure</p> </li> <li> <p>2 surgery</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0137"> <li> <p>47 deaths from all causes</p> </li> <li> <p>41 myocardial infarction during follow‐up</p> </li> <li> <p>11 heart failure</p> </li> <li> <p>1 ventricular arrhythmia</p> </li> <li> <p>6 surgery</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Balcon</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1967</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0138"> <li> <p>13 deaths from all causes</p> </li> <li> <p>11 heart failure</p> </li> <li> <p>7 shock</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0139"> <li> <p>14 deaths from all causes</p> </li> <li> <p>5 heart failure</p> </li> <li> <p>7 shock</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Barbar</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1967</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0140"> <li> <p>10 deaths from all causes</p> </li> <li> <p>20 heart failure</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0141"> <li> <p>12 deaths from all causes</p> </li> <li> <p>18 heart failure</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Barber</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1976</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0142"> <li> <p>47 deaths from all causes</p> </li> <li> <p>9 heart failure</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0143"> <li> <p>46 deaths from all causes</p> </li> <li> <p>17 heart failure</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Basu</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1997</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0144"> <li> <p>2 deaths from cardiac causes</p> </li> <li> <p>4 myocardial infarction during follow‐up</p> </li> <li> <p>5 heart failure</p> </li> <li> <p>3 unstable angina</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0145"> <li> <p>3 deaths from cardiac causes</p> </li> <li> <p>8 myocardial infarction during follow‐up</p> </li> <li> <p>5 heart failure</p> </li> <li> <p>6 unstable angina</p> </li> <li> <p>2 CABG/PTCA</p> </li> <li> <p>1 cerebrovascular accident</p> </li> <li> <p>1 ventricular arrhythmia</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>BEAT‐AMI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2016</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0146"> <li> <p>4 ventricular tachycardia</p> </li> <li> <p>8 revascularisation</p> </li> <li> <p>1 atrial fibrillation</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0147"> <li> <p>1 deaths from all causes</p> </li> <li> <p>2 myocardial infarction during follow‐up</p> </li> <li> <p>11 ventricular tachycardia</p> </li> <li> <p>3 cardiogenic shock</p> </li> <li> <p>1 stroke</p> </li> <li> <p>13 revascularisations</p> </li> <li> <p>3 atrial fibrillation</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Briant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1970</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0148"> <li> <p>8 deaths from all causes</p> </li> <li> <p>4 myocardial infarction during follow‐up</p> </li> <li> <p>3 heart failure</p> </li> <li> <p>1 pulmonary edema</p> </li> <li> <p>1 post‐infarction angina pectoris</p> </li> <li> <p>1 coronary insufficiency</p> </li> <li> <p>8 ventricular tachycardia</p> </li> <li> <p>3 ventricular fibrillation</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0149"> <li> <p>7 deaths from all causes</p> </li> <li> <p>4 myocardial infarction during follow‐up</p> </li> <li> <p>3 heart failure</p> </li> <li> <p>4 post‐infarction angina pectoris</p> </li> <li> <p>2 coronary insufficiency</p> </li> <li> <p>2 ventricular tachycardia</p> </li> <li> <p>2 ventricular fibrillation</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Campbell</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1984</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0150"> <li> <p>1 death from all causes</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0151"> <li> <p>2 deaths from all causes</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CAPRICORN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0152"> <li> <p>116 deaths from all causes</p> </li> <li> <p>34 myocardial infarction during follow‐up</p> </li> <li> <p>118 hospitalisations for heart failure</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0153"> <li> <p>151 deaths from all causes</p> </li> <li> <p>57 myocardial infarction during follow‐up</p> </li> <li> <p>138 hospitalisations for heart failure</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clausen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1966</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0154"> <li> <p>18 deaths from all causes</p> </li> <li> <p>9 thromboembolic complications</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0155"> <li> <p>19 deaths from all causes</p> </li> <li> <p>6 thromboembolic complications</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>COMMIT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0156"> <li> <p>1774 deaths from all causes</p> </li> <li> <p>464 myocardial infarction during follow‐up</p> </li> <li> <p>3224 heart failure</p> </li> <li> <p>247 stroke</p> </li> <li> <p>200 presumed cardiac rupture</p> </li> <li> <p>30 pulmonary embolus</p> </li> <li> <p>370 atrioventricular block</p> </li> <li> <p>1141 cardiogenic shock</p> </li> <li> <p>581 ventricular fibrillation</p> </li> <li> <p>685 other cardiac arrest (including asystole, but excluding ventricular fibrillation and arrhythmia) </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0157"> <li> <p>1797 deaths from all causes</p> </li> <li> <p>568 myocardial infarction during follow‐up</p> </li> <li> <p>2902 heart failure</p> </li> <li> <p>220 stroke</p> </li> <li> <p>233 presumed cardiac rupture</p> </li> <li> <p>35 pulmonary embolus</p> </li> <li> <p>357 atrioventricular block</p> </li> <li> <p>885 cardiogenic shock</p> </li> <li> <p>698 ventricular fibrillation</p> </li> <li> <p>632 other cardiac arrest (including asystole, but excluding ventricular fibrillation and arrhythmia) </p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CPRG</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1980</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0158"> <li> <p>9 deaths from all causes</p> </li> <li> <p>3 myocardial infarction during follow‐up</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0159"> <li> <p>5 deaths from all causes</p> </li> <li> <p>7 myocardial infarction during follow‐up</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EARLY‐BAMI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2016</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0160"> <li> <p>11 deaths from all causes</p> </li> <li> <p>3 myocardial infarction during follow‐up</p> </li> <li> <p>8 ICD implantation</p> </li> <li> <p>4 hospitalisation for heart failure</p> </li> <li> <p>2 cardiogenic shock</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0161"> <li> <p>11 deaths from all causes</p> </li> <li> <p>2 myocardial infarction during follow‐up</p> </li> <li> <p>4 ICD implantation</p> </li> <li> <p>3 hospitalisation for heart failure</p> </li> <li> <p>1 cardiogenic shock</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EMIT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0162"> <li> <p>2 deaths from all causes</p> </li> <li> <p>4 myocardial infarction during follow‐up</p> </li> <li> <p>7 heart failure</p> </li> <li> <p>2 AV‐block</p> </li> <li> <p>1 VT/VF</p> </li> <li> <p>8 silent myocardial ischaemic episode</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0163"> <li> <p>1 death from all causes</p> </li> <li> <p>2 myocardial infarction during follow‐up</p> </li> <li> <p>8 heart failure</p> </li> <li> <p>2 AV‐block</p> </li> <li> <p>2 VT/VF</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Evemy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1977</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0164"> <li> <p>9 deaths from all causes</p> </li> <li> <p>5 heart failure</p> </li> <li> <p>3 cardiogenic shock</p> </li> <li> <p>3 ventricular fibrillation</p> </li> <li> <p>2 ventricular tachycardia</p> </li> <li> <p>4 second degree AV‐block</p> </li> <li> <p>3 complete AV‐block</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0165"> <li> <p>6 deaths from all causes</p> </li> <li> <p>8 heart failure</p> </li> <li> <p>3 ventricular fibrillation</p> </li> <li> <p>4 ventricular tachycardia</p> </li> <li> <p>9 atrial fibrillation</p> </li> <li> <p>1 complete AV‐block</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gardtman</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0166"> <li> <p>5 deaths from all causes</p> </li> <li> <p>1 ventricular tachycardia</p> </li> <li> <p>17 heart failure</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0167"> <li> <p>4 deaths from all causes</p> </li> <li> <p>4 ventricular tachycardia</p> </li> <li> <p>1 AV block III</p> </li> <li> <p>19 heart failure</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Göteborg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1981</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0168"> <li> <p>169 deaths from all causes</p> </li> <li> <p>157 myocardial infarction during follow‐up</p> </li> <li> <p>34 stroke</p> </li> <li> <p>16 CABG</p> </li> <li> <p>70 hospitalisation for any cause</p> </li> <li> <p>42 heart failure</p> </li> <li> <p>16 AV‐block II‐III</p> </li> <li> <p>6 ventricular fibrillation</p> </li> <li> <p>15 sudden circulatory collapse</p> </li> <li> <p>10 rupture of ventricular wall</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0169"> <li> <p>179 deaths from all causes</p> </li> <li> <p>156 myocardial infarction during follow‐up</p> </li> <li> <p>37 stroke</p> </li> <li> <p>22 CABG</p> </li> <li> <p>91 hospitalisation for any cause</p> </li> <li> <p>42 heart failure</p> </li> <li> <p>11 AV‐block II‐III</p> </li> <li> <p>17 ventricular fibrillation</p> </li> <li> <p>25 sudden circulatory collapse</p> </li> <li> <p>15 rupture of ventricular wall</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hanada</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0170"> <li> <p>1 myocardial infarction during follow‐up</p> </li> <li> <p>1 heart failure</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Heber</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1986</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0171"> <li> <p>12 deaths from all causes</p> </li> <li> <p>14 heart failure</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0172"> <li> <p>7 death from all causes</p> </li> <li> <p>9 heart failure</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ICSG</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1984</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0173"> <li> <p>3 deaths from all causes</p> </li> <li> <p>2 myocardial infarction during follow‐up</p> </li> <li> <p>11 heart failure</p> </li> <li> <p>2 ventricular fibrillation</p> </li> <li> <p>3 cerebrovascular accident</p> </li> <li> <p>3 II/III AV‐block</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0174"> <li> <p>4 deaths from all causes</p> </li> <li> <p>2 myocardial infarction during follow‐up</p> </li> <li> <p>12 heart failure</p> </li> <li> <p>4 ventricular fibrillation</p> </li> <li> <p>1 cerebrovascular accident</p> </li> <li> <p>3 II/III AV‐block</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ISIS‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1986</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0175"> <li> <p>1071 deaths from all causes</p> </li> <li> <p>148 myocardial infarctions during follow‐up</p> </li> <li> <p>189 cardiac arrest</p> </li> <li> <p>180 complete heart block</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0176"> <li> <p>1120 deaths from all causes</p> </li> <li> <p>161 myocardial infarction during follow‐up</p> </li> <li> <p>198 cardiac arrest</p> </li> <li> <p>152 complete heart block</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Johannessen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1987</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0177"> <li> <p>2 deaths from all causes</p> </li> <li> <p>1 peripheral abdominal embolus</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0178"> <li> <p>3 atrial fibrillation</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kaul</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1988</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0179"> <li> <p>4 deaths from all causes</p> </li> <li> <p>4 post‐infarction angina pectoris</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0180"> <li> <p>3 deaths from all causes</p> </li> <li> <p>4 myocardial infarction during follow‐up</p> </li> <li> <p>9 post‐infarction angina pectoris</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ledwich</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1968</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0181"> <li> <p>2 deaths from all causes</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0182"> <li> <p>3 deaths from all causes</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lloyd</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1988</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0183"> <li> <p>3 ventricular tachycardia</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0184"> <li> <p>14 ventricular tachycardia</p> </li> <li> <p>2 ventricular fibrillation</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mcmurray</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1991</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0185"> <li> <p>1 ventricular fibrillation</p> </li> <li> <p>2 2nd degree AV‐block</p> </li> <li> <p>1 atrial fibrillation</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0186"> <li> <p>1 ventricular tachycardia</p> </li> <li> <p>1 heart failure</p> </li> <li> <p>1 AV‐block II</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>METOCARD‐CNIC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0187"> <li> <p>6 deaths from all causes</p> </li> <li> <p>1 myocardial infarction during follow‐up</p> </li> <li> <p>5 malignant ventricular arrhythmia</p> </li> <li> <p>1 advanced AV‐block</p> </li> <li> <p>6 cardiogenic shock</p> </li> <li> <p>11 heart failure</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0188"> <li> <p>6 deaths from all causes</p> </li> <li> <p>3 myocardial infarction during follow‐up</p> </li> <li> <p>10 malignant ventricular arrhythmia</p> </li> <li> <p>2 advanced AV‐block</p> </li> <li> <p>7 cardiogenic shock</p> </li> <li> <p>9 heart failure</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Miami</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1985</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0189"> <li> <p>123 deaths from all causes</p> </li> <li> <p>85 myocardial infarction during follow‐up</p> </li> <li> <p>37 ventricular tachycardia</p> </li> <li> <p>74 asystole</p> </li> <li> <p>160 AV block II‐III</p> </li> <li> <p>699 heart failure</p> </li> <li> <p>86 cardiogenic shock</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0190"> <li> <p>142 deaths from all causes</p> </li> <li> <p>111 myocardial infarction during follow‐up</p> </li> <li> <p>40 ventricular tachycardia</p> </li> <li> <p>64 asystole</p> </li> <li> <p>153 AV block II‐III</p> </li> <li> <p>660 heart failure</p> </li> <li> <p>93 cardiogenic shock</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MILIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1984</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0191"> <li> <p>24 deaths from all causes</p> </li> <li> <p>25 heart failure</p> </li> <li> <p>17 ventricular tachycardia</p> </li> <li> <p>8 heart block</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0192"> <li> <p>20 deaths from all causes</p> </li> <li> <p>31 heart failure</p> </li> <li> <p>28 ventricular tachycardia</p> </li> <li> <p>9 heart block</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mueller</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1980</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0193"> <li> <p>2 deaths from all causes</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0194"> <li> <p>1 death from all causes</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Multicenter trial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1966</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0195"> <li> <p>15 deaths from all causes</p> </li> <li> <p>17 heart failure</p> </li> <li> <p>9 cardiac arrest</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0196"> <li> <p>12 deaths from all causes</p> </li> <li> <p>7 heart failure</p> </li> <li> <p>7 cardiac arrest</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nielsen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1967</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0197"> <li> <p>18 deaths from all causes</p> </li> <li> <p>2 myocardial infarction during follow‐up</p> </li> <li> <p>7 thrombo‐embolic complications</p> </li> <li> <p>2 heart failure</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0198"> <li> <p>19 deaths from all causes</p> </li> <li> <p>6 thrombo‐embolic complications</p> </li> <li> <p>6 heart failure</p> </li> <li> <p>2 cardiogenic shock</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Norris</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1968</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0199"> <li> <p>31 deaths from all causes</p> </li> <li> <p>7 AV‐block</p> </li> <li> <p>38 heart failure</p> </li> <li> <p>7 VT/VF</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0200"> <li> <p>24 deaths from all causes</p> </li> <li> <p>7 AV‐block</p> </li> <li> <p>43 heart failure</p> </li> <li> <p>9 VT/VF</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Norris</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1978</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0201"> <li> <p>1 heart failure</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0202"> <li> <p>1 heart failure</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Norris</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1980</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0203"> <li> <p>1 death from all causes</p> </li> <li> <p>1 ventricular fibrillation</p> </li> <li> <p>1 cardiogenic shock</p> </li> <li> <p>3 heart failure</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0204"> <li> <p>1 ventricular fibrillation</p> </li> <li> <p>1 cardiogenic shock</p> </li> <li> <p>2 AV‐block II‐III</p> </li> <li> <p>8 heart failure</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Norris</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1984</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0205"> <li> <p>15 deaths from all causes,</p> </li> <li> <p>7 ventricular fibrillation</p> </li> <li> <p>22 atrial fibrillation</p> </li> <li> <p>13 AV block II‐III</p> </li> <li> <p>14 bundle‐branch block</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0206"> <li> <p>14 deaths from all causes,</p> </li> <li> <p>18 ventricular fibrillation</p> </li> <li> <p>23 atrial fibrillation</p> </li> <li> <p>8 AV block II‐III</p> </li> <li> <p>14 bundle‐branch block</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NPT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1982</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0207"> <li> <p>25 deaths from all causes</p> </li> <li> <p>27 myocardial infarction during follow‐up</p> </li> <li> <p>22 heart failure</p> </li> <li> <p>1 ventricular fibrillation</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0208"> <li> <p>37 deaths from all causes</p> </li> <li> <p>31 myocardial infarction during follow‐up</p> </li> <li> <p>16 heart failure</p> </li> <li> <p>4 ventricular fibrillation</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Owensby</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1985</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0209"> <li> <p>1 death from all causes</p> </li> <li> <p>2 myocardial infarction during follow‐up</p> </li> <li> <p>23 heart failure</p> </li> <li> <p>6 AV‐block II‐III</p> </li> <li> <p>13 ventricular tachycardia</p> </li> <li> <p>4 ventricular fibrillation</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0210"> <li> <p>1 death from all causes</p> </li> <li> <p>2 myocardial infarction during follow‐up</p> </li> <li> <p>23 heart failure</p> </li> <li> <p>5 AV‐block II‐III</p> </li> <li> <p>12 ventricular tachycardia</p> </li> <li> <p>3 ventricular fibrillation</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Peter</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1978</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0211"> <li> <p>1 death from all causes</p> </li> <li> <p>1 myocardial infarction during follow‐up</p> </li> <li> <p>5 heart failure</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0212"> <li> <p>2 deaths from all causes</p> </li> <li> <p>3 myocardial infarction during follow‐up</p> </li> <li> <p>5 heart failure</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Raeder</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1967</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0213"> <li> <p>2 deaths from all causes</p> </li> <li> <p>1 AV‐block II‐III</p> </li> <li> <p>2 atrial fibrillation</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0214"> <li> <p>2 deaths from all causes</p> </li> <li> <p>1 AV‐block II‐III</p> </li> <li> <p>1 atrial fibrillation</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ramsdale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1982</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0215"> <li> <p>1 heart failure</p> </li> <li> <p>1 complete heart block</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ranganathan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1988</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0216"> <li> <p>1 death from all causes</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0217"> <li> <p>3 deaths from all causes</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RIMA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0218"> <li> <p>1 death from cardiac causes</p> </li> <li> <p>3 myocardial infarction during follow‐up</p> </li> <li> <p>3 unstable angina</p> </li> <li> <p>3 heart failure</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0219"> <li> <p>1 death from cardiac causes</p> </li> <li> <p>2 myocardial infarction during follow‐up</p> </li> <li> <p>6 unstable angina</p> </li> <li> <p>2 heart failure</p> </li> <li> <p>6 revascularisations</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rolli</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1980</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0220"> <li> <p>1 bundle block or hemiblock</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0221"> <li> <p>2 ventricular fibrillation</p> </li> <li> <p>3 heart failure</p> </li> <li> <p>2 bundle branch block or hemiblock</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Salathia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1985</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0222"> <li> <p>49 deaths from all causes</p> </li> <li> <p>11 ventricular fibrillation</p> </li> <li> <p>9 with AV‐block II‐III</p> </li> <li> <p>47 heart failure</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0223"> <li> <p>52 deaths from all causes</p> </li> <li> <p>14 ventricular fibrillation</p> </li> <li> <p>18 with AV‐block II‐III</p> </li> <li> <p>35 heart failure</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tereschenko</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0224"> <li> <p>3 deaths from all causes</p> </li> <li> <p>4 heart failure</p> </li> <li> <p>6 post‐infarction angina pectoris</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0225"> <li> <p>2 deaths from all causes</p> </li> <li> <p>7 heart failure</p> </li> <li> <p>5 post‐infarction angina pectoris</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Thompson</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1979</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0226"> <li> <p>3 deaths from all causes</p> </li> <li> <p>6 heart failure</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0227"> <li> <p>3 deaths from all causes</p> </li> <li> <p>6 heart failure</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TIARA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1987</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0228"> <li> <p>7 deaths from all causes</p> </li> <li> <p>3 myocardial infarction during follow‐up</p> </li> <li> <p>7 ventricular tachycardia</p> </li> <li> <p>10 heart failure</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0229"> <li> <p>12 deaths from all causes</p> </li> <li> <p>6 myocardial infarction during follow‐up</p> </li> <li> <p>16 ventricular tachycardia</p> </li> <li> <p>3 ventricular fibrillation</p> </li> <li> <p>18 heart failure</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tonkin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1981</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0230"> <li> <p>1 death from all causes</p> </li> <li> <p>6 myocardial infarction during follow‐up</p> </li> <li> <p>14 heart failure</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0231"> <li> <p>1 death from all causes</p> </li> <li> <p>1 myocardial infarction during follow‐up</p> </li> <li> <p>16 heart failure</p> </li> <li> <p>1 AV‐block</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Van De Werf</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1993</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0232"> <li> <p>1 death from all causes</p> </li> <li> <p>9 myocardial infarction during follow‐up</p> </li> <li> <p>6 pulmonary edema</p> </li> <li> <p>4 pericarditis</p> </li> <li> <p>3 cardiogenic shock</p> </li> <li> <p>9 AV block II‐III</p> </li> <li> <p>21 ventricular tachycardia</p> </li> <li> <p>2 ventricular fibrillation</p> </li> <li> <p>1 stroke</p> </li> <li> <p>2 bleeding requiring transfusion</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0233"> <li> <p>4 death from all causes</p> </li> <li> <p>10 myocardial infarction during follow‐up</p> </li> <li> <p>3 pericarditis</p> </li> <li> <p>1 cardiac rupture</p> </li> <li> <p>7 AV block II‐III</p> </li> <li> <p>18 ventricular tachycardia</p> </li> <li> <p>3 ventricular fibrillation</p> </li> <li> <p>2 stroke</p> </li> <li> <p>1 bleeding requiring transfusion</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Von Essen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1982</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0234"> <li> <p>1 death from all causes</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0235"> <li> <p>1 death from all causes</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wilcox (atenolol)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1980</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0236"> <li> <p>19 deaths from all causes</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0237"> <li> <p>10 deaths from all causes</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wilcox (propranolol)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1980</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0238"> <li> <p>17 death from all causes</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0239"> <li> <p>9 deaths from all causes</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yang</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1984</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0240"> <li> <p>2 AV‐block II</p> </li> <li> <p>1 ventricular fibrillation</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0241"> <li> <p>1 AV‐block II</p> </li> <li> <p>2 atrial fibrillation</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yusuf</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1980</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0242"> <li> <p>36 death form all causes</p> </li> <li> <p>46 heart failure</p> </li> <li> <p>13 AV block II‐III</p> </li> <li> <p>4 cardiac arrest</p> </li> <li> <p>3 pulmonary embolus</p> </li> <li> <p>1 renal failure</p> </li> <li> <p>1 cardiogenic shock</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012484-list-0243"> <li> <p>44 death form all causes</p> </li> <li> <p>6 myocardial infarction during follow‐up</p> </li> <li> <p>56 heart failure</p> </li> <li> <p>18 AV block II‐III</p> </li> <li> <p>15 cardiac arrest</p> </li> <li> <p>2 ventricular septal defect</p> </li> <li> <p>4 cardiogenic shock</p> </li> </ul> </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Serious adverse events ‐ maximum follow‐up</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/full#CD012484-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012484-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Beta‐blockers versus placebo or no intervention less than 3 months follow‐up</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 All‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80452</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.90, 0.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 All‐cause mortality ‐ Acute/subacute phase <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80452</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.90, 0.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Acute phase</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>76857</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.90, 1.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Subacute phase</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3595</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.50, 1.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 All‐cause mortality ‐ Reperfusion/no reperfusion <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80452</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.90, 0.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 No reperfusion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>78206</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.90, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Reperfusion (PCI , CABG, thrombolytics)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2246</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.43, 1.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 All‐cause mortality ‐ Type of beta‐blocker <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80452</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.90, 0.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Alprenolol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>599</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [0.77, 1.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Atenolol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>16890</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.74, 0.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Esmolol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.21, 3.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4 Labetolol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>166</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.0 [0.60, 41.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5 Metoprolol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>55034</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.91, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.6 Oxprenolol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>313</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.38 [0.47, 4.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.7 Pindolol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>629</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.49, 2.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.8 Practolol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>486</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.65, 1.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.9 Propranolol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2630</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.76, 1.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.10 Timolol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>704</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.33, 1.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.11 Carvedilol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2753</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.25, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.12 Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>108</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.93 [0.18, 20.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 All‐cause mortality ‐ Intravenously/orally commenced <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80452</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.90, 0.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Intravenously commenced</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1036</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.46, 2.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Orally commenced</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5658</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.74, 1.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>73758</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.90, 1.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 All‐cause mortality ‐ Above/below 75 years of age <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>79161</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.90, 0.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Below 75 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12602</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.74, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66559</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.90, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 All‐cause mortality ‐ NSTEMI/STEMI/UAP <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>53337</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.92, 1.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 STEMI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1828</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.48, 2.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>51509</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.92, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 All‐cause mortality ‐ Registration status <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80452</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.90, 0.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Pre‐registration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>47642</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.93, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Post‐registration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>269</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.16, 1.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3 No registration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>32541</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.80, 0.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 All‐cause mortality ‐ Funding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80452</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.90, 0.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 Industry funded or unknown funded trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>78702</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.90, 1.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 Non‐industry funded trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1750</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.60, 1.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 All‐cause mortality ‐ Trials at low risk of bias <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>46122</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.93, 1.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 All‐cause mortality ‐ 'Best‐worst case scenario' <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80522</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.89, 0.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 All‐cause mortality ‐ 'Worst‐best case scenario' <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80522</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.86, 1.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Beta‐blockers versus placebo or no intervention less than 3 months follow‐up</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/references#CD012484-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012484-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Beta‐blockers versus placebo or no intervention at maximum follow‐up beyond 3 months</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 All‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>25210</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.87, 0.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 All‐cause mortality ‐ Acute/subacute phase <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>25210</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.87, 0.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Acute phase</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>21368</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.89, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Subacute phase</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3842</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.68, 0.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 All‐cause mortality ‐ Reperfusion/no reperfusion <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>25210</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.87, 0.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 No reperfusion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>23768</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.87, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Reperfusion (PCI , CABG, thrombolytics)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1442</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.52, 1.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 All‐cause mortality ‐ Type of beta‐blocker <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>25098</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.87, 0.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Alprenolol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>566</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.74, 1.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Atenolol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>16696</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.88, 1.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Carvedilol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2899</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.64, 0.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4 Labetolol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>166</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.71 [0.71, 4.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5 Metoprolol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2593</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.79, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.6 Pindolol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>529</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.67, 1.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.7 Practolol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>386</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.68, 1.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.8 Propranolol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1075</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.64, 1.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.9 Timolol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.07, 16.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.10 Esmolol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 7.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 All‐cause mortality ‐ Above/below 75 years of age <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>25210</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.87, 0.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Below 75 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5862</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.83, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19348</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.86, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 All‐cause mortality ‐ Intravenously/orally commenced <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>25210</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.87, 0.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Intravenously commenced</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>370</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.30, 2.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Orally commenced</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4614</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.72, 0.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20226</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.89, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 All‐cause mortality ‐ Registration status <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>25210</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.87, 0.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Pre‐registration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1164</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.51, 1.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Post‐registration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>269</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [0.70, 2.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3 No registration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>23777</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.87, 0.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 All‐cause mortality ‐ NSTEMI/STEMI/UAP <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2128</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.70, 1.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 STEMI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1164</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.51, 1.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>964</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.69, 1.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 All‐cause mortality ‐ Length of intervention period <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>25210</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.87, 0.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 0 to 7 days length of intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>16651</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.89, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 7 to 30 days length of intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>946</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.60, 1.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.3 1 month and more length of intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7613</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.80, 0.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 All‐cause mortality ‐ Funding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>25210</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.87, 0.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 Industry funded or unknown funded trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>23877</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.87, 0.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 Non‐industry funded trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1333</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.69, 1.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 All‐cause mortality ‐ Trials at low risk of bias <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>270</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.31, 2.85]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 All‐cause mortality ‐ 'Best‐worst case scenario' <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>25283</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.81, 0.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 All‐cause mortality ‐ 'Worst‐best case scenario' <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>25283</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.85, 1.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Beta‐blockers versus placebo or no intervention at maximum follow‐up beyond 3 months</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/references#CD012484-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012484-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Beta‐blockers versus placebo or no intervention less than 3 months follow‐up</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 MACE (Composite of cardiovascular death and non‐fatal myocardial infarction) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>165</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Beta‐blockers versus placebo or no intervention less than 3 months follow‐up</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/references#CD012484-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012484-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Beta‐blockers versus placebo or no intervention at maximum follow‐up beyond 3 months</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 MACE (Composite of cardiovascular death and non‐fatal myocardial infarction) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>475</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.43, 1.52]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Beta‐blockers versus placebo or no intervention at maximum follow‐up beyond 3 months</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/references#CD012484-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012484-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Beta‐blockers versus placebo or no intervention less than 3 months follow‐up</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Cardiovascular mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72622</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.87, 0.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Cardiovascular mortality ‐ Acute/subacute phase <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72622</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.87, 0.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Acute phase</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72309</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.87, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Subacute phase</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>313</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.23 [0.41, 3.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Cardiovascular mortality ‐ Reperfusion/no reperfusion <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72622</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.87, 0.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 No reperfusion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>71702</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.87, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Reperfusion (PCI , CABG, thrombolytics)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>920</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.29, 1.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Cardiovascular mortality ‐ Type of beta‐blocker <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72622</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.87, 0.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Esmolol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.21, 3.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Atenolol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>16221</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.75, 0.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Metoprolol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>54501</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.88, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4 Oxprenolol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>313</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.23 [0.41, 3.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5 Propranolol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1103</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.65, 1.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.6 Timolol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>344</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.53 [0.20, 1.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Cardiovascular mortality ‐ Above/below 75 years of age <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72622</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.87, 0.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Below 75 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>56308</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.88, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>16314</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.75, 0.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Cardiovascular mortality ‐ Intravenously/orally commenced <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72622</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.87, 0.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Intravenously commenced</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>766</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.42, 2.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Orally commenced</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>549</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.54, 1.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>71307</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.87, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Cardiovascular mortality ‐ NSTEMI/STEMI/UAP <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>49303</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.89, 1.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 STEMI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>726</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.35, 2.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 NSTEMI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3 Unstable angina pectoris</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.4 Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>48577</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.89, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Cardiovascular mortality ‐ Registration status <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72622</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.87, 0.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Pre‐registration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>46578</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.91, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Post‐registration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3 No registration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>26044</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.76, 0.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Cardiovascular mortality ‐ Funding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72622</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.87, 0.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 Industry funded or unknown funded trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72560</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.87, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 Non‐industry funded trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.65 [0.11, 62.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Cardiovascular mortality ‐ Trials with low risk of bias <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>45852</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.91, 1.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Cardiovascular mortality ‐ 'Best‐worst case scenario' <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72681</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.72, 0.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Cardiovascular mortality ‐ 'Worst‐best case scenario' <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72681</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.79, 1.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Beta‐blockers versus placebo or no intervention less than 3 months follow‐up</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/references#CD012484-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012484-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Beta‐blockers versus placebo or no intervention at maximum follow‐up beyond 3 months</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Cardiovascular mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>22457</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.84, 0.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Cardiovascular mortality ‐ Acute/subacute phase <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>22457</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.84, 0.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Acute phase</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18615</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.86, 1.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Subacute phase</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3842</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.65, 0.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Cardiovascular mortality ‐ Reperfusion/no reperfusion <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>22457</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.84, 0.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 No reperfusion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20386</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.84, 0.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Reperfusion (PCI , CABG, thrombolytics)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2071</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.46, 1.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Cardiovascular mortality ‐ Type of beta‐blocker <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>22457</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.84, 0.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Esmolol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 7.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Alprenolol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.22, 4.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Atenolol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>16219</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.86, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4 Carvedilol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2899</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.61, 0.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5 Metoprolol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1827</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.59, 1.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.6 Pindolol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>529</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.63, 1.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.7 Propranolol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>806</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.47, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Cardiovascular mortality ‐ Above/below 75 years of age <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>22457</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.84, 0.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Below 75 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5366</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.68, 0.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>17091</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.86, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Cardiovascular mortality ‐ Intravenously/orally commenced <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>22457</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.84, 0.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Intravenously commenced</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.33, 1.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Orally commenced</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4307</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.67, 0.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>17151</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.86, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Cardiovascular mortality ‐ NSTEMI/STEMI/UAP <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.49, 1.59]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 STEMI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1793</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.44, 1.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>209</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.27, 3.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Cardiovascular mortality ‐ Registration status <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>22457</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.84, 0.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Pre‐registration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1793</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.44, 1.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 No registration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20664</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.84, 0.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Cardiovascular mortality ‐ Length of intervention period <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>22457</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.84, 0.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 0 to 7 days length of intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>17026</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.86, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 1 month and more length of intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5431</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.69, 0.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Cardiovascular mortality ‐ Funding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>22457</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.84, 0.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 Industry funded or unknown funded trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>21393</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.84, 0.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 Non‐industry funded trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1064</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.36, 2.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Cardiovascular mortality ‐ 'Best‐worst case scenario' <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>22587</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.53, 0.86]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Cardiovascular mortality ‐ 'Worst‐best case scenario' <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>22587</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.83, 1.36]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Beta‐blockers versus placebo or no intervention at maximum follow‐up beyond 3 months</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/references#CD012484-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012484-tbl-0013"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Beta‐blockers versus placebo or no intervention less than 3 months follow‐up</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Myocardial infarction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>67562</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.74, 0.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Myocardial infarction ‐ Acute/subacute phase <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>67562</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.74, 0.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Acute phase</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>67249</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.75, 0.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Subacute phase</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>313</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.09, 1.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Myocardial infarction ‐ Reperfusion/no reperfusion <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>67562</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.74, 0.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 No reperfusion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66372</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.74, 0.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Reperfusion (PCI , CABG, thrombolytics)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1190</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.44, 1.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Myocardial infarction ‐ Type of beta‐blocker <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>67562</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.74, 0.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Esmolol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [0.01, 4.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Atenolol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12312</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.48, 1.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Metoprolol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>53921</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.72, 0.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4 Oxprenolol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>313</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.09, 1.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5 Pindolol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.15, 6.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.6 Propranolol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>225</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.08, 14.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.7 Timolol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>432</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.26, 2.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.8 Xamoterol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.12 [0.13, 73.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.9 Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>108</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.93 [0.37, 10.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Myocardial infarction ‐ Above/below 75 years of age <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>67432</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.74, 0.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Below 75 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9561</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.58, 0.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>57871</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.76, 0.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Myocardial infarction ‐ Intravenously/orally commenced <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>67562</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.74, 0.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Intravenously commenced</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>996</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [0.28, 4.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Orally commenced</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>452</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.16, 4.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.74, 0.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Myocardial infarction ‐ NSTEMI/STEMI/UAP <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>49361</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.71, 0.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 STEMI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>996</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.29, 3.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 NSTEMI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3 Unstable angina pectoris</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.4 Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>48365</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.71, 0.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Myocardial infarction ‐ Registration status <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>67562</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.74, 0.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Pre‐registration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>46848</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.73, 0.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Post‐registration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3 No registration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20714</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.70, 0.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Myocardial infarction ‐ Funding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>67562</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.74, 0.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 Industry funded or unknown funded trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>67067</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.74, 0.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 Non‐industry funded trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>495</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.23 [0.22, 6.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Myocardial infarction ‐ Trials with low risk of bias <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>45852</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.72, 0.92]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Myocardial infarction ‐ 'Best‐worst case scenario' <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>67620</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.61, 0.92]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Myocardial infarction ‐ 'Worst‐best case scenario' <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>67620</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.67, 1.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Beta‐blockers versus placebo or no intervention less than 3 months follow‐up</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/references#CD012484-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012484-tbl-0014"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Beta‐blockers versus placebo or no intervention at maximum follow‐up beyond 3 months</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Myocardial infarction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6825</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.74, 1.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Myocardial infarction ‐ Acute/subacute phase <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6825</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.74, 1.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Acute phase</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2983</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.72, 1.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Subacute phase</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3842</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.62, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Myocardial infarction ‐ Reperfusion/no reperfusion <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6825</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.74, 1.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 No reperfusion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4658</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.67, 1.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Reperfusion (PCI , CABG, thrombolytics)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2167</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.46, 1.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Myocardial infarction ‐ Type of beta‐blocker <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6825</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.74, 1.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Esmolol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [0.01, 4.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Alprenolol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.28, 3.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Landiolol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>96</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.35 [0.01, 8.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4 Carvedilol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2899</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.43, 0.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5 Metoprolol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2426</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.84, 1.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.6 Pindolol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>529</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.61, 1.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.7 Propranolol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>610</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.08, 3.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.8 Timolol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.57 [0.82, 52.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Myocardial infarction ‐ Above/below 75 years of age <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6729</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.72, 1.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Below 75 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5665</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.69, 1.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1064</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.35 [0.45, 4.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Myocardial infarction ‐ Intravenously/orally commenced <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6825</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.74, 1.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Intravenously commenced</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1095</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.26, 3.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Orally commenced</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.62, 1.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1723</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.46, 1.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Myocardial infarction ‐ NSTEMI/STEMI/UAP <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2098</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.57, 2.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 STEMI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1889</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.45, 2.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>209</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.19 [0.42, 3.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Myocardial infarction ‐ Registration status <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6825</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.74, 1.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Pre‐registration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1793</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [0.48, 2.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 No registration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5032</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.68, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Myocardial infarction ‐ Length of intervention period <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6913</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.71, 1.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 0 to 7 days length of intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1183</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.51 [0.46, 4.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 7 to 30 days length of intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.57 [0.82, 52.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.3 1 month and more length of intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5642</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.74, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Myocardial infarction ‐ Funding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6825</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.77, 1.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 Industry funded or unknown funded trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5665</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.77, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 Non‐industry funded trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1160</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.31, 2.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Myocardial infarction ‐ 'Best‐worst case scenario' <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6951</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.56 [0.37, 0.85]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Myocardial infarction ‐ 'Worst‐best case scenario' <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6951</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.95, 1.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Beta‐blockers versus placebo or no intervention at maximum follow‐up beyond 3 months</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/references#CD012484-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012484-tbl-0015"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Beta‐blockers versus placebo or no intervention less than 3 months follow‐up</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Angina on a dichotomous scale <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>98</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.31, 1.58]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Beta‐blockers versus placebo or no intervention less than 3 months follow‐up</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/references#CD012484-tbl-0015">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012484-tbl-0016"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Beta‐blockers versus placebo or no intervention at maximum follow‐up beyond 3 months</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Angina on a dichotomous scale <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>844</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.18, 2.30]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Beta‐blockers versus placebo or no intervention at maximum follow‐up beyond 3 months</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012484.pub2/references#CD012484-tbl-0016">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD012484.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD012484-note-0005">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD012484-note-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD012484-note-0003">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD012484-note-0011">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ms#CD012484-note-0013">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD012484-note-0004">Polski</a> </li> <li class="section-language"> <a class="" href="ru#CD012484-note-0002">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD012484-note-0001">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD012484-note-0010">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012484\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012484\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012484\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012484\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012484\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012484\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012484\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012484\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012484\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012484\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012484\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012484\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012484\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012484\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012484\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012484\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012484\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012484\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=uQyIsxpV&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012484.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012484.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD012484.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD012484.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012484.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740726590602"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012484.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740726590605"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012484.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e975af8a0f3c9',t:'MTc0MDcyNjU5MS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 